

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number  
**WO 01/36432 A2**

BO

- (51) International Patent Classification<sup>7</sup>: **C07H**
- (21) International Application Number: PCT/US00/31162
- (22) International Filing Date:  
15 November 2000 (15.11.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/166,415 19 November 1999 (19.11.1999) US  
60/215,136 30 June 2000 (30.06.2000) US
- (71) Applicant (for all designated States except US): **HUMAN GENOME SCIENCES, INC.** [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **RUBEN, Steven, M.** [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). **KOMATSOULIS, George, A.** [US/US]; 9518 Garwood Steet, Silver Spring, MD 20901 (US). **BAKER, Kevin, P.** [US/US]; 14006 Indian Run Drive, Darnestown, MD 20878 (US). **YOUNG, Paul, E.** [US/US]; 122 Beckwith Street, Gaithersburg, MD 20878 (US).
- (74) Agents: **HOOVER, Kenley, K.** et al.; c/o Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/36432 A2

(54) Title: 18 HUMAN SECRETED PROTEINS

(57) Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

## 18 Human Secreted Proteins

### *Field of the Invention*

This invention relates to newly identified polynucleotides, polypeptides encoded by these polynucleotides, antibodies that bind these polypeptides, uses of  
5 such polynucleotides, polypeptides, and antibodies, and their production.

### *Background of the Invention*

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or  
10 organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic  
15 reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

20 Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in  
25 secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins  
30 include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of

the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical diseases, disorders, and/or conditions by using secreted proteins or the genes  
5 that encode them.

### ***Summary of the Invention***

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells,  
10 antibodies, and recombinant and synthetic methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting diseases, disorders, and/or conditions related to the polypeptides and polynucleotides, and therapeutic methods for treating such diseases, disorders, and/or conditions. The invention further relates to screening methods for identifying binding partners of the  
15 polypeptides.

### ***Detailed Description***

#### **Definitions**

The following definitions are provided to facilitate understanding of certain  
20 terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be  
25 contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA  
30 preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As



shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH<sub>2</sub>PO<sub>4</sub>; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA<sup>+</sup> sequences (such as any 3' terminal polyA<sup>+</sup> tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of

ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

Many proteins (and translated DNA sequences) contain regions where the amino acid composition is highly biased toward a small subset of the available

residues. For example, membrane spanning domains and signal peptides (which are also membrane spanning) typically contain long stretches where Leucine (L), Valine (V), Alanine (A), and Isoleucine (I) predominate. Poly-Adenosine tracts (polyA) at the end of cDNAs appear in forward translations as poly-Lysine (poly-K) and poly-Phenylalanine (poly-F) when the reverse complement is translated. These regions are often referred to as "low complexity" regions.

Such regions can cause database similarity search programs such as BLAST to find high-scoring sequence matches that do not imply true homology. The problem is exacerbated by the fact that most weight matrices (used to score the alignments generated by BLAST) give a match between any of a group of hydrophobic amino acids (L,V and I) that are commonly found in certain low complexity regions almost as high a score as for exact matches.

In order to compensate for this, BLASTX.2 (version 2.0a5MP-WashU) employs two filters ("seg" and "xnu") which "mask" the low complexity regions in a particular sequence. These filters parse the sequence for such regions, and create a new sequence in which the amino acids in the low complexity region have been replaced with the character "X". This is then used as the input sequence (sometimes referred to herein as "Query" and/or "Q") to the BLASTX program. While this regime helps to ensure that high-scoring matches represent true homology, there is a negative consequence in that the BLASTX program uses the query sequence that has been masked by the filters to draw alignments.

Thus, a stretch of "X"s in an alignment shown in the following application does not necessarily indicate that either the underlying DNA sequence or the translated protein sequence is unknown or uncertain. Nor is the presence of such stretches meant to indicate that the sequence is identical or not identical to the sequence disclosed in the alignment of the present invention. Such stretches may simply indicate that the BLASTX program masked amino acids in that region due to the detection of a low complexity region, as defined above. In all cases, the reference sequence(s) (sometimes referred to herein as "Subject", "Sbjct", and/or "S") indicated in the specification, sequence table (Table 1), and/or the deposited clone is (are) the definitive embodiment(s) of the present invention, and should not be construed as

limiting the present invention to the partial sequence shown in an alignment, unless specifically noted otherwise herein.

### **Polynucleotides and Polypeptides of the Invention**

5

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 1**

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: 96 and/or SEQ ID  
10 NO: 98. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind  
15 polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

The translation product of this gene shares sequence homology with adult-specific brush border protein (See, e.g., Genbank accession number  
pir|C45665|C45665 >sp|Q05005|BB19\_RABIT BRUSH BORDER 19.3 KD  
20 PROTEIN PRECURSOR; all references available through this accession are hereby incorporated by reference herein.) which is proteolytically processed in the intestine, targeted to the brush border membrane of the enterocytes, and has esterase and phospholipase A/lysophospholipase activity.

This gene is expressed primarily in the following tissues/cDNA libraries:  
25 Primary Dendritic Cells, lib 1, and to a lesser extent in colon (as Normal Colon and Colon Normal III).

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to  
30 dendritic cells and disorders of the colon. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of

the above tissues or cells, particularly of the immune and gastrointestinal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another  
5 tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The similarity of this protein to a brush border (intestinal epithelium) protein and the detection of the transcript in the colon suggest that the protein product of this  
10 gene may be useful for diagnosis and/or treatment of a variety of disorders of the digestive system, including but not limited to Crohn's disease, colitis, intestinal ulcers, and diverticulitis.

Moreover, detection of this transcript in dendritic cells indicates this gene and/or gene product may be useful for the diagnosis and treatment of a variety of  
15 immune system disorders. For example, this gene and/or gene product may play a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness for treatment of cancer (e.g. by boosting immune responses). Expression in cells of  
20 lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it would also be useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated  
25 cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that  
30 influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages,

and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,  
 5 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 2

10

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.  
 15 gb|AAD51875.1|AF087433\_1 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "(AF087433) leprecan [Rattus norvegicus]" A partial alignment demonstrating the observed homology is shown immediately below.

```

20  >gb|AAD51875.1|AF087433_1 (AF087433) leprecan [Rattus norvegicus]
    >sp|AAD51875|AAD51875 Leprecan.
    Length = 728

    Minus Strand HSPs:
25  Score = 2916 (1026.5 bits), Expect = 0.0, Sum P(3) = 0.0
    Identities = 546/592 (92%), Positives = 569/592 (96%), Frame = -1

30  Q: 2162 PYNYLQVAYFKINKLEKAVAAHTFFVGNPEHMEMQNLDYYQTM SGVKEADFKDLETQP 1983
    PYNYLQVAYFKINKLEKAVAAHTFFVGNPEHMEM+QNLDYYQTM SGVKE DFKDLE +P
    S: 137 PYNYLQVAYFKINKLEKAVAAHTFFVGNPEHMEMQNLDYYQTM SGVKEEDFKDLEAKP 196

    Q: 1982 HMQEFLGVRVLYSEEQPEAVPHLEAALQEYFVAYEECRALCEGPDYDGYNYLEYNADL 1803
    HM EFLGVRVLYSEE+P EAVPHLEAALQEYFVA EECRALCEGPDYDGYNYL+Y+ADL
35  S: 197 HMQEFLGVRVLYSEEKPLEAVPHLEAALQEYFVADEECRALCEGPDYDGYNYLDYSADL 256

    Q: 1802 FQAITDHYIQVLNCKQNCVTELASHPSREKPPEDFLPSHYNYLQFAYYNIGNYTQAVECA 1623
    FQAITDHY+QVL+CKQNCVTELASHPSREKPPEDFLPSHYNYLQFAYYNIGNYTQA+ECA
40  S: 257 FQAITDHYVQLSCKQNCVTELASHPSREKPPEDFLPSHYNYLQFAYYNIGNYTQAIECA 316

    Q: 1622 KTYLLFFPNDEVMQNLAYYAAMLGEEHTRSIGPRESKEYRQRSLLLEKELLFFAYDVFG 1443
    KTYLLFFPNDEVM+QNLAYY A+LGEE SI PRE+A+EYR RSLLEKELLFFAYD+FG
    S: 317 KTYLLFFPNDEVMQNLAYYTAVLGEEEAASSISPRENAQEYRHSLLLEKELLFFAYDIFG 376

45  Q: 1442 IPFVDPDSWTPEEVIPKRLQEKQKSERETAVRISQEIGNLMKEIETLVEEKTKESSLDOVSR 1263
    IPFVDPDSWTPEEVIPKRLQEKQKSERETAVRISQEIGNLMKEIETLVEEKTKESSLDOVSR
    S: 377 IPFVDPDSWTPEEVIPKRLQEKQKSERETAVRISQEIGNLMKEIETLVEEKTKESSLDOVSR 436
  
```

5 Q: 1262 LTREGGPLL YEGISLT MNSK L NGSQRV VMDGVISDHECQELQRLTNVAATSGDGYRGQT 1083  
 LTREGGPLL YEGI+LTMNSK+LNGSQRV VMDGVISD ECQELQRLTN AATSGDGYRGQT  
 S: 437 LTREGGPLL YEGINLT MNSK V L NGSQRV VMDGVISDDECQELQRLTNAAATSGDGYRGQT 496

10 Q: 1082 SPHTPNEKFYGVTVFKALKLGQEGKVPLQSAHLYYNVTEKVR RIMESYFRLDTPLYFSYS 903  
 SPHTPNEKFYGVTV KALKLGQEGKVPLQSAH+YYNVTEKVR R+MESYFRLDTPLYFSYS  
 S: 497 SPHTPNEKFYGVTVL KALKLGQEGKVPLQSAHMYYNVTEKVR RVMESYFRLDTPLYFSYS 556

15 Q: 902 HLCRTAIEEVQAERKDDSHPVHVDNCILNAETLVCVKEPPAYTFRDYSAILYLNGDFDG 723  
 HLCRTAIEE QAERKD SHPVHVDNCILNAE+LVC+KEPPAYTFRDYSAILYLNGDFDG  
 S: 557 HLCRTAIEESQAERKDDSHPVHVDNCILNAESLVCKEPPAYTFRDYSAILYLNGDFDG 616

20 Q: 722 GNIFYFTELDAKTVTAEVQPQCGRVGFSSGTENPHGVKAVTRGQRCAIALWFTLDPRHSE 543  
 GNIFYFTELDAKTVTAEVQPQCGRVGFSSGTENPHGVKAVTRGQRCAIALWFTLDPRHSE  
 S: 617 GNIFYFTELDAKTVTAEVQPQCGRVGFSSGTENPHGVKAVTRGQRCAIALWFTLDPRHSE 676

Q: 542 RDRVQADDLVKMLFSPEEMDLSQEQLDAQGPPEPAQESLSGSESKPKDEL 387  
 RDRVQADDLVKMLFSPEE+DL QEQLP QG P+P +ESLS ES+PKDEL  
 S: 677 RDRVQADDLVKMLFSPEEVDLPQEQLPDQGSFKPGEESLSDRESQPKDEL 728

Score = 176 (62.0 bits), Expect = 0.0, Sum P(3) = 0.0  
 Identities = 36/83 (43%), Positives = 42/83 (50%), Frame = -3

25 Q: 2505 WGMVTPDLLFAEGTAAYARGDWPGVVL SMEXXXXXXXXXXXXXXXXXXTQCAADFPW--EL 2332  
 W + PDLL+AEGTAAYARGDWPGVVL+ME T+CA + PW +L  
 S: 20 WNVAAPDLLY AEGTAAYARGDWPGVVLNMERALRSRAALRALRLRCRTRCATELPWAPDL 79

30 Q: 2331 DDPWXXXXXXXXXXXXLRLDLSFF 2263  
 D L DL FF  
 S: 80 DLGPASSLNHDPGAAALHDLRFF 102

The segments of gb|AAD51875.1|AF087433\_1 that are shown as "S" above are set out in the sequence listing as SEQ ID NO: 99 and SEQ ID NO: 101 Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: 100 and/or SEQ ID NO: 102 which correspond to the Q sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.



In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, an amino acid sequence selected from the group:

PRDCKKKQKSERETAVRISQEIGNLMKEIETLVEEKTKESLDVSRLTREGGPLL  
YEGISLTMNSKLLNGSQRVVMDGVISDHECQELQRLTNVAATSGDGYRGQTS  
5 PHTPNEKFYGVTVFKALKLGQEGKVPLQSAHLYYNVTEKVRRLMESYFRLDT  
PLYFSYSHLVCRTAIEEVQAERKDDSHPVHVDNCILNAETLVCVKEPPAYTFR  
DYSAILYLNGDFDGGNFYFTELDAKTVTAEVQPQCGRVGFSSGTENPHGVK  
AVTRGQRCAIALWFTLDPRHSERDRVQADDLVKMLFSPEEMDLSQEQPLDA  
QQGPPEPAQESLSGSESKPKDEL (SEQ ID NO: 103) and

10 YYAAMLGEEHTRSIGPRESAKEYRQRSLLKELLFFAYDVFGIPFVDPDSWTP  
EEVIPKR (SEQ ID NO: 104). Moreover, fragments and variants of these  
polypeptides (such as, for example, fragments as described herein, polypeptides at  
least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides  
and polypeptides encoded by the polynucleotide which hybridizes, under stringent  
15 conditions, to the polynucleotide encoding these polypeptides ) are encompassed by  
the invention. Antibodies that bind polypeptides of the invention are also  
encompassed by the invention. Polynucleotides encoding these polypeptides are also  
encompassed by the invention.

The gene encoding the disclosed cDNA is believed to reside on chromosome  
20 1. Accordingly, polynucleotides related to this invention are useful as a marker in  
linkage analysis for chromosome 1.

Based on the sequence similarity, the translation product of this clone is  
expected to share at least some biological activities with leprecan and/or other  
proteoglycans. Such activities are known in the art, some of which are described  
25 elsewhere herein.

This gene is expressed primarily in mesenchymal cells, and to a lesser extent  
in hematopoietic and epithelial cells.

Polynucleotides and polypeptides of the invention are useful as reagents for  
differential identification of the tissue(s) or cell type(s) present in a biological sample  
30 and for diagnosis of diseases and conditions which include but are not limited to  
disorders of development and differentiation (e.g. hematopoiesis). Similarly,  
polypeptides and antibodies directed to these polypeptides are useful in providing

immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or  
5   bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based upon the observed tissue distribution, this gene product may be useful  
10   in the diagnosis and/or treatment of a variety of disorders. Elevated expression in mesenchymal cells indicates that it may be useful in fibrosis, osteoporosis, osteoarthritis, autoimmunity, myocardial infarction, scleroderma, and fibrotic disorders. Similarly, expression by hematopoietic cells and epithelial cells indicates possible involvement in immune system dysfunction, immune modulation,  
15   inflammation, autoimmunity, regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness for treatment of cancer (e.g. by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product  
20   would be involved in immune functions. Therefore it would also be useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and  
25   tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits  
30   hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the

protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues, acute renal failure, leukemias, metabolic disorders, wasting disease, cachexia, and susceptibility to infections.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 3

10

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. emb|CAA68759.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "gp210 (AA 1-1886) [Rattus norvegicus]" A partial alignment demonstrating the observed homology is shown immediately below.

```

20  >emb|CAA68759.1| gp210 (AA 1-1886) [Rattus norvegicus] >pir|S04921|S04921
      nuclear pore protein gp210 precursor - rat >sp|P11654|GP21_RAT
      INTEGRAL MEMBRANE GLYCOPROTEIN GP210 PRECURSOR.
      Length = 1886

25  Plus Strand HSPs:

      Score = 3765 (1325.3 bits), Expect = 0.0, Sum P(2) = 0.0
      Identities = 727/833 (87%), Positives = 768/833 (92%), Frame = +2

30  Q: 131 AAAXKLNIPKVLPPFTRATRVNFTLEASEGCRYWLSTRPEVASIEPLGLDEQQCSQKAVV 310
      A A KLNIPKVLPPFTRATRVNFTLEASEGCRYW STRPEVASIEPLG EQQCSQKAVV
      S: 23 AVAAKLNIPKVLPPFTRATRVNFTLEASEGCRYWSSTRPEVASIEPLGSSEQCSQKAVV 82

35  Q: 311 QARLTQPARLTSIIFAEDITTGQVLRCDIAVDLIHQIVSTTRELYLEDSPLELKIQAL 490
      QARLTQPARLTSIIFAEDITTGQVLRCDIAVDLIH IQIVSTTRELYLEDSPLELKIQAL
      S: 83 QARLTQPARLTSIIFAEDITTGQVLRCDIAVDLIHQIVSTTRELYLEDSPLELKIQAL 142

40  Q: 491 DSEGNTFSTLAGLVFEWTIVKDSEADRFSDSHNALRILTFLESTYIPPSYISEMEKAAKQ 670
      DSEGNTFSTLAGLVF+WTIVKD+EA+ FSDSHNALRILTFLESTYIPPSYISEMEKAAKQ
      S: 143 DSEGNTFSTLAGLVFDWTIVKDTEANGFSDSHNALRILTFLESTYIPPSYISEMEKAAKQ 202

45  Q: 671 GDTILVSGMKTGSKKLKARIQEAVYKNVRPAXVRLILENILLNPAYDVYLMVGTSIHYK 850
      GDTILVSGMKTGS KKKARIQEAVYKNVRPA VRLILENILLNPAYDVYL+VGTSIHYK
      S: 203 GDTILVSGMKTGSKKLKARIQEAVYKNVRPAEVRLLILENILLNPAYDVYLLVGTSIHYK 262

      Q: 851 VQKIRQGKITELXMPDQYELQLQNSIPGPEGDPTRPVAVLAQDTSMTALQLGQSSLVL 1030
      VQKIRQGKITEL MPDQYELQLQNSIP P+GDP RPVAVL QDTS VTA+Q+GQS+LVL
      S: 263 VQKIRQGKITELSMPSDQYELQLQNSIPDPQGDPAFPVAVLTQDTSRVTAMQMGSNLVL 322

      Q: 1031 GHRSI RMQASRLPNSTIYVVEPGYLGFTVHPGDRWVLETGRLYEITIEVFDKFSNKVYV 1210

```

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65

GHR SIRMQ G A S R L P N S T I Y V V E G Y L G F T V H P G D R W V L E T G L Y + T I E V F D + S N K V Y  
S: 323 GHR SIRMQ G A S R L P N S T I Y V V E A G Y L G F T V H P G D R W V L E T G H L Y A V T I E V F D R S S N K V Y P 382

Q: 1211 S D N I R I E T V L P A E F F E V L S S S Q N G S Y H R I R A L K R G Q T A I D A A L T S V V D Q D G G V H I L Q V P V 1390  
S D N I R I E V P A E F F E V L S S S Q N G S Y H + R A + + Q T I A + L T S V V D Q D G G V H + L Q V P V  
S: 383 S D N I R I E A V F P A E F F E V L S S S Q N G S Y H H V R A I Q S G Q T T I S A L T S V V D Q D G G V H I L Q V P V 442

Q: 1391 W N Q Q E V E I H I P I T L Y P S I L T F P W Q P K T G A Y Q Y T I R A H X X X X X X X X X X H L V A T V T V K G V 1570  
W N Q Q E V + I H I P I T L Y P S I L T F P W Q P K T G A Y Q Y T I + A H + + V A T V T V K G V  
S: 443 W N Q Q E V D I H I P I T L Y P S I L T F P W Q P K T G A Y Q Y T I K A H G S G N F T W S S S S Y M V A T V T V K G V 502

Q: 1571 M T T G S D I G F S V I Q A H D V Q N P L H F G E M K V Y V I E P H S M E F A P C Q V E A R V G Q A L E L P L R I S G L 1750  
M T T G D G S V I + A H D V Q N P L H F G E M K V Y V I E P S M E F A P C Q V E A R V G L E L P L I S G L  
S: 503 M T T G G D T G L S V I R A H D V Q N P L H F G E M K V Y V I E P S S M E F A P C Q V E A R V G H T L E L P L T I S G L 562

Q: 1751 M P G G A S E V V T L S D C S H F D L A V E V E N Q G V F Q P L P G R L P P G S E H C S G V R V K A E A Q G S T T L L V 1930  
M P G G + S E V V T L S D C S H F D L V E V E N Q G V F Q P L P G R L P P G E H C S G V + V + A + A Q G S T T L L V  
S: 563 M P G G S S E V V T L S D C S H F D L V E V E N Q G V F Q P L P G R L P P G P E H C S G V K R A D A Q G S T T L L V 622

Q: 1931 S Y R H G H V H L S A K I T I A A Y L P L K A V D P S S V A L V T L G S S K E M L F E G G P R P W I L E P S K F F Q N V 2110  
S Y H G H V H L A K I T + A A Y L P L K A V D P S S V A + V T L G S S K E M L F E G G P R P W + L E P S K F F + N V  
S: 623 S Y T H G H V H L G A K I T L A A Y L P L K A V D P S S V A V V T L G S S K E M L F E G G P R P W L E P S K F F R N V 682

Q: 2111 T A E D T S I G L A L F A P H S S R N Y Q Q H W I L V T C Q A L G E Q V I A L S V G N K P S L T N F P P A V E P A V V 2290  
T + E D T S I L + L P + S R N Y Q Q H + L V T C Q A L G E Q V I A L S V G N + P S L + N F P P A V E P V V  
S: 683 T S E D T G S I S L S L L G P P A S R N Y Q Q H R V L V T C Q A L G E Q V I A L S V G N R P S L S N F P P A V E P T V V 742

Q: 2291 K F V C A P P S R L T L V P V Y T S P Q L D M S C P L L Q Q N K Q V V P V S S H R N P L L D L A A Y D Q E G R R F D N F 2470  
K V C A P P S R L T L + P V Y P Q L D + S C P L L Q Q N K Q V V P V S S H R N P L L D L A Y D Q + G R R F D N F  
S: 743 K S V C A P P S R L T L M P V Y A L P Q L D L S C P L L Q Q N K Q V V P V S S H R N P L L D L G A Y D Q Q G R R F D N F 802

Q: 2471 S S L S I Q W E S T R P V L A S I E P E L P M Q L V S Q D D E S G Q K L H G L Q A I L V H E A S G T T A 2629  
S S L S I Q W E S R P + L A S I E + P M Q L V S Q D D + G Q K L H G L Q + V H E A S G T T A  
S: 803 S S L S I Q W E S F R P L L A S I E V D Q P M Q L V S Q D D G N G Q K L H G L Q T V S V H E A S G T T A 855

Score = 1296 (456.2 bits), Expect = 0.0, Sum P(2) = 0.0  
Identities = 251/315 (79%), Positives = 286/315 (90%), Frame = +1

Q: 2626 S I T A T A T G Y Q E S H L S S X R T K Q P H D P L V P L S A S I E L I L V E D V R V S P E E V T I Y N H P G I Q A E L 2805  
+ I + A T A T G Y Q + S H L S + K Q D P L V P + S A S I E L I L V E D V R V S P E E V T I Y N H P G + Q E L  
S: 855 A I S A T A T G Y Q Q S H L S A A G V K Q L R D P L V P V S A S I E L I L V E D V R V S P E E V T I Y N H P G V Q V E L 914

Q: 2806 R I R E G S G Y F F L N T S T A D V V K V A Y Q E A R G V A M V H P L P G S S T I M I H D L C L V F P A P A K A V V Y 2985  
I E G S G Y F F L N T S T D + + V A Y Q + R G V A M V H P L P G S S T + M + H D L C L F P A P A K A + +  
S: 915 H I T E G S G Y F F L N T S T Q D I I N V A Y Q D T R G V A M V H P L P G S S T V M V H D L C L T F P A P A K A T I H 974

Q: 2986 V S D I Q E L Y I R V V D K V E I G K T V K A Y V R V L D L H K K P F L A K Y F P F M D L K L R A A S P I I T L V A L D 3165  
V S D I Q E L Y + R V V D K V E I G K V K A Y V R V L D + K K P F L A K Y F F M D L K L R A A S I I T L V L D  
S: 975 V S D I Q E L Y R V V D K V E I G K A V K A Y V R V L D F Y K K P F L A K Y F T F M D L K L R A A S Q I I T L V T L D 1034

Q: 3166 E A L D N Y T I T F L I R G V A I G Q T S L T A S V T N K A G Q R I N S X P Q Q I E V F P P F R L M P R K V T L L I G A 3345  
E A L D N Y T T F L + G V A I G Q T S L + A S V T + K + G Q R + + S Q Q I E V F P P F R L + P R K V T L + I G A  
S: 1035 E A L D N Y T A T F L V H G V A I G Q T S L S A S V T D K S G Q R V S S T A Q Q I E V F P P F R L I P R K V T L I I G A 1094

Q: 3346 T M Q V T S E G G P Q P Q S N I L F S I S N E S V A L V S A A G L V Q G L A I G N G T V S G L V Q A V D A E T G K V V I 3525  
+ Q + T S E G G P Q P Q S N I L F S I + N E S V A V S + A G L V + G L + G N G + V G + V Q A V D A E T G K V + I  
S: 1095 M I Q I T S E G G P Q P Q S N I L F S I N N E S V A A V S S A G L V R G L M V G N G S V L G V V Q A V D A E T G K V I I 1154

Q: 3526 I S Q D L V Q V E V L L R A 3570  
+ S Q D V + V E V L L + A  
S: 1155 V S Q D H V E V E V L Q L Q A 1169

Score = 45 (15.8 bits), Expect = 0.0, Sum P(2) = 0.0  
Identities = 15/47 (31%), Positives = 21/47 (44%), Frame = +3

Q: 2595 P F W F T R H Q E P Q H H C H W L P G V P P Q - - - L X Q N K A A A \* P S G A S V G L H R A H 2732  
P T H P Q H H + L P L + + A + P S G + + H  
S: 1840 P L A L T P H A S P Q H S P H - - Y L A S S P T A F N T L P S D R K A S P P S G L W S P A Y A S H 1886

The segments of emb|CAA68759.1| that are shown as "S" above are set out in the sequence listing as SEQ ID NO: 105, SEQ ID NO: 107 and SEQ ID NO: 109. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: 106, SEQ ID NO: 108 and/or SEQ ID NO: 110 which correspond to the "Q" sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in neutrophils as outlined by distribution in the following tissues/cDNA libraries: Neutrophils IL-1 and LPS induced and to a lesser extent in neutrophils control; Neutrophils control, re-excision; Stratagene fetal retina 937202; Neutrophils IL-1 and LPS induced; PC3 Prostate cell line; Stratagene lung (#937210); SKIN; CD34 positive cells (Cord Blood); NCI\_CGAP\_Gas1; T cell helper II; NCI\_CGAP\_Phe1; Brain frontal cortex; Human Ovarian Cancer Reexcision; Stratagene hNT neuron (#937233); Dendritic Cells From CD34 Cells; NCI\_CGAP\_Kid6; Human fetal heart, Lambda ZAP Express; Human Cerebellum; NCI\_CGAP\_GCB1; Brain-medulloblastoma; NCI\_CGAP\_SS1; Stratagene ovary (#937217); human ovarian cancer; Anergic T-cell; Soares fetal liver spleen 1NFLS; Stratagene schizo brain S11; Human Frontal Cortex, Schizophrenia; NCI\_CGAP\_Lip2; Stratagene placenta (#937225); Hippocampus, Alzheimer Subtracted; Human Hypothalamus, Schizophrenia; Human Rhabdomyosarcoma; HUMAN B CELL LYMPHOMA; H. Frontal cortex, epileptic, re-excision; Soares\_NhHMPu\_S1; NCI\_CGAP\_GC2; Human Neutrophil, Activated; Nine Week

- Old Early Stage Human; Soares\_testis\_NHT; NCI\_CGAP\_Pr7; Human Fibrosarcoma; NCI\_CGAP\_AA1; Stomach cancer (human),re-excision; Jurkat T-cell G1 phase; Human Prostate; Soares\_pineal\_gland\_N3HPG; Human Placenta (re-excision); Human Activated T-Cells, re-excision; Human Fetal Brain; Ovarian Tumor
- 5 10-3-95; Human Fetal Heart; Endothelial-induced; Monocyte activated; Activated T-cell(12h)/Thiouridine-re-excision; Stanley Frontal NB pool 2; Early Stage Human Brain, random primed; NCI\_CGAP\_Pr16; NCI\_CGAP\_Kid1; Dermatofibrosarcoma Protuberance; stomach cancer (human); NCI\_CGAP\_Thy1; Human Whole Brain #2 - Oligo dT > 1.5Kb; Human Osteosarcoma; Human Chronic Synovitis; TF-1 Cell Line
- 10 GM-CSF Treated; NCI\_CGAP\_Pr1; Human Activated T-Cells; Fetal Heart; Fetal Liver, subtraction II; Early Stage Human Brain; Adipocytes; human tonsils; Activated T-Cell (12hs)/Thiouridine labelledEco; Smooth muscle,control; Soares\_placenta\_8to9weeks\_2NbHP8to9W; Human 8 Week Whole Embryo; Soares\_fetal\_lung\_NbHL19W; Colon Normal III;
- 15 Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Stanley Frontal SN pool 1; Liver, normal; Fetal brain, Stratagene; Colorectal Tumor; NCI\_CGAP\_GCB0; Human Fetal Lung; NCI\_CGAP\_Lym5; prostate-edited; H. Atrophic Endometrium; Human Prostate Cancer, Stage B2, re-excision; Human Placenta; Stratagene neuroepithelium NT2RAMI 937234; Lung, Cancer (4005163 B7): Invasive, Poorly Diff.
- 20 Adenocarcinoma, Metastatic; H. Whole Brain #2, re-excision; Human Prostate Cancer, Stage C fraction; Human Stomach,re-excision; NCI\_CGAP\_Ov2; Prostate BPH; Brain Frontal Cortex, re-excision; NCI\_CGAP\_Alv1; Human Neutrophil; NCI\_CGAP\_Pr3; CD34 depleted Buffy Coat (Cord Blood); Gessler Wilms tumor; Stratagene NT2 neuronal precursor 937230; B-Cells; Human Brain, Striatum;
- 25 Monocyte activated, re-excision; Human Osteoblasts II; Stratagene HeLa cell s3 937216; Hemangiopericytoma; Human Testes Tumor, re-excision; NCI\_CGAP\_CLL1; Human Adrenal Gland Tumor; Human Ovary; Human Gall Bladder; Pancreas Islet Cell Tumor; Stratagene colon (#937204); Human T-Cell Lymphoma; Human Substantia Nigra; Colon Normal II; Bone marrow; 12 Week
- 30 Early Stage Human II, Reexcision; Soares retina N2b4HR; NCI\_CGAP\_Kid5; Spleen, Chronic lymphocytic leukemia; Human Testes; Bone Marrow Cell Line (RS4,11); Soares\_fetal\_heart\_NbHH19W; Primary Dendritic Cells, lib 1; Human

- Corpus Colosum; HE7, subtracted by hybridization with E7 cDNA; HCC cell line metastasis to liver; Stanley Frontal SB pool 1; Stanley Frontal SN pool 2; NCI\_CGAP\_Mel3; Human Leiomyeloid Carcinoma; NCI\_CGAP\_Li2; Human Macrophage; L428 cell line; Human Bone Marrow; Human Hypothalamus,
- 5 Alzheimer's; Larynx Normal; NCI\_CGAP\_Br5; brain stem; Testes; NCI\_CGAP\_Br4; NCI\_CGAP\_HSC1; Human Uterus, normal; Human 8 Week Whole Embryo, subtracted; Chromosome 7 Fetal Brain cDNA Library; NCI\_CGAP\_Lar1; NCI\_CGAP\_Pr8; Resting T-Cell; Human Fetal Brain, random primed; LNCAP untreated; NCI\_CGAP\_Sch1; NCI\_CGAP\_Pr4.1; NCI\_CGAP\_Pr11; Human OB
- 10 HOS control fraction I; NCI\_CGAP\_Pr6; Human colon carcinoma (HCC) cell line, remake; Human Cerebellum, subtracted; Human Umbilical Vein Endothelial Cells, fract. A; HSC172 cells; NCI\_CGAP\_Ov23; Smooth muscle, control, re-excision; Human Fetal Bone; human colon cancer; Lung, Cancer (4005313 A3): Invasive Poorly Differentiated Lung Adenocarcinoma,; Smooth muscle-ILb induced; Amniotic
- 15 Cells - TNF induced; H. cerebellum, Enzyme subtracted; STRATAGENE Human skeletal muscle cDNA library, cat. #936215.; Weizmann Olfactory Epithelium; Resting T-Cell, re-excision; Human Pineal Gland; Raji Cells, cyclohexamide treated; NCI\_CGAP\_Ut4; CD34 positive cells (cord blood),re-ex; NCI\_CGAP\_Ut3; Human Tonsils, Lib 2; Healing groin wound - zero hr post-incision (control); Hepatocellular
- 20 Tumor,re-excision; Human pancreatic islet; Ovary, Cancer: (15799A1F) Poorly differentiated carcinoma; NCI\_CGAP\_Co14; LNCAP prostate cell line; NCI\_CGAP\_Lym12; Human Manic Depression Tissue; H. Lymph node breast Cancer; Human Adult Small Intestine; Human Umbilical Vein, Reexcision; Stratagene ovarian cancer (#937219); Human Thymus; NCI\_CGAP\_Ut1;
- 25 NCI\_CGAP\_Pr22; Stratagene fetal spleen (#937205); Human Uterine Cancer; Human Umbilical Vein Endothelial Cells, uninduced; Human Fetal Dura Mater; Stratagene pancreas (#937208); Stromal cell TF274; NCI\_CGAP\_Gas4; Human Adult Testes, Large Inserts, Reexcision; Ovary, Normal: (9805C040R); Human Hippocampus; Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma; Stratagene
- 30 endothelial cell 937223; Ovary, Cancer: (4004576 A8); NCI\_CGAP\_Br2; Human Chondrosarcoma; Human Thymus; Synovial Fibroblasts (control); Human Thymus Stromal Cells; Human Whole Six Week Old Embryo; Rejected Kidney, lib 4;

Stratagene liver (#937224); Smooth muscle, serum induced, re-exc; Colon Tumor; 12  
 Week Old Early Stage Human; Human Placenta; Normal colon; NCI\_CGAP\_GC4;  
 Dendritic cells, pooled; Human Synovial Sarcoma; Primary Dendritic cells, frac 2;  
 Human Osteoclastoma; Human Microvascular Endothelial Cells, fract. A; Hodgkin's  
 5 Lymphoma II; NCI\_CGAP\_Lu5; normalized infant brain cDNA;  
 Soares\_parathyroid\_tumor\_NbHPA; Soares melanocyte 2NbHM; Colon Tumor II;  
 Soares\_total\_fetus\_Nb2HF8\_9w and Soares infant brain 1NIB.

Polynucleotides and polypeptides of the invention are useful as reagents for  
 differential identification of the tissue(s) or cell type(s) present in a biological sample  
 10 and for diagnosis of diseases and conditions which include but are not limited to  
 immune cells (e.g. neutrophils and T-cells), cells of the epidermis (e.g. epithelial  
 cells, dendritic cells, and melanocytes), and neuronal cells. Similarly, polypeptides  
 and antibodies directed to these polypeptides are useful in providing immunological  
 probes for differential identification of the tissue(s) or cell type(s). For a number of  
 15 disorders of the above tissues or cells (particularly of the immune, integumentary,  
 central and peripheral nervous systems) expression of this gene at significantly higher  
 or lower levels may be routinely detected in certain tissues or cell types (e.g.,  
 cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial  
 fluid and spinal fluid) or another tissue or sample taken from an individual having  
 20 such a disorder, relative to the standard gene expression level, i.e., the expression  
 level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in immune tissue (e.g., neutrophils and T-cells)  
 indicates that polypeptides and polynucleotides of the invention are useful for the  
 diagnosis and treatment of a variety of immune system disorders. Briefly, the  
 25 expression indicates a role in regulating the proliferation; survival; differentiation;  
 and/or activation of hematopoietic cell lineages, including blood stem cells.  
 Involvement in the regulation of cytokine production, antigen presentation, or other  
 processes indicates a usefulness for treatment of cancer (e.g. by boosting immune  
 responses). Expression in cells of lymphoid origin, indicates the natural gene product  
 30 would be involved in immune functions.

The tissue distribution also indicates polynucleotides and polypeptides  
 corresponding to this gene would be useful for the detection, treatment, and/or



prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. For example, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 4

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gb|AAB86925.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "(AF023657) endo-alpha-D-mannosidase [Rattus norvegicus]" A partial alignment demonstrating the observed homology is shown immediately below.

30

```
>gb|AAB86925.1| (AF023657) endo-alpha-D-mannosidase [Rattus norvegicus]
>sp|O35390|O35390 ENDO-ALPHA-D-MANNOSIDASE.
Length = 451
```

## Plus Strand HSPs:

Score = 507 (178.5 bits), Expect = 7.9e-48, P = 7.9e-48  
 Identities = 90/123 (73%), Positives = 99/123 (80%), Frame = +1

5 Q: 403 DFQKSDRINSETNTKLNKLSVEITMKPSKASXXXXXXXXXXXXXHVFFYYSWYGNPQFDGK 582  
 DFQ+SDRI+ ETNTK+LK +T+ P +AS H FFYSWYGNPQFDGK  
 10 S: 49 DFQKSDRIDMETNTKDLKGAGVTVHPRASEVNLEELPPLNYFVHAFYYSWYGNPQFDGK 108

Q: 583 YIHWNHPVXEHWDPRIAKNYPQGRHNPXDDIGXSFYPELGSYSSRDPSVIETHMRQMRSA 762  
 Y+HWNHPV EHWDPRIAKNYPQGRH+P DDIG SFYPELGSYSSRDPSVIETHM+QMRSA  
 15 S: 109 YVHWNHPVLEHWDPRIAKNYPQGRHSPDDIGSSFYPELGSYSSRDPSVIETHMKQMRSA 168

Q: 763 SIG 771  
 SIG  
 15 S: 169 SIG 171

The segment of gb|AAB86925.1| that is shown as "S" above is set out in the  
 20 sequence listing as SEQ ID NO: 111 Based on the structural similarity these  
 homologous polypeptides are expected to share at least some biological activities.  
 Such activities are known in the art, some of which are described elsewhere herein.  
 Assays for determining such activities are also known in the art, some of which have  
 been described elsewhere herein. Preferred polypeptides of the invention comprise a  
 25 polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID  
 NO: 112 which corresponds to the Q sequence in the alignment shown above (gaps  
 introduced in a sequence by the computer are, of course, removed). Moreover,  
 fragments and variants of these polypeptides (such as, for example, fragments as  
 described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or  
 30 99% identical to these polypeptides and polypeptides encoded by the polynucleotide  
 which hybridizes, under stringent conditions, to the polynucleotide encoding these  
 polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides  
 of the invention are also encompassed by the invention. Polynucleotides encoding  
 these polypeptides are also encompassed by the invention.

35 In specific embodiments, polypeptides of the invention comprise, or  
 alternatively consists of, an amino acid sequence selected from the group:  
 SIGTPRIAKNYPQGRHNPPDDIGSSFYPELASYSRDPSVIETH (SEQ ID NO:  
 113),  
 MRQMRSASIGVLALSWYPPDVNDENGEPTDNLVPTILDKAHKYNLKVTFHIE  
 40 PYSNRDDQNMKYKNVYIIDKYGNHPAFYRYKTKTGNALPMFYVYDSYITKP  
 EKWANLLTSGSRSIRNSPYDGLFIALLVEEKHKYDILQSGFDGIYTYFATNGF

TYGSSHQNWASLKLFCDKYNLIFIPSVGPGYIDTSIRPWNTQNTRNRINGKYY  
 EIGLSAALQDTPPA (SEQ ID NO: 114),  
 SIGTPRIAKNYPQGRHNPPDDIGSSFYPELASYSRRDPSVIETHMRQMRSASIG  
 VLALSWYPPDVNDENGEPTDNLVPTILDKAHKYNLKVTFHIEPYSNRDDQNM  
 5 YKNVKYIIDKYGNHPAFYRYKTKTGNALPMFYVYDSYITKPEKWANLLTTS  
 SRSIRNSPYDGLFIALLVEEKHKYDILQSGFDGIYTYFATNGFTYGSSHQNWAS  
 LKLFCDKYNLIFIPSVGPGYIDTSIRPWNTQNTRNRINGKYYEIGLSAALQDTP  
 PA (SEQ ID NO: 115),  
 PRIAKNYPQGRHNPPDDIGSSFYPELASYSRRDPSVIETHMRQMRSASIGVLAL  
 10 SWYPPDVNDENGEPTDNLVPTILDKAHKYNLKVTFHIEPYSNRDDQNM  
 VKYIIDKYGNHPAFYRYKTKTGNALPMFYVYDSYITKPEKWANLLTTS  
 RNSPYDGLFIALLVEEKHKYDILQSGFDGIYTYFATNGFTYGSSHQNWASLKL  
 FCDKYNLIFIPSVGPGYIDTSIRPWNTQNTRNRINGKYYEIGLSAALQDTPPA  
 (SEQ ID NO: 116),  
 15 EGTQIEKAVPKRTSNTVYLDYRPHKPGLYLELTRKWSEKYSKERATYALDRQ  
 LPVS (SEQ ID NO: 117), and  
 DFQKSDRINSETNTKNLKSVEITMKPSKASELNLDLPPLNNYLHVFYYSWYG  
 NPQFDGKYIHWNHPVLEHWDP (SEQ ID NO: 118). Moreover, fragments and  
 variants of these polypeptides (such as, for example, fragments as described herein,  
 20 polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to  
 these polypeptides and polypeptides encoded by the polynucleotide which hybridizes,  
 under stringent conditions, to the polynucleotide encoding these polypeptides ) are  
 encompassed by the invention. Antibodies that bind polypeptides of the invention are  
 also encompassed by the invention. Polynucleotides encoding these polypeptides are  
 25 also encompassed by the invention.

This gene is expressed primarily in the following tissues/cDNA libraries:  
 NCI\_CGAP\_GCB1 and to a lesser extent in Soares\_parathyroid\_tumor\_NbHPA;  
 Soares\_placenta\_8to9weeks\_2NbHP8to9W; Colon Tumor II; Soares fetal liver spleen  
 1NFLS; TEST1, Human adult Testis tissue; Human Adult Liver, subtracted;  
 30 NCI\_CGAP\_Ut3; Salivary Gland, Lib 2; NCI\_CGAP\_Co10; KMH2; HUMAN  
 JURKAT MEMBRANE BOUND POLYSOMES; Liver, Hepatoma; NTERA2,  
 control; Human Ovary; PC3 Prostate cell line; NCI\_CGAP\_Kid11; Normal colon; 12

Week Early Stage Human II, Reexcision; NCI\_CGAP\_GC6; Anergic T-cell;  
 Soares\_multiple\_sclerosis\_2NbHMSP; Human fetal heart, Lambda ZAP Express;  
 NCI\_CGAP\_Lu5; Keratinocyte; T cell helper II; Soares\_total\_fetus\_Nb2HF8\_9w;  
 Soares\_NFL\_T\_GBC\_S1; Soares\_fetal\_heart\_NbHH19W; Soares\_testis\_NHT and  
 5 Primary Dendritic Cells, lib 1.

Polynucleotides and polypeptides of the invention are useful as reagents for  
 differential identification of the tissue(s) or cell type(s) present in a biological sample  
 and for diagnosis of diseases and conditions which include but are not limited to  
 disorders of immune cells, liver, spleen, heart, colon, and/or testes. Similarly,  
 10 polypeptides and antibodies directed to these polypeptides are useful in providing  
 immunological probes for differential identification of the tissue(s) or cell type(s). For  
 a number of disorders of the above tissues or cells (particularly of the immune,  
 hepatic, splenic, cardiovascular, gastrointestinal, and/or reproductive systems)  
 expression of this gene at significantly higher or lower levels may be routinely  
 15 detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or  
 bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another  
 tissue or sample taken from an individual having such a disorder, relative to the  
 standard gene expression level, i.e., the expression level in healthy tissue or bodily  
 fluid from an individual not having the disorder.

20 Based on its homology to endo-alpha-D-mannosidase enzymes, this gene and  
 its encoded polypeptides may be useful for the diagnosis and treatment of disorders  
 related to incorrect folding and glycosylation of proteins. The protein may also be  
 useful for commercial use in the expression and production of recombinant proteins.  
 The gene, when expressed in certain cell types may allow for greater yields of  
 25 bioactive protein to be produced.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 5**

This gene is expressed primarily in the following tissues/cDNA libraries:  
 30 NCI\_CGAP\_HSC2; NCI\_CGAP\_Bm25 and to a lesser extent in NCI\_CGAP\_Ov37;  
 NCI\_CGAP\_Kid3; NCI\_CGAP\_Br16; NCI\_CGAP\_Ov31; NCI\_CGAP\_Bm20;  
 Stratagene endothelial cell 937223; H Macrophage (GM-CSF treated), re-excision;

- Human Fetal Kidney, Reexcision; NCI\_CGAP\_Kid5; Colon Tumor II; Colon Normal III; Soares\_NhHMPu\_S1; 7 Week Old Early Stage Human, subtracted; Bone Cancer; NCI\_CGAP\_Ov33; NCI\_CGAP\_Ov36; Human Colon Cancer, subtracted; NCI\_CGAP\_Ov26; NCI\_CGAP\_Br15; NCI\_CGAP\_Lu25; Human Fetal Brain;
- 5 NCI\_CGAP\_Lu26; Human placenta cDNA (TFujiwara); Lung, Cancer (4005313 A3); Invasive Poorly Differentiated Lung Adenocarcinoma;; Aorta endothelial cells + TNF-a; Human Primary Breast Cancer; Lung Carcinoma A549 TNFalpha activated; Breast Cancer cell line, MDA 36; Amniotic Cells - Primary Culture; Human endometrial stromal cells-treated with progesterone; Human Umbilical Vein,
- 10 Reexcision; Breast Cancer Cell line, angiogenic; Human Dermal Endothelial Cells,untreated; Human umbilical vein endothelial cells, IL-4 induced; Human Thymus; NCI\_CGAP\_CLL1; Human Whole Six Week Old Embryo; NCI\_CGAP\_Co3; Smooth muscle, serum induced,re-exc; CHME Cell Line,untreated; NCI\_CGAP\_GC4; Endothelial cells-control; HUMAN B CELL LYMPHOMA;
- 15 Human fetal heart, Lambda ZAP Express; Soares\_parathyroid\_tumor\_NbHPA; T cell helper II and Soares\_fetal\_heart\_NbHH19W.

- Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to
- 20 disorders of the brain, kidneys, colon, and endothelial cells (e.g. particularly as related to tumor growth and metastasis). Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells (particularly of the central nervous, renal, and gastrointestinal system)
- 25 expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily
- 30 fluid from an individual not having the disorder.

Based on expression in the brain, this gene and its encoded polypeptides may be useful for the detection, treatment, and/or prevention of neurodegenerative disease

states, behavioral disorders, or inflammatory conditions. For example, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, 5 trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene 10 product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival.

Based on expression in the kidney indicates that polypeptides and polynucleotides of the invention are useful in the treatment and/or detection of kidney 15 diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Furthermore, the protein may also be used 20 to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

25

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 6**

The translation product of this gene shares sequence homology with, as a non- 30 limiting example, the sequence accessible through the following database accession no. gb|AAA99891.1| (all information available through the recited accession number

is incorporated herein by reference) which is described therein as "  
prolylcarboxypeptidase [Homo sapiens]."

Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: 120 and SEQ ID NO: 119.

Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, an amino acid sequence selected from the group:

ADAEGDMGSAPWAPVLLLALGLRGLQAGARRAPDPGFQERFFQQLDHFNF  
ERFGNKTFPQRFLVSDRFWVRGEGPIFFYTGNEDVWAFANNSAFVAELAAE  
RGALLVFAEHRYYGKSLPFGAQSTQRGTRSC (SEQ ID NO: 121) and  
MGSAPWAPVLLLALGLRGLQAGARRAPDPGFQERFFQQLDHFNFERFGNK  
TFPQRFLVSDRFWVRGEGPIFFYTGNEDVWAFANNSXFVAELAAERGALLV  
FAEHRYYGKSLPFGAQSTQRGHTELLTVEQALADFAELLRALRRDLGAQDAP  
AIAFGGSYGGMLSAYLRMKYPHLVAGALAASAPVLAVAGLGDSNQFFRDVT  
ADFEGQSPKCTQGVREAFRQIKDLFLQGAYDTVRWEFGTCQPLSDEKDLTQL  
FMFARNAFTVLAMMDYPYPTDFLGLPANPVKVGCDRLLEAQRTGLRALA  
GLVYNASGSEHCYDIYRLYHSCADPTGCGTGPDARAWDYQACTEINLTFASN  
NVTDMFPDLPFTDELQRQYCLDTWGVWPRPDWLLTSFWGGDLRAASNIIFS  
GNLDPWAGGGIRNLSASVIAVTIQGGAHHLDRASHPEDPASVVEARKLEA  
TIIGEWVKAARREQPALRGGPRLSL (SEQ ID NO: 122). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%

identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding  
5 these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the following tissues/cDNA libraries:  
Human Eosinophils, testis, and immune cells (notably dendritic and macrophage cells) and to a lesser extent in Human Lung; NTERA2 teratocarcinoma cell line+retinoic acid (14 days); Synovial Fibroblasts (control); T Cell helper I; T cell  
10 helper II and Primary Dendritic Cells, lib 1.

Polynucleotides encoding said polypeptides are also encompassed by the invention. Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited  
15 to testicular, reproductive, and immune system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells (particularly of the reproductive system and immune system) expression of this gene at significantly higher or lower levels may be  
20 routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 Expression of this gene and its encoded polypeptides in the testis indicates that this gene may be useful for the diagnosis and treatment of male reproductive tract pathologies including infertility and testicular cancer. Expression of this gene and its encoded polypeptides in immune cells particularly macrophages and dendritic cells indicates that this gene may be useful for the treatment and diagnosis of disorders of  
30 the immune system such as autoimmune syndromes such as systemic lupus erythematosus and rheumatoid arthritis as well as immune deficiency syndromes and allergies. Furthermore, since these immune cells function as antigen presenting cells,



the gene and its protein may be useful for the treatment of cancer and other diseases where priming of immune system with specific disease antigens may prove useful.

The homology of this gene and its products to prolylcarboxypeptidases suggest that this novel gene encodes a protease which may be responsible for the catalytic conversion of inactive precursors to their active form or alternately destruction of active immune modulating molecules to inactive forms. The protease may be a specific target for small molecules that modulate proteolytic activities and thereby modulate immune function. In addition, expression of this gene product in the testis and testicular cancer tissue may implicate this gene product in normal testicular function. In addition, this gene product would be useful in the treatment of male infertility, and/or could be used as a male contraceptive. Therefore, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product would be useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications.

25

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 7**

The gene encoding the disclosed cDNA is believed to reside on chromosome 14 at cytogenetic locus 14q11.2-q12. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 14.

30

This gene is expressed primarily in fetal and cancerous tissues and to a lesser extent in a variety of normal tissues. Specifically, this transcript has been detected in

the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in Soares\_NhHMPu\_S1; Soares\_pregnant\_uterus\_NbHPU; NCI\_CGAP\_Co8; Soares\_senescent\_fibroblasts\_NbHSF; NCI\_CGAP\_Kid3; H. Frontal cortex,epileptic,re-excision; Keratinocyte; Soares\_parathyroid\_tumor\_NbHPA;

5 Soares melanocyte 2NbHM; Soares\_total\_fetus\_Nb2HF8\_9w; H. Epididymus, caput & corpus; Human Infant Brain; NCI\_CGAP\_Co3; Human Placenta; Soares retina N2b4HR; NCI\_CGAP\_Kid5; Soares ovary tumor NbHOT; Nine Week Old Early Stage Human; Soares\_fetal\_lung\_NbHL19W; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Soares placenta Nb2HP; Soares\_testis\_NHT; NCI\_CGAP\_GCB1; Soares fetal liver

10 spleen 1NFLS; Human Tongue, frac 2; Tongue Normal; Normal trachea; Human aorta polyA+ (TFujiwara); CD40 activated monocyte dendritic cells; NTERA2 teratocarcinoma cell line+retinoic acid (14 days); Palate normal; Human pancreatic islet; Ovary, Cancer: (15799A1F) Poorly differentiated carcinoma; Healing groin wound, 7.5 hours post incision; Synovial hypoxia; Synovial Fibroblasts (II1/TNF),

15 subt; Healing groin wound, 6.5 hours post incision; Breast, Normal: (4005522B2); NCI\_CGAP\_Gas4; Stratagene HeLa cell s3 937216; Spinal cord; NCI\_CGAP\_Br2; Hemangiopericytoma; Human Eosinophils; Soares breast 3NbHBst; H Macrophage (GM-CSF treated), re-excision; Human Fetal Lung III; Human Synovial Sarcoma; Human Fetal Heart; human tonsils; Human Neutrophil, Activated; Human Amygdala;

20 Human fetal heart, Lambda ZAP Express; Human Testes; NCI\_CGAP\_Lu5; Osteoblasts; Colon Normal III and Soares\_fetal\_heart\_NbHH19W.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to

25 cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or

30 bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the

standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The relative specificity of this transcript for fetal tissue and cancers indicates this protein may play a role in the regulation of cellular division, and may show utility  
5 in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. For example, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure  
10 to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain degenerative disorders, such as spinal muscular atrophy (SMA). Alternatively, this gene product may be involved in the pattern of cellular proliferation that accompanies early embryogenesis. Thus, aberrant expression of this gene product in tissues - particularly adult tissues - may correlate  
15 with patterns of abnormal cellular proliferation, such as found in various cancers. Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating,  
20 detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein would be useful in modulating the immune response to aberrant polypeptides, as may exist in  
25 proliferating and cancerous cells and tissues. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets  
30 for the above listed tissues.

In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various wound-healing models and/or tissue trauma.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 8

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.  
 10 gb|AAC36301.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "(AC004877) spondin-mucin-like; similar to P98167 (PID:g1711548)" A partial alignment demonstrating the observed homology is shown immediately below.

```

15 >gb|AAC36301.1| (AC004877) spondin-mucin-like; similar to P98167
    (PID:g1711548); details of intron/exon structure uncertain [Homo
    sapiens] >sp|O75851|O75851 WUGSC:H_DJ0751H13.1 PROTEIN (FRAGMENT).
    Length = 4123

20 Plus Strand HSPs:

    Score = 586 (206.3 bits), Expect = 1.3e-54, Sum P(2) = 1.3e-54
    Identities = 97/100 (97%), Positives = 97/100 (97%), Frame = +2

25 Q: 2 PDQECVLPWPSAWSSCSAPCGGGTMRHRTCEGGPGVAPCQAQDTEQRQECNLQPCPEC 181
    P QECVLPWPSAWSSCSAPCGGGTMRHRTCEGGPGVAPCQAQDTEQRQECNLQPCPEC
    S: 3880 PHQECVLPWPSAWSSCSAPCGGGTMRHRTCEGGPGVAPCQAQDTEQRQECNLQPCPEC 3939

30 Q: 182 PPGQVLSACATSCPCLCWLQPGAICVQEPQPGCGLEG 301
    PPGQVLSACATSCPCLCWLQPGAICVQEPQPGCGC G
    S: 3940 PPGQVLSACATSCPCLCWLQPGAICVQEPQPGCGCPGG 3979

    Score = 190 (66.9 bits), Expect = 4.7e-14, Sum P(2) = 4.7e-14
    Identities = 50/149 (33%), Positives = 63/149 (42%), Frame = +2

35 Q: 32 WSAWSSCSAPCGGGTMRHRTCEG-GPGVAPCQAQDT--EQRQECNLQPCPE--CPPGQV 196
    W+ W CS CG G R R GPG C T ++R+ CNL+ CPE CP G
    S: 3598 WAPWPCSRSCGVGQRRRLRAYRPPGPGHWCNPILTAYQERRFCNLACPEAGCPAGME 3657

40 Q: 197 LSACATSCPCLCWLQPGAICVQEP-CQPGCGLEGSCCTMARVCLPLPAPAPSILCXXX 373
    + CA CP C LQ G +C + CQ GC C +GS C+P+ C
    S: 3658 VVTCANRCPRRCSDLQEGIVCQDDQVCQKGCRCPKGSL-EQDGGCVPIGH-----CDCT 3710

45 Q: 374 XXXXXXXXXXXXXQGLCSPGTAPRCVCHCGAFSCS 478
    Q C+ C C G SC+
    S: 3711 DAQGHSWAPGSQHQDACN-----NCSCQAGQLSCT 3740
  
```

The segments of gb|AAC36301.1| that are shown as "S" above are set out in the sequence listing as SEQ ID NO: 123 and SEQ ID NO: 125 Based on the structural

similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: 124 and/or SEQ ID NO: 126 which correspond to the Q sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, an amino acid sequence selected from the group:

HEPDQECVLPWWSAWSSCSAPCGGGT (SEQ ID NO: 127),  
 MERHRTCEGGPGVAPCQAQDTEQRQECNLQPCPECPPGQVLSA  
 CATSCPCLCWHLQPGAICVQEPQPGCGCPGGQLLHNGTCVPPTACPTQHS  
 LPWGLTLTLEEQAQELPPGTVLTRNCTRCVCHGGAFSCSLVDCQECPLGKRG  
 SRWPRGSWGSASRRWR (SEQ ID NO: 128),  
 HEPDQECVLPWWSAWSSCSAPCGGGTMERHRTCEGGPGVAPCQAQDTEQR  
 QECNLQPCPECPPGQVLSACATSCPCLCWHLQPGAICVQEPQPGCGCPGGQ  
 LLHNGTCVPPTACPTQHSLPWGLTLTLEEQAQELPPGTVLTRNCTRCVCHG  
 GAFSCSLVDCQECPLGKGRSRWPRGSWGSASRRWR (SEQ ID NO: 129),  
 VPPGETWQQVAPGELGLCEQTCLEMNATKTQSNCSARASGVCVQPGHFRS  
 QAGPCVPEDHCECWHLGRPHLPGEWQEACESCLCLSGRPVCTQHCSPLTCA  
 QGEEMVLEPGSCCPSCRREAPEEQSPSCQLLTELNFTKGTCTYLDQVEVSYCS  
 GYCPSSSTHVMPEEPYLSQCDCCSYRLDPESPVRILNLRCLGGHTEPVVLPVI  
 HSCQCSSCQGTGFRHVAQAVLELLGSSDPPASASQCAGVTGRNHCTQPPDLIF  
 (SEQ ID NO: 130), and

PDQECVLPWPSAWSSCSAPCGGGTMERHRTCEGGPGVAPCQAQDTEQRQE  
 CNLQPCPECPPPGQVLSACATSCPCLCWLQPGAICVQEPCQPGCGCPGGQLL  
 HNGTCVPPTACPCTQHSLPWGLTLTLEEQAQELPPGTVLTRNCTRCVCHGGA  
 FSCSLVDCQECPLGKRGSRWPRGSWGSASRRRAWR (SEQ ID NO: 131).

- 5 Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind  
 10 polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

The gene encoding the disclosed cDNA is believed to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

- 15 This gene is expressed primarily in the following tissues/cDNA libraries:  
 NTERA2 teratocarcinoma cell line with retinoic acid (14 days); fetal heart and prostate.

- Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample  
 20 and for diagnosis of diseases and conditions which include but are not limited to cancer (for example, prostate cancer) and heart disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive, immune, and  
 25 cardiovascular systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily  
 30 fluid from an individual not having the disorder.

Based on expression in teratocarcinoma prostate and fetal heart, this gene and its encoded polypeptides may be useful for the diagnosis and treatment of

developmental conditions especially in the developing cardiovascular system (e.g., septal or valve defects of the heart). The gene may also be useful for the treatment of teratocarcinoma especially as a target for immune therapy where antibodies against the gene products are used as a therapy. Based on its homology to SCO spondin the gene may be involved in cell-cell interactions that mediate organ and tissue formation or neuron guidance.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 9

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: 132 and/or SEQ ID NO: 133. Also preferred are the polynucleotides encoding these polypeptides. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

The protein has homology to seven transmembrane protein present in the yeasts *S.cerevisiae* and *S.pombe*:

```

25 >gi|600466|emb|CAA58187.1|orf 00929 [Saccharomyces cerevisiae]
    >gi|1419938|emb|CAA99104.1|ORF YOL092w [Saccharomyces
    cerevisiae] >pir|S57377|S57377 probable membrane protein
    YOL092w - yeast (Saccharomyces cerevisiae)
    >sp|Q12010|Q12010 CHROMOSOME XV READING FRAME ORF
30 YOL092w.
    Length = 308

    Score = 94.8 bits (232), Expect = 6e-19
    Identities = 76/264 (28%), Positives = 122/264 (45%), Gaps = 60/264 (22%)

35 Query: 5 LSLWFLLGWIGGDSNLIQSFLADQLPLQTYTAVYYVLADLVMLTLYFYYKFRTRPSL-- 62
    LSL F++ W+ GD NL+G+ + L A YY +AD+++L +Y +P++
    Sbjct: 45 LSLFVVLWLAGDVFNLMGAVMQHLLSTMIILAAYYTVADIILLGQCLWYDNEEKPAVDP 104

40 Query: 63 ----LSAPINSVLLFLMGMACATPLLSAAGP-----VAAP-----RE 95
    + PIN +L + PLL++ G +AAP R
    Sbjct: 105 IHLSPANPINENVLHDFNE-QQPLNSQGQPNRIDEEMAAPSSDGNAGDDNLRVNSRN 163

```

Query: 96 AFRGRALLS-----VESGSKPFTRQEV--IGFVIGSISSVLY 130  
 + ++S VE S P ++ + + G +S++LY  
 Sbjct: 164 LIKDIFIVSGVVFVGFISWYVTVYCVNYTQPPVEDPSLPVPELQINWMAQIFGYLSALLY 223

5 Query: 131 LLSRLPQIRTNFLRKSTQGISYSLFALVMLGNTLYGLSVLLKNPEEGQSEGSYLLHHLPW 190  
 L SR+PQI NF RKS +GIS+ F LGNT + SV++ + + YL+ + W  
 Sbjct: 224 LGSRIPIQLLNFKRKSCGIFLFFLACLGNTTFIFSVIVIS-----LDWKYLIMNASW 278

10 Query: 191 LVGSLGVLLDITIISIQLVYRRS 214  
 LVGS+G L +D +I QF +Y+R+  
 Sbjct: 279 LVGSIGTLFMDFVIFSQFFIYKRN 302

15 Score = 34.0 bits (76), Expect = 1.1  
 Identities = 18/47 (38%), Positives = 29/47 (61%), Gaps = 1/47 (2%)

Query: 121 VIGSISSVLYLLSRLPQIRTNFLRKSTQGISYSLFALVMLGNTLYGL 167  
 + GSIS +++ +PQI NF RKS+ G+S LF ++ L ++ L  
 Sbjct: 16 ISGISISCIWIVFVPQIYENFYRKSSDGLSL-LFVVLWLAGDVFNL 61

20

>gi|1314162|emb|CAA97356.1| seven transmembrane protein  
 [Schizosaccharomyces pombe]  
 >gi|5542022|gb|AAD45180.1|L49134\_1 seven transmembrane  
 25 protein [Schizosaccharomyces pombe] >pir|T11590|T11590  
 hypothetical protein SPAC17C9.10 - fission yeast  
 (Schizosaccharomyces pombe) >sp|Q10482|YDFA\_SCHPO  
 HYPOTHETICAL 30.6 KD PROTEIN C17C9.10 IN CHROMOSOME I.  
 >sp|AAD45180|AAD45180 Seven transmembrane protein.  
 Length = 271

30

Score = 89.3 bits (218), Expect = 3e-17  
 Identities = 62/225 (27%), Positives = 101/225 (44%), Gaps = 18/225 (8%)

35 Query: 3 QALSLWFLLGWIGGDSNIGSFLADQLPLQTYTAVYYVLADLVMLTLYFYKFRTRPSL 62  
 +++S FL+ W+ GD N++GS + + YY++D +L +YY+++ +  
 Sbjct: 47 ESISDLFLIINLIGDFFNVLGSIIYGNVSSTVLVLSFYIYVSDSTLLMQIYYRKAARRI 106

40 Query: 63 LSA---PINSVLLFLMGMACATPLLSAAGPVAAPREAFR-----GRALLSVES 107  
 S P+ G+ + R+ F G ++S S  
 Sbjct: 107 ASREHEPLLQSRSLBEGLHAPIGKQIWWDRSLTRQQFGVMGCVVIVSTIVGNLIISAS 166

45 Query: 108 GSKPFTRQEVIGFVIGSISSVLYLLSRLPQIRTNFLRKSTQGISYSLFALVMLGNTLYGL 167  
 K F G ISSVLY +R+PQI N KST+G+S F L +GNT Y  
 Sbjct: 167 SDKSDDDLNAPFTTAGCISVVLYFCARIPQIIKNHKAKSTEGLSIIFVLASVGNTSYAF 226

Query: 168 SVLLKNPEEGQSEGSYLLHHLPLWVGLVLLDITIISIQLVYR 212  
 S+L+ + +Y +LPW++G+ + LD I QF+ YR  
 Sbjct: 227 SILVFPASDYL---NYTYANLPWILGAFSTIPLDIYIFYQFIKYR 268

50

Furthermore, the polypeptide encoded by this gene is predicted to have transmembrane domains which comprise the following amino acid sequences: TAVYYVLADLVMLTLYF (SEQ ID NO: 134), VLLFLMGMACATPLLSA (SEQ ID NO: 135), VIGFVIGSISSVLYLLS (SEQ ID NO: 136),  
 55 LFALVMLGNTLYGLSVL (SEQ ID NO: 137), and SLGVLLDITIISIQLV (SEQ ID NO: 138). Accordingly, preferred polypeptides comprise amino acid sequences predicted to reside outside the cell membrane (i.e. either in the extracellular or intracellular environment).



Such preferred polypeptides comprise, or alternatively consist of the following amino acid sequences: LIGSFLADQLPL (SEQ ID NO: 139),  
 YKFRTRPSLLSAPINSVLLFLMGMACATPLLSAAGPVAAPREAFRGRALLSVE  
 SGSKPFTR (SEQ ID NO: 140), LPQIRTNFLRKSTQGISY (SEQ ID NO: 141),  
 5 KNPEEGQSEGSYLLHHLPLWL (SEQ ID NO: 142), and RRSTAASELEPLLPS  
 (SEQ ID NO: 143). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the  
 10 polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the following tissues/cDNA libraries:  
 15 Human Fetal Kidney, Reexcision; Monocyte activated and to a lesser extent in Adipocytes, re-excision; Monocyte activated, re-excision; Human Hippocampus; Human Thymus Stromal Cells and Soares placenta Nb2HP.

Polynucleotides encoding said polypeptides are also encompassed by the invention. Polynucleotides and polypeptides of the invention are useful as reagents  
 20 for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to disorders of immune cells (e.g. monocytes and stromal cells), kidneys, and neuronal cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the  
 25 tissue(s) or cell type(s). For a number of disorders of the above tissues or cells (particularly of the immune, renal, and central nervous systems) expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample  
 30 taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Homology of the protein encoded by this gene to seven transmembrane domain proteins of yeast is highly suggestive that these proteins function as receptors and are responsible for cell-cell communications. Such seven transmembrane receptors may also function as entry points for viruses into the cell. Based on its  
5 expression in monocytes and kidney this gene and its encoded products may be useful for the diagnosis and treatment of disorders of immunity including autoimmune disorders such as systemic lupus erythematosus, lupus nephritis and rheumatoid arthritis as well as immune deficiency syndromes, allergies, asthma and malignancies or other dysplastic syndromes of the myeloid lineage.

10 The tissue distribution indicates polynucleotides and polypeptides corresponding to this gene would be useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. For example, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,  
15 Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including  
20 disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival.

25 The tissue distribution in kidney indicates that polypeptides and polynucleotides of the invention are useful in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilm's  
30 Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate

cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5

## FEATURES OF PROTEIN ENCODED BY GENE NO: 10

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gb|AAC27079.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "claudin-2 [Mus musculus]" A partial alignment demonstrating the observed homology is shown immediately below.

```

>gb|AAC27079.1| (AF072128) claudin-2 [Mus musculus] >sp|O88552|O88552
      CLAUDIN-2.
      Length = 230

Plus Strand HSPs:

Score = 496 (174.6 bits), Expect = 1.2e-46, P = 1.2e-46
Identities = 94/113 (83%), Positives = 98/113 (86%), Frame = +3

Q: 192 PSWKTSSYVGASIVTAVGFPSKGLWMECATHSTGITQCDIYSTLLGLPADIQAAQAMMVTX 371
    P+W+TSSYVGASIVTAVGFPSKGLWMECATHSTGITQCDIYSTLLGLPADIQAAQAMMVT
S: 28 PNWRTSSYVGASIVTAVGFPSKGLWMECATHSTGITQCDIYSTLLGLPADIQAAQAMMVT 87

Q: 372 XXXXXXXXXXXXVGMRCTVFCQESRAKDRVAVAGGVFFILGSLGFI PXAWN 530
    VVGMRCTVFCQ+SRKDRVAV GGVFFILG +LGFIP AAWN
S: 88 SAMSSLACIISVGMRCTVFCQDSRAKDRVAVVGGVFFILGGILGFIPVAWN 140

```

The segment of gb|AAC27079.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO: 144 Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID

40

NO: 145 which corresponds to the Q sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed). Also preferred are the polynucleotides encoding these polypeptides. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein,  
 5 polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are  
 10 also encompassed by the invention.

Claudin-2 is an integral membrane protein localized to tight junctions (Furuse, M., et al., J Cell Biol 1998 Jun 29;141(7):1539-50). Based on the sequence similarity with Claudin-2, the translation product of this clone is expected to share at least some biological activities with claudin-2 and other related proteins such as occludin. Such  
 15 activities are known in the art, some of which are described elsewhere herein (for example, cell-to-cell communication and cell-to-cell adhesion).

The polypeptide encoded by this gene is predicted to have transmembrane domains comprising amino acid sequences MVTSSAISLACIISVV (SEQ ID NO: 146), AVAGGVFFILGGLLGFI (SEQ ID NO: 147), and LGIISLFSLIAGIILC  
 20 (SEQ ID NO: 148).

Accordingly, preferred polypeptides of this gene product comprise, or alternatively consist of, the following amino acid sequences:  
 MASLGLQLVGYILGLLGTLVA (SEQ ID NO: 149),  
 MLLPSWKTSSYVGASIVTAVGFSKGLWMECATHSTGITQCDIYSTLLGLPADI  
 25 QAA SEQ ID NO: 150Q (SEQ ID NO: ), RCTVFCQESRAK (SEQ ID NO: 151),  
 HGILRDFYSPLVPDSMKFE (SEQ ID NO: 152), and  
 RNRSNYYDAYQAQPLATRSSPRPGQPPKVKSEFNSYSLTGYV (SEQ ID NO:  
 153). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%,  
 30 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind

polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in pancreas tumor and gall bladder, and to a lesser extent in colon tumors and breast cancer.

5 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to disorders of the pancreas (for example, diabetes and pancreatic cancer), disorders of the gall bladder (for example, gall stones, incontinence, and bladder cancer), disorders of the stomach and colon (for example, ulcers and colon cancer) and disorders of the mammary glands (for example, breast cancer). Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of exocrine organs and the gastrointestinal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based upon the elevated expression of this gene product in a variety of cancers - particularly of epithelial organs such as breast, colon, and pancreas - it may be a useful diagnostic and/or therapeutic for numerous cancers, possibly with an emphasis on those cancers of an epithelial origin. Similarly, based upon the expression in a variety of organs involved in metabolism and digestion, it may be useful in the diagnosis and/or treatment of such disorders as acute renal failure, diverticulitis, inflammatory bowel disease, pancreatitis, diabetes, and other metabolic dysfunctions.

30

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 11**

Preferred polypeptides of the invention comprise, or alternatively consist of, a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: 154. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 5 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

10 The translation product of this gene shares some sequence homology with various chains of the T-cell receptor, which are important in signaling between different cells of the immune system.

The gene encoding the disclosed cDNA is thought to reside on the X chromosome. Accordingly, polynucleotides related to this invention are useful as a 15 marker in linkage analysis for the X chromosome.

This gene is expressed primarily in the following tissues/cDNA libraries:  
Human Placenta; Soares placenta Nb2HP; Soares infant brain 1NIB and to a lesser extent in Soares\_pregnant\_uterus\_NbHPU; Monocyte activated; Dendritic cells, pooled; Human Chronic Synovitis; Rejected Kidney, lib 4; Human Adult  
20 Pulmonary, re-excision; normalized infant brain cDNA; Soares\_testis\_NHT; Stratagene placenta (#937225); Spinal Cord, re-excision; Monocyte activated, re-excision; Macrophage-oxLDL, re-excision; Human Placenta; Stratagene lung (#937210); NCI\_CGAP\_Kid5; Colon Tumor II; Soares\_NFL\_T\_GBC\_S1; Soares\_fetal\_heart\_NbHH19W; HPAS (human pancreas, subtracted);  
25 NCI\_CGAP\_Kid8; Human Placenta; Human Liver; NCI\_CGAP\_Ut3; Human adult small intestine, re-excision; Palate normal; Human Adipose Tissue, re-excision; NCI\_CGAP\_Pr3; Human Thymus; Macrophage-oxLDL; Human Placenta (re-excision); Spinal cord; Human Chondrosarcoma; Ulcerative Colitis; Human Gall Bladder; 12 Week Old Early Stage Human; Human T-Cell Lymphoma; Colon  
30 Normal II; Bone marrow; Human Bone Marrow, treated; NCI\_CGAP\_Lu5; Soares\_parathyroid\_tumor\_NbHPA and Soares\_fetal\_liver\_spleen\_1NFLS\_S1.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to inflammatory diseases and tumours. Such inflammatory diseases include of

5 inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis, scleroderma, idiopathic inflammatory myopathies, dermatomyositis, polymyositis, Sjogren's syndrome, systemic vaculitis, sarcoidosis, autoimmune hemolytic anemia, immune pancytopenia, paroxysmal nocturnal hemoglobinuria, autoimmune thrombocytopenia,

10 idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia, thyroiditis, Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis, diabetes mellitus, immune-mediated renal disease, glomerulonephritis, tubulointerstitial nephritis, demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, idiopathic polyneuropathy,

15 hepatobiliary diseases, infectious hepatitis A, B, C, D, E, nonhepatotropic viruses, autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, sclerosing cholangitis, inflammatory and fibrotic lung diseases, gluten-sensitive enteropathy, Whipple's disease, autoimmune or immune-mediated skin diseases allergic diseases of the lung such as eosinophilic pneumonias, idiopathic

20 pulmonary fibrosis and hypersensitivity pneumonitis transplantation associated diseases disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, central, and peripheral nervous systems, expression of this

25 gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an

30 individual not having the disorder.

Based on expression in myeloid cells including monocytes and dendritic cells this gene and its encoded polypeptides may be useful for modulation of immune

responses including the diagnosis and treatment of autoimmune diseases as well as immune deficiency syndromes allergies, inflammatory disease and asthma. The polypeptides may also be useful as a target for the treatment of myeloid malignancies and myeloid dysplasias. Since these immune cell types may also function as antigen presenting cells this gene may be useful for the activation of the antigen presenting process and thereby prove useful for the priming of the immune system against disease specific (for example, tumor) antigens. The tissue distribution indicates the polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis and treatment of a variety of immune system disorders. For example, the expression pattern indicates this gene and/or gene product may play a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness for treatment of cancer (e.g. by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it would also be useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma.

Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the



protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. For example, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain degenerative disorders, such as spinal muscular atrophy (SMA). Alternatively, this gene product may be involved in the pattern of cellular proliferation that accompanies early embryogenesis. Thus, aberrant expression of this gene product in tissues - particularly adult tissues - may correlate with patterns of abnormal cellular proliferation, such as found in various cancers. Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein would be useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 12**

Preferred polypeptides of the invention comprise, or alternatively consist of, a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: 155 and/or SEQ ID NO: 156. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

The gene encoding the disclosed cDNA is believed to reside on chromosome 16. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 16.

This gene is expressed primarily in colon and colon carcinoma, and to a lesser extent in a variety of epithelial and endothelial cell types.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to disorders of the colon (for example, colon cancer). Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the gastrointestinal tract, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based upon the observed tissue distribution, this gene product may be useful in the diagnosis and/or treatment of a variety of disorders, including colon cancer, inflammatory bowel disease, diverticulitis, fibrosis, angiogenesis, ischemia, coronary

artery disease, myocardial infarction, acute renal failure, metabolic disorders, immune system dysfunction, and other hematopoietic disorders.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 13

The gene encoding the disclosed cDNA is believed to reside on chromosome 15. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 15.

10 This gene is expressed primarily in brain and hematopoietic cells, and to a lesser extent in fetal heart.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to  
15 disorders of the brain (for example Alzheimer's disease), heart (for example, cardiovascular disease), and immune cells (for example, leukemia and autoimmune disorders). Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,  
20 particularly of the central nervous, cardiovascular, and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene  
25 expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based upon the elevated expression of this gene product in brain and hematopoietic cells, it may be useful in the diagnosis and/or treatment of hematopoietic disorders, immune system dysfunction, leukemias, inflammation,  
30 immune modulation, allergy, asthma, ARDS, susceptibility to infections, neurodegenerative disorders, Schizophrenia, dementias, learning disorders, vertigo, impaired cognition, and loss of memory. Similarly, expression of this gene product in

fetal heart indicates that it may play a role in normal cardiac function, and may be useful in the diagnosis and treatment of cardiovascular disorders, coronary occlusions, myocardial infarction, heart fibrosis, arrhythmias, and impaired circulation or blood pressure disease.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 14

The gene encoding the disclosed cDNA is believed to reside on chromosome  
10 2. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 2.

The gene product encoded by this gene is predicted to be a Type I A transmembrane protein. Accordingly, preferred polypeptides comprise the predicted amino terminal signal sequence (MKILVAFLVLTIFGIQSHG SEQ ID NO:157)),  
15 the predicted extracellular domain  
(YEVFNIIISPSNNGGNVQETVTIDNEKNTAIIHAGSCSSTTIFDYKHGYIASRV  
LSRRACFILKMDHQNIPPLNNLQWYIYEKQALDNMFSSKYTWVKYNPLESLI  
KDVDWFLLGSPIEKLCKHIPLYKGEVVENTHNVGAGGCAK (SEQ ID  
NO:158)), and the predicted transmembrane domain (AGLLGILGISICADIHV (SEQ  
20 ID NO:159)). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind  
25 polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention. This gene is expressed primarily in stomach and to a lesser extent in lung and fetal heart.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample  
30 and for diagnosis of diseases and conditions which include but are not limited to disorders of the gastrointestinal organs (e.g. stomach), lungs, and heart. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing

immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the gastrointestinal and cardiovascular systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and  
5 wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based upon the elevated expression of this gene in stomach, it may be useful  
10 in the diagnosis and/or treatment of digestive disorders, stomach cancer, ulcers, metabolic disorders, and eating disorders. Similarly, elevated expression of this gene product in lung and fetal heart suggest that it also may be useful in cardiac and respiratory disorders such as asthma, ARDS, lung fibrosis, cardiovascular disease, myocardial infarction, arrhythmias, improving the breathing patterns of premature or  
15 newborn infants, microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional  
20 supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 15**

25 The gene encoding the disclosed cDNA is believed to reside on chromosome 14. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 14.

The protein product of this gene has marked similarity to cytoplasmic dynein heavy chain from the Norway Rat (*Rattus norvegicus*); identified by accession  
30 dbj|BAA02996.1. A partial alignment (generated by the program BLASTX) with this sequence is shown below:

```

>dbj|BAA02996.1| cytoplasmic dynein heavy chain [Rattus norvegicus]
>pir|A38905|A38905 dynein heavy chain, cytosolic - rat
>sp|P38650|DYHC_RAT DYNEIN HEAVY CHAIN, CYTOSOLIC (DYHC) (MAP 1C).
>gb|AAA16065.1| dynein heavy chain [Homo sapiens] {SUB 1882-2022}
5 >gb|AAC52796.1| dynein heavy chain [Rattus norvegicus] {SUB
1880-1959} >gb|AAC50701.1| dynein heavy chain [Homo sapiens] {SUB
1880-1956}
Length = 4644

10 Plus Strand HSPs:

Score = 385 (176.4 bits), Expect = 2.5e-105, Sum P(3) = 2.5e-105
Identities = 73/74 (98%), Positives = 74/74 (100%), Frame = +2

15 Query: 446 QGRQNISPDKIPWSALKTLMAQSIYGGGRVDNEFDQRLNTFLERLFTTRSFDFSEFKLACK 625
+GRQNISPDKIPWSALKTLMAQSIYGGGRVDNEFDQRLNTFLERLFTTRSFDFSEFKLACK
Sbjct: 4226 KGRQNISPDKIPWSALKTLMAQSIYGGGRVDNEFDQRLNTFLERLFTTRSFDFSEFKLACK 4285

20 Query: 626 VDGHKDIQMPDGIR 667
VDGHKDIQMPDGIR
Sbjct: 4286 VDGHKDIQMPDGIR 4299

Score = 311 (142.5 bits), Expect = 2.5e-105, Sum P(3) = 2.5e-105
Identities = 56/58 (96%), Positives = 58/58 (100%), Frame = +2

25 Query: 47 QSPNERARLYFLLAWFHAIQERLRYAPLGWSKKYEFGESDLRSACDVTWLDLDTAK SEQ ID NO:
161220
+SPNERARLYFLLAWFHA+IQERLRYAPLGWSKKYEFGESDLRSACDVTWLDLDTAK
30 Sbjct: 4169 KSPNERARLYFLLAWFHAVIQERLRYAPLGWSKKYEFGESDLRSACDVTWLDLDTAK 4226

Score = 188 (86.1 bits), Expect = 2.5e-105, Sum P(3) = 2.5e-105
Identities = 35/36 (97%), Positives = 35/36 (97%), Frame = +3

35 Query: 768 RREEFVQWVELLPDTQTPSWLGLPNNAERVLLTTQG 875
RREEFVQWVELLPD QTPSWLGLPNNAERVLLTTQG
Sbjct: 4299 RREEFVQWVELLPDAQTPSWLGLPNNAERVLLTTQG 4334

Score = 36 (16.5 bits), Expect = 1.7e-84, Sum P(3) = 1.7e-84
Identities = 5/11 (45%), Positives = 8/11 (72%), Frame = +3

40 Query: 789 WVLELLPDTQTP 821
W+ L+P T +P
Sbjct: 4385 WLHLIPQTLSP 4395

```

45 Dynein is known to be involved in microtubule-dependent motility.

This gene is expressed primarily in the following tissues/cDNA libraries:  
Human Brain, Striatum; Nine Week Old Early Stage Human and to a lesser extent in  
Smooth muscle-ILb induced; H. Whole Brain #2, re-excision; Human Adipose  
Tissue, re-excision; Jurkat T-cell G1 phase; Human Testes Tumor, re-excision;  
50 Dendritic cells, pooled and NCI\_CGAP\_Mel15.

Polynucleotides and polypeptides of the invention are useful as reagents for  
differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include but are not limited to  
disorders of the brain, testes, smooth muscle, and immune cells. Similarly,  
55 polypeptides and antibodies directed to these polypeptides are useful in providing  
immunological probes for differential identification of the tissue(s) or cell type(s). For

a number of disorders of the above tissues or cells, particularly of the central nervous, reproductive, immune, and skeletomuscular systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and similarity to rat dynein suggest that the protein product of this gene might be useful in diagnosis and/or treatment of cancer and other proliferative disorders. For example, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain degenerative disorders, such as spinal muscular atrophy (SMA). Alternatively, this gene product may be involved in the pattern of cellular proliferation that accompanies early embryogenesis. Thus, aberrant expression of this gene product in tissues - particularly adult tissues - may correlate with patterns of abnormal cellular proliferation, such as found in various cancers. Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein would be useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Moreover, expression in the brain indicates polynucleotides and polypeptides corresponding to this gene would be useful for the detection, treatment, and/or prevention of neurodegenerative disease states. For example, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 16**

25

This gene is expressed primarily in the following tissues/cDNA libraries: Human Adult Testes, Large Inserts, Reexcision and to a lesser extent in Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Soares breast 2NbHBst; Soares adult brain N2b4HB55Y; NCI\_CGAP\_Ut2; Human Osteoblasts II; Human adult testis, large inserts; PC3 Prostate cell line; Brain frontal cortex; Ovary, Cancer(4004650 A3): Well-Differentiated Micropapillary Serous Carcinoma; Primary Dendritic cells, frac 2; Osteoblasts and Soares\_testis\_NHT.



Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to disorders of the testes, liver, spleen, brain, and/or bones. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells (particularly of the reproductive, hepatic, splenic, immune, skeletal, and central nervous systems) expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on its expression in testis and ovarian cancers, this gene and its encoded products may be useful for the diagnosis and treatment of germ line disorders including sterility and testicular or ovarian cancers. The gene products may also be used as a target for immune therapy for treatment of such cancers. The gene may also prove useful for maintaining germ-cell lines and for culturing such cells in vitro. In addition, expression of this gene product in the testis may implicate this gene product in normal testicular function. In addition, this gene product would be useful in the treatment of male infertility, and/or could be used as a male contraceptive. Therefore, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product would be useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles

in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications.

The tissue distribution indicates polynucleotides and polypeptides corresponding to this gene would be useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. For example, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival.

The tissue distribution also indicates the polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis and treatment of a variety of immune system disorders. For example, the expression pattern indicates this gene and/or gene product may play a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness for treatment of cancer (e.g. by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it would also be useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue

injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 17**

15

This gene is expressed primarily in ovarian tumors.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to ovarian cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the human reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based upon the specific expression of this gene product in ovarian tumors, it may be useful in the diagnosis and/or treatment of ovarian cancer and reproductive disorders.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 18**

This gene is expressed primarily in the hippocampus, particular from  
5 Alzheimer's patients.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to neurological disorders (for example, Alzheimer's disease). Similarly, polypeptides  
10 and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or  
15 bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based upon the specific expression of this gene product in hippocampus -  
20 particularly derived from Alzheimer's patients - polypeptides and polynucleotides of the invention may be useful in the diagnosis and/or treatment of neurodegenerative disorders, such as Alzheimer's, schizophrenia, ALS, and Parkinson's, as well as in the treatment or diagnosis of memory deficits, impaired cognition, and learning disorders. Moreover tissue distribution in the brain also indicates polynucleotides and  
25 polypeptides corresponding to this gene may be useful for the detection, treatment, and/or prevention of additional neurodegenerative disease states, behavioral disorders, or inflammatory conditions. For example, the uses include, but are not limited to the detection, treatment, and/or prevention of Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia,  
30 trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS,

psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Table 1

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HDPTM61	PTA-871 10/26/99	pCMVSPORT 3.0	11	1921	1	1921	85	85	53	1	17	18	261
1	HDPTM61	PTA-871 10/26/99	pCMVSPORT 3.0	29	344	11	344	34	34	71	1	17	18	103
2	HUVFY29	PTA-871 10/26/99	Uni-ZAP XR	12	2577	1	2577	24	24	54	1	18	19	359
2	HUVFY29	PTA-871 10/26/99	Uni-ZAP XR	30	2615	9	2615	24	24	72	1	18	19	173
3	HTAGN51	PTA-871 10/26/99	Uni-ZAP XR	13	3665	1	2155	134	134	55	1	25	26	831
3	HTAGN51	PTA-871 10/26/99	Uni-ZAP XR	31	3599	29	2086	65	65	73	1	25	26	886
4	HPJEZ38	PTA-871 10/26/99	Uni-ZAP XR	14	4603	1	4603	152	152	56	1	25	26	133
4	HPJEZ38	PTA-871 10/26/99	Uni-ZAP XR	32	1187	1	1187	226	226	74	1	25	26	209
4	HPJEZ38	PTA-871 10/26/99	Uni-ZAP XR	33	1476	41	819		1366	75	1	1	2	81
5	HUVFB80	PTA-871 10/26/99	Uni-ZAP XR	15	1190	1	1190	28	28	57	1	17	18	123

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
5	HUVFB80	PTA-871 10/26/99	Uni-ZAP XR	34	674	1	674	21	21	76	1	17	18	123
6	HFIDQ92	PTA-871 10/26/99	pSport1	16	1699	366	1699			58	1			0
6	HFIDQ92	PTA-871 10/26/99	pSport1	35	1680	1	1680	31	31	77	1	21	22	492
6	HFIDQ92	PTA-871 10/26/99	pSport1	36	593	15	593	20	20	78	1	21	22	128
7	HKABW11	PTA-871 10/26/99	pCMVSPORT 2.0	17	2437	1	2437	75	75	59	1	28	29	105
7	HKABW11	PTA-871 10/26/99	pCMVSPORT 2.0	37	2755	374	2755	424	424	79	1	28	29	105
8	HHFLH45	PTA-871 10/26/99	Uni-ZAP XR	18	1762	1	1762	224	224	60	1	31	32	89
8	HHFLH45	PTA-871 10/26/99	Uni-ZAP XR	38	501	1	501	217	217	80	1	31	32	89
8	HHFLH45	PTA-871 10/26/99	Uni-ZAP XR	39	847	1	847		428	81	1	1	2	79
9	HFKLE15	PTA-871 10/26/99	Uni-ZAP XR	19	1482	1	1482	205	205	61	1	19	20	226
9	HFKLE15	PTA-871 10/26/99	Uni-ZAP XR	40	1550	1	1550	269	269	82	1	19	20	334

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
10	HTPIH83	PTA-871 10/26/99	Uni-ZAP XR	20	1481	1	1481	118	118	62	1	24	25	230
10	HTPIH83	PTA-871 10/26/99	Uni-ZAP XR	41	530	1	530	111	111	83	1	24	25	140
10	HTPIH83	PTA-871 10/26/99	Uni-ZAP XR	42	1046	1	688		951	84	1	1	2	86
11	HMSOW51	PTA-871 10/26/99	Uni-ZAP XR	21	1865	1	1865	57	57	63	1	19	20	399
11	HMSOW51	PTA-871 10/26/99	Uni-ZAP XR	43	1754	73	1754	126	126	85	1	19	20	399
12	HUCNC61	PTA-871 10/26/99	pSport1	22	2331	1	2331	181	181	64	1	31	32	331
13	HIDAF73	PTA-871 10/26/99	pSport1	23	2277	1	2277	198	198	65	1	32	33	470
13	HIDAF73	PTA-871 10/26/99	pSport1	44	263	1	263		46	86	1	14	15	27
13	HIDAF73	PTA-871 10/26/99	pSport1	45	2135	1512	2135		2	87	1	1	2	485
14	HNSAA27	PTA-871 10/26/99	pSport1	24	811	1	811	37	37	66	1	20	21	184
14	HNSAA27	PTA-871 10/26/99	pSport1	46	755	1	755	64	64	88	1	20	21	184



Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
15	HWBAO29	PTA-871 10/26/99	pCMVSPORT 3.0	25	1495	1	1495		2	67	1	1	2	120
15	HWBAO29	PTA-871 10/26/99	pCMVSPORT 3.0	47	733	1	733	47	47	89	1	18	19	101
15	HWBAO29	PTA-871 10/26/99	pCMVSPORT 3.0	48	495	1	495		322	90	1	1	2	50
16	HTLJC07	PTA-871 10/26/99	Uni-ZAP XR	26	1251	690	1251	851	851	68	1	19	20	133
16	HTLJC07	PTA-871 10/26/99	Uni-ZAP XR	49	559	1	559	169	169	91	1	19	20	130
16	HTLJC07	PTA-871 10/26/99	Uni-ZAP XR	50	898	1	898	239	239	92	1	19	20	184
17	HOFMA42	PTA-871 10/26/99	pCMVSPORT 2.0	27	595	1	594	32	32	69	1	28	29	37
17	HOFMA42	PTA-871 10/26/99	pCMVSPORT 2.0	51	612	1	612	37	37	93	1	28	29	37
18	HAVUR23	PTA-871 10/26/99	Other	28	451	1	451	30	30	70	1	20	21	77
18	HAVUR23	PTA-871 10/26/99	Other	52	272	1	272	35	35	94	1	20	21	77

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related  
5 DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits  
10 contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq."  
15 and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is  
20 identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal  
25 peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

30 SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently

accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also

5 hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1.

10 Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the

15 actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the

20 generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods.

25 The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

30 The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed

herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a deposited clone, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

Table 2 provides predicted epitopes contained in certain embodiments of the invention and polynucleotide sequences that may be disclaimed according to certain embodiments of the invention. The first column refers to each "Gene #" described above in Table 1. The second column provides the sequence identifier, "NT SEQ ID NO:X", for polynucleotide sequences disclosed in Table 1. The third column provides the sequence identifier, "AA SEQ ID NO:Y", for polypeptide sequences disclosed in Table 1. The fourth column provides a unique integer "ntA" where "ntA" is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X, and the fifth column provides a unique integer "ntB" where "ntB" is any integer between 15 and the final nucleotide of SEQ ID NO:X, where both ntA and ntB correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where ntB is greater than or equal to a + 14. For each of the polynucleotides shown as SEQ ID NO:X, the uniquely defined integers can be substituted into the general formula of a-b, and used to describe polynucleotides which may be preferably excluded from the invention. Column 6 lists residues comprising predicted epitopes contained in the polypeptides encoded by each of the preferred ORFs (SEQ ID NO:Y). Identification of potential immunogenic regions was performed according to the method of Jameson and Wolf ((1988) CABIOS, 4; 181-186); specifically, the Genetics Computer Group (GCG) implementation of this algorithm, embodied in the program PEPTIDESTRUCTURE

(Wisconsin Package v10.0, Genetics Computer Group (GCG), Madison, Wisc.). This method returns a measure of the probability that a given residue is found on the surface of the protein. Regions where the antigenic index score is greater than 0.9 over at least 6 amino acids are indicated in Table 2 as "Predicted epitopes".

- 5 Polypeptides of the invention may possess one, two, three, four, five or more antigenic epitopes comprising residues described in Table 2. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly.

- 10 Table 3 summarizes the expression profile of polynucleotides corresponding to the clones disclosed in Table 1. The first column provides a unique clone identifier, "Clone ID", for a cDNA clone related to each contig sequence disclosed in Table 1. Column 2, "Library Code(s)" shows the expression profile of tissue and/or cell line libraries which express the polynucleotides of the invention. Each Library
- 15 Code in column 2 represents a tissue/cell source identifier code corresponding to the Library Code and Library description provided in Table 5. Expression of these polynucleotides was not observed in the other tissues and/or cell libraries tested. One of skill in the art could routinely use this information to identify tissues which show a predominant expression pattern of the corresponding polynucleotide of the invention
- 20 or to identify polynucleotides which show predominant and/or specific tissue expression.

- Table 4, column 1, provides a nucleotide sequence identifier, "SEQ ID NO:X," that matches a nucleotide SEQ ID NO:X disclosed in Table 1, column 5. Table 4, column 2, provides the chromosomal location, "Cytologic Band or
- 25 Chromosome," of polynucleotides corresponding to SEQ ID NO:X. Chromosomal location was determined by finding exact matches to EST and cDNA sequences contained in the NCBI (National Center for Biotechnology Information) UniGene database. Given a presumptive chromosomal location, disease locus association was determined by comparison with the Morbid Map, derived from Online Mendelian
- 30 Inheritance in Man (Online Mendelian Inheritance in Man, OMIM™. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine

(Bethesda, MD) 2000. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>. If the putative chromosomal location of the Query overlapped with the chromosomal location of a Morbid Map entry, the OMIM reference identification number of the morbid map entry is provided in Table 4, column 3, labelled "OMIM Reference(s)."

- 5 A key to the OMIM reference identification numbers is provided in Table 6.

Table 5 provides a key to the Library Code disclosed in Table 3. Column 1 provides the Library Code disclosed in Table 3, column 2. Column 2 provides a description of the tissue or cell source from which the corresponding library was derived. Library codes corresponding to diseased Tissues are indicated in column 3  
10 with the word "disease".

Table 6 provides a key to the OMIM reference identification numbers disclosed in Table 4, column 3. OMIM reference identification numbers (Column 1) were derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute for Genetic Medicine, Johns  
15 Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine, (Bethesda, MD) 2000. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>). Column 2 provides diseases associated with the cytologic band disclosed in Table 4, column 2, as determined using the Morbid Map database.

Table 2

Gene #	NT SEQ ID NO: X	AA SEQ ID NO: Y	nt A	nt B	Predicted Epitopes
1	11	53	1 - 1907	15 - 1921	Arg-63 to Gly-72, Glu-87 to Ala-97, Pro-125 to Asp-131.
1	29	71	1 - 330	15 - 344	Arg-63 to Gly-72, Glu-87 to Ala-97.
2	12	54	1 - 2563	15 - 2577	Asp-88 to Ala-96, Arg-141 to Asn-147, Lys-198 to His-205, Ser-217 to Glu-223, Pro-249 to Gly-254, His-289 to Phe-296, Ala-348 to Pro-359.
2	30	72	1 - 2601	15 - 2615	Asp-88 to Ala-96, Arg-131 to Trp-138.
3	13	55	1 - 3651	15 - 3665	Ser-165 to His-174, Met-196 to Asp-204, Lys-212 to Leu-218, Pro-277 to Leu-285, Pro-290 to Arg-298, Ser-402 to Ser-407, Trp-465 to Gly-470, His-698 to His-706, Asp-793 to Asn-801.
3	31	73	1 - 3585	15 - 3599	
4	14	56	1 - 4589	15 - 4603	Phe-59 to Lys-77, Lys-84 to Ser-89, Trp-110 to Tyr-120.
4	32	74	1 - 1173	15 - 1187	
4	33	75	1 - 1462	15 - 1476	His-9 to Ile-14, Tyr-58 to Phe-64, Thr-75 to Phe-81.
5	15	57	1 - 1176	15 - 1190	Tyr-51 to Thr-72, Arg-94 to Lys-110.
5	34	76	1 - 660	15 - 674	
6	16	58	1 - 1685	15 - 1699	
6	35	77	1 - 1666	15 - 1680	Arg-24 to Phe-31, Glu-46 to Pro-54, Gln-119 to His-125, Phe-209 to Gly-219, Pro-248 to Leu-255, Ser-317 to Asp-324, Pro-342 to Asp-348, Asp-375 to Leu-383, Arg-477 to Pro-482.
6	36	78	1 - 579	15 - 593	Arg-24 to Phe-31, Glu-46 to Pro-54, Gln-119 to Cys-128.
7	17	59	1 - 2423	15 - 2437	
7	37	79	1 - 2741	15 - 2755	

8	18	60	1 - 1748	15 - 1762	Pro-53 to Arg-59, Ala-64 to Cys-69.
8	38	80	1 - 487	15 - 501	
8	39	81	1 - 833	15 - 847	Pro-13 to Ser-19, Glu-25 to Glu-31, Pro-44 to Gly-53, Gly-74 to Arg-79.
9	19	61	1 - 1468	15 - 1482	Lys-55 to Ser-61, Ser-107 to Arg-114, Leu-143 to Gln-148, Asn-173 to Gly-181.
9	40	82	1 - 1536	15 - 1550	Lys-55 to Ser-61, Ser-107 to Arg-114.
10	20	62	1 - 1467	15 - 1481	Ser-29 to Ser-34, Ser-186 to Asp-196, Arg-206 to Ser-225.
10	41	83	1 - 516	15 - 530	Ser-29 to Ser-34.
10	42	84	1 - 1032	15 - 1046	
11	21	63	1 - 1851	15 - 1865	Val-29 to Val-37, Asp-71 to His-76, Gln-78 to Gly-84, Met-105 to His-110, Trp-117 to Asn-123, Lys-179 to Pro-187, Gly-218 to Asp-224, Leu-237 to Ala-243, Thr-256 to Asp-268, Ser-275 to Lys-280, Arg-308 to Glu-314, Glu-326 to Glu-332, Cys-343 to Asp-359.
11	43	85	1 - 1740	15 - 1754	Val-29 to Val-37, Asp-71 to His-76, Gln-78 to Gly-84, Met-105 to His-110, Trp-117 to Asn-123, Lys-179 to Pro-187, Gly-218 to Asp-224, Leu-237 to Ala-243, Thr-256 to Asp-268, Ser-275 to Lys-280, Arg-308 to Glu-314, Glu-326 to Glu-332, Cys-343 to Asp-359.
12	22	64	1 - 2317	15 - 2331	Arg-71 to Glu-79, Asn-114 to Gly-124, Arg-144 to Thr-156, Met-213 to Asp-219, His-233 to Phe-244, Phe-304 to Tyr-309.
13	23	65	1 - 2263	15 - 2277	Ser-32 to Leu-47, Tyr-53 to Gly-60, Leu-82 to Gln-87, Arg-106 to Ser-113, Glu-131 to Val-136, Arg-146 to Gly-153,



					Asp-169 to Gly-175, Ala-179 to Asp-198, Met-207 to Ser-212, Gln-244 to Glu-258, Glu-293 to Ser-299, Asp-303 to Ala-308, Glu-336 to Gln-343, Glu-430 to Ala-437.
13	44	86	1 - 249	15 - 263	Pro-8 to Arg-16.
13	45	87	1 - 2121	15 - 2135	Ser-47 to Leu-62, Tyr-68 to Gly-75, Leu-97 to Gln-102, Arg-121 to Ser-128, Glu-146 to Val-151, Arg-161 to Gly-168, Asp-184 to Gly-190, Ala-194 to Asp-213, Met-222 to Ser-227, Gln-259 to Glu-273, Glu-308 to Ser-314, Asp-318 to Ala-323, Glu-351 to Gln-358, Glu-445 to Ala-452.
14	24	66	1 - 797	15 - 811	Pro-29 to Val-36, Ser-112 to Trp-117.
14	46	88	1 - 741	15 - 755	Pro-29 to Val-36, Ser-112 to Trp-117.
15	25	67	1 - 1481	15 - 1495	Pro-14 to Ala-22, Gly-45 to Tyr-50, Phe-52 to Leu-57, Trp-67 to Ala-72, Arg-80 to Arg-85, Gly-95 to Trp-103, Ser-105 to Gln-113.
15	47	89	1 - 719	15 - 733	Arg-28 to Ser-44.
15	48	90	1 - 481	15 - 495	Lys-45 to Arg-50.
16	26	68	1 - 1237	15 - 1251	Leu-31 to Leu-39, Gly-59 to Gly-64, Ala-72 to Thr-89, Lys-116 to Lys-133.
16	49	91	1 - 545	15 - 559	Leu-31 to Leu-39, Gly-59 to Gly-64, Ala-72 to Thr-89, Lys-116 to Lys-130.
16	50	92	1 - 884	15 - 898	Leu-31 to Leu-39, Gly-59 to Gly-64, Ala-72 to Thr-89, Pro-177 to Tyr-184.
17	27	69	1 - 581	15 - 595	Met-1 to Ala-7.
17	51	93	1 - 598	15 - 612	Met-1 to Ala-7.
18	28	70	1 - 437	15 - 451	Gln-51 to Ser-59.
18	52	94	1 - 258	15 - 272	Gln-51 to Ser-59.

Table 3

Clone ID	Library Code(s)
HDPTM61	H0521 S0358 S0374
HUVFY29	H0012 H0013 H0024 H0026 H0046 H0050 H0063 H0083 H0087 H0100 H0124 H0135 H0144 H0261 H0306 H0356 H0417 H0486 H0497 H0520 H0521 H0522 H0529 H0543 H0544 H0545 H0546 H0547 H0550 H0551 H0553 H0599 H0610 H0617 H0618 H0623 H0624 H0628 H0638 H0644 H0650 H0667 H0672 H0711 L1290 S0022 S0027 S0032 S0045 S0134 S0152 S0192 S0194 S0206 S0208 S0210 S0358 S0426 S3014
HTAGN51	H0069 H0134 H0264 H0265 H0309 H0520 H0522 H0556 H0580 H0634 H0635 L1290 S0038
HPJEZ38	H0038 H0083 H0090 H0098 H0428 H0478 H0494 H0509 H0519 H0520 H0521 H0543 H0560 H0624 H0648 L1290 S0114 S0152 S0360 S0374
HUVFB80	H0100 H0149 H0178 H0181 H0204 H0266 H0295 H0305 H0318 H0381 H0412 H0422 H0483 H0484 H0521 H0529 H0543 H0545 H0587 H0590 H0620 H0623 H0633 H0638 H0646 H0656 H0690 H0698 L1290 S0045 S0134 S0278 S0358 S0360 S0420 S3014 T0049
HFIDQ92	H0024 H0033 H0038 H0052 H0059 H0060 H0087 H0141 H0144 H0196 H0249 H0253 H0254 H0255 H0257 H0265 H0306 H0309 H0318 H0341 H0412 H0423 H0424 H0441 H0445 H0457 H0478 H0484 H0486 H0494 H0521 H0522 H0539 H0540 H0542 H0543 H0544 H0545 H0547 H0549 H0550 H0551 H0556 H0559 H0561 H0585 H0587 H0607 H0616 H0617 H0618 H0622 H0633 H0638 H0647 H0656 H0657 H0658 H0659 H0661 H0670 H0672 H0673 H0674 H0682 H0685 L1290 S0003 S0027 S0040 S0044 S0051 S0052 S0112 S0126 S0144 S0192 S0210 S0212 S0222 S0250 S0328 S0330 S0344 S0354 S0356 S0358 S0380 S0388 S0432 S0470 S3012 S3014 S6028 T0006
HKABW11	H0024 H0038 H0050 H0135 H0144 H0264 H0333 H0380 H0457 H0494 H0520 H0547 H0549 H0553 H0586 H0587 H0599 H0628 H0638 H0646 H0660 H0662 H0694 H0696 H0707 L1290 S0010 S0031 S0126 S0194 S0222 S0242 S0278 S0310 S0330 S0358 S0456 T0010
HHFLH45	H0547 H0619 S0190
HFKLE15	H0051 H0551 H0620 L1290 S0002 S0342 S0426
HTPIH83	H0014 H0015 H0484 H0622 L1290 S0360
HMSOW51	H0011 H0014 H0030 H0031 H0052 H0063 H0090 H0122 H0170 H0251 H0270 H0309 H0318 H0333 H0355 H0436 H0457 H0488 H0506 H0521 H0529 H0539 H0545 H0553 H0555 H0575 H0580 H0581 H0590 H0607 H0644 H0647 H0650 H0662 H0670 H0674 H0682 H0690 H0691 H0706 L1290 S0002 S0026 S0031 S0116 S0134 S0142 S0260 S0280 S0300 S0330 S0344 S0354 S0360 S0364 S0426 T0010
HUCNC61	H0008 H0009 H0011 H0012 H0013 H0014 H0015 H0024 H0031 H0032 H0036 H0038 H0039 H0041 H0045 H0046 H0049 H0050 H0051 H0052 H0056 H0057 H0059 H0063 H0068 H0081 H0083 H0087 H0090 H0098 H0100 H0108 H0123 H0124 H0128 H0130 H0132 H0134 H0136 H0138 H0140 H0144 H0147 H0150 H0156 H0159 H0163 H0165 H0166 H0169 H0170 H0171 H0181 H0188 H0212 H0214 H0222 H0231 H0232 H0234 H0250 H0251 H0255 H0257 H0266 H0268 H0269 H0271 H0290 H0292 H0293 H0295 H0299 H0305 H0309 H0313 H0316 H0318 H0328 H0330 H0333 H0339 H0341 H0346 H0349 H0350 H0351 H0352 H0359 H0370 H0373 H0375 H0391 H0392 H0393 H0394 H0396 H0402 H0411 H0412 H0413 H0421 H0422 H0423 H0427 H0428 H0435 H0436 H0441 H0455 H0478 H0486 H0492 H0494 H0506 H0509 H0517 H0519 H0521 H0522 H0542 H0543 H0544 H0545 H0546 H0547 H0551 H0559 H0560 H0561 H0575 H0576 H0580 H0581 H0583 H0586 H0587 H0589 H0592 H0594 H0595 H0596 H0597 H0598 H0600 H0615 H0616 H0617 H0619 H0620

	H0622 H0623 H0624 H0625 H0626 H0633 H0634 H0635 H0638 H0643 H0645 H0646 H0648 H0650 H0651 H0653 H0656 H0657 H0658 H0659 H0660 H0661 H0662 H0664 H0665 H0667 H0668 H0670 H0672 H0676 H0682 H0684 H0687 H0690 L1290 S0003 S0007 S0010 S0013 S0022 S0026 S0027 S0028 S0031 S0032 S0037 S0040 S0044 S0045 S0046 S0049 S0050 S0051 S0114 S0116 S0118 S0126 S0132 S0134 S0142 S0144 S0146 S0148 S0150 S0182 S0190 S0192 S0194 S0206 S0210 S0214 S0218 S0222 S0276 S0278 S0280 S0282 S0316 S0318 S0330 S0334 S0342 S0354 S0356 S0358 S0360 S0366 S0368 S0374 S0376 S0378 S0380 S0390 S0406 S0420 S0422 S0424 S0430 S0456 S0468 S0470 S3012 S3014 S6024 T0002 T0003 T0006 T0008 T0039 T0040 T0041 T0048 T0049 T0060 T0067 T0068 T0069 T0082 T0104 T0109 T0110 T0115
HIDAF73	H0038 H0040 H0042 H0266 H0318 H0327 H0328 H0421 H0423 H0486 H0494 H0497 H0510 H0517 H0521 H0538 H0539 H0542 H0543 H0556 H0559 H0575 H0579 H0580 H0581 H0586 H0591 H0619 H0625 H0648 H0649 H0658 H0689 L1290 S0002 S0010 S0038 S0116 S0142 S0152 S0210 S0330 S0360 S0380 S6014 T0010 T0040
HNSAA27	L1290 S0434
HWBAO29	H0580 H0634 L1290
HTLJC07	H0522 H0618 L1290 S0001
HOFMA42	H0415
HAVUR23	S0414

**Table 4**

<b>SEQ ID NO: X</b>	<b>Cytologic Band or Chromosome:</b>	<b>OMIM Reference(s):</b>
17	14q11.2-q12	160760 182600 186880 190195 222700 600243 600792 601369 602086 602279
21	Xq12-q13.3	300011 300032 300127 301310 304040 305100 305450 308380 309605 311800 311870 312760 313700 314250 314580 314670

**Table 5**

<b>Library Code</b>	<b>Library Description</b>	<b>Disease</b>
H0008	Whole 6 Week Old Embryo	
H0009	Human Fetal Brain	
H0011	Human Fetal Kidney	
H0012	Human Fetal Kidney	
H0013	Human 8 Week Whole Embryo	
H0014	Human Gall Bladder	
H0015	Human Gall Bladder, fraction II	
H0024	Human Fetal Lung III	
H0026	Namalwa Cells	
H0030	Human Placenta	
H0031	Human Placenta	
H0032	Human Prostate	
H0033	Human Pituitary	
H0036	Human Adult Small Intestine	
H0038	Human Testes	
H0039	Human Pancreas Tumor	disease
H0040	Human Testes Tumor	disease
H0041	Human Fetal Bone	
H0042	Human Adult Pulmonary	
H0045	Human Esophagus, Cancer	disease
H0046	Human Endometrial Tumor	disease
H0049	Human Fetal Kidney	
H0050	Human Fetal Heart	
H0051	Human Hippocampus	
H0052	Human Cerebellum	
H0056	Human Umbilical Vein, Endo. remake	
H0057	Human Fetal Spleen	
H0059	Human Uterine Cancer	disease
H0060	Human Macrophage	
H0063	Human Thymus	
H0068	Human Skin Tumor	disease
H0069	Human Activated T-Cells	
H0081	Human Fetal Epithelium (Skin)	
H0083	HUMAN JURKAT MEMBRANE BOUND POLYSOMES	
H0087	Human Thymus	
H0090	Human T-Cell Lymphoma	disease
H0098	Human Adult Liver, subtracted	
H0100	Human Whole Six Week Old Embryo	
H0108	Human Adult Lymph Node, subtracted	
H0122	Human Adult Skeletal Muscle	
H0123	Human Fetal Dura Mater	
H0124	Human Rhabdomyosarcoma	disease
H0128	Jurkat cells, thiouridine activated	
H0130	LNCAP untreated	
H0132	LNCAP + 30nM R1881	
H0134	Raji Cells, cyclohexamide treated	
H0135	Human Synovial Sarcoma	
H0136	Supt Cells, cyclohexamide treated	
H0138	Activated T-Cells, 0 hrs.	

H0140	Activated T-Cells, 8 hrs.	
H0141	Activated T-Cells, 12 hrs.	
H0144	Nine Week Old Early Stage Human	
H0147	Human Adult Liver	
H0149	7 Week Old Early Stage Human, subtracted	
H0150	Human Epididymus	
H0156	Human Adrenal Gland Tumor	disease
H0159	Activated T-Cells, 8 hrs., ligation 2	
H0163	Human Synovium	
H0165	Human Prostate Cancer, Stage B2	disease
H0166	Human Prostate Cancer, Stage B2 fraction	disease
H0169	Human Prostate Cancer, Stage C fraction	disease
H0170	12 Week Old Early Stage Human	
H0171	12 Week Old Early Stage Human, II	
H0178	Human Fetal Brain	
H0181	Human Primary Breast Cancer	disease
H0188	Human Normal Breast	
H0196	Human Cardiomyopathy, subtracted	
H0204	Human Colon Cancer, subtracted	
H0212	Human Prostate, subtracted	
H0214	Raji cells, cyclohexamide treated, subtracted	
H0222	Activated T-Cells, 8 hrs, subtracted	
H0231	Human Colon, subtraction	
H0232	Human Colon, differential expression	
H0234	human colon cancer, metastatic to liver, differentially expressed	
H0249	HE7, subtracted by hybridization with E7 cDNA	
H0250	Human Activated Monocytes	
H0251	Human Chondrosarcoma	disease
H0253	Human adult testis, large inserts	
H0254	Breast Lymph node cDNA library	
H0255	breast lymph node CDNA library	
H0257	HL-60, PMA 4H	
H0261	H. cerebellum, Enzyme subtracted	
H0264	human tonsils	
H0265	Activated T-Cell (12hs)/Thiouridine labelledEco	
H0266	Human Microvascular Endothelial Cells, fract. A	
H0268	Human Umbilical Vein Endothelial Cells, fract. A	
H0269	Human Umbilical Vein Endothelial Cells, fract. B	
H0270	HPAS (human pancreas, subtracted)	
H0271	Human Neutrophil, Activated	
H0290	Human OB HOS treated (1 nM E2) fraction I	
H0292	Human OB HOS treated (10 nM E2) fraction I	
H0293	WI 38 cells	
H0295	Amniotic Cells - Primary Culture	
H0299	HCBA's differential consolidation	
H0305	CD34 positive cells (Cord Blood)	
H0306	CD34 depleted Buffy Coat (Cord Blood)	
H0309	Human Chronic Synovitis	disease
H0313	human pleural cancer	disease
H0316	HUMAN STOMACH	
H0318	HUMAN B CELL LYMPHOMA	disease
H0327	human corpus colosum	
H0328	human ovarian cancer	disease

H0330	HCBB's Subtractive (- mito genes)	
H0333	Hemangiopericytoma	disease
H0339	Duodenum	
H0341	Bone Marrow Cell Line (RS4,11)	
H0346	Brain-medulloblastoma	disease
H0349	human adult liver cDNA library	
H0350	Human Fetal Liver, mixed 10 & 14 week	
H0351	Glioblastoma	disease
H0352	wilm's tumor	disease
H0355	Human Liver	
H0356	Human Kidney	
H0359	KMH2 cell line	
H0370	H. Lymph node breast Cancer	disease
H0373	Human Heart	
H0375	Human Lung	
H0380	Human Tongue, frac 2	
H0381	Bone Cancer	disease
H0391	H. Meningioma, M6	
H0392	H. Meningioma, M1	
H0393	Fetal Liver, subtraction II	
H0394	A-14 cell line	
H0396	L1 Cell line	
H0402	CD34 depleted Buffy Coat (Cord Blood), re-excision	
H0411	H Female Bladder, Adult	
H0412	Human umbilical vein endothelial cells, IL-4 induced	
H0413	Human Umbilical Vein Endothelial Cells, uninduced	
H0415	H. Ovarian Tumor, II, OV5232	disease
H0417	Human Pituitary, subtracted VIII	
H0421	Human Bone Marrow, re-excision	
H0422	T-Cell PHA 16 hrs	
H0423	T-Cell PHA 24 hrs	
H0424	Human Pituitary, subt IX	
H0427	Human Adipose	
H0428	Human Ovary	
H0435	Ovarian Tumor 10-3-95	
H0436	Resting T-Cell Library,II	
H0441	H. Kidney Cortex, subtracted	
H0445	Spleen, Chronic lymphocytic leukemia	disease
H0455	H. Striatum Depression, subt	
H0457	Human Eosinophils	
H0478	Salivary Gland, Lib 2	
H0483	Breast Cancer cell line, MDA 36	
H0484	Breast Cancer Cell line, angiogenic	
H0486	Hodgkin's Lymphoma II	disease
H0488	Human Tonsils, Lib 2	
H0492	HL-60, RA 4h, Subtracted	
H0494	Keratinocyte	
H0497	HEL cell line	
H0506	Ulcerative Colitis	
H0509	Liver, Hepatoma	disease
H0510	Human Liver, normal	
H0517	Nasal polyps	
H0519	NTERA2, control	

H0520	NTERA2 + retinoic acid, 14 days	
H0521	Primary Dendritic Cells, lib 1	
H0522	Primary Dendritic cells, frac 2	
H0529	Myeloid Progenitor Cell Line	
H0538	Merkel Cells	
H0539	Pancreas Islet Cell Tumor	disease
H0540	Skin, burned	
H0542	T Cell helper I	
H0543	T cell helper II	
H0544	Human endometrial stromal cells	
H0545	Human endometrial stromal cells-treated with progesterone	
H0546	Human endometrial stromal cells-treated with estradiol	
H0547	NTERA2 teratocarcinoma cell line+retinoic acid (14 days)	
H0549	H. Epididymus, caput & corpus	
H0550	H. Epididymus, cauda	
H0551	Human Thymus Stromal Cells	
H0553	Human Placenta	
H0555	Rejected Kidney, lib 4	disease
H0556	Activated T-cell(12h)/Thiouridine-re-excision	
H0559	HL-60, PMA 4H, re-excision	
H0560	KMH2	
H0561	L428	
H0575	Human Adult Pulmonary, re-excision	
H0576	Resting T-Cell, re-excision	
H0579	Pericardium	
H0580	Dendritic cells, pooled	
H0581	Human Bone Marrow, treated	
H0583	B Cell lymphoma	disease
H0585	Activated T-Cells, 12 hrs, re-excision	
H0586	Healing groin wound, 6.5 hours post incision	disease
H0587	Healing groin wound, 7.5 hours post incision	disease
H0589	CD34 positive cells (cord blood), re-ex	
H0590	Human adult small intestine, re-excision	
H0591	Human T-cell lymphoma, re-excision	disease
H0592	Healing groin wound - zero hr post-incision (control)	disease
H0594	Human Lung Cancer, re-excision	disease
H0595	Stomach cancer (human), re-excision	disease
H0596	Human Colon Cancer, re-excision	
H0597	Human Colon, re-excision	
H0598	Human Stomach, re-excision	
H0599	Human Adult Heart, re-excision	
H0600	Healing Abdomen wound, 70&90 min post incision	disease
H0607	H. Leukocytes, normalized cot 50A3	
H0610	H. Leukocytes, normalized cot 5A	
H0615	Human Ovarian Cancer Reexcision	disease
H0616	Human Testes, Reexcision	
H0617	Human Primary Breast Cancer Reexcision	disease
H0618	Human Adult Testes, Large Inserts, Reexcision	
H0619	Fetal Heart	
H0620	Human Fetal Kidney, Reexcision	
H0622	Human Pancreas Tumor, Reexcision	disease
H0623	Human Umbilical Vein, Reexcision	
H0624	12 Week Early Stage Human II, Reexcision	



H0625	Ku 812F Basophils Line	
H0626	Saos2 Cells, Untreated	
H0628	Human Pre-Differentiated Adipocytes	
H0633	Lung Carcinoma A549 TNFalpha activated	disease
H0634	Human Testes Tumor, re-excision	disease
H0635	Human Activated T-Cells, re-excision	
H0638	CD40 activated monocyte dendritic cells	
H0643	Hep G2 Cells, PCR library	
H0644	Human Placenta (re-excision)	
H0645	Fetal Heart, re-excision	
H0646	Lung, Cancer (4005313 A3): Invasive Poorly Differentiated Lung Adenocarcinoma,	
H0647	Lung, Cancer (4005163 B7): Invasive, Poorly Diff. Adenocarcinoma, Metastatic	disease
H0648	Ovary, Cancer: (4004562 B6) Papillary Serous Cystic Neoplasm, Low Malignant Pot	disease
H0649	Lung, Normal: (4005313 B1)	
H0650	B-Cells	
H0651	Ovary, Normal: (9805C040R)	
H0653	Stromal Cells	
H0656	B-cells (unstimulated)	
H0657	B-cells (stimulated)	
H0658	Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma	disease
H0659	Ovary, Cancer (15395A1F): Grade II Papillary Carcinoma	disease
H0660	Ovary, Cancer: (15799A1F) Poorly differentiated carcinoma	disease
H0661	Breast, Cancer: (4004943 A5)	disease
H0662	Breast, Normal: (4005522B2)	
H0664	Breast, Cancer: (9806C012R)	disease
H0665	Stromal cells 3.88	
H0667	Stromal cells(HBM3.18)	
H0668	stromal cell clone 2.5	
H0670	Ovary, Cancer(4004650 A3): Well-Differentiated Micropapillary Serous Carcinoma	
H0672	Ovary, Cancer: (4004576 A8)	
H0673	Human Prostate Cancer, Stage B2, re-excision	
H0674	Human Prostate Cancer, Stage C, re-excision	
H0676	Colon, Cancer: (9808C064R)-total RNA	
H0682	Ovarian cancer, Serous Papillary Adenocarcinoma	
H0684	Ovarian cancer, Serous Papillary Adenocarcinoma	
H0685	Adenocarcinoma of Ovary, Human Cell Line, # OVCAR-3	
H0687	Human normal ovary(#9610G215)	
H0689	Ovarian Cancer	
H0690	Ovarian Cancer, # 9702G001	
H0691	Normal Ovary, #9710G208	
H0694	Prostate cancer (adenocarcinoma)	
H0696	Prostate Adenocarcinoma	
H0698	NK CellsYao20 IL2 treated for 48 hrs	
H0706	Human Adult Skeletal Muscle	
H0707	Stomach Cancer(S007635)	
H0711	Ovarian Cancer Cell Line(Xenograft) ES-2	
L1290	Soares adult brain N2b4HB55Y	
S0001	Brain frontal cortex	
S0002	Monocyte activated	

S0003	Human Osteoclastoma	disease
S0007	Early Stage Human Brain	
S0010	Human Amygdala	
S0013	Prostate	
S0022	Human Osteoclastoma Stromal Cells - unamplified	
S0026	Stromal cell TF274	
S0027	Smooth muscle, serum treated	
S0028	Smooth muscle, control	
S0031	Spinal cord	
S0032	Smooth muscle-ILb induced	
S0037	Smooth muscle, IL1b induced	
S0038	Human Whole Brain #2 - Oligo dT > 1.5Kb	
S0040	Adipocytes	
S0044	Prostate BPH	disease
S0045	Endothelial cells-control	
S0046	Endothelial-induced	
S0049	Human Brain, Striatum	
S0050	Human Frontal Cortex, Schizophrenia	disease
S0051	Human Hypothalamus, Schizophrenia	disease
S0052	neutrophils control	
S0112	Hypothalamus	
S0114	Anergic T-cell	
S0116	Bone marrow	
S0118	Smooth muscle control 2	
S0126	Osteoblasts	
S0132	Epithelial-TNF $\alpha$ and INF induced	
S0134	Apoptotic T-cell	
S0142	Macrophage-oxLDL	
S0144	Macrophage (GM-CSF treated)	
S0146	prostate-edited	
S0148	Normal Prostate	
S0150	LNCAP prostate cell line	
S0152	PC3 Prostate cell line	
S0182	Human B Cell 8866	
S0190	Prostate BPH, Lib 2, subtracted	
S0192	Synovial Fibroblasts (control)	
S0194	Synovial hypoxia	
S0206	Smooth Muscle- HASTE normalized	
S0208	Mesangial cell, frac 1	
S0210	Mesangial cell, frac 2	
S0212	Bone Marrow Stromal Cell, untreated	
S0214	Human Osteoclastoma, re-excision	disease
S0218	Apoptotic T-cell, re-excision	
S0222	H. Frontal cortex, epileptic, re-excision	disease
S0242	Synovial Fibroblasts (IL1/TNF), subt	
S0250	Human Osteoblasts II	disease
S0260	Spinal Cord, re-excision	
S0276	Synovial hypoxia-RSF subtracted	
S0278	H Macrophage (GM-CSF treated), re-excision	
S0280	Human Adipose Tissue, re-excision	
S0282	Brain Frontal Cortex, re-excision	
S0300	Frontal lobe, dementia, re-excision	
S0310	Normal trachea	

S0316	Human Normal Cartilage,Fraction I	
S0318	Human Normal Cartilage Fraction II	
S0328	Palate carcinoma	disease
S0330	Palate normal	
S0334	Human Normal Cartilage Fraction III	
S0342	Adipocytes,re-excision	
S0344	Macrophage-oxLDL, re-excision	
S0354	Colon Normal II	
S0356	Colon Carcinoma	disease
S0358	Colon Normal III	
S0360	Colon Tumor II	disease
S0364	Human Quadriceps	
S0366	Human Soleus	
S0368	Human Pancreatic Langerhans	
S0374	Normal colon	
S0376	Colon Tumor	disease
S0378	Pancreas normal PCA4 No	
S0380	Pancreas Tumor PCA4 Tu	disease
S0388	Human Hypothalamus,schizophrenia, re-excision	disease
S0390	Smooth muscle, control, re-excision	
S0406	Rectum tumour	
S0414	Hippocampus, Alzheimer Subtracted	
S0420	CHME Cell Line,untreated	
S0422	Mo7e Cell Line GM-CSF treated (1ng/ml)	
S0424	TF-1 Cell Line GM-CSF Treated	
S0426	Monocyte activated, re-excision	
S0430	Aryepiglottis Normal	
S0432	Sinus piriformis Tumour	
S0434	Stomach Normal	disease
S0456	Tongue Normal	
S0468	Ea.hy.926 cell line	
S0470	Adenocarcinoma	disease
S3012	Smooth Muscle Serum Treated, Norm	
S3014	Smooth muscle, serum induced,re-exc	
S6014	H. hypothalamus, frac A	
S6024	Alzheimers, spongy change	disease
S6028	Human Manic Depression Tissue	disease
T0002	Activated T-cells	
T0003	Human Fetal Lung	
T0006	Human Pineal Gland	
T0008	Colorectal Tumor	disease
T0010	Human Infant Brain	
T0039	HSA 172 Cells	
T0040	HSC172 cells	
T0041	Jurkat T-cell G1 phase	
T0048	Human Aortic Endothelium	
T0049	Aorta endothelial cells + TNF-a	
T0060	Human White Adipose	
T0067	Human Thyroid	
T0068	Normal Ovary, Premenopausal	
T0069	Human Uterus, normal	
T0082	Human Adult Retina	
T0104	HCC cell line metastasis to liver	

T0109	Human (HCC) cell line liver (mouse) metastasis, remake	
T0110	Human colon carcinoma (HCC) cell line, remake	
T0115	Human Colon Carcinoma (HCC) cell line	

Table 6

OMIM Reference	Description
160760	Cardiomyopathy, familial hypertrophic, 1, 192600 Central core disease, one form
182600	Spastic paraplegia-3A
186880	Leukemia/lymphoma, T-cell
190195	Ichthyosiform erythroderma, congenital, 242100 Ichthyosis, lamellar, autosomal recessive, 242300
222700	Lysinuric protein intolerance
300011	Cutis laxa, neonatal Menkes disease, 309400 Occipital horn syndrome, 304150
300032	Alpha-thalassemia/mental retardation syndrome, type 2, 301040 Juberg-Marsidi syndrome, 309590
300127	Mental retardation, X-linked, 60
301310	Anemia, sideroblastic, with spinocerebellar ataxia
304040	Charcot-Marie-Tooth neuropathy, X-linked-1, dominant, 302800
305100	Anhidrotic ectodermal dysplasia
305450	FG syndrome
308380	Combined immunodeficiency, X-linked, moderate, 312863 Severe combined immunodeficiency, X-linked, 300400
309605	Mental retardation, X-linked, syndromic-4, with congenital contractures and low fingertip arches
311800	Hemolytic anemia due to PGK deficiency Myoglobinuria/hemolysis due to PGK deficiency
311870	Muscle glycogenosis
312760	Turner syndrome
313700	Androgen insensitivity, several forms Breast cancer, male, with Reifenstein syndrome Perineal hypospadias Prostate cancer Spinal and bulbar muscular atrophy of Kennedy, 313200
314250	Dystonia-3, torsion, with parkinsonism, Filipino type
314580	Wieacker-Wolff syndrome
314670	X-inactivation, familial skewed
600243	Temperature-sensitive apoptosis
600792	Deafness, autosomal recessive 5
601369	Deafness, autosomal dominant 9
602086	Arrhythmogenic right ventricular dysplasia-3
602279	Oculopharyngeal muscular dystrophy, 164300 Oculopharyngeal muscular dystrophy, autosomal recessive, 257950

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the secreted protein.

The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or a cDNA contained in ATCC deposit Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide encoded by the cDNA contained in ATCC deposit Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide sequence encoded by the cDNA contained in ATCC deposit Z are also encompassed by the invention.

#### **Signal Sequences**

The present invention also encompasses mature forms of the polypeptide having the polypeptide sequence of SEQ ID NO:Y and/or the polypeptide sequence encoded by the cDNA in a deposited clone. Polynucleotides encoding the mature forms (such as, for example, the polynucleotide sequence in SEQ ID NO:X and/or the

polynucleotide sequence contained in the cDNA of a deposited clone) are also encompassed by the invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough  
5 endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species of the protein. Further, it has long been known that cleavage specificity of a secreted protein is ultimately determined by the primary structure of  
10 the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide.

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, *Virus Res.* 3:271-286 (1985), uses the information from a short N-terminal  
15 charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, *Nucleic Acids Res.* 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of  
20 these methods is in the range of 75-80%. (von Heinje, *supra.*) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et  
25 al., *Protein Engineering* 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

30 As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence

shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone, in a mammalian cell (e.g., COS cells, as described below). These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

#### **Polynucleotide and Polypeptide Variants**

The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X, the complementary strand thereto, and/or the cDNA sequence contained in a deposited clone.

The present invention also encompasses variants of the polypeptide sequence disclosed in SEQ ID NO:Y and/or encoded by a deposited clone.

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence contained in a deposited cDNA clone or the



complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein).

- 5 Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

The present invention is also directed to polypeptides which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%,  
10 95%, 96%, 97%, 98%, 99% identical to, for example, the polypeptide sequence shown in SEQ ID NO:Y, the polypeptide sequence encoded by the cDNA contained in a deposited clone, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein).

By a nucleic acid having a nucleotide sequence at least, for example, 95%  
15 "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95%  
20 identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified  
25 as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best  
30 overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp.

App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to  
5 calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3'  
10 deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are  
15 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected  
20 score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query  
25 sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score  
30 calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the

deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, an amino acid sequences shown in Table 1 (SEQ ID NO:Y) or to the amino acid sequence encoded by cDNA contained in a deposited clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window

Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not

matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., *J. Biol. Chem.* 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., *J. Biotechnology* 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (*J. Biol. Chem.* 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over

3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, 5 Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological 10 functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic 15 activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the 20 art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural 25 selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid 30 substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used.

- 5 (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic  
10 residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues,  
20 where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino  
25 acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification or (v) fusion of the polypeptide with another compound, such as albumin (including, but not limited to, recombinant albumin (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by  
30 reference in their entirety)). Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a peptide or polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

#### **Polynucleotide and Polypeptide Fragments**

The present invention is also directed to polynucleotide fragments of the polynucleotides of the invention.

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence which: is a portion of that contained in a deposited clone, or encoding the polypeptide encoded by the cDNA in a deposited clone; is a portion of that shown in SEQ ID NO:X or the complementary strand thereto, or is a portion of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:Y. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt,



and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in a deposited clone or the nucleotide sequence shown in SEQ ID NO:X. In this context "about" includes the particularly recited value, a value larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X, or the complementary strand thereto, or the cDNA contained in a deposited clone. In this context "about" includes the particularly recited ranges, and ranges larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40,

41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, and ranges or values larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotides encoding these domains are also contemplated.

Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

Preferably, the polynucleotide fragments of the invention encode a polypeptide which demonstrates a functional activity. By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) polypeptide of invention protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide of the invention for binding) to an antibody to the polypeptide of the invention], immunogenicity (ability to generate antibody which binds to a polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

The functional activity of polypeptides of the invention, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods.

For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the invention for binding to an antibody of the polypeptide of the invention, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

In another embodiment, where a ligand for a polypeptide of the invention identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel

chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky, E., et al., 1995, Microbiol. Rev. 59:94-123. In another embodiment, physiological correlates of binding of a polypeptide of the invention to its substrates (signal transduction) can be assayed.

5 In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the invention and fragments, variants derivatives and analogs thereof to elicit related biological activity related to that of the polypeptide of the invention (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope  
10 of the invention.

### **Epitopes and Antibodies**

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID  
15 NO:Y, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. Z or encoded by a polynucleotide that hybridizes to the complement of the sequence of SEQ ID NO:X or contained in ATCC deposit No. Z under stringent hybridization conditions or lower stringency hybridization conditions as defined supra. The present invention further encompasses  
20 polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or lower  
25 stringency hybridization conditions defined supra.

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide  
30 encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies

described *infra*. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross- reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985), further described in U.S. Patent No. 4,631,211).

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., *supra*; Wilson et al., *supra*; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to

an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very  
5 least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., supra; Wilson et al., supra, and Bittle et al., J. Gen. Virol., 66:2347-  
10 2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS),  
15 while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an  
20 immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the  
25 peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention comprising an immunogenic or antigenic epitope can be fused to other polypeptide sequences. For example, the polypeptides  
30 of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof), or albumin (including but not limited to recombinant

albumin (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by reference in their entirety)), resulting in chimeric polypeptides. Such fusion proteins may facilitate purification and may increase half-life in vivo. This has been shown

5 for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., *Nature*, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an

10 FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion disulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., *J. Biochem.*,

15 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991,

20 *Proc. Natl. Acad. Sci. USA* 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni<sup>2+</sup>

25 nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to

30 modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721;

5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308- 13 (1998) (each of these patents and publications are hereby incorporated by reference in its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

### **Antibodies**

Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule. In preferred embodiments, the immunoglobulin



molecules of the invention are IgG1. In other preferred embodiments, the immunoglobulin molecules of the invention are IgG4.

Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')<sub>2</sub>, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, ship rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be

excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, or  $10^{-15}$  M.

The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the

epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes  
5 antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand  
10 binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described  
15 supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

The invention also features receptor-specific antibodies which both prevent  
20 ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but  
25 do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists  
30 for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No.

5,811,097; Deng et al., Blood 92(6):1981-1988 (1998); Chen et al., Cancer Res. 58(16):3668-3678 (1998); Harrop et al., J. Immunol. 161(4):1786-1794 (1998); Zhu et al., Cancer Res. 58(15):3209-3214 (1998); Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998); Pitard et al., J. Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241 (1997); Carlson et al., J. Biol. Chem. 272(17):11295-11301 (1997); Taryman et al., Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998); Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties).

- 10       Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g.,
- 15       Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

- As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus
- 20       or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438;
- 25       WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

- The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include
- 30       antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of

numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

5           The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of- interest can be produced by various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal  
10   antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and  
15   potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be  
20   produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not  
25   limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma  
30   technology are routine and well known in the art and are discussed in detail in the Examples (e.g., Example 16). In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an

immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are  
5 selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

Accordingly, the present invention provides methods of generating  
10 monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody  
15 able to bind a polypeptide of the invention.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')<sub>2</sub> fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments).  
20 F(ab')<sub>2</sub> fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which  
25 carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid  
30 surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage

gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., *J. Immunol. Methods* 182:41-50 (1995); Ames et al., *J. Immunol. Methods* 184:177-186 (1995); Kettleborough et al., *Eur. J. Immunol.* 24:952-958 (1994); Persic et al., *Gene* 187 9-18 (1997); Burton et al., *Advances in Immunology* 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')<sub>2</sub> fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., *BioTechniques* 12(6):864-869 (1992); and Sawai et al., *AJRI* 34:26-34 (1995); and Better et al., *Science* 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., *Methods in Enzymology* 203:46-88 (1991); Shu et al., *PNAS* 90:7995-7999 (1993); and Skerra et al., *Science* 240:1038-1040 (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214 (1986); Gillies et al., (1989) *J. Immunol.*

Methods 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entirety.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into



mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, *Int. Rev. Immunol.* 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespersen et al., *Bio/technology* 12:899-903 (1988)).

Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using

techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

#### *Polynucleotides Encoding Antibodies*

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., BioTechniques 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library

generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe  
5 specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

Once the nucleotide sequence and corresponding amino acid sequence of the  
10 antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor,  
15 NY and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties ), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, the amino acid sequence of the heavy and/or light  
20 chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted  
25 within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of  
30 the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino

acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423-42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242:1038-1041 (1988)).

#### 25 *Methods of Producing Antibodies*

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a

polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as

bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems  
5 infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO,  
10 BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole  
15 recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., *Gene* 45:101 (1986); Cockett et al., *Bio/Technology* 8:2  
20 (1990)).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which  
25 direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., *EMBO J.* 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, *Nucleic  
30 Acids Res.* 13:3101-3109 (1985); Van Heeke & Schuster, *J. Biol. Chem.* 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such

fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the  
5 GST moiety.

In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus  
10 and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric  
15 gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad.  
20 Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and  
25 initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression  
30 of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein.

Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgp<sup>r</sup>t- or ap<sup>r</sup>t- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt,



which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 5 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, 1993, TIB TECH 11(5):155-215; and hygro, which confers resistance to hygromycin (Santerre et al., Gene 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. 10 (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., J. Mol. Biol. 150:1 (1981), which are incorporated by reference herein in their entireties.

15       The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in 20 culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., Mol. Cell. Biol. 3:257 (1983)).

      The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second 25 vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic 30 free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler, Proc. Natl. Acad. Sci. USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for  
5 the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

10 The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through  
15 linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention  
20 to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., supra, and PCT publication WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., PNAS  
25 89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446-2452(1991), which are incorporated by reference in their entireties.

The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may  
30 be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any

combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991); Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337-11341(1992) (said references incorporated by reference in their entireties).

As discussed, supra, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., Nature 331:84-86 (1988). The polypeptides of the present invention fused or conjugated to an antibody having disulfide-linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A 232,262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to

identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58 (1995); Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred  
5       embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags  
10       useful for purification include, but are not limited to, the "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the "flag" tag.

The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used  
15       diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent  
20       materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No.  
25       4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone,  
30       fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin,

and aequorin; and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$  or  $^{99}\text{Tc}$ .

Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example,  $^{213}\text{Bi}$ . A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor,  $\alpha$ -interferon,  $\beta$ -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- $\alpha$ , TNF- $\beta$ , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"),

granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58 (1982).

Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

### *Immunophenotyping*

The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present invention may be useful as a cell specific marker, or more specifically as a cellular marker that is differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific

epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison *et al.*, *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

#### *Assays For Antibody Binding*

The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasyolol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A

and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., <sup>32</sup>P or <sup>125</sup>I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes



the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

10 The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g.,  $^3\text{H}$  or  $^{125}\text{I}$ ) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g.,  $^3\text{H}$  or  $^{125}\text{I}$ ) in the presence of increasing amounts of an unlabeled second antibody.

#### *Therapeutic Uses*

The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any

one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention,

including fragments thereof. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, and  $10^{-15}$  M.

### *Gene Therapy*

In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, TIBTECH 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990).

In a preferred aspect, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other

desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific

5       embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or  
10       indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be  
15       accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun;  
20       Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target  
25       cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT  
30       Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination

(Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., Biotherapy 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., J. Clin. Invest. 93:644-651 (1994); Kiem et al., Blood 83:1467-1473 (1994); Salmons and Gunzberg, Human Gene Therapy 4:129-141 (1993); and Grossman and Wilson, Curr. Opin. in Genetics and Devel. 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, Current Opinion in Genetics and Development 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., Human Gene Therapy 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., Science 252:431-434 (1991); Rosenfeld et al., Cell 68:143-155 (1992); Mastrangeli et al., J. Clin. Invest. 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., Gene Therapy 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., Proc. Soc. Exp. Biol. Med. 204:289-300 (1993); U.S. Patent No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth. Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages,

neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

5 In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or  
10 progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

15 In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.

#### 20 *Demonstration of Therapeutic or Prophylactic Activity*

The compounds or pharmaceutical compositions of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition  
25 include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a  
30 specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

*Therapeutic/Prophylactic Administration and Composition*

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment;



this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when  
5 administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)  
10

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, supra; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., *Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose  
20 (see, e.g., Goodson, in *Medical Applications of Controlled Release*, supra, vol. 2, pp. 115-138 (1984)).  
25

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered in vivo to promote  
30 expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by

use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (see e.g.,  
5 Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a  
10 pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic  
15 is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid  
20 carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering  
25 agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as  
30 pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of

the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compounds of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

#### *Diagnosis and Imaging*

Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect, diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

The invention provides a diagnostic assay for diagnosing a disorder, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level,

whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99}\text{Tc}$ ); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods

including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce  
5 diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of <sup>99m</sup>Tc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of  
10 Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the  
15 labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by  
20 repeating the method for diagnosing the disease or disease, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label  
25 used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

30 In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with

a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is  
5 detected in a patient using magnetic resonance imaging (MRI).

### *Kits*

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified  
10 antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present  
15 invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

20 In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically  
25 immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide  
30 antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may

also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound



recombinant antigens, and a reporter-labeled anti-human antibody for detecting surface-bound anti-antigen antibody.

### **Fusion Proteins**

5           Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target  
10 cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

          Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur  
15 through linker sequences.

          Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell  
20 or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

          Moreover, polypeptides of the present invention, including fragments, and  
25 specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any combination thereof, including both entire domains and portions thereof), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins  
30 consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).)

Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).) Polynucleotides comprising or alternatively consisting of nucleic acids which encode these fusion proteins are also encompassed by the invention.

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

#### **Vectors, Host Cells, and Protein Production**

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells (e.g., *Saccharomyces cerevisiae* or *Pichia pastoris* (ATCC Accession No. 201178)); insect cells such as *Drosophila* S2 and *Spodoptera Sf9* cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A,

pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

10 Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the  
15 polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography,  
20 phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can  
25 also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant  
30 production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-

mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some  
5 proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In one embodiment, the yeast *Pichia pastoris* is used to express the polypeptide of the present invention in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A  
10 main step in the methanol metabolization pathway is the oxidation of methanol to formaldehyde using O<sub>2</sub>. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O<sub>2</sub>. Consequently, in a growth medium depending on methanol as a main  
15 carbon source, the promoter region of one of the two alcohol oxidase genes (*AOX1*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOX1* gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., et al., *Mol. Cell. Biol.* 5:1111-21 (1985); Koutz, P.J., et al., *Yeast* 5:167-77 (1989); Tschopp, J.F., et al., *Nucl. Acids Res.* 15:3859-76 (1987).  
20 Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the *AOX1* regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

In one example, the plasmid vector pPIC9K is used to express DNA encoding  
25 a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially as described in "*Pichia* Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a protein of the invention by virtue of the strong *AOX1* promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal  
30 peptide (i.e., leader) located upstream of a multiple cloning site.

Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG as required.

In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination, resulting in the formation of a new transcription unit (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman & Co., N.Y., and Hunkapiller et al., Nature, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a

polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the  
5 common amino acids, 2,4-diaminobutyric acid,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid,  $\gamma$ -Abu, e-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,  $\beta$ -alanine, fluoro-  
10 amino acids, designer amino acids such as  $\beta$ -methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The invention encompasses polypeptides which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation,  
15 amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease,  $\text{NaBH}_4$ ; acetylation, formylation, oxidation, reduction; metabolic  
20 synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, *e.g.*, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and  
25 addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of the  
30 polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent NO: 4,179,337). The chemical moieties for

derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog). For example, the polyethylene glycol may have an average molecular weight of about 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, 95,000, or 100,000 kDa.

As noted above, the polyethylene glycol may have a branched structure. Branched polyethylene glycols are described, for example, in U.S. Patent No. 5,643,575; Morpurgo *et al.*, *Appl. Biochem. Biotechnol.* 56:59-72 (1996); Vorobjev *et al.*, *Nucleosides Nucleotides* 18:2745-2750 (1999); and Caliceti *et al.*, *Bioconjug. Chem.* 10:638-646 (1999), the disclosures of each of which are incorporated herein by reference.

The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik *et al.*, *Exp. Hematol.* 20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may



be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

As suggested above, polyethylene glycol may be attached to proteins via linkage to any of a number of amino acid residues. For example, polyethylene glycol can be linked to a proteins via covalent bonds to lysine, histidine, aspartic acid, glutamic acid, or cysteine residues. One or more reaction chemistries may be employed to attach polyethylene glycol to specific amino acid residues (e.g., lysine, histidine, aspartic acid, glutamic acid, or cysteine) of the protein or to more than one type of amino acid residue (e.g., lysine, histidine, aspartic acid, glutamic acid, cysteine and combinations thereof) of the protein.

One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

As indicated above, pegylation of the proteins of the invention may be accomplished by any number of means. For example, polyethylene glycol may be attached to the protein either directly or by an intervening linker. Linkerless systems for attaching polyethylene glycol to proteins are described in Delgado *et al.*, *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992); Francis *et al.*, *Intern. J. of Hematol.* 68:1-18 (1998); U.S. Patent No. 4,002,531; U.S. Patent No. 5,349,052; WO 95/06058; and WO 98/32466, the disclosures of each of which are incorporated herein by reference.

One system for attaching polyethylene glycol directly to amino acid residues of proteins without an intervening linker employs tresylated MPEG, which is produced by the modification of monmethoxy polyethylene glycol (MPEG) using tresylchloride ( $\text{ClSO}_2\text{CH}_2\text{CF}_3$ ). Upon reaction of protein with tresylated MPEG, polyethylene glycol is directly attached to amine groups of the protein. Thus, the invention includes protein-polyethylene glycol conjugates produced by reacting proteins of the invention with a polyethylene glycol molecule having a 2,2,2-trifluoroethane sulphonyl group.

Polyethylene glycol can also be attached to proteins using a number of different intervening linkers. For example, U.S. Patent No. 5,612,460, the entire disclosure of which is incorporated herein by reference, discloses urethane linkers for connecting polyethylene glycol to proteins. Protein-polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein by a linker can also be produced by reaction of proteins with compounds such as MPEG-succinimidylsuccinate, MPEG activated with 1,1'-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG-p-nitrophenolcarbonate, and various MPEG-succinate derivatives. A number additional polyethylene glycol derivatives and reaction chemistries for attaching polyethylene glycol to proteins are described in WO 98/32466, the entire disclosure of which is incorporated herein by reference. Pegylated protein products produced using the reaction chemistries set out herein are included within the scope of the invention.

The number of polyethylene glycol moieties attached to each protein of the invention (*i.e.*, the degree of substitution) may also vary. For example, the pegylated proteins of the invention may be linked, on average, to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12,

15, 17, 20, or more polyethylene glycol molecules. Similarly, the average degree of substitution within ranges such as 1-3, 2-4, 3-5, 4-6, 5-7, 6-8, 7-9, 8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16, 15-17, 16-18, 17-19, or 18-20 polyethylene glycol moieties per protein molecule. Methods for determining the degree of substitution are  
5 discussed, for example, in Delgado *et al.*, *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992).

The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their  
10 preparation, and compositions (preferably, *Therapeutics*) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

Multimers encompassed by the invention may be homomers or heteromers.  
15 As used herein, the term homomer, refers to a multimer containing only polypeptides corresponding to the amino acid sequence of SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone (including fragments, variants, splice variants, and fusion proteins, corresponding to these polypeptides as described herein). These homomers may contain polypeptides having identical or different amino acid  
20 sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (*e.g.*, containing polypeptides having  
25 identical or different amino acid sequences) or a homotrimer (*e.g.*, containing polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

As used herein, the term heteromer refers to a multimer containing one or  
30 more heterologous polypeptides (*i.e.*, polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional

embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, 5 for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the 10 invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence ( e.g., that recited in the sequence 15 listing, or contained in the polypeptide encoded by a deposited clone). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent 20 associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the 25 heterologous sequence contained in an Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the 30 contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627

(hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

Another method for preparing multimer polypeptides of the invention involves  
5 use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different  
10 proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide  
15 sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are  
20 those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

25 In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-  
30 Flag® antibody.

The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers

of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

5 Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers  
10 containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see,  
15 e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein  
20 technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic  
25 polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides  
30 of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into

liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

### **Uses of the Polynucleotides**

5           Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

          The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers,  
10       since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

          Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be  
15       selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

20       Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled  
25       flow-sorted chromosomes, preselection by hybridization to construct chromosome specific-cDNA libraries and computer mapping techniques (See, e.g., Shuler, Trends Biotechnol 16:456-459 (1998) which is hereby incorporated by reference in its entirety)..

          Precise chromosomal location of the polynucleotides can also be achieved  
30       using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see

Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes).

The polynucleotides of the present invention would likewise be useful for radiation hybrid mapping, HAPPY mapping, and long range restriction mapping. For a review of these techniques and others known in the art, see, e.g., Dear, "Genome Mapping: A Practical Approach," IRL Press at Oxford University Press, London (1997); Aydin, J. Mol. Med. 77:691-694 (1999); Hacia et al., Mol. Psychiatry 3:483-492 (1998); Herrick et al., Chromosome Res. 7:409-423 (1999); Hamilton et al., Methods Cell Biol. 62:265-280 (2000); and/or Ott, J. Hered. 90:68-70 (1999) each of which is hereby incorporated by reference in its entirety.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.



Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the present invention in cells or body fluid from an individual and comparing the measured gene expression level with a standard level of polynucleotide expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder.

In still another embodiment, the invention includes a kit for analyzing samples for the presence of proliferative and/or cancerous polynucleotides derived from a test subject. In a general embodiment, the kit includes at least one polynucleotide probe containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the present invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the present invention, where each probe has one strand containing a 31' mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a disorder, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the present invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

By "measuring the expression level of polynucleotide of the present invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the present invention or the level of the mRNA encoding the polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or

estimated and compared to a standard polypeptide level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder. As will be appreciated in the art, once a standard polypeptide  
5 level or mRNA level is known, it can be used repeatedly as a standard for comparison.

By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains the polypeptide of the present invention or mRNA. As indicated, biological samples  
10 include body fluids (such as semen, lymph, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and other tissue sources found to express the polypeptide of the present invention. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred  
15 source.

The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides are attached to a solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174.  
20 Further, such a gene chip with polynucleotides of the present invention attached may be used to identify polymorphisms between the polynucleotide sequences, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e. their location, as well as, their existence) would be beneficial in identifying disease loci for many disorders, including cancerous diseases and conditions. Such a  
25 method is described in US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

The present invention encompasses polynucleotides of the present invention that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the  
30 preferred form if the polynucleotides are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine,

thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, *Science* 254, 1497 (1991); and M. Egholm, O. Buchardt, L.Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, *Nature* 365, 666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point ( $T_{sub.m}$ ) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Pathological cell proliferative diseases, disorders, and/or conditions are often associated with inappropriate activation of proto-oncogenes. (Germann, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in *Neoplastic Diseases of the Blood*, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)). Neoplasias are now believed to result from the qualitative alteration of a normal

cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Germann et al., supra) It is likely that mutated or altered expression of specific genes is involved in the pathogenesis of some leukemias, among other tissues and cell types. (Germann et al., supra) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Germann et al., supra)

For example, c-myc expression is highly amplified in the non-lymphocytic leukemia cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580) However, it has been shown that exposure of HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness would not be limited to treatment of proliferative diseases, disorders, and/or conditions of hematopoietic cells and tissues, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456

(1988); and Dervan et al., Science 251:1360 (1991) ) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while  
5 antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat or prevent disease.

Polynucleotides of the present invention are also useful in gene therapy. One  
10 goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

15 The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for  
20 identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative  
25 to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an  
30 individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

#### **Uses of the Polypeptides**

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression

in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell. Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99\text{m}}\text{Tc}$ ), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

10 In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers  
15 for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example,  $^{131}\text{I}$ ,  
20  $^{112}\text{In}$ ,  $^{99\text{m}}\text{Tc}$ ), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a  
25 human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99\text{m}}\text{Tc}$ . The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging:  
30 The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Moreover, polypeptides of the present invention can be used to treat, prevent, and/or diagnose disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune response to proliferative cells or tissues).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat, prevent, and/or diagnose disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also



be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

5

### **Gene Therapy Methods**

Another aspect of the present invention is to gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a polypeptide of the present invention. This method requires a polynucleotide which codes for a polypeptide of the invention that operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a polynucleotide of the invention *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, see Beldegrun et al., J. Natl. Cancer Inst., 85:207-216 (1993); Ferrantini et al., Cancer Research, 53:107-1112 (1993); Ferrantini et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura et al., Cancer Research 50: 5102-5106 (1990); Santodonato, et al., Human Gene Therapy 7:1-10 (1996); Santodonato, et al., Gene Therapy 4:1246-1255 (1997); and Zhang, et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver,

30

and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences  
5 that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such  
10 methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs of the invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors  
15 include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving  
20 the expression of polynucleotide sequence of the invention. Suitable promoters include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter;  
25 the ApoAI promoter; human globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotides of the invention.

Unlike other gene therapy techniques, one major advantage of introducing  
30 naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA

sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct of the invention can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked *nucleic acid* sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

5       The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

10       In certain embodiments, the polynucleotide constructs of the invention are complexed in a liposome preparation. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA ,  
15   84:7413-7416 (1987), which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA , 86:6077-6081 (1989), which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem., 265:10189-10192 (1990), which is herein incorporated by reference), in functional form.

20       Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference). Other commercially  
25   available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication NO: WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of  
30   DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., Felgner et al., Proc.

Natl. Acad. Sci. USA, 84:7413-7417, which is herein incorporated by reference.

Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred. The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., *Methods of Immunology*, 101:512-527 (1983), which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass tube and subsequently hydrating with a solution of the material to be encapsulated. SUVs are prepared by extended sonication of MLVs to produce a homogeneous population of unilamellar liposomes. The material to be entrapped is added to a

suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods include  $\text{Ca}^{2+}$ -EDTA chelation (Papahadjopoulos et al., *Biochim. Biophys. Acta*, 394:483 (1975); Wilson et al., *Cell*, 17:77 (1979)); ether injection (Deamer et al., *Biochim. Biophys. Acta*, 443:629 (1976); Ostro et al., *Biochem. Biophys. Res. Commun.*, 76:836 (1977); Fraley et al., *Proc. Natl. Acad. Sci. USA*, 76:3348 (1979)); detergent dialysis (Enoch et al., *Proc. Natl. Acad. Sci. USA*, 76:145 (1979)); and reverse-phase evaporation (REV) (Fraley et al., *J. Biol. Chem.*, 255:10431 (1980); Szoka et al., *Proc. Natl. Acad. Sci. USA*, 75:145 (1978); Schaefer-Ridder et al., *Science*, 215:166 (1982)), which are herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ratio will be from about 5:1 to about 1:5. More preferably, the ratio will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent NO: 5,676,954 (which is herein incorporated by reference) reports on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding polypeptides of the invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis

virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected  
5 include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy, 1:5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any  
10 means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO<sub>4</sub> precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding polypeptides of the invention. Such retroviral vector  
15 particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express polypeptides of the invention.

In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with polynucleotides of the invention contained in an adenovirus vector. Adenovirus can be manipulated such that it encodes and expresses polypeptides of the invention, and  
20 at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for many years with an excellent safety profile (Schwartz et al., Am. Rev. Respir. Dis.,  
25 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld et al., Science, 252:431-434 (1991); Rosenfeld et al., Cell, 68:143-155 (1992)). Furthermore, extensive studies to attempt to establish adenovirus as a causative agent in human cancer were uniformly negative  
30 (Green et al. Proc. Natl. Acad. Sci. USA, 76:6606 (1979)).

Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel., 3:499-503 (1993);

Rosenfeld et al., *Cell*, 68:143-155 (1992); Engelhardt et al., *Human Genet. Ther.*, 4:759-769 (1993); Yang et al., *Nature Genet.*, 7:362-369 (1994); Wilson et al., *Nature*, 365:691-692 (1993); and U.S. Patent NO: 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can  
5 be grown in human 293 cells. These cells contain the E1 region of adenovirus and constitutively express E1a and E1b, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

10 Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses  
15 may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, *Curr.*  
20 *Topics in Microbiol. Immunol.*, 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678,  
25 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct containing polynucleotides of the invention is inserted into the AAV vector using standard cloning methods, such as those found  
30 in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including



lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention.

- 5 These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express the desired gene product.

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding the  
10 polypeptide sequence of interest) via homologous recombination (see, e.g., U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method  
15 involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently  
20 complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5' end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

25 The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the  
30 amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can  
5 be delivered by any method, included direct needle injection, intravenous injection, topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such  
10 that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

The polynucleotides encoding polypeptides of the present invention may be administered along with other polynucleotides encoding other angiogenic proteins. Angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth  
15 factors, VEGF-1, VEGF-2 (VEGF-C), VEGF-3 (VEGF-B), epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

20 Preferably, the polynucleotide encoding a polypeptide of the invention contains a secretory signal sequence that facilitates secretion of the protein. Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be  
25 homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct  
30 needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid

(tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the  
5 rat livers. (Kaneda et al., Science, 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries. Administration of a composition locally within the area of arteries refers to injecting  
10 the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue  
15 inside the wound.

Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a  
20 particular site.

Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad.  
25 Sci. USA, 189:11277-11281 (1992), which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a  
30 polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian. Therapeutic compositions of the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly

### **Biological Activities**

The polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

### **Immune Activity**

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of the immune system, by, for example, activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer and some autoimmune diseases, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of

the present invention can be used as a marker or detector of a particular immune system disease or disorder.

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells.

Examples of immunologic deficiency syndromes include, but are not limited to: blood protein diseases, disorders, and/or conditions (e.g., agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, polynucleotides or polypeptides, and/or agonists or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies), blood platelet diseases, disorders, and/or conditions (e.g., thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment or prevention of heart attacks (infarction), strokes, or scarring.

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing autoimmune disorders. Many autoimmune disorders result from inappropriate

recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of polynucleotides and polypeptides of the invention that can inhibit an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Autoimmune diseases or disorders that may be treated, prevented, and/or diagnosed by polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, one or more of the following:

10 autoimmune hemolytic anemia, autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenia purpura, autoimmunocytopenia, hemolytic anemia, antiphospholipid syndrome, dermatitis, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, glomerulonephritis (e.g. IgA nephropathy), Multiple Sclerosis, Neuritis, Uveitis Ophthalmia,

15 Polyendocrinopathies, Purpura (e.g., Henloch-Schoenlein purpura), Reiter's Disease, Stiff-Man Syndrome, Autoimmune Pulmonary Inflammation, Autism, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye, autoimmune thyroiditis, hypothyroidism (i.e., Hashimoto's thyroiditis, systemic lupus erythematosus, Goodpasture's syndrome, Pemphigus, Receptor autoimmunities such

20 as, for example, (a) Graves' Disease, (b) Myasthenia Gravis, and (c) insulin resistance, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, rheumatoid arthritis, scleroderma with anti-collagen antibodies, mixed connective tissue disease, polymyositis/dermatomyositis, pernicious anemia, idiopathic Addison's disease, infertility, glomerulonephritis such as primary glomerulonephritis and IgA

25 nephropathy, bullous pemphigoid, Sjogren's syndrome, diabetes mellitus, and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis), chronic active hepatitis, primary biliary cirrhosis, other endocrine gland failure, vitiligo, vasculitis, post-MI, cardiomyopathy syndrome, urticaria, atopic dermatitis, asthma, inflammatory myopathies, and other inflammatory, granulomatous,

30 degenerative, and atrophic disorders.

Additional autoimmune disorders (that are probable) that may be treated, prevented, and/or diagnosed with the compositions of the invention include, but are

not limited to, rheumatoid arthritis (often characterized, e.g., by immune complexes in joints), scleroderma with anti-collagen antibodies (often characterized, e.g., by nucleolar and other nuclear antibodies), mixed connective tissue disease (often characterized, e.g., by antibodies to extractable nuclear antigens (e.g., ribonucleoprotein)), polymyositis (often characterized, e.g., by nonhistone ANA), pernicious anemia (often characterized, e.g., by antiparietal cell, microsomes, and intrinsic factor antibodies), idiopathic Addison's disease (often characterized, e.g., by humoral and cell-mediated adrenal cytotoxicity, infertility (often characterized, e.g., by antispermatozoal antibodies), glomerulonephritis (often characterized, e.g., by glomerular basement membrane antibodies or immune complexes), bullous pemphigoid (often characterized, e.g., by IgG and complement in basement membrane), Sjogren's syndrome (often characterized, e.g., by multiple tissue antibodies, and/or a specific nonhistone ANA (SS-B)), diabetes mellitus (often characterized, e.g., by cell-mediated and humoral islet cell antibodies), and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis) (often characterized, e.g., by beta-adrenergic receptor antibodies).

Additional autoimmune disorders (that are possible) that may be treated, prevented, and/or diagnosed with the compositions of the invention include, but are not limited to, chronic active hepatitis (often characterized, e.g., by smooth muscle antibodies), primary biliary cirrhosis (often characterized, e.g., by mitochondrial antibodies), other endocrine gland failure (often characterized, e.g., by specific tissue antibodies in some cases), vitiligo (often characterized, e.g., by melanocyte antibodies), vasculitis (often characterized, e.g., by Ig and complement in vessel walls and/or low serum complement), post-MI (often characterized, e.g., by myocardial antibodies), cardiomyopathy syndrome (often characterized, e.g., by myocardial antibodies), urticaria (often characterized, e.g., by IgG and IgM antibodies to IgE), atopic dermatitis (often characterized, e.g., by IgG and IgM antibodies to IgE), asthma (often characterized, e.g., by IgG and IgM antibodies to IgE), and many other inflammatory, granulomatous, degenerative, and atrophic disorders.

In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated,

prevented, and/or diagnosed using for example, antagonists or agonists, polypeptides or polynucleotides, or antibodies of the present invention.

In a preferred embodiment polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used as an agent to boost  
5 immunoresponsiveness among B cell and/or T cell immunodeficient individuals.

B cell immunodeficiencies that may be ameliorated or treated by administering the polypeptides or polynucleotides of the invention, and/or agonists thereof, include, but are not limited to, severe combined immunodeficiency (SCID)-X linked, SCID-autosomal, adenosine deaminase deficiency (ADA deficiency), X-  
10 linked agammaglobulinemia (XLA), Bruton's disease, congenital agammaglobulinemia, X-linked infantile agammaglobulinemia, acquired agammaglobulinemia, adult onset agammaglobulinemia, late-onset agammaglobulinemia, dysgammaglobulinemia, hypogammaglobulinemia, transient hypogammaglobulinemia of infancy, unspecified hypogammaglobulinemia,  
15 agammaglobulinemia, common variable immunodeficiency (CVI) (acquired), Wiskott-Aldrich Syndrome (WAS), X-linked immunodeficiency with hyper IgM, non X-linked immunodeficiency with hyper IgM, selective IgA deficiency, IgG subclass deficiency (with or without IgA deficiency), antibody deficiency with normal or elevated Igs, immunodeficiency with thymoma, Ig heavy chain deletions, kappa  
20 chain deficiency, B cell lymphoproliferative disorder (BLPD), selective IgM immunodeficiency, recessive agammaglobulinemia (Swiss type), reticular dysgenesis, neonatal neutropenia, severe congenital leukopenia, thymic aplasia or dysplasia with immunodeficiency, ataxia-telangiectasia, short limbed dwarfism, X-linked lymphoproliferative syndrome (XLP), Nezelof  
25 syndrome-combined immunodeficiency with Igs, purine nucleoside phosphorylase deficiency (PNP), MHC Class II deficiency (Bare Lymphocyte Syndrome) and severe combined immunodeficiency.

T cell deficiencies that may be ameliorated or treated by administering the polypeptides or polynucleotides of the invention, and/or agonists thereof include, but  
30 are not limited to, for example, DiGeorge anomaly, thymic hypoplasia, third and fourth pharyngeal pouch syndrome, 22q11.2 deletion, chronic mucocutaneous candidiasis, natural killer cell deficiency (NK), idiopathic CD4+ T-lymphocytopenia,



immunodeficiency with predominant T cell defect (unspecified), and unspecified immunodeficiency of cell mediated immunity. In specific embodiments, DiGeorge anomaly or conditions associated with DiGeorge anomaly are ameliorated or treated by, for example, administering the polypeptides or polynucleotides of the invention, or antagonists or agonists thereof.

Other immunodeficiencies that may be ameliorated or treated by administering polypeptides or polynucleotides of the invention, and/or agonists thereof, include, but are not limited to, severe combined immunodeficiency (SCID; e.g., X-linked SCID, autosomal SCID, and adenosine deaminase deficiency), ataxia-telangiectasia, Wiskott-Aldrich syndrome, short-limber dwarfism, X-linked lymphoproliferative syndrome (XLP), Nezelof syndrome (e.g., purine nucleoside phosphorylase deficiency), MHC Class II deficiency. In specific embodiments, ataxia-telangiectasia or conditions associated with ataxia-telangiectasia are ameliorated or treated by administering the polypeptides or polynucleotides of the invention, and/or agonists thereof.

In a specific preferred embodiment, rheumatoid arthritis is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment, systemic lupus erythematosus is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment, idiopathic thrombocytopenia purpura is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment IgA nephropathy is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, and/or diagnosed using antibodies against the protein of the invention.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, and/or diagnosed using polypeptides, antibodies, or polynucleotides of the invention, and/or

agonists or antagonists thereof. Moreover, these molecules can be used to treat, prevent, and/or diagnose anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

Moreover, inflammatory conditions may also be treated, diagnosed, and/or prevented with polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. Such inflammatory conditions include, but are not limited to, for example, respiratory disorders (such as, e.g., asthma and allergy); gastrointestinal disorders (such as, e.g., inflammatory bowel disease); cancers (such as, e.g., gastric, ovarian, lung, bladder, liver, and breast); CNS disorders (such as, e.g., multiple sclerosis, blood-brain barrier permeability, ischemic brain injury and/or stroke, traumatic brain injury, neurodegenerative disorders (such as, e.g., Parkinson's disease and Alzheimer's disease), AIDS-related dementia, and prion disease); cardiovascular disorders (such as, e.g., atherosclerosis, myocarditis, cardiovascular disease, and cardiopulmonary bypass complications); as well as many additional diseases, conditions, and disorders that are characterized by inflammation (such as, e.g., chronic hepatitis (B and C), rheumatoid arthritis, gout, trauma, septic shock, pancreatitis, sarcoidosis, dermatitis, renal ischemia-reperfusion injury, Grave's disease, systemic lupus erythematosus, diabetes mellitus (i.e., type 1 diabetes), and allogenic transplant rejection).

In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to treat, diagnose, and/or prevent transplantation rejections, graft-versus-host disease, autoimmune and inflammatory diseases (e.g., immune complex-induced vasculitis, glomerulonephritis, hemolytic anemia, myasthenia gravis, type II collagen-induced arthritis, experimental allergic and hyperacute xenograft rejection, rheumatoid arthritis, and systemic lupus erythematosus (SLE)). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. Polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also be used to modulate and/or diagnose inflammation. For example, since polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists of the invention may inhibit the activation, proliferation and/or differentiation of cells involved in an inflammatory response, these molecules can be used to treat, diagnose, or prognose, inflammatory conditions, both chronic and acute conditions, including, but not limited to, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, and resulting from over production of cytokines (e.g., TNF or IL-1).

Polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the invention can be used to treat, detect, and/or prevent infectious agents. For example, by increasing the immune response, particularly increasing the proliferation activation and/or differentiation of B and/or T cells, infectious diseases may be treated, detected, and/or prevented. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also directly inhibit the infectious agent (refer to section of application listing infectious agents, etc), without necessarily eliciting an immune response.

Additional preferred embodiments of the invention include, but are not limited to, the use of polypeptides, antibodies, polynucleotides and/or agonists or antagonists in the following applications:

Administration to an animal (e.g., mouse, rat, rabbit, hamster, guinea pig, pigs, micro-pig, chicken, camel, goat, horse, cow, sheep, dog, cat, non-human primate, and human, most preferably human) to boost the immune system to produce increased quantities of one or more antibodies (e.g., IgG, IgA, IgM, and IgE), to induce higher affinity antibody production (e.g., IgG, IgA, IgM, and IgE), and/or to increase an immune response.

Administration to an animal (including, but not limited to, those listed above, and also including transgenic animals) incapable of producing functional endogenous antibody molecules or having an otherwise compromised endogenous immune system, but which is capable of producing human immunoglobulin molecules by means of a reconstituted or partially reconstituted immune system from another animal (see, e.g., published PCT Application Nos. WO98/24893, WO/9634096, WO/9633735, and WO/9110741.

A vaccine adjuvant that enhances immune responsiveness to specific antigen.

An adjuvant to enhance tumor-specific immune responses.

10 An adjuvant to enhance anti-viral immune responses. Anti-viral immune responses that may be enhanced using the compositions of the invention as an adjuvant, include virus and virus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: AIDS, meningitis, Dengue, EBV, and hepatitis (e.g., hepatitis B). In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: HIV/AIDS, Respiratory syncytial virus, Dengue, Rotavirus, Japanese B encephalitis, Influenza A and B, Parainfluenza, Measles, Cytomegalovirus, Rabies, Junin, Chikungunya, Rift Valley fever, Herpes simplex, and yellow fever.

25 An adjuvant to enhance anti-bacterial or anti-fungal immune responses. Anti-bacterial or anti-fungal immune responses that may be enhanced using the compositions of the invention as an adjuvant, include bacteria or fungus and bacteria or fungus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: tetanus, Diphtheria, botulism, and meningitis type B. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: *Vibrio cholerae*, *Mycobacterium leprae*, *Salmonella typhi*, *Salmonella paratyphi*, *Meissneria meningitidis*,

30

*Streptococcus pneumoniae*, Group B streptococcus, *Shigella spp.*, Enterotoxigenic *Escherichia coli*, Enterohemorrhagic *E. coli*, *Borrelia burgdorferi*, and Plasmodium (malaria).

5 An adjuvant to enhance anti-parasitic immune responses. Anti-parasitic immune responses that may be enhanced using the compositions of the invention as an adjuvant, include parasite and parasite associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a parasite. In another specific embodiment, the compositions of the invention are used as an  
10 adjuvant to enhance an immune response to Plasmodium (malaria).

As a stimulator of B cell responsiveness to pathogens.

As an activator of T cells.

As an agent that elevates the immune status of an individual prior to their receipt of immunosuppressive therapies.

15 As an agent to induce higher affinity antibodies.

As an agent to increase serum immunoglobulin concentrations.

As an agent to accelerate recovery of immunocompromised individuals.

As an agent to boost immunoresponsiveness among aged populations.

As an immune system enhancer prior to, during, or after bone marrow  
20 transplant and/or other transplants (e.g., allogeneic or xenogeneic organ transplantation). With respect to transplantation, compositions of the invention may be administered prior to, concomitant with, and/or after transplantation. In a specific embodiment, compositions of the invention are administered after transplantation, prior to the beginning of recovery of T-cell populations. In another specific  
25 embodiment, compositions of the invention are first administered after transplantation after the beginning of recovery of T cell populations, but prior to full recovery of B cell populations.

As an agent to boost immunoresponsiveness among individuals having an acquired loss of B cell function. Conditions resulting in an acquired loss of B cell  
30 function that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are

not limited to, HIV Infection, AIDS, bone marrow transplant, and B cell chronic lymphocytic leukemia (CLL).

As an agent to boost immunoresponsiveness among individuals having a temporary immune deficiency. Conditions resulting in a temporary immune deficiency that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, recovery from viral infections (e.g., influenza), conditions associated with malnutrition, recovery from infectious mononucleosis, or conditions associated with stress, recovery from measles, recovery from blood transfusion, recovery from surgery.

As a regulator of antigen presentation by monocytes, dendritic cells, and/or B-cells. In one embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention enhance antigen presentation or antagonizes antigen presentation in vitro or in vivo. Moreover, in related embodiments, said enhancement or antagonization of antigen presentation may be useful as an anti-tumor treatment or to modulate the immune system.

As an agent to direct an individuals immune system towards development of a humoral response (i.e. TH2) as opposed to a TH1 cellular response.

As a means to induce tumor proliferation and thus make it more susceptible to anti-neoplastic agents. For example, multiple myeloma is a slowly dividing disease and is thus refractory to virtually all anti-neoplastic regimens. If these cells were forced to proliferate more rapidly their susceptibility profile would likely change.

As a stimulator of B cell production in pathologies such as AIDS, chronic lymphocyte disorder and/or Common Variable Immunodeficiency.

As a therapy for generation and/or regeneration of lymphoid tissues following surgery, trauma or genetic defect.

As a gene-based therapy for genetically inherited disorders resulting in immuno-incompetence such as observed among SCID patients.

As an antigen for the generation of antibodies to inhibit or enhance immune mediated responses against polypeptides of the invention.

As a means of activating T cells.

As a means of activating monocytes/macrophages to defend against parasitic diseases that effect monocytes such as Leshmania.

As pretreatment of bone marrow samples prior to transplant. Such treatment would increase B cell representation and thus accelerate recover.

5 As a means of regulating secreted cytokines that are elicited by polypeptides of the invention.

Additionally, polypeptides or polynucleotides of the invention, and/or agonists thereof, may be used to treat or prevent IgE-mediated allergic reactions. Such allergic reactions include, but are not limited to, asthma, rhinitis, and eczema.

10 All of the above described applications as they may apply to veterinary medicine.

Antagonists of the invention include, for example, binding and/or inhibitory antibodies, antisense nucleic acids, or ribozymes. These would be expected to reverse many of the activities of the ligand described above as well as find clinical or  
15 practical application as:

A means of blocking various aspects of immune responses to foreign agents or self. Examples include autoimmune disorders such as lupus, and arthritis, as well as immunoresponsiveness to skin allergies, inflammation, bowel disease, injury and pathogens.

20 A therapy for preventing the B cell proliferation and Ig secretion associated with autoimmune diseases such as idiopathic thrombocytopenic purpura, systemic lupus erythramatosus and MS.

An inhibitor of B and/or T cell migration in endothelial cells. This activity disrupts tissue architecture or cognate responses and is useful, for example in  
25 disrupting immune responses, and blocking sepsis.

An inhibitor of graft versus host disease or transplant rejection.

A therapy for B cell and/or T cell malignancies such as ALL, Hodgkins disease, non-Hodgkins lymphoma, Chronic lymphocyte leukemia, plasmacytomas, multiple myeloma, Burkitt's lymphoma, and EBV-transformed diseases.

30 A therapy for chronic hypergammaglobulinemia evident in such diseases as monoclonalgammopathy of undetermined significance (MGUS), Waldenstrom's disease, related idiopathic monoclonalgammopathies, and plasmacytomas.

A therapy for decreasing cellular proliferation of Large B-cell Lymphomas.

A means of decreasing the involvement of B cells and Ig associated with Chronic Myelogenous Leukemia.

An immunosuppressive agent(s).

5 Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate IgE concentrations in vitro or in vivo.

In another embodiment, administration of polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the invention, may be used to treat or prevent IgE-mediated allergic reactions including, but not limited to, asthma,  
10 rhinitis, and eczema.

The agonists and antagonists may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as described herein.

The agonists or antagonists may be employed for instance to inhibit polypeptide chemotaxis and activation of macrophages and their precursors, and of  
15 neutrophils, basophils, B lymphocytes and some T-cell subsets, e.g., activated and CD8 cytotoxic T cells and natural killer cells, in certain auto-immune and chronic inflammatory and infective diseases. Examples of autoimmune diseases are described herein and include multiple sclerosis, and insulin-dependent diabetes. The antagonists or agonists may also be employed to treat infectious diseases including  
20 silicosis, sarcoidosis, idiopathic pulmonary fibrosis by, for example, preventing the recruitment and activation of mononuclear phagocytes. They may also be employed to treat idiopathic hyper-eosinophilic syndrome by, for example, preventing eosinophil production and migration. The antagonists or agonists or may also be employed for treating atherosclerosis, for example, by preventing monocyte  
25 infiltration in the artery wall.

Antibodies against polypeptides of the invention may be employed to treat ARDS.

Agonists and/or antagonists of the invention also have uses in stimulating wound and tissue repair, stimulating angiogenesis, stimulating the repair of vascular  
30 or lymphatic diseases or disorders. Additionally, agonists and antagonists of the invention may be used to stimulate the regeneration of mucosal surfaces.



In a specific embodiment, polynucleotides or polypeptides, and/or agonists thereof are used to treat or prevent a disorder characterized by primary or acquired immunodeficiency, deficient serum immunoglobulin production, recurrent infections, and/or immune system dysfunction. Moreover, polynucleotides or polypeptides, and/or agonists thereof may be used to treat or prevent infections of the joints, bones, skin, and/or parotid glands, blood-borne infections (e.g., sepsis, meningitis, septic arthritis, and/or osteomyelitis), autoimmune diseases (e.g., those disclosed herein), inflammatory disorders, and malignancies, and/or any disease or disorder or condition associated with these infections, diseases, disorders and/or malignancies) including, but not limited to, CVID, other primary immune deficiencies, HIV disease, CLL, recurrent bronchitis, sinusitis, otitis media, conjunctivitis, pneumonia, hepatitis, meningitis, herpes zoster (e.g., severe herpes zoster), and/or pneumocystis carinii.

In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention are used to treat, and/or diagnose an individual having common variable immunodeficiency disease ("CVID"; also known as "acquired agammaglobulinemia" and "acquired hypogammaglobulinemia") or a subset of this disease.

In a specific embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to treat, diagnose, and/or prevent (1) cancers or neoplasms and (2) autoimmune cell or tissue-related cancers or neoplasms. In a preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat, diagnose, and/or prevent acute myelogenous leukemia. In a further preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat, diagnose, and/or prevent, chronic myelogenous leukemia, multiple myeloma, non-Hodgkins lymphoma, and/or Hodgkins disease.

In another specific embodiment, polynucleotides or polypeptides, and/or agonists or antagonists of the invention may be used to treat, diagnose, prognose, and/or prevent selective IgA deficiency, myeloperoxidase deficiency, C2 deficiency, ataxia-telangiectasia, DiGeorge anomaly, common variable immunodeficiency (CVI),

X-linked agammaglobulinemia, severe combined immunodeficiency (SCID), chronic granulomatous disease (CGD), and Wiskott-Aldrich syndrome.

Examples of autoimmune disorders that can be treated or detected are described above and also include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prognosed, prevented, and/or diagnosed using antibodies against the polypeptide of the invention.

As an agent to boost immunoresponsiveness among B cell immunodeficient individuals, such as, for example, an individual who has undergone a partial or complete splenectomy.

Additionally, polynucleotides, polypeptides, and/or antagonists of the invention may affect apoptosis, and therefore, would be useful in treating a number of diseases associated with increased cell survival or the inhibition of apoptosis. For example, diseases associated with increased cell survival or the inhibition of apoptosis that could be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related

glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, polynucleotides, polypeptides, and/or antagonists of the invention are used to inhibit growth, progression, and/or metastasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and

brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Hyperproliferative diseases and/or disorders that could be detected and/or treated by polynucleotides, polypeptides, and/or antagonists of the invention, include, but are not limited to neoplasms located in the: liver, abdomen, bone, breast, digestive system, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention. Examples of such hyperproliferative disorders include, but are not limited to:

hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

## **Hyperproliferative Disorders**

A polynucleotides or polypeptides, or agonists or antagonists of the invention can be used to treat, prevent, and/or diagnose hyperproliferative diseases, disorders, and/or conditions, including neoplasms. A polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative diseases, disorders, and/or conditions can be treated, prevented, and/or diagnosed. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating, preventing, and/or diagnosing hyperproliferative diseases, disorders, and/or conditions, such as a chemotherapeutic agent.

Examples of hyperproliferative diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative diseases, disorders, and/or conditions can also be treated, prevented, and/or diagnosed by a polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative diseases, disorders, and/or conditions include, but are not limited to: hypergammaglobulinemia, lymphoproliferative diseases, disorders, and/or conditions, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

Thus, the present invention provides a method for treating or preventing cell proliferative diseases, disorders, and/or conditions by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

Another embodiment of the present invention provides a method of treating or preventing cell-proliferative diseases, disorders, and/or conditions in individuals

comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the poynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature

320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference.

5 In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes  
10 needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use  
15 of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts,  
20 which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the  
25 polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in  
30 tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating, preventing, and/or diagnosing one or more of the described diseases, disorders, and/or conditions. Methods for  
5 producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may  
10 be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of  
15 the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

In particular, the antibodies, fragments and derivatives of the present invention are useful for treating, preventing, and/or diagnosing a subject having or developing cell proliferative and/or differentiation diseases, disorders, and/or conditions as  
20 described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example, which serve to increase the number or  
25 activity of effector cells which interact with the antibodies.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of diseases, disorders, and/or conditions related to polynucleotides or  
30 polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those



with a dissociation constant or  $K_d$  less than  $5 \times 10^{-6}M$ ,  $10^{-6}M$ ,  $5 \times 10^{-7}M$ ,  $10^{-7}M$ ,  $5 \times 10^{-8}M$ ,  $10^{-8}M$ ,  $5 \times 10^{-9}M$ ,  $10^{-9}M$ ,  $5 \times 10^{-10}M$ ,  $10^{-10}M$ ,  $5 \times 10^{-11}M$ ,  $10^{-11}M$ ,  $5 \times 10^{-12}M$ ,  $10^{-12}M$ ,  $5 \times 10^{-13}M$ ,  $10^{-13}M$ ,  $5 \times 10^{-14}M$ ,  $10^{-14}M$ ,  $5 \times 10^{-15}M$ , and  $10^{-15}M$ .

Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference). Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al., Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference). Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by reference).

Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as  
5 activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering  
10 compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with with heterologous polypeptides,  
15 heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present  
20 invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

### **Cardiovascular Disorders**

25 Polynucleotides or polypeptides, or agonists or antagonists of the invention may be used to treat, prevent, and/or diagnose cardiovascular diseases, disorders, and/or conditions, including peripheral artery disease, such as limb ischemia.

Cardiovascular diseases, disorders, and/or conditions include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral  
30 arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus

arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilog of Fallot, ventricular heart septal defects.

Cardiovascular diseases, disorders, and/or conditions also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

Heart valve disease include aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

Myocardial diseases include alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial  
5 reperfusion injury, and myocarditis.

Myocardial ischemias include coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms,  
10 angiodyplasia, angiomas, bacillary angiomas, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular diseases, disorders, and/or conditions, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis,  
15 erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, ataxia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer,  
20 vasculitis, and venous insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication,  
25 carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

Cerebrovascular diseases, disorders, and/or conditions include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral  
30 arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural

hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

Embolisms include air embolisms, amniotic fluid embolisms, cholesterol  
5 embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

Ischemia includes cerebral ischemia, ischemic colitis, compartment  
10 syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

15 Polynucleotides or polypeptides, or agonists or antagonists of the invention, are especially effective for the treatment of critical limb ischemia and coronary disease.

Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous  
20 injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides of the invention may be administered as part of a *Therapeutic*,  
25 described in more detail below. Methods of delivering polynucleotides of the invention are described in more detail herein.

#### **Anti-Angiogenesis Activity**

The naturally occurring balance between endogenous stimulators and  
30 inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound

healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes

5 pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of eye diseases, disorders, and/or conditions, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995);

10 Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have

15 accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

The present invention provides for treatment of diseases, disorders, and/or conditions associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or

20 antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the

25 present invention provides a method of treating, preventing, and/or diagnosing an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety

30 of additional methods in order to therapeutically treat or prevent a cancer or tumor. Cancers which may be treated, prevented, and/or diagnosed with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors,

including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat or prevent cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating, preventing, and/or diagnosing other diseases, disorders, and/or conditions, besides cancers, which involve angiogenesis. These diseases, disorders, and/or conditions include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided for treating, preventing, and/or diagnosing hypertrophic scars and keloids, comprising

the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating, preventing, and/or diagnosing neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

Moreover, Ocular diseases, disorders, and/or conditions associated with neovascularization which can be treated, prevented, and/or diagnosed with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalmol.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalmol.* 22:291-312 (1978).

Thus, within one aspect of the present invention methods are provided for treating or preventing neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of



diseases, disorders, and/or conditions can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause),  
5 toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in  
10 eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-  
15 angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent  
20 complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing  
25 front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed  
30 between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-

3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for treating or preventing neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat or prevent early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating or preventing proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for treating or preventing retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

Additionally, diseases, disorders, and/or conditions which can be treated, prevented, and/or diagnosed with the polynucleotides, polypeptides, agonists and/or antagonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome,

pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

Moreover, diseases, disorders, and/or conditions and/or states, which can be treated, prevented, and/or diagnosed with the the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, solid tumors, blood born  
5 tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and  
10 uivietis, delayed wound healing, endometriosis, vascluogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma  
15 fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (Rochele minalia quintosa), ulcers (*Helicobacter pylori*), Bartonellosis and bacillary angiomatosis.

20 In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a  
25 peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

30 Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized

to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat  
5 tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti-angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized  
10 during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide,  
15 agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the  
20 anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

Within one aspect of the present invention, polynucleotides, polypeptides,  
25 agonists and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

30 The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive

Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

5           Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

10           Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

15           Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo  
20           molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example,  
25           molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

          A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4;  
30           protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence

of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; 5 Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; 10 alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolmidazole; and metalloproteinase inhibitors such as BB94.

15

#### **Diseases at the Cellular Level**

Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides and/or antagonists or agonists of the invention, include cancers (such as 20 follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast 25 cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and 30 adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, the polynucleotides or polypeptides, and/or

agonists or antagonists of the invention are used to inhibit growth, progression, and/or metasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated, prevented or diagnosed by the polynucleotides or polypeptides, or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative diseases, disorders, and/or conditions (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis,

Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g.,  
5 hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

#### **Wound Healing and Epithelial Cell Proliferation**

10 In accordance with yet a further aspect of the present invention, there is provided a process for utilizing the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds.  
15 Polynucleotides or polypeptides, as well as agonists or antagonists of the invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat  
20 exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote dermal reestablishment subsequent to dermal  
25 loss

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are a non-exhaustive list of grafts that polynucleotides or polypeptides, agonists or antagonists  
30 of the invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepdermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft,



epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omentum graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, can be used to promote skin strength and to improve the appearance of aged skin.

It is believed that the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may have a cytoprotective effect on the small intestine mucosa. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. The polynucleotides or polypeptides, and/or

agonists or antagonists of the invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large intestine, respectively. Thus, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat diseases associated with the under expression of the polynucleotides of the invention.

Moreover, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to prevent and heal damage to the lungs due to various pathological states. A growth factor such as the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and bronchiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of alveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated, prevented, and/or diagnosed using the polynucleotides or polypeptides, and/or agonists or antagonists of the invention. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary dysplasia, in premature infants.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could stimulate the proliferation and differentiation of hepatocytes and,

thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetrachloride and other hepatotoxins known in the art).

5           In addition, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to maintain the islet function so as to alleviate, delay or  
10   prevent permanent manifestation of the disease. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

#### 15   Neurological Diseases

Nervous system diseases, disorders, and/or conditions, which can be treated, prevented, and/or diagnosed with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases, disorders, and/or conditions which  
20   result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated, prevented, and/or diagnosed in a patient (including human and non-human mammalian patients) according to the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1)  
25   ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3) malignant lesions, in which a portion of  
30   the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is

destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6) lesions associated with nutritional diseases, disorders, and/or conditions, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

20 In a preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral hypoxia. In one aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral ischemia. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral infarction. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose or prevent neural cell injury associated with a stroke. In a further aspect of this embodiment, the polypeptides, polynucleotides, or agonists

or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with a heart attack.

The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture; (2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, the method set forth in Arakawa et al. (J. Neurosci. 10:3507-3515 (1990)); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk et al. (Exp. Neurol. 70:65-82 (1980)) or Brown et al. (Ann. Rev. Neurosci. 4:17-42 (1981)); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron diseases, disorders, and/or conditions that may be treated, prevented, and/or diagnosed according to the invention include, but are not limited to, diseases, disorders, and/or conditions such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as diseases, disorders, and/or conditions that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-

Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary  
Motor sensory Neuropathy (Charcot-Marie-Tooth Disease).

Further, polypeptides or polynucleotides of the invention may play a role in  
neuronal survival; synapse formation; conductance; neural differentiation, etc. Thus,  
5 compositions of the invention (including polynucleotides, polypeptides, and agonists  
or antagonists) may be used to diagnose and/or treat or prevent diseases or disorders  
associated with these roles, including, but not limited to, learning and/or cognition  
disorders. The compositions of the invention may also be useful in the treatment or  
prevention of neurodegenerative disease states and/or behavioural disorders. Such  
10 neurodegenerative disease states and/or behavioral disorders include, but are not  
limited to, Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette  
Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder,  
panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors,  
including disorders in feeding, sleep patterns, balance, and perception. In addition,  
15 compositions of the invention may also play a role in the treatment, prevention and/or  
detection of developmental disorders associated with the developing embryo, or  
sexually-linked disorders.

Additionally, polypeptides, polynucleotides and/or agonists or antagonists of  
the invention, may be useful in protecting neural cells from diseases, damage,  
20 disorders, or injury, associated with cerebrovascular disorders including, but not  
limited to, carotid artery diseases (e.g., carotid artery thrombosis, carotid stenosis, or  
Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral  
anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery  
diseases, cerebral embolism and thrombosis (e.g., carotid artery thrombosis, sinus  
25 thrombosis, or Wallenberg's Syndrome), cerebral hemorrhage (e.g., epidural or  
subdural hematoma, or subarachnoid hemorrhage), cerebral infarction, cerebral  
ischemia (e.g., transient cerebral ischemia, Subclavian Steal Syndrome, or  
vertebrobasilar insufficiency), vascular dementia (e.g., multi-infarct), leukomalacia,  
periventricular, and vascular headache (e.g., cluster headache or migraines).

30 In accordance with yet a further aspect of the present invention, there is  
provided a process for utilizing polynucleotides or polypeptides, as well as agonists or  
antagonists of the present invention, for therapeutic purposes, for example, to

stimulate neurological cell proliferation and/or differentiation. Therefore, polynucleotides, polypeptides, agonists and/or antagonists of the invention may be used to treat and/or detect neurologic diseases. Moreover, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used as a marker or  
5 detector of a particular nervous system disease or disorder.

Examples of neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include brain diseases, such as metabolic brain diseases which includes phenylketonuria such as maternal phenylketonuria, pyruvate carboxylase deficiency,  
10 pyruvate dehydrogenase complex deficiency, Wernicke's Encephalopathy, brain edema, brain neoplasms such as cerebellar neoplasms which include infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms, supratentorial neoplasms, canavan disease, cerebellar diseases such as cerebellar ataxia which include spinocerebellar degeneration such as  
15 ataxia telangiectasia, cerebellar dyssynergia, Friederich's Ataxia, Machado-Joseph Disease, olivopontocerebellar atrophy, cerebellar neoplasms such as infratentorial neoplasms, diffuse cerebral sclerosis such as encephalitis periaxialis, globoid cell leukodystrophy, metachromatic leukodystrophy and subacute sclerosing panencephalitis.

20 Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include cerebrovascular disorders (such as carotid artery diseases which include carotid artery thrombosis, carotid stenosis and Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral  
25 arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis such as carotid artery thrombosis, sinus thrombosis and Wallenberg's Syndrome, cerebral hemorrhage such as epidural hematoma, subdural hematoma and subarachnoid hemorrhage, cerebral infarction, cerebral ischemia such as transient cerebral ischemia, Subclavian Steal Syndrome and vertebrobasilar insufficiency,  
30 vascular dementia such as multi-infarct dementia, periventricular leukomalacia, vascular headache such as cluster headache and migraine.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include dementia such as AIDS Dementia Complex, presenile dementia such as Alzheimer's Disease and Creutzfeldt-Jakob Syndrome, senile dementia such as  
5 Alzheimer's Disease and progressive supranuclear palsy, vascular dementia such as multi-infarct dementia, encephalitis which include encephalitis periaxialis, viral encephalitis such as epidemic encephalitis, Japanese Encephalitis, St. Louis Encephalitis, tick-borne encephalitis and West Nile Fever, acute disseminated encephalomyelitis, meningoencephalitis such as uveomeningoencephalitic syndrome,  
10 Postencephalitic Parkinson Disease and subacute sclerosing panencephalitis, encephalomalacia such as periventricular leukomalacia, epilepsy such as generalized epilepsy which includes infantile spasms, absence epilepsy, myoclonic epilepsy which includes MERRF Syndrome, tonic-clonic epilepsy, partial epilepsy such as complex partial epilepsy, frontal lobe epilepsy and temporal lobe epilepsy, post-traumatic  
15 epilepsy, status epilepticus such as Epilepsia Partialis Continua, and Hallervorden-Spatz Syndrome.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hydrocephalus such as Dandy-Walker Syndrome and normal pressure  
20 hydrocephalus, hypothalamic diseases such as hypothalamic neoplasms, cerebral malaria, narcolepsy which includes cataplexy, bulbar poliomyelitis, cerebri pseudotumor, Rett Syndrome, Reye's Syndrome, thalamic diseases, cerebral toxoplasmosis, intracranial tuberculoma and Zellweger Syndrome, central nervous system infections such as AIDS Dementia Complex, Brain Abscess, subdural  
25 empyema, encephalomyelitis such as Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis, Necrotizing Hemorrhagic Encephalomyelitis, Visna, and cerebral malaria.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention  
30 include meningitis such as arachnoiditis, aseptic meningitis such as viral meningitis which includes lymphocytic choriomeningitis, Bacterial meningitis which includes Haemophilus Meningitis, Listeria Meningitis, Meningococcal Meningitis such as



Waterhouse-Friderichsen Syndrome, Pneumococcal Meningitis and meningeal tuberculosis, fungal meningitis such as Cryptococcal Meningitis, subdural effusion, meningoencephalitis such as uvemeningoencephalitic syndrome, myelitis such as transverse myelitis, neurosyphilis such as tabes dorsalis, poliomyelitis which includes  
5 bulbar poliomyelitis and postpoliomyelitis syndrome, prion diseases (such as Creutzfeldt-Jakob Syndrome, Bovine Spongiform Encephalopathy, Gerstmann-Straussler Syndrome, Kuru, Scrapie), and cerebral toxoplasmosis.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention  
10 include central nervous system neoplasms such as brain neoplasms that include cerebellar neoplasms such as infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms and supratentorial neoplasms, meningeal neoplasms, spinal cord neoplasms which include epidural neoplasms, demyelinating diseases such as Canavan Diseases, diffuse cerebral  
15 scleritis which includes adrenoleukodystrophy, encephalitis periaxialis, globoid cell leukodystrophy, diffuse cerebral sclerosis such as metachromatic leukodystrophy, allergic encephalomyelitis, necrotizing hemorrhagic encephalomyelitis, progressive multifocal leukoencephalopathy, multiple sclerosis, central pontine myelinolysis, transverse myelitis, neuromyelitis optica, Scrapie, Swayback, Chronic Fatigue  
20 Syndrome, Visna, High Pressure Nervous Syndrome, Meningism, spinal cord diseases such as amyotonia congenita, amyotrophic lateral sclerosis, spinal muscular atrophy such as Werdnig-Hoffmann Disease, spinal cord compression, spinal cord neoplasms such as epidural neoplasms, syringomyelia, Tabes Dorsalis, Stiff-Man Syndrome, mental retardation such as Angelman Syndrome, Cri-du-Chat Syndrome, De Lange's  
25 Syndrome, Down Syndrome, Gangliosidoses such as gangliosidoses G(M1), Sandhoff Disease, Tay-Sachs Disease, Hartnup Disease, homocystinuria, Laurence-Moon-Biedl Syndrome, Lesch-Nyhan Syndrome, Maple Syrup Urine Disease, mucopolysaccharidosis such as fucosidosis, neuronal ceroid-lipofuscinosis, oculocerebrorenal syndrome, phenylketonuria such as maternal phenylketonuria, Prader-Willi Syndrome, Rett  
30 Syndrome, Rubinstein-Taybi Syndrome, Tuberous Sclerosis, WAGR Syndrome, nervous system abnormalities such as holoprosencephaly, neural tube defects such as anencephaly which includes hydranencephaly, Arnold-Chiari Deformity,

encephalocele, meningocele, meningomyelocele, spinal dysraphism such as spina bifida cystica and spina bifida occulta.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention

5 include hereditary motor and sensory neuropathies which include Charcot-Marie Disease, Hereditary optic atrophy, Refsum's Disease, hereditary spastic paraplegia, Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies such as Congenital Analgesia and Familial Dysautonomia, Neurologic manifestations (such as agnosia that include Gerstmann's Syndrome, Amnesia such as retrograde amnesia,

10 apraxia, neurogenic bladder, cataplexy, communicative disorders such as hearing disorders that includes deafness, partial hearing loss, loudness recruitment and tinnitus, language disorders such as aphasia which include agraphia, anomia, broca aphasia, and Wernicke Aphasia, Dyslexia such as Acquired Dyslexia, language development disorders, speech disorders such as aphasia which includes anomia,

15 broca aphasia and Wernicke Aphasia, articulation disorders, communicative disorders such as speech disorders which include dysarthria, echolalia, mutism and stuttering, voice disorders such as aphonia and hoarseness, decerebrate state, delirium, fasciculation, hallucinations, meningism, movement disorders such as angelman syndrome, ataxia, athetosis, chorea, dystonia, hypokinesia, muscle hypotonia,

20 myoclonus, tic, torticollis and tremor, muscle hypertonia such as muscle rigidity such as stiff-man syndrome, muscle spasticity, paralysis such as facial paralysis which includes Herpes Zoster Oticus, Gastroparesis, Hemiplegia, ophthalmoplegia such as diplopia, Duane's Syndrome, Horner's Syndrome, Chronic progressive external ophthalmoplegia such as Kearns Syndrome, Bulbar Paralysis, Tropical Spastic

25 Paraparesis, Paraplegia such as Brown-Sequard Syndrome, quadriplegia, respiratory paralysis and vocal cord paralysis, paresis, phantom limb, taste disorders such as ageusia and dysgeusia, vision disorders such as amblyopia, blindness, color vision defects, diplopia, hemianopsia, scotoma and subnormal vision, sleep disorders such as hypersomnia which includes Kleine-Levin Syndrome, insomnia, and somnambulism,

30 spasm such as trismus, unconsciousness such as coma, persistent vegetative state and syncope and vertigo, neuromuscular diseases such as amyotonia congenita, amyotrophic lateral sclerosis, Lambert-Eaton Myasthenic Syndrome, motor neuron

disease, muscular atrophy such as spinal muscular atrophy, Charcot-Marie Disease and Werdnig-Hoffmann Disease, Postpoliomyelitis Syndrome, Muscular Dystrophy, Myasthenia Gravis, Myotonia Atrophica, Myotonia Confenita, Nemaline Myopathy, Familial Periodic Paralysis, Multiplex Paramyoclonus, Tropical Spastic Paraparesis  
5 and Stiff-Man Syndrome, peripheral nervous system diseases such as acrodynia, amyloid neuropathies, autonomic nervous system diseases such as Adie's Syndrome, Barre-Lieou Syndrome, Familial Dysautonomia, Horner's Syndrome, Reflex Sympathetic Dystrophy and Shy-Drager Syndrome, Cranial Nerve Diseases such as Acoustic Nerve Diseases such as Acoustic Neuroma which includes  
10 Neurofibromatosis 2, Facial Nerve Diseases such as Facial Neuralgia, Melkersson-Rosenthal Syndrome, ocular motility disorders which includes amblyopia, nystagmus, oculomotor nerve paralysis, ophthalmoplegia such as Duane's Syndrome, Horner's Syndrome, Chronic Progressive External Ophthalmoplegia which includes Kearns Syndrome, Strabismus such as Esotropia and Exotropia, Oculomotor Nerve Paralysis,  
15 Optic Nerve Diseases such as Optic Atrophy which includes Hereditary Optic Atrophy, Optic Disk Drusen, Optic Neuritis such as Neuromyelitis Optica, Papilledema, Trigeminal Neuralgia, Vocal Cord Paralysis, Demyelinating Diseases such as Neuromyelitis Optica and Swayback, and Diabetic neuropathies such as diabetic foot.

20 Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include nerve compression syndromes such as carpal tunnel syndrome, tarsal tunnel syndrome, thoracic outlet syndrome such as cervical rib syndrome, ulnar nerve compression syndrome, neuralgia such as causalgia, cervico-brachial neuralgia, facial  
25 neuralgia and trigeminal neuralgia, neuritis such as experimental allergic neuritis, optic neuritis, polyneuritis, polyradiculoneuritis and radiculities such as polyradiculitis, hereditary motor and sensory neuropathies such as Charcot-Marie Disease, Hereditary Optic Atrophy, Refsum's Disease, Hereditary Spastic Paraplegia and Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies  
30 which include Congenital Analgesia and Familial Dysautonomia, POEMS Syndrome, Sciatica, Gustatory Sweating and Tetany).

**Infectious Disease**

A polypeptide or polynucleotide and/or agonist or antagonist of the present invention can be used to treat, prevent, and/or diagnose infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated, prevented, and/or diagnosed. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polypeptide or polynucleotide and/or agonist or antagonist of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papilloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or

diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention  
5 are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose AIDS.

Similarly, bacterial or fungal agents that can cause disease or symptoms and  
10 that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., *Corynebacterium*, *Mycobacterium*, *Nocardia*), *Cryptococcus neoformans*, Aspergillosis, Bacillaceae  
15 (e.g., Anthrax, *Clostridium*), Bacteroidaceae, Blastomycosis, *Bordetella*, *Borrelia* (e.g., *Borrelia burgdorferi*), Brucellosis, Candidiasis, *Campylobacter*, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, *E. coli* (e.g., Enterotoxigenic *E. coli* and Enterohemorrhagic *E. coli*), Enterobacteriaceae (*Klebsiella*, *Salmonella* (e.g., *Salmonella typhi*, and *Salmonella paratyphi*), *Serratia*, *Yersinia*), *Erysipelothrix*,  
20 *Helicobacter*, Legionellosis, Leptospirosis, *Listeria*, Mycoplasmatales, *Mycobacterium leprae*, *Vibrio cholerae*, Neisseriaceae (e.g., *Acinetobacter*, Gonorrhea, Meningococcal), *Meisseria meningitidis*, Pasteurellaceae Infections (e.g., *Actinobacillus*, *Haemophilus* (e.g., *Haemophilus influenza* type B), *Pasteurella*, *Pseudomonas*, Rickettsiaceae, Chlamydiaceae, *Treponema* spp., *Leptospira* spp.,  
25 *Shigella* spp., Staphylococcal, Meningiococcal, Pneumococcal and Streptococcal (e.g., *Streptococcus pneumoniae* and Group B Streptococcus). These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections),  
30 paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea,

meningitis (e.g., meningitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections.

- 5 Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: tetanus, Diphtheria, botulism, and/or meningitis type B.

- 10 Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, 15 Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., Plasmodium virax, Plasmodium falciparum, Plasmodium malariae and Plasmodium ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS 20 related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.

- 25 Preferably, treatment or prevention using a polypeptide or polynucleotide and/or agonist or antagonist of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the 30 polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

**Regeneration**

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues  
5 could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs  
10 (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide and/or agonist or antagonist of the  
15 present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide and/or agonist or antagonist of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated, prevented, and/or diagnosed include of tendinitis, carpal tunnel  
20 syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a  
polynucleotide or polypeptide and/or agonist or antagonist of the present invention to  
25 proliferate and differentiate nerve cells. Diseases that could be treated, prevented, and/or diagnosed using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic diseases, disorders, and/or conditions (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral  
30 neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-

Drager syndrome), could all be treated, prevented, and/or diagnosed using the polynucleotide or polypeptide and/or agonist or antagonist of the present invention.

### **Chemotaxis**

5           A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then  
10 fight off and/or heal the particular trauma or abnormality.

          A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat, prevent, and/or diagnose inflammation, infection, hyperproliferative diseases, disorders, and/or conditions, or any immune system  
15 disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat, prevent, and/or diagnose wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat, prevent, and/or diagnose wounds.

20           It is also contemplated that a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may inhibit chemotactic activity. These molecules could also be used to treat, prevent, and/or diagnose diseases, disorders, and/or conditions. Thus, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention could be used as an inhibitor of chemotaxis.

25

### **Binding Activity**

          A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit  
30 (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.



Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural  
5 receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell  
10 membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

15 The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations,  
20 polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

25 Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

30 Additionally, the receptor to which a polypeptide of the invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein

polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of polypeptides of the invention thereby effectively generating agonists and antagonists of polypeptides of the invention. See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., *Curr. Opinion Biotechnol.* 8:724-33 (1997); Harayama, S. *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, L. O., et al., *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. *Biotechniques* 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides of the invention may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired polynucleotide

sequence of the invention molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides of the invention may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In  
5 another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptides of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a  
10 growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs),  
15 nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the polypeptides of the invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide. The  
20 biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the  
25 polypeptide of the present invention, the compound to be screened and 3[H] thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the  
30 uptake of 3[H] thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of

3[H] thymidine. Both agonist and antagonist compounds may be identified by this procedure.

In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat, prevent, and/or diagnose disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues. Therefore, the invention includes a method of identifying compounds which bind to the polypeptides of the invention comprising the steps of: (a) incubating a candidate binding compound with the polypeptide; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with the polypeptide, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Also, one could identify molecules bind a polypeptide of the invention experimentally by using the beta-pleated sheet regions contained in the polypeptide sequence of the protein. Accordingly, specific embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, the amino acid sequence of each beta pleated sheet regions in a disclosed polypeptide sequence. Additional embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of,

any combination or all of contained in the polypeptide sequences of the invention. Additional preferred embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, the amino acid sequence of each of the beta pleated sheet regions in one of the polypeptide sequences of the invention. Additional  
5   embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, any combination or all of the beta pleated sheet regions in one of the polypeptide sequences of the invention.

### **Targeted Delivery**

10       In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or  
15   prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic  
20   protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific  
25   destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of  
30   toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes

known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed  
5 antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or  
10 mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

### **Drug Screening**

Further contemplated is the use of the polypeptides of the present invention, or  
15 the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

20 This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic  
25 or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

30 Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the

present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound  
5 form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564,  
10 published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art.  
15 Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present  
20 invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

#### 25 **Polypeptides of the Invention Binding Peptides and Other Molecules**

The invention also encompasses screening methods for identifying polypeptides and nonpolypeptides that bind polypeptides of the invention, and the polypeptide of the invention binding molecules identified thereby. These binding molecules are useful, for example, as agonists and antagonists of the polypeptides of  
30 the invention. Such agonists and antagonists can be used, in accordance with the invention, in the therapeutic embodiments described in detail, below.

This method comprises the steps of:

- a. contacting a polypeptide of the invention with a plurality of molecules; and
- b. identifying a molecule that binds the polypeptide of the invention.

The step of contacting the polypeptide of the invention with the plurality of molecules may be effected in a number of ways. For example, one may contemplate

5 immobilizing the polypeptide of the invention on a solid support and bringing a solution of the plurality of molecules in contact with the immobilized polypeptide of the invention. Such a procedure would be akin to an affinity chromatographic process, with the affinity matrix being comprised of the immobilized polypeptide of the invention. The molecules having a selective affinity for the polypeptide of the

10 invention can then be purified by affinity selection. The nature of the solid support, process for attachment of the polypeptide of the invention to the solid support, solvent, and conditions of the affinity isolation or selection are largely conventional and well known to those of ordinary skill in the art.

Alternatively, one may also separate a plurality of polypeptides into

15 substantially separate fractions comprising a subset of or individual polypeptides. For instance, one can separate the plurality of polypeptides by gel electrophoresis, column chromatography, or like method known to those of ordinary skill for the separation of polypeptides. The individual polypeptides can also be produced by a transformed host cell in such a way as to be expressed on or about its outer surface (e.g., a recombinant

20 phage). Individual isolates can then be "probed" by the polypeptide of the invention, optionally in the presence of an inducer should one be required for expression, to determine if any selective affinity interaction takes place between the polypeptide of the invention and the individual clone. Prior to contacting the polypeptide of the invention with each fraction comprising individual polypeptides, the polypeptides

25 could first be transferred to a solid support for additional convenience. Such a solid support may simply be a piece of filter membrane, such as one made of nitrocellulose or nylon. In this manner, positive clones could be identified from a collection of transformed host cells of an expression library, which harbor a DNA construct encoding a polypeptide having a selective affinity for a polypeptide of the invention.

30 Furthermore, the amino acid sequence of the polypeptide having a selective affinity for the polypeptide of the invention can be determined directly by conventional means or the coding sequence of the DNA encoding the polypeptide can frequently be



determined more conveniently. The primary sequence can then be deduced from the corresponding DNA sequence. If the amino acid sequence is to be determined from the polypeptide itself, one may use microsequencing techniques. The sequencing technique may include mass spectroscopy.

5           In certain situations, it may be desirable to wash away any unbound polypeptide of the invention, or alternatively, unbound polypeptides, from a mixture of the polypeptide of the invention and the plurality of polypeptides prior to attempting to determine or to detect the presence of a selective affinity interaction. Such a wash step may be particularly desirable when the polypeptide of the invention  
10 or the plurality of polypeptides is bound to a solid support.

          The plurality of molecules provided according to this method may be provided by way of diversity libraries, such as random or combinatorial peptide or nonpeptide libraries which can be screened for molecules that specifically bind to a polypeptide of the invention. Many libraries are known in the art that can be used, e.g., chemically  
15 synthesized libraries, recombinant (e.g., phage display libraries), and in vitro translation-based libraries. Examples of chemically synthesized libraries are described in Fodor et al., 1991, Science 251:767-773; Houghten et al., 1991, Nature 354:84-86; Lam et al., 1991, Nature 354:82-84; Medynski, 1994, Bio/Technology 12:709-710; Gallop et al., 1994, J. Medicinal Chemistry 37(9):1233-1251; Ohlmeyer  
20 et al., 1993, Proc. Natl. Acad. Sci. USA 90:10922-10926; Erb et al., 1994, Proc. Natl. Acad. Sci. USA 91:11422-11426; Houghten et al., 1992, Biotechniques 13:412; Jayawickreme et al., 1994, Proc. Natl. Acad. Sci. USA 91:1614-1618; Salmon et al., 1993, Proc. Natl. Acad. Sci. USA 90:11708-11712; PCT Publication No. WO 93/20242; and Brenner and Lerner, 1992, Proc. Natl. Acad. Sci. USA 89:5381-5383.

25           Examples of phage display libraries are described in Scott and Smith, 1990, Science 249:386-390; Devlin et al., 1990, Science, 249:404-406; Christian, R. B., et al., 1992, J. Mol. Biol. 227:711-718; Lenstra, 1992, J. Immunol. Meth. 152:149-157; Kay et al., 1993, Gene 128:59-65; and PCT Publication No. WO 94/18318 dated Aug. 18, 1994.

30           In vitro translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated Apr. 18, 1991; and Mattheakis et al., 1994, Proc. Natl. Acad. Sci. USA 91:9022-9026.

By way of examples of nonpeptide libraries, a benzodiazepine library (see e.g., Bunin et al., 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712) can be adapted for use. Peptoid libraries (Simon et al., 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371) can also be used. Another example of a library that can be used, in which the amide  
5 functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).

The variety of non-peptide libraries that are useful in the present invention is great. For example, Ecker and Crooke, 1995, Bio/Technology 13:351-360 list  
10 benzodiazepines, hydantoins, piperazinediones, biphenyls, sugar analogs, beta-mercaptoketones, arylacetic acids, acylpiperidines, benzopyrans, cubanes, xanthines, aminimides, and oxazolones as among the chemical species that form the basis of various libraries.

Non-peptide libraries can be classified broadly into two types: decorated  
15 monomers and oligomers. Decorated monomer libraries employ a relatively simple scaffold structure upon which a variety functional groups is added. Often the scaffold will be a molecule with a known useful pharmacological activity. For example, the scaffold might be the benzodiazepine structure.

Non-peptide oligomer libraries utilize a large number of monomers that are  
20 assembled together in ways that create new shapes that depend on the order of the monomers. Among the monomer units that have been used are carbamates, pyrrolinones, and morpholinos. Peptoids, peptide-like oligomers in which the side chain is attached to the alpha amino group rather than the alpha carbon, form the basis of another version of non-peptide oligomer libraries. The first non-peptide oligomer  
25 libraries utilized a single type of monomer and thus contained a repeating backbone. Recent libraries have utilized more than one monomer, giving the libraries added flexibility.

Screening the libraries can be accomplished by any of a variety of commonly known methods. See, e.g., the following references, which disclose screening of  
30 peptide libraries: Parmley and Smith, 1989, Adv. Exp. Med. Biol. 251:215-218; Scott and Smith, 1990, Science 249:386-390; Fowlkes et al., 1992; BioTechniques 13:422-427; Oldenburg et al., 1992, Proc. Natl. Acad. Sci. USA 89:5393-5397; Yu et al.,

1994, Cell 76:933-945; Staudt et al., 1988, Science 241:577-580; Bock et al., 1992, Nature 355:564-566; Tuerk et al., 1992, Proc. Natl. Acad. Sci. USA 89:6988-6992; Ellington et al., 1992, Nature 355:850-852; U.S. Pat. No. 5,096,815, U.S. Pat. No. 5,223,409, and U.S. Pat. No. 5,198,346, all to Ladner et al.; Rebar and Pabo, 1993, Science 263:671-673; and CT Publication No. WO 94/18318.

In a specific embodiment, screening to identify a molecule that binds a polypeptide of the invention can be carried out by contacting the library members with a polypeptide of the invention immobilized on a solid phase and harvesting those library members that bind to the polypeptide of the invention. Examples of such screening methods, termed "panning" techniques are described by way of example in Parmley and Smith, 1988, Gene 73:305-318; Fowlkes et al., 1992, BioTechniques 13:422-427; PCT Publication No. WO 94/18318; and in references cited herein.

In another embodiment, the two-hybrid system for selecting interacting proteins in yeast (Fields and Song, 1989, Nature 340:245-246; Chien et al., 1991, Proc. Natl. Acad. Sci. USA 88:9578-9582) can be used to identify molecules that specifically bind to a polypeptide of the invention.

Where the polypeptide of the invention binding molecule is a polypeptide, the polypeptide can be conveniently selected from any peptide library, including random peptide libraries, combinatorial peptide libraries, or biased peptide libraries. The term "biased" is used herein to mean that the method of generating the library is manipulated so as to restrict one or more parameters that govern the diversity of the resulting collection of molecules, in this case peptides.

Thus, a truly random peptide library would generate a collection of peptides in which the probability of finding a particular amino acid at a given position of the peptide is the same for all 20 amino acids. A bias can be introduced into the library, however, by specifying, for example, that a lysine occur every fifth amino acid or that positions 4, 8, and 9 of a decapeptide library be fixed to include only arginine. Clearly, many types of biases can be contemplated, and the present invention is not restricted to any particular bias. Furthermore, the present invention contemplates specific types of peptide libraries, such as phage displayed peptide libraries and those that utilize a DNA construct comprising a lambda phage vector with a DNA insert.

As mentioned above, in the case of a polypeptide of the invention binding

molecule that is a polypeptide, the polypeptide may have about 6 to less than about 60 amino acid residues, preferably about 6 to about 10 amino acid residues, and most preferably, about 6 to about 22 amino acids. In another embodiment, a polypeptide of the invention binding polypeptide has in the range of 15-100 amino acids, or 20-50 amino acids.

The selected polypeptide of the invention binding polypeptide can be obtained by chemical synthesis or recombinant expression.

#### **Antisense And Ribozyme (Antagonists)**

In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained a deposited clone. In one embodiment, antisense sequence is generated internally by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, Neurochem., 56:560 (1991). Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., Nucleic Acids Research, 6:3073 (1979); Cooney et al., Science, 241:456 (1988); and Dervan et al., Science, 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide. A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoRI site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is

heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl<sub>2</sub>, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoR1/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the mature polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid of the invention. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding a polypeptide of the invention, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, *Nature*, 29:304-310 (1981), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell*, 22:787-797 (1980), the herpes thymidine promoter (Wagner et al., *Proc. Natl. Acad. Sci. U.S.A.*, 78:1441-1445 (1981), the regulatory sequences of the metallothionein gene (Brinster et al., *Nature*, 296:39-42 (1982)), etc.

The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of interest. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA,

forming a stable duplex; in the case of double stranded antisense nucleic acids of the invention, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA sequence of the invention it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, *e.g.*, the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., *Nature*, 372:333-335 (1994). Thus, oligonucleotides complementary to either the 5' - or 3' - non-translated, non-coding regions of a polynucleotide sequence of the invention could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5' -, 3' - or coding region of mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger et al., *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556 (1989); Lemaitre et al., *Proc. Natl. Acad. Sci.*, 84:648-652 (1987); PCT Publication

NO: WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication NO: WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., *BioTechniques*, 6:958-976 (1988)) or intercalating agents. (See, e.g., Zon, *Pharm. Res.*, 5:539-549 (1988)). To this end,  
 5 the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil,  
 10 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine,  
 15 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil,  
 20 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose,  
 25 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl  
 30 phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded

hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., Nucl. Acids Res., 15:6625-6641 (1987)).

The oligonucleotide is a 2-O-methylribonucleotide (Inoue et al., Nucl. Acids Res., 15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 5 215:327-330 (1987)).

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. 10 (Nucl. Acids Res., 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A., 85:7448-7451 (1988)), etc.

While antisense nucleotides complementary to the coding region sequence of the invention could be used, those complementary to the transcribed untranslated 15 region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science, 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs 20 corresponding to the polynucleotides of the invention, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5' -UG-3' . The construction and production of hammerhead ribozymes is well 25 known in the art and is described more fully in Haseloff and Gerlach, Nature, 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within each nucleotide sequence disclosed in the sequence listing. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA corresponding to the polynucleotides of the invention; i.e., to 30 increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.



As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the polynucleotides of the invention in vivo. DNA constructs encoding the ribozyme may be introduced into the cell in the same  
5 manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since  
10 ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or  
15 prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the  
20 present invention may also be desirous in cases such as restenosis after balloon angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

The antagonist/agonist may also be employed to treat, prevent, and/or  
25 diagnose the diseases described herein.

Thus, the invention provides a method of treating or preventing diseases, disorders, and/or conditions, including but not limited to the diseases, disorders, and/or conditions listed throughout this application, associated with overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense  
30 molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention

### **Other Activities**

5           The polypeptide of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. These polypeptide may also be employed to stimulate angiogenesis and limb regeneration, as discussed  
10   above.

          The polypeptide may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

15           The polypeptide of the present invention may also be employed stimulate neuronal growth and to treat, prevent, and/or diagnose neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. The polypeptide of the invention may have the ability to stimulate chondrocyte growth, therefore, they may  
20   be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

          The polypeptide of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

          The polypeptide of the invention may also be employed for preventing hair  
25   loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, the polypeptides of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

          The polypeptide of the invention may also be employed to maintain organs  
30   before transplantation or for supporting cell culture of primary tissues.

          The polypeptide of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

5       The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, polypeptides or polynucleotides and/or agonist or antagonists of the present invention may be used to  
10       modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive diseases,  
15       disorders, and/or conditions), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used as a food additive or preservative, such as to increase or  
20       decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

#### **Other Preferred Embodiments**

Other preferred embodiments of the claimed invention include an isolated  
25       nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of  
30       positions beginning with the nucleotide at about the position of the 5' Nucleotide of

the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of  
5 positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the  
10 range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide  
15 sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

20 A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X  
25 in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under  
30 stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization

conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1,  
5 which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous  
10 nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the  
15 complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule  
20 comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete  
25 nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X  
30 wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table

1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

5        Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence  
10        determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

      A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic  
15        acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained  
20        in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

      The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least  
25        one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

      Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a  
30        biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a

nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

5           The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

10           Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID  
15 NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

20           Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

          Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of  
25 positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

          Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the  
30 amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid  
5 sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human  
10 cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in  
15 Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA  
20 clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human  
25 cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1  
30 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.



Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence

selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to  
 5 increase the level of said protein activity in said individual.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit,  
 10 goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

In specific embodiments of the invention, for each "Contig ID" listed in the fourth column of Table 7, preferably excluded are one or more polynucleotides  
 15 comprising, or alternatively consisting of, a nucleotide sequence referenced in the fifth column of Table 7 and described by the general formula of a-b, whereas a and b are uniquely determined for the corresponding SEQ ID NO:X referred to in column 3 of Table 7. Further specific embodiments are directed to polynucleotide sequences excluding one, two, three, four, or more of the specific polynucleotide sequences  
 20 referred to in the fifth column of Table 7. In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

**TABLE 7**

Gene No.	cDNA Clone ID	NT SEQ ID NO: X	Contig ID	Public Accession Numbers
2	HUVFY29	12	1037526	AI345945, AW167532, AI979198, AA887980, AI922895, AW172505, AW068699, AI220452, AI384022, AA906045, AI051642, AI752832, AI679629, AW382001, AW381993, W57580, AA928578, AA424120, AI694093, AI684121, AW275841, AI801528, AI338995, AI755011, AI910958, N27682, AW419188, N26255,

				AI076061, AI569410, AW029073, AI223003, AA584015, AI200039, AA700061, AI891147, AW068700, N54893, AA834185, H64554, AI347188, AA191199, AA976184, R61034, R80157, H71049, N20845, R80158, R15992, R55407, T56854, AA911911, AA357074, R60915, AA496717, AA378716, H71563, AI364037, R67284, AA584035, R52915, T56855, R33739, AI364619, H13917, AA911927, AA765707, R31920, AA284898, N88489, N87515, R33627, AA189101, AI868837, AW197102, AA284721, H90451, H13862, AW239089, AA954829, AI758550, AA334668, H64655, N83879, AI572016, AA362503, N83896, AI699540, AW073927, AA496774, C02108, AA092193, AI188630, AF087433, AF165163, AF165164, and D16367.
2	HUVFY29	30	897853	AI345945, AW167532, AI979198, AA887980, AI922895, AW172505, AW068699, AI220452, AI384022, AA906045, AI752832, AI051642, AI679629, AW382001, AW381993, W57580, AA928578, AA424120, AI694093, N27682, AI684121, AI338995, AI755011, AW275841, AI801528, AI910958, AW419188, N26255, AI076061, AI569410, AW029073, AI223003, AA584015, AI200039, AA700061, AI891147, AW068700, N54893, AA834185, H64554, AI347188, AA191199, AA976184, R61034, R80157, H71049, N20845, R80158, R15992, R55407, T56854, AA911911, AA357074, R60915, AA496717, AA378716, H71563, AI364037, R67284, AA584035, R52915, T56855, R33739, AI364619, H13917, AA911927, AA765707, R31920, AA284898, N88489, R33627, N87515, AA189101, AI868837, AW197102, AA284721, H90451, H13862, AW239089, AA954829, AI758550, AA334668, H64655, N83879, AI572016, AA362503, N83896, AI699540, AW073927, AA496774, C02108, AA092193, AI188630, N71226, C15737, AI557278, AF165163, AF087433, AF165164, and D16367.
3	HTAGN51	13	1048891	T99718, AI672210, and AW270191.
3	HTAGN51	31	906580	AA995856, AI672210, AW270191, AL119604, T99718, Y00826, AF113751, AB020713, AA255512, AA282876, AA283032, AA420593, AA483157, AA483242, AA491774, AA491825, AA491980, AA493272, AA493718, AA502863, AA505839, AA507521, AA515147, AA515158, AA547997, AA548059, AA548259, AA548549, AA552753, AA552844, AA554985, AA557741, AA563828, AA564736, AA564831, AA565136, AA565516, H56134, H78512, H92599, H95100, H96481, N22409, AA581666, AA581901, AA581910, AA582052, AA584907, AA583392, AA583603, AA584459, AA584534, AA584627,

				AA584743, AA584747, AA584834, AA586654, AA586665, AA587520, AA593542, AA594081, AA594147, AA594706, AA595827, AA601406, AA601412, AA601418, AA601495, AA601625, AA601628, AA603182, AA604932, AA613153, AA613193, AA618000, AA618459, AA631445, AA572730, AA577765, AA577773, AA577803, AA577825, AA577875, AA577884, AA577921, AA577931, AA578885, AA661560, AA664727, AA665322, AA713821, AA713895, AA714107, AA714486, AA715716, AA715807, AA720777, AA720805, AA720943, AA721030, AA721049, AA730122, AA736954, AA737245, AA736489, AA742398, AA745295, AA749350, AA761416, AA767964, AA769182, AA804967, AA804973, AA808402, AA824585, AA829583, AA834071, AA834194, AA836427, AA836838, AA856868, AA872859, AA873328, AA911390, AA935394, AA937357, AA971198, AA976274, AA983272, AA983440, AA989133, N29555, N75439, N84325, N85750, W37681, W90097, W93753, N86042, N89024, N89311, AA017128, AA018677, AA082639, AA084139, AA088273, AA091426, AA093759, AA094022, AA095145, AA096335, AA121766, AA121767, AA121839, AA121840, AA121876, AA132944, AA136395, AA136629, AA136943, AA136977, AA157151, AA159480, AA160931, AA165176, AA164621, AA167809, AA167240, AA167241, AA167453, AA167491, AA167492, AA167468, AA167543, AA167544, AA167579, AA169847, AA169141, AA169228, AA169233, AA169557, AA169344, AA169346, AA169351, AA176467, AA176906, AA179044, AA179174, AA179365, AA179963, AA179985, AA180281, AA180454, AA181443, AA188613, AA188692, AA188716, AA188953, AA188838, AA191062, AA191204, AA194957, AA195197, AA206780, AA206908, AA643815, AA649905, AA651698, AA211180, AA211914, AA214036, AA218670, AA218754, AA218852, AA218913, AA218880, AA219034, AA219167, AA219168, AA219209, AA219222, AA219479, AA077547, AA227287, AA227893, AA249258, AA252123, AA257010, AA399244, AA421028, AA437400, AA448567, AA451922, AA458671, AA458672, AA458716, AA458783, AA464904, AA464929, AA464930, AA485341, AA485874, AA487777, AA487851, AA487953, AA487954, AA486097, AA486160, AA486768, AA486808, AA487304, AA487519, AA491346, AA489850, AA489899, AA489968, AA489989, AA490015, AA490032, AA490150, AA490183, AA490246, AA496279, AA504660, AA504676, AA504875, AA504927, AA505040, C75155, AA598981, AA634823, AA662979, AA662985, AA663003, AA663004, AA663029, AA663091, AA663223, AA663367, AA663500, AA668151, AA668186,
--	--	--	--	---

				AA668235, AA668252, AA668281, AA668292, AA668327, AA668372, AA668412, AA668496, AA668699, AA680277, AA456204, AA456920, AA457089, AA457176, AA457219, AA457283, AA457322, AA457507, AA457548, AA457599, AA457601, AA434080, AA434354, AA679143, AA679325, AA708186, AA716403, AA719211, AA722310, AA683065, AA683238, AA758129, AA774908, AA775210, AA775329, AA776006, AA778726, AA778953, AA778965, AA780571, AA780730, AA780751, AA782269, AA782279, AA782321, AA833652, AA773127, T03057, T03259, AA984451, AA984452, AI026095, T39228, T40391, T40631, T41239, T48646, T48647, T49954, T49955, T55332, T56669, T57324, T59577, T59685, T59821, T59968, T60702, T63021, T63167, T63720, T63875, F06978, T65750, T65825, F01046, T89256, T92131, T93559, T94346, T94701, T94872, T94919, T96260, T99749, R05946, R06051, R14500, T68944, AA772877, AA773954, AA774057, AA774071, AA694367, AI246137, AI270057, AI298238, AI356307, AI370186, AI453652, AI475824, AI468889, AI565003, AI623435, AI627881, AI174659, AI185790, AI198511, AI201329, AI204938, AI654729, AI219575, AI242491, AI267152, AI267267, AI267283, AI267387, AI267399, AI267434, and AI267690.
4	HPJEZ38	14	1027344	AI650349, AA877499, AA761166, AI120532, AI079253, AI587307, AI093091, AI769686, AI050667, AA826264, AI278422, AI278417, AA250932, AI372945, W15253, W39173, AA894448, N49198, H80483, AA251061, Z21185, AA247168, AA313041, AI743863, AA975408, AA360755, Z21307, AA846588, H81402, AI650555, AI823521, AW043656, AF023657, AC002554, and Z73358.
4	HPJEZ38	32	893112	AI743863, AI650555, AI823521, AW043656, AA247168, AA305409, C14331, D59859, D59275, D51423, D80268, D80253, D59467, D80247, D80024, D80366, C14389, D51799, D80166, D59619, D80210, D80240, D51060, D81030, D57483, D80439, D58283, D80212, D59889, D80188, D80248, D80022, D80219, D80195, C14429, D80391, D80164, D80043, D59787, D80227, D59502, C14014, D80038, D59610, D51022, D81026, D80269, D80196, D80133, D50979, AA514186, D80522, AA305578, D50995, D59927, D80251, C15076, D80193, D80045, D80302, AA514188, D80241, AW360811, D80378, AW177440, AA809122, D51103, AW178893, D80157, AW178906, AW377671, AW375405, D51759, T03269, C75259, AW366296, AW360844, AW179328, AW360817, AW375406, AW378534, AW179332, AW377672, AW179023,

				AW178905, C05695, AW378528, AW178762, D59373, D45260, AW378532, AI557751, D59653, C06015, AW176467, AW177501, AW177511, D80134, T48593, AW177731, AW352171, AW377676, D58253, AW352170, AW178907, AW179019, AW179024, H67854, AW179020, D51250, AI535686, D80132, AW177505, AW360841, AW352120, D51221, AW178983, AW178775, AW178909, AW177456, AW179329, AW178980, AW178914, AW178774, AW177733, AW178908, AW178754, AW179018, C14344, AW352158, AW367967, AI525923, AW352117, C03092, AW360834, H67866, AW369651, D51079, AW179004, AW367950, AW179012, AW178986, T11417, D81111, AW378543, AW378525, AW378540, AW352163, AW177728, F13647, AI525917, D58246, D80949, C14407, D80064, AW177734, D59317, T03116, AW179009, D80014, C14973, AW178781, AW178911, D80258, D59627, AW177722, D59474, C14227, D59503, AI525920, AA285331, D80168, AI910186, AW378533, AA514184, AW352174, D80228, C14298, AI905856, D58101, C14957, AI525235, D60010, AW177508, AI535850, D59551, AW177497, D60214, AI525227, C14046, AI557774, N66429, T02974, D51213, AI525222, AI525912, AW177723, AI525215, Z21582, AI525242, AW378542, AI525925, AW378539, D45273, C05763, C16955, AI535959, Z33452, Z30160, AI525216, AW360855, T03048, AI525237, D51053, H67858, C04682, T02868, D51097, AI525928, A84916, A62298, A62300, A45456, AR018138, AF058696, A82595, AR008278, AJ132110, AB028859, Y17188, A30438, AR060385, AB002449, X82626, I50126, I50132, I50128, I50133, X67155, AR008443, A94995, D26022, Y12724, A25909, A67220, D89785, A78862, D34614, Y17187, AR016514, AR066488, AR060138, A26615, AR052274, AR008277, AR008281, Y09669, AR066487, A43192, A43190, AR038669, D88547, X64588, AR054175, I14842, X68127, AR016691, AR016690, U46128, D50010, A63261, I82448, AR025207, AR008408, AR062872, A70867, I79511, AR066490, A64136, A68321, I18367, U79457, D13509, AR060133, AB012117, AF123263, AR032065, and AR060382.
4	HPJEZ38	33	898192	AL120532, AI587307, AI093091, AI769686, AI050667, AI372945, AA250932, W15253, N49198, W39173, AA894448, AA975408, Z21307, AA846588, AC002554, and Z73358.
5	HUVFB80	34	905862	AI339070, AI197975, AI884792, C17500, AI380351, AI500421, AI884995, AA877126,



				W57931, AA233986, AA721704, AI310201, AI560951, AI743233, AA143237, AI344492, AI245590, AA442443, AW072495, F26488, AA304268, AI027135, AI079317, AA928555, AI541347, AA570158, AA143295, AI583496, AA862400, AI583807, H46464, AI362876, AI541281, AI879450, AI749104, AA933040, AI312953, AI312975, AA340388, AI307429, AI312160, AI308315, AW074978, AI334907, AW301798, AI318626, AI311886, AI308517, AW075157, AI344868, AI376475, AI370083, AI345291, AI053448, AI312354, AI250091, AI252344, AI590450, AW301956, AA282746, AI335498, AW268184, AI307561, AI611858, AI307014, AI340917, AI370101, AI252601, AW301942, AI308028, AI612046, AI309430, AI802845, AI611379, AI344924, AW084805, AI250220, AI583821, AI348908, AW302779, AI417297, AA247751, AI382677, AA327360, AI609988, AI689385, F36474, and AL133448.
6	HFIDQ92	16	1045310	T77533, T77569, R73928, H81027, H81122, N21106, N31120, AA195503, AA232666, AA234053, AA459172, AA659810, AA827020, AA837019, AA976790, AI017858, AA187119, AA776129, AI074833, AI040698, AI089608, AI092056, AI092747, AI261793, AI361823, AI423459, AI140300, AI187933, AI193296, AI333448, AI674608, AI678665, AI733817, AI792638, AI818482, AI824152, AI829513, AI868090, AI911875, AI914098, AI872239, AI925446, AI950508, AW080558, AW084366, AW239061, AW338401, and AW339048.
6	HFIDQ92	35	1042503	AW080558, AI925446, AA418493, AW339048, AI829513, AI660226, AI818482, AI872239, AW338401, AI678665, AA418395, AI826565, AI361823, AI950508, AI140300, AI282830, AI911875, AI094773, AI089608, N31120, AI092747, AI333448, AI017858, AW239061, AA303148, AA326586, AA232666, AA976790, AI074833, AA234053, AA659810, AI423459, AI811974, AA187119, AI261793, AI824152, AI914098, AI187933, AI792638, AI733817, N21106, AA459172, AL047842, R73928, AI193296, T77533, AI904651, H81027, AA776129, T77569, AA827020, AA837019, AA362126, AA322056, AA362125, AA360105, AW084366, AA362200, AA303147, AA372107, AA579573, AI092056, AI674608, H81122, AW168333, AW083295, AI520897, AI868090, AA364341, AA481969, AW026121, AI800138, AI554343, AL119457, AW074869, AL042382, AW058233, AI874151, AI568132, AI927755, AW084219, AL079794, AL042544, AI540754, AW268261, AI340627, AI582483, AI400725, AA911767, AW196105, H42825, AI829327, AI573026, AI919593, AI580674, AW168485,

				AI634305, AI537837, AL119399, AI817430, AI349645, AI446124, AW023590, AW167448, AI348847, AI310575, AI345677, AI564749, AI307736, AI349622, AW193203, AI340533, AI345527, AI348854, AI625464, AI281867, AI494201, AI611348, AW189415, AW167918, AI696969, AL036631, AI433034, AA769433, AI345347, AI282679, AW102816, AW302992, AI610667, AI922577, AA464027, AA603709, AI431909, AI244136, AI799195, AI473451, AI889147, AI805688, AI702406, AI349957, AI890507, AI345005, AI627748, AI269636, AI648408, AL036214, AI446373, AW089572, AW268253, AW169653, AI312428, AW268072, AI073952, F36308, AW072588, AI922091, AW082594, AI345737, AI921386, AI335426, AI348777, AI539238, AI345253, AI307569, AI345736, AI343091, AW263453, AI251221, AI571133, AI310582, AI677824, AI597953, AI568138, AI345224, AI568765, AI921254, AI919107, AI340511, AI866111, AI687065, AI889148, AW130930, AI915243, AI784230, AL036215, AI620093, AI920782, AI311892, AW274192, AI312156, AI452993, AI344935, AI589947, AI680457, AA833760, AW073697, AI567351, AI783861, AW152024, AI382670, AA287231, AW088328, AI923034, AI573093, AI338212, AI524663, AW088591, AI689420, AI862144, AI434453, AI251830, AI648567, N29277, AI144266, AI817244, AI446405, AI567582, AI573167, AI349276, AI345735, AI924686, AI610645, W33163, N22406, AI954507, AI241923, AI950664, AI345608, AI445990, AI680498, AW303089, AW089640, AA613907, AI698401, AA580663, AI288285, AI699143, AI690748, AW087814, AI868931, AI559599, AI364788, AI933992, AW130863, N99092, AI419650, AI567612, AW079336, AI348917, AF154502, AF132676, AF061836, Y11587, AF090943, E03348, E03349, I41145, AL133640, AF078844, AB007812, U49434, AI8777, AL080127, E04233, A08916, AL137463, S61953, I89947, D89079, I48978, A08913, I89931, A08912, AJ012755, A08910, AL080086, I49625, U77594, A08909, AL133014, X84990, AR038854, AL049466, A08908, X52128, I00734, AF111851, E00617, E00717, E00778, AL080060, X70685, AL122045, U72620, X00861, AL137705, AL122111, AF079763, AR059958, AF113676, X53587, AF113694, AL133558, S68736, A52563, AF137367, AL133565, AF012536, AL122049, AF118064, AF118070, AL133098, I89934, I89944, AR000496, U39656, Z72491, A27171, AF113013, AL050277, AL137557, AF215669, X80340, A90832, AL049465, U68387,
--	--	--	--	---

				AF158248, U80742, X65873, AL137292, AF008439, Y10655, S75997, I26207, X82434, AF100931, AF017437, AL137526, X87582, X62580, AF125948, L31396, S79832, L31397, AF022363, AF081197, AF081195, I09360, AL122050, U91329, AL133557, AL080158, X92070, A45787, AL133568, AL133113, AL137665, U78525, AF162270, AL080074, AL137521, AL137478, AF125949, AF026124, U96683, AL050108, I80064, X72889, AL049464, AF111112, AL110171, AF113690, AF118094, AL133093, X79812, I48979, AF051325, E06743, M86826, AL122098, AL117578, AL137656, AL137658, AL050138, AL133010, X93495, AL117432, E02221, AL137548, AF061943, AL122123, AR011880, AR038969, AL137283, AL049300, U67958, M30514, U58996, Y10080, AJ242859, AL117585, AL110225, AF146568, AL080137, AL117394, AL050155, AL117649, AL137294, AL137300, AF057300, AF057299, A08911, X81464, A21103, AF067790, U00763, AL133104, AL137429, AL137556, AF028823, AF113689, L19437, E05822, AL080159, AL133645, AF210052, L30117, AL137648, AL137538, AF017152, U87620, S69510, AL133075, AF061795, AL137712, AF151685, AL133016, AL096744, I66342, AJ003118, AL133077, E15569, AL117440, AF061981, AL122118, AL137273, AL080148, AF030513, AL137527, AL122121, AF106862, AF000145, AL137476, A18788, A93016, AC002467, AL050146, AF119337, A08907, Y14314, AL049452, AL133665, A08915, A12297, AL133072, E12747, AB019565, X96540, AR013797, E02253, AL133080, I03321, AL049382, AF118090, AL137271, AL133081, I42402, AL137459, AL137550, AJ238278, AL117460, AL050116, U00686, AF040751, S78214, AF090901, AL110222, AJ006417, S76508, AF104032, AF026816, AF036941, AR020905, AF091084, AF113019, AF110329, AF126247, AF113677, and S36676.
6	HFIDQ92	36	894300	AW239061 and AF154502.
7	HKABW11	17	926717	AW204767, AA524030, AA148504, C75306, AA411378, AA187643, AI913405, AA553972, AI279367, AA557539, AI086373, H19373, AA813734, AI310328, AI025024, AI796974, AA476672, AI679347, AI335949, AI167654, AA741032, AA741293, AI122655, W00451, AI274864, AI093767, AA625058, AA456480, AI972640, AI972692, AA954705, AW131571, AI970809, AI242314, T80465, AI214584, AI359090, R60850, R60851, AA621499, AA406309, AA035238, AA454588, R83489, AA351094, AA351093, AA843897, AI810698, AI681508, AW055376, AA193421, AA429751,

				AI222600, AW452223, N72171, T97644, H92364, W07063, AA156593, AA007328, AA931492, H18933, N78923, AA938747, AA854581, AA918712, H95621, AA194030, AW028947, AA834389, R70836, AA007327, AI694772, W39084, W23853, R70783, AA099828, R13646, W02937, D62606, N94633, T97645, AA428068, W25268, AI572252, T16699, AA092352, C19087, AI247269, AA350097, AW080211, AW080354, R38496, AI567028, R39026, D79817, AA098908, AI251906, AI950892, AL042382, AL119457, AL043975, AW149925, AI815232, AI927755, AI433157, AI812107, AI978703, AI491775, AI491842, AL079794, AI866469, AL042544, AI954183, AL048656, AI824648, AL119399, AW132056, AI909697, AW160916, AI627360, AL119511, AW104724, AL039086, AI637584, AI274759, AW131282, AI432969, AL120853, AI587114, AL079741, AA572758, AI539153, AI802542, AI207510, AI564719, AL045500, AI702073, AL048323, AL048340, AI889376, AW238730, AL121270, AW160376, AI619502, AW026882, AI540845, AI934295, AI634224, AL119791, AI538885, AI445025, AW162189, AI284517, AW083783, AI524671, AI678989, AI537273, AI312542, AI623941, AL043168, AW148408, AI499393, AL041150, AI687127, AI569583, AL046595, AI610690, AI539771, AI590021, AA420722, AI580190, AI884318, AW087207, AI917963, AI801325, AL121365, AI340603, AI537677, AI590830, AI633125, AI249497, AL036396, AI682971, AL038605, AI469532, AA613907, AW167146, AI440239, AW104827, AW088793, AL119836, AI500523, AI285448, AI340519, AI439762, AI800464, AI500706, AI625079, AI635461, AI500662, AA635382, AI340627, AL042365, AI343030, AI286256, AW075667, AI591040, AL119863, AI468959, AI002285, AI536685, AA830625, AW166970, AI689420, AI862139, AL039132, AI343059, AL036802, AL047041, AI312428, AI799470, AW169671, AI349933, AI560099, AI499131, AA641818, AI816010, AI863382, AW074172, AI815855, AI345347, AI624056, AI537303, AI932953, AI687728, AW152182, AI783504, AI567128, AI863241, AI621209, AA504326, AI648684, AI521560, AI445432, AI580435, AI521244, AI619754, AI499285, AL049829, D87461, AF030769, AL137550, I48978, Y11587, AL117435, AF104032, AL133080, I89947, A08913, AF017152, AF125948, AL137459, Z97214, I48979, A08916, L31396, AF090900, A08910, L31397, A65341, AL050116, AF090943, AF177401, AL110225, AF090896, AL133560, I89931, AL050149, AF146568, I49625,
--	--	--	--	---

				AL137292, A58524, A58523, AF097996, E02349, AR013797, AF113677, AJ000937, Z82022, I09499, AF113019, AL137283, AF090934, AF113689, A77033, A77035, U77594, AF091084, AL117460, Y11254, AL133016, AL117394, AL050393, U49908, AL080124, A08909, AF017437, AL122050, AF111851, AL122093, AF090901, AL122123, AL117457, AL049938, AL122111, AL117583, AL133606, AF113694, AF113699, AF118094, AF106862, X82434, AL050024, AL133075, AF090903, AL080137, AR011880, S78214, AL110280, AF126247, L13297, AL049452, AL137548, AB019565, Y16645, A08908, AF118070, AL133640, Y09972, AL122121, E03348, AL133093, AF118090, AL050155, AF113690, AL096744, AL049466, AL050108, A03736, X98834, S61953, AL110196, AF090886, I66342, S68736, U42766, AF079765, AL049382, AL049314, AF183393, AL110221, AF158248, AF039138, AF039137, AL050277, AL137271, AJ238278, AF113691, AF113013, AL035458, S36676, AL049430, X70685, AR059958, AF125949, U00763, AL049300, AL133081, AL133557, U68233, I92592, Z37987, AL137529, A08912, X63574, AF078844, AL080060, AL049464, I33392, I03321, A93016, AF100931, AF118064, AL137557, AJ242859, X84990, AL117585, AF106697, E07108, A58545, AF113676, AL050146, AL137527, AL050092, E07361, U58996, Y07905, AR038854, AF106827, AF111849, U87620, AL137656, AL133113, AL133031, AB029065, AR029490, AL122098, X83508, AL137648, X65873, AL137479, AB016226, I42402, U53505, A52563, AL137521, AL133565, AL137523, AF141289, A23630, E12747, Y10080, AL122110, AL117416, AF106657, AF119358, L04504, AF114170, L19437, AL137478, Z72491, I17544, AL133568, U35846, I89934, AL137463, A08907, X79812, AL117649, S77771, AL137705, AL050138, AR034821, E01614, E13364, S76508, U91329, U88966, AF061943, U72620, AJ012755, X63410, A18777, AL137429, Y13350, AL137538, AB007812, E06743, AL096751, X72889, X56039, A65340, AL049283, U57715, AL110197, AF079763, A07647, Y14314, AL080163, AL110218, E01573, E02319, I46765, AL133104, M81784, L40363, AF031147, M96857, AF061795, AF151685, AL137658, AF061573, I00734, AL137539, U75932, AR020905, and E05822.
7	HKABW11	37	904652	AW204767, AA524030, AA411378, AA148504, C75306, AA187643, AI913405, AA553972, AI279367, AI086373, H19373,

				AA813734, AA557539, AI310328, AI679347, AI796974, AI025024, AI167654, AA476672, AI335949, AA741032, AI122655, AA741293, W00451, AI972692, AA625058, AI274864, AI093767, AA456480, AI972640, AA429751, AA954705, T80465, AI242314, AW131571, AI970809, AI359090, R60850, AI214584, AA621499, R60851, AA454588, AA035238, AI681508, AA351094, AA351093, AA843897, AW055376, AI810698, AA193421, AI222600, AW452223, H18933, N72171, AA156593, T97644, AA931492, W07063, AA007328, AA938747, AW028947, N78923, AA854581, R83489, AA918712, H95621, AA406309, AA194030, AA834389, R70836, AA007327, AI694772, W39084, W23853, R70783, AA099828, R13646, H92364, W02937, D62606, T97645, AA428068, AW080211, N94633, W25268, AI247269, AI572252, T16699, C19087, AA092352, AA350097, R38496, AW080354, AI567028, R39026, D79817, AA098908, D87461, AL049829, and AF030769.
8	HHFLH45	18	1009252	AI692966, AI281699, AI241829, AA613450, AC004877, AJ133488, AF078930, AL121652, and Z82188.
8	HHFLH45	38	895615	AC004877.
8	HHFLH45	39	897950	AI692966, AI281699, AI241829, AA613450, AC004877, Z82188, and AL121652.
9	HFKLE15	19	1009250	AI149537, AW130188, AA715418, AI280504, AW149288, AA378852, AI284543, AI792575, AI250552, AW069227, AI254770, AI251284, AI251034, AI251203, AI223626, AI804747, AI755214, AA916430, AI754567, T74524, AW004884, AI754105, AI890324, AW304580, AW338179, R27485, AW084445, AA410788, AW270385, AI732710, AI732677, AI469599, AI912401, AA533025, AI634187, AI338981, AI801505, AI133083, AW068596, AI891080, AI282253, AW438542, AI613389, AI355246, AA904211, AI923052, AI754170, AW303196, AA223174, AW173759, H07953, AI369580, AI254779, AA714110, AI354423, AW301350, AA493226, AA873573, AA503019, AI457313, AI345695, AI251241, AA084619, AI054398, AW327624, AW275432, AW069412, AA937809, AW410784, AL119838, AI963720, AI687343, AA315361, AA714011, AI275982, AI278972, AW021917, AI380617, AL119691, AA831638, AL079734, AL135377, AA188676, AW270771, AI801482, AA492114, AA515048, AA483606, AI040051, AW193265, AW407578, AL044340, AI224619, T11828, H73550, AI884522, AA570740, AA535216, AA613627, AI745151, AI056177, AA515351, AA086318, AL042373, AI192631, AI160786, AI609972, AI669421, AA610509, AI281881, AI613280,

				AI491765, AA634837, AI064843, AW271904, AI133514, AI620992, AA574442, AI244254, AI821892, AA947265, AA582746, AA502098, AA501461, AW069657, AA631507, AI589230, AA169245, AW270258, AA833875, AA833896, AI521525, AI181917, AI357823, AW089550, AI792521, AA503298, AI049868, AW274349, AL035413, AC006111, AC004232, AC007011, AL021154, AC006312, AP000555, AL020997, AC005486, AL117258, AC005746, AL031295, AL133448, AL022320, AL133163, U91326, AC004648, AC005058, AC004796, AC002528, AL023553, AC005399, AC004955, AC004694, Z84469, AL034420, AC004491, AP000208, AP000130, L44140, AC005015, AC000075, AL133246, AC007114, AC005566, AC002301, AL049839, AC003663, AC002044, AC004963, U95740, AC005529, AC004895, AC005088, U51244, AL078581, AC002990, AC006077, AL022316, U63721, Z85987, AP000510, AC005480, Z85996, AP000501, AC005207, AC005081, AC004644, Z93244, AC002544, AC007731, AC005500, AD001502, Z69917, Z85986, AC006547, AF001549, AC002316, AC007684, AC005057, AL035249, AL031584, AL031779, AC002039, AP000117, AC002045, U47924, AC005255, AC005736, AP000694, AC002476, Z84480, Z84484, AC002375, AC004158, AC007536, AL139054, Z84466, AC005412, AL022313, AC005664, AC006271, AC005324, AC005527, AP000193, AC004755, AC005048, AP000350, AC005874, AF134471, AC007193, AP000207, AP000129, AP000246, AC004000, AP001052, Z93016, AC002073, AC000353, AL050318, AC008012, AC005899, AP000689, AL034549, AC005409, AL049570, AC005913, Z98036, AL031681, AB003151, AC004148, AC007151, AC005972, AC004805, AL020993, AL049636, AC005261, AC004774, AF064861, AC004143, AF165926, AL121825, AL031289, Z95152, AL008582, AC005632, AL035455, AL031311, AL096791, AC005591, AL031120, AC006001, AC004150, AC005548, AL133445, AC002128, AC005682, AL024498, AP000011, AC004509, AC004149, AC006210, AL035361, AL117329, AC005372, AL021939, AL022332, AL022318, AC005280, AC002996, AC005256, AC002472, Z98749, AC002430, AC005725, AC007052, AL079342, AC005154, AC006241, AC005102, AP000036, AC002126, AC004967, AC007546, AP000152, AC007384, AL049843, Z82214, AF030453, AC005340, AC005971, AC005953, AC007565, AL021918, Z83844, AL035684, AL049540, AL096768, AC005363, AC009363, AC006515, AC006539, AC004033, AC006252, AC002365, AC000029, AL034417, AL035659, AC004990,
--	--	--	--	---

				Z98304, AC004253, Z83847, AL022323, AC005781, AL035634, AC005041, AL008709, AL031005, AL034423, AC009516, AL031427, AC009946, Z82244, AC006449, AC004659, AL031283, AL035587, AD000671, AL132987, AC005921, AC007488, AL031281, AC006057, U62293, AF097732, AC005200, AC003110, AC002994, AL121655, Z83822, AL033392, AC007277, AF111168, AC005094, AP000115, AL008730, AC003982, AC002077, AC005952, AC004841, AC007842, AC004865, AL049653, AC007435, AC003682, AL109628, AP000547, AC007938, and AC008273.
9	HFKLE15	40	898191	AI149537, AW130188, AA715418, AI280504, AW149288, AA378852, AI284543, AI254770, AI792575, AI250552, AW069227, AI251034, AI223626, AI251284, AI251203, R27485, AI804747, AI755214, AA916430, AI754567, T74524, AW004884, AW270385, AI754105, AI732710, AI732677, AI890324, AW304580, AW338179, AA410788, AW084445, AW438542, AI469599, AI912401, AI613389, AA533025, AI634187, AI338981, AI801505, AI133083, AW303196, AW068596, AI282253, AI254779, AI891080, AW301350, AI355246, AA904211, AI923052, AW021917, AW274349, AI754170, AA501461, AA223174, H07953, AW173759, AI369580, AA503298, AA714110, AI354423, AA493226, AA873573, AA503019, AW270771, AI457313, AW069412, AA515048, AI345695, AI251241, AA084619, AI054398, AW327624, AW275432, AA937809, AI380617, AW410784, AL119838, AI963720, AI687343, AA315361, AL119691, AA714011, AI275982, AI278972, AA831638, AL079734, AL135377, AA188676, AA704393, AA492114, AI056177, AI801482, AA483606, AW271904, AI040051, AW407578, AW023111, AW193265, AW270258, AL044340, AI224619, AA535216, T11828, H73550, AI884522, AA570740, AI745151, AA613627, AA515351, AA086318, AL042373, AI160786, AI192631, AI669421, AI821892, AI609972, AI064843, AA610509, AI281881, AI491765, AI133514, AI613280, AA634837, AI620992, AA631507, AI817658, AI244254, AA574442, AA714288, AA947265, AA582746, AA502098, AW069657, AI792521, AA169245, AL035413, AC006111, AC004232, AL021154, AC007011, AP000555, AC006312, AL020997, AC005486, AC005746, AL117258, AL133448, AC002301, AL031295, AL022320, AL133163, AC004796, AC004648, AC005058, AL023553, AC002528, AC005399, AC004955, AL034420, Z84469, AC000075, AP000130, AP000208, AC004491, AP000501, AC005015, AC007114, AC005566, AC004963, AC005409, AC003663, AC002044, U95740, AC002544,



				AC005529, AC005088, U51244, AC002990, AL022316, AL078581, AC006077, Z85987, AP000510, AC005480, Z85996, AC004644, AC005081, AC005207, AL133246, Z93244, Z84480, Z98036, Z85986, AC006547, AL078638, AC007731, AC007684, AD001502, Z69917, AC005500, U91326, AL031584, AF001549, AC002316, AL035249, AC005057, AL031779, AP000117, AC002045, U47924, AC005255, AC002476, AC005736, AP000689, AP000694, AC005664, Z84484, AC004158, Z84466, AL022313, AC002375, AC007536, AL139054, AC005412, AB003151, AC006271, AC005324, AP000193, AC005048, AC005527, AC004755, AP000350, AC004694, AC007193, AC005874, AF134471, AC004774, AC004000, AP000246, AP000207, AP000129, AP001052, AC002073, AL133445, AC008012, AC000353, AL050318, Z93016, AL034549, Z83844, AL031681, AL049570, AC005913, AC004148, AL031311, AC005972, AC004805, AL020993, AL049636, AC005261, AF064861, AL121825, AC004143, AF165926, AL031289, Z95152, AL008582, AL049839, AL035455, AC005632, AC005041, AL031120, AL096791, AC005591, AC006001, AC005952, AL035361, AC005682, AC002128, AL024498, AL022332, AP000011, AC004509, AC004149, AC005899, AC006210, AL022318, AC005372, AL021939, AL117329, AC005280, AC002996, AC005256, AC002430, AC002472, AC007052, AC004990, AC007384, AC009946, AL079342, AC005725, AC005154, AC006241, AC004967, AC007546, AC005102, AP000036, AC002126, AP000152, AC005363, AL049843, AF030453, AC005971, AC007565, AC005340, Z82214, AL021918, AL035684, AL034417, AL049540, AC004895, AC004150, AL096768, AL132987, AC009363, L44140, AC006515, AC006539, AL009172, AC000029, AC004033, AC004865, AC005953, AC006252, AC002365, AL035659, Z98304, AC004253, AL022323, AL035634, Z83847, AC000159, AC005781, AL008709, AC006597, AL031005, AC007151, AL034423, AC005829, AC004659, AC004263, AP000967, AL031427, AC007227, AL035587, Z82244, AL031283, AC007488, AD000671, AP000212, AP000134, AL033392, AC005921, AL031281, AF111168, AF097732, AC006057, U62293, AC003110, AC002994, AC005200, Z83822, AC005094, AL008730, AC007277, AC002077, AP000115, AC003982, AC004841, AL049653, AC007842, AL109628, AC007435, AC008273, and AC006121.
10	HTPIH83	20	919916	AW385836, AW006504, AI769564, AA552647, AW015998, AI343787, AI285131, AA976345, AI949846, AI685788, AI953481, AW083920, AI262767, AW194732, AA345449,

				AA639438, T86266, AI469683, AI244378, AI659323, T86158, AI932964, AI913916, and AF072128.
10	HTPIH83	41	895024	AI953481, T86266, AA345449, and AF072128.
10	HTPIH83	42	898088	AW385836, AW006504, AI769564, AA552647, AW015998, AI343787, AI285131, AA976345, AI949846, AI685788, AW083920, AA345449, AI262767, AW194732, AA639438, AI469683, AI244378, AI659323, T86158, AI932964, AI913916, and AF072128.
11	HMSOW51	21	1019015	AW071975, AI129815, AI922669, AA702864, W32947, AI343825, AI168499, AA627735, AI554367, AI335089, AA875852, AI290781, AA442570, AA486920, AI357884, R39812, AI088635, W79882, W17367, H05057, N78991, AA972857, R62969, R59135, R56601, AA436814, R66262, AA813538, W74268, AA133776, Z43556, R14044, R81029, T48889, AA228697, R56602, AA142932, R63023, Z39624, F02373, AA993978, R59136, R66723, R67603, AA133775, R80928, T48888, AA368546, AA228698, AA115592, AA328299, AA486747, AL036146, AI445165, AL040243, AI269696, AI521012, AW071417, AI273142, AW150578, AI869367, AI800433, AL121328, AI648684, AI922901, AA508692, N80094, AL036631, AI497733, AW161579, AL038445, AL043326, AI800453, AA640779, AW238730, AA572758, AW169653, AI783504, AL079963, AI620284, AI340603, AI537677, AI498579, AL036274, AI917055, AL041772, AL036396, AI815855, AI349933, AW103371, AI868831, AI284517, AI633419, AI590120, AI348897, AI866002, AI571909, AI433976, AI828731, AW023590, AI610645, AI539771, AW268220, AI950664, AI097248, AI636719, AI539153, AI866608, AI554245, AW403717, AI929108, AI340582, AL036403, AL039086, AI567612, AI499285, AI923768, AI567351, AL119863, AI349645, AI678302, AI862144, AL045500, AW026882, AW068845, AI564719, AI815232, AI873731, AI524671, AL120853, AL036736, AA613907, AW089572, AI619502, AI802542, AW082040, AL036802, AW148320, AI784252, AA287231, AL038605, AW075413, AI500077, AL119791, AI433157, AI926790, AI889376, AL038779, AW074993, AI349614, AL042544, AI334450, AI343112, AL038565, AI921248, AW268253, AI349598, AI569583, AI269862, AI312152, AI445414, AI309401, AI872711, AI345735, AI312428, AI648663, AI500523, AI554427, AI340519, AI567978, AI349937, AI251205, AI349957, AI308032, AI307708, AI500659, AI284131, AI702073, AI753683, AI344785, AI745485, AL045266, AA804740, AI799199, AW051258, AI923989, AI754897,

			AI677796, AI538829, AI290154, AI866585, AL047042, AI570384, AW183130, AI886753, AI499463, AL042627, AA225339, AA427700, AI362637, AI284509, AI873644, AI366549, AI281762, AI686926, AI572418, AW022682, AI521244, AI446373, AI224992, AI344928, AL046926, AI349772, AW059837, AI828682, AW074869, AI343059, AL041150, AL047763, AL040827, AI345347, AI572569, AI572892, AI679764, AI640379, AI702433, AL121286, AW195969, AW302965, AW087445, AI690426, AI457135, AI591074, AI475151, AL042382, AW167203, AW102761, AI612759, AW117882, AW103893, AI249962, AI561299, AI476109, AW190042, AI801325, AI922676, AI888953, AI336575, AI132502, AL034397, I48979, A08916, AF177401, AL122050, I89947, I48978, I89931, A08910, Y11587, AL117457, AF061943, A08913, AF090934, AL133093, AR059958, AL049382, AL049314, AF113677, S78214, AL110221, AL133016, AL049452, E03348, AF113689, A08909, AL137459, AF113019, A65341, I49625, AF090903, AF090896, AL050393, AF113690, I33392, AJ242859, AL133557, AL096744, AL133072, AL137550, AL133080, AL133606, AL133640, L31396, AF090901, L31397, AF104032, Y16645, U67958, AL117583, AL133560, AF125949, AL050108, A03736, AR011880, AJ000937, AF113013, AL050116, AL080124, U35846, AF017152, E07108, AL133075, AF113676, S68736, AL080137, A12297, AF078844, AL080060, I03321, Y11254, AL110196, AL050149, AF146568, AF106862, AF118064, AF118070, AF113691, AF090900, AL137527, AL133565, AL122121, AL049466, AF113694, A93016, AF097996, AL050024, A77033, A77035, AL137538, AL122093, AL049430, AL050277, AL137648, AL050146, AF091084, X84990, AF113699, AF158248, AL137557, AL137271, AF111851, AJ238278, AL117460, AL133113, U42766, AB019565, AF079765, X63574, AF017437, AF090943, AL049938, X72889, E02349, AL110225, U72620, Z82022, AL122118, U00763, U80742, I26207, AL122123, A58524, A58523, AL137283, X82434, AL122098, U91329, AF087943, AL117585, AF125948, AL137463, AL117394, AL122110, E07361, AL049464, AF183393, AL117435, I09360, X70685, AF153205, A08912, X65873, AL080159, AL110197, AL080127, AL050138, X93495, AF118094, AL049283, U96683, AL137521, X96540, AL049300, E15569, AL050172, AL122049, AF067728, I42402, AL133568, AF111112, Y09972, AL133014, X98834, AL137294, AJ012755, A93350,
--	--	--	---

				AL133077, Y14314, AL080074, AF119337, AL137526, AL137560, AR000496, U39656, I00734, AR038969, E00617, E00717, E00778, S61953, U58996, AF026124, AL133104, AL137705, AF026816, AF057300, AF057299, AL137476, E08263, E08264, AL137556, AF079763, Z72491, AF003737, M30514, AF162270, E08631, AF132676, AF061836, AL133098, A07647, AL080158, AL110280, AR038854, AL133067, AF210052, AF008439, E05822, AL137523, AF100931, X87582, L30117, A45787, AL117440, AF185576, AJ006417, E04233, AF111849, E02221, A90832, AF051325, AF106827, E12747, AL133081, X92070, U68387, I41145, AF030513, AL137533, AL137480, AL122111, X53587, I17767, Z37987, I66342, AL137488, AL080086, L19437, X62580, U68233, I92592, AL137300, U78525, Y07905, AL117432, AF081197, E06743, and AL137273.
11	HMSOW51	43	902853	W32947, AA486920, W79882, AW071975, W17367, R59135, AI922669, AI129815, R56601, R66262, AA442570, AA702864, Z43556, R14044, R81029, AA228697, R63023, AI168499, AI343825, AA627735, AI554367, AI335089, AI290781, AA875852, AA133775, AA368546, R39812, AI357884, AI088635, T48888, R62969, N78991, AA972857, H05057, W74268, AA436814, AA813538, AA228698, AA133776, AA115592, T48889, R56602, AA328299, AA142932, Z39624, F02373, R80928, AA993978, R67603, R66723, R59136, AJ132502, and AL034397.
12	HUCNC61	22	905580	AW085582, AI889737, AI741786, AL135455, AI147732, AI765660, AI769124, AI435583, AI453110, N46860, AI241236, AI367630, AW009193, AI087977, AA542984, AI382157, AW006671, AW021676, AI394183, AI660654, AI694000, AA100766, AA132196, AI367733, AA487029, AI275790, AW389145, AI280697, H19050, AA226190, AA641064, AI721084, AA243501, AI983989, AA494141, AA652616, AA100713, AW001553, H19340, AA486589, AA243813, AI200396, AA923695, AI266736, AI161354, AI282647, AA152188, F35666, R72215, AA662129, H11204, AI074886, AI350966, AI826221, AA350170, N47180, H16296, F28566, AA131935, AA594883, H81579, AA598405, AA662093, H81238, AI247304, Z44850, F10346, AI368893, AA318812, F03820, AA070851, AA456832, AW239138, AA662318, R72174, AA211243, AW075391, AI572457, AA566037, R60651, T66011, AW299697, AI471101, AI652050, F13476, AA553434, N56415, AI525965, AI632031, AI280271, AI383661, AA486895, H81160, AA551633, AL134524, AA650304,

				T10474, AI371538, AL119418, AL042420, AC003108, U91321, AJ236936, AC005089, U73166, AL008721, AC002565, AC004967, AC002352, AC007030, AL034549, AC003101, AC004526, AC006449, AC006211, AL049758, AC005911, AC002425, AL050307, AC005562, AC007055, AC004990, AC004504, AC005088, AC002430, AF067844, and AA604963.
13	HIDAF73	23	941957	AW085581, AA779984, AA772280, AA179220, AI742804, AI742683, AI951170, AI814573, AA863099, AW082910, AW337217, W60903, AI923000, AI151292, AA903039, AI869309, AA770643, R54209, AI347390, AI123767, AA860324, AI587201, AI829045, AW083161, AA159302, AA146620, AI215757, AA977562, R54210, AI204447, AA350753, AA724122, AA627619, H04999, AI033238, AA055855, AA159401, AA216361, AA628733, H05000, AI206527, M62122, AA972816, AA627489, W58621, W24376, AI763072, AA143551, H60541, AA678441, AW104981, T92781, AA916574, T33570, AA757975, AA179219, AA609011, H60540, AA910900, AA937162, AA679734, AA887700, AA973495, AA852296, AA376209, AA852295, AW044332, AA630803, AW166663, D20854, T92704, AW193718, N93654, AA630011, AA093581, W60950, AA887532, R35990, W58620, and AA731287.
13	HIDAF73	44	895117	AI190647, AA987679, AI918338, AA780007, AA725258, AI741156, AA743656, AA630154, AI539473, AI360343, AI052387, AI745201, N57808, AA933054, AI095863, AA152196, AW043714, N70711, AI382077, N68563, AI126119, AA807867, AA716324, AI208742, AA625585, AI739611, AI017163, AI718175, AI797012, AA782051, AI313189, AI765354, AW188175, AA659911, AA459002, AA976098, AA719265, AA621317, AI702842, AA724267, AA131262, AA758069, AA719129, AA917517, AA987343, AA053929, AI223786, AA975991, AI418870, AI306519, N39614, AI361324, N55180, AI681279, N47809, AA022902, W95005, AA287916, AI348351, AI911018, W84793, AI024337, AA987345, R53581, AA131350, AI160473, AI913697, N57887, R00251, AI686849, AL119457, AL119399, AL119324, AL042544, Z99396, AL119443, AW392670, AL119418, AW372827, AW384394, AL119483, AL134902, AW363220, AL119497, AL119355, AL119319, AL119464, AL119363, U46349, AL119484, AL119391, AL036418, AL038837, U46350, AL119341, AL119522, U46351, U46341, AL037051, AL036725, AA631969, AL119335, AL119396, AL119496, AL036858, U46347, AL119444, AL042984, AL037205,

				AL134538, AL039074, AL119439, AL119401, U46346, AL036924, AL038509, AL042614, AL042965, AL042975, AL134536, AL134525, U46345, AL043029, AL043033, AL042551, AL037094, AL037526, AL037085, AL043011, AL043019, AL036196, AL037082, AL042450, AL037639, AL042542, AL037077, AL036767, AL036190, AL043003, AL036268, AL038520, AF151874, AR060234, AR066494, A81671, AR023813, AR064707, AR069079, AB026436, and AR054110.
13	HIDAF73	45	905873	AW085581, AA779984, AA772280, AA179220, AI742804, AI742683, AI951170, AI814573, AA863099, AW082910, AW337217, W60903, AI923000, AI151292, AA903039, AI869309, AA770643, R54209, AI347390, AI123767, AA860324, AI587201, AI829045, AW083161, AA159302, AA146620, AI215757, AA977562, R54210, AI204447, AA350753, AA724122, AA627619, H04999, AI033238, AA055855, AA159401, AA216361, AA628733, H05000, AI206527, M62122, AA972816, AA627489, W58621, W24376, AI763072, AA143551, H60541, AA678441, AW104981, T92781, AA916574, T33570, AA757975, AA179219, AA609011, H60540, AA910900, AA937162, AA679734, AA887700, AA973495, AA852296, AA376209, AA852295, AW044332, AA630803, AW166663, D20854, T92704, AW193718, N93654, AA630011, AA093581, W60950, AA887532, R35990, W58620, and AA731287.
14	HNSAA27	24	997304	AI821357, AI140949, AI732254, AI820676, T90496, AW152618, T94416, T90592, T94503, AA470491, AL119863, AI282326, AI572892, AI453413, AI270183, AI872545, AL036146, AI554245, AI269862, AL079963, AI590830, AL042627, AI802542, AI698391, AI537273, AW071417, AI288305, AW051258, AI619502, AL042628, AA292158, AW190042, AI702406, AI921248, AI866770, AI434468, AI889189, AI274508, AW302988, AI886753, AL045266, AI917252, AI620284, AW268220, AI334450, AI500077, AW162071, AI345347, AI874261, AA640779, AW020693, AI537677, AW081036, AI521560, AA572758, AI933589, AI312428, AI889376, AI610402, AL039086, AI524671, AI340603, AI500061, AI633125, AI890833, AI926790, AI564719, AI591420, AI801325, AI932794, AI611738, AI632408, AI677796, AW118518, AI873604, AI570807, AW026882, AW050522, AI612913, AI923370, AI281772, AW117746, N80094, AI492540, AI627360, AI475371, AI433157, AI702073, AI796743, AI476046, AI678357, AL121286, AI696612, AW238730, AI829327, AI499285, AA508692, AI873644, AI783504, AI468872, AI445992,

			AI521012, AI285448, AI582932, AI520809, AI288285, AL040241, AI340582, AI950892, F34800, AI499986, AL036274, AI815855, AW149925, AL040243, AI500523, AL037454, AW080746, AL038605, AW274192, AI306613, AI500662, AL041573, AL041772, AI888661, AI699011, AI335209, AI923989, AL036631, AI621179, AI804983, AI274507, AI446373, AI868831, AI859464, AI281782, AW169671, AI349645, AI349004, AA225339, AL080046, AI537515, AI133559, AW129659, AL047763, AI648509, AI915291, AI452560, AI493576, AI800433, AW073994, AI608936, AI889953, AI340519, AL134999, AI805603, AI439762, AI702068, AI433976, AI862144, AL045500, AI922901, AI318280, AI567940, AI824746, AW075381, AW071349, AW068845, AW150578, AL036804, AI538085, AI978703, AI271796, AW022682, AL036396, AI340627, AI800453, AL036403, AI866608, AL121014, Z99428, AW302992, AI284517, AI445165, AI571909, AI680162, AI569583, AI497733, AL041150, AL036802, AW029611, AW169653, AI635067, AA806720, AI627988, AL046944, AI269696, AI633419, AI500706, AI498579, AI799183, AI866002, AI866090, AI670009, AI955917, AI250369, AI866573, AI648684, AL039132, AI610645, AI869367, AL042745, AW148320, AI784252, AI349933, AI686906, AI252023, AI950664, N33175, AW075413, AI874166, AW132056, AL036736, AI609127, AW089572, AI348897, AI308035, AI284131, AI567769, AI620003, AI862139, AI174394, AW161579, AI539153, AI687362, AI815232, AI866457, AI539771, AI567351, AW074993, AI344928, AI349614, AI431975, AI539028, AW103371, AI886124, AL036541, AW268122, AI343112, AW193911, I89947, E02349, AF017437, I48979, I48978, AL122093, AF090903, AF177401, A08910, Y16645, A08909, A77033, A77035, A08916, A08913, AL117457, AL137550, AF183393, AL049430, AF113677, I33392, AL137271, AL117583, AF125949, AF158248, AB019565, AL133557, A03736, S78214, AL137538, I89931, AL137527, X63574, AF087943, AF111851, AL117435, AF090934, AF118070, I49625, AL133560, U35846, AF113019, AL133075, S68736, AL050393, AF113694, AF113689, AF113691, AF090900, AF061943, A65341, Y11254, AF125948, AF113690, AF090943, Y11587, AL122050, AL137459, AR059958, AL110221, AL133016, AL117585, AF026816, AF090896, X65873, AL133606, X82434, AL133640, X84990, AL137463, AL049466, AF091084, AL050024, AL133080, AL050146, AL050138, AL122110, AL080159,
--	--	--	---

				AL049314, AL117460, AL050149, AR011880, AF118064, AJ000937, AL050277, AL080124, AF106862, E07108, AL050116, AL133113, X72889, AL049464, Z82022, AL049452, AL049300, U67958, AF113699, AL049382, AL122098, AF146568, AF090901, AL122049, AF067728, X70685, AJ238278, AF017152, AL080127, L31396, AL050108, U80742, U42766, L31397, AF078844, AL133093, AF113013, AL080060, I03321, A58524, A58523, E03348, AL137557, U00763, AF113676, AL080137, AF079765, AL110280, U72620, A93016, AF118094, AL049938, AL110196, AJ242859, AR038969, AL137521, AL122121, AF104032, AL049283, AL096744, AL122123, AL117394, AL133565, AF097996, AJ012755, X98834, AL110225, A08912, X96540, X93495, AL137560, U58996, AL137648, A12297, AL137480, E07361, AL137283, I42402, I26207, A93350, Y14314, AL133067, E15569, I09360, AL133072, AL133014, AF061573, U91329, E05822, AF119337, AF026124, AL110197, AF153205, AF111849, AL023657, Y09972, AF111112, AF057300, AF057299, AL133568, AF185576, S61953, AR038854, AL137533, E08263, E08264, E06743, AR000496, U39656, I00734, AL133077, I09499, E00617, E00717, E00778, AL050172, AL080148, U96683, E02221, AF003737, AL137556, A45787, AF079763, AL137476, Y07905, AL133104, AF106827, AJ006417, AF028823, AF162270, A07647, I66342, X87582, AL137523, AL080074, Z37987, AL117440, D83032, AF210052, X62580, AR013797, AL137526, Z72491, AL137292, AF067790, AL137478, M30514, AL133098, I17767, E08631, AF008439, L30117, E04233, U49908, AR020905, AL137429, L19437, AL137488, A90832, AL137294, I96214, AR034830, S36676, AF061795, AF151685, U68387, X53587, AF100931, AF126247, A65340, AL133665, and U78525.
14	HNSAA27	46	895007	AI821357, AI140949, AI732254, AI820676, T90496, AW152618, T94416, T90592, and T94503.
15	HWBAO29	25	948565	AI906417, AI986267, AW364583, AA297168, AI907264, AA775077, AA662043, AA211455, AA315241, AA298939, AA642822, AI751043, AA904275, AW304580, T74524, AL040374, AW407578, AA483606, AA570740, AI590906, AI521525, AA568204, AI654738, AI754170, AI537020, AI281881, AA315361, AW410354, AW327868, AW192179, AA713946, AI926102, AA715173, AA715075, AA838091, AW069412, AI254779, AI445934, H68343, AI356440, T06598, AA084609, AA659832,



				AA613624, AA491594, AL048135, AI114733, AI133552, AA833875, AA833896, AI907412, AW328202, AI791227, AA877992, AI569401, AI439840, AA302971, AI040051, AA569247, AI149478, AW020150, AB002323, AC005200, AC005207, AP000036, AF165926, AP000193, AL031432, AC004031, AC005409, AP000100, AP000117, AP000510, AC004659, AC005808, AC008273, AC002480, AP000263, AP000556, AL109627, AC005972, AL031255, AL049761, AC006455, AC004686, AC004757, AC002365, AC006312, AC004967, AL022332, AC007216, AP000350, AC005048, AP000141, AL049539, AC002375, AC005071, AC005962, AL049839, AL033524, AC007993, AC005486, U95742, AC003982, AC006285, AC005632, Z83847, AC004024, AC010205, AC005324, AL034423, AL049776, D87675, AL022336, AC006023, Z69917, AC004000, Z84467, AC004253, AC005088, AC005529, AC004466, AP000493, AC007172, AP000114, AP000046, AC005527, AC004752, AC004020, AC004878, AC005015, AL022311, AC002128, AC006252, AL035071, AF134726, AC007731, AC005500, AJ239322, AC004834, AC007664, U95740, AC004552, AC005746, U91326, AL031663, Z85987, AC002044, AC003101, AC002302, AC004685, AC019014, AC005736, AC004033, Z99716, AC005081, AC002316, AP000552, AC007565, AC005245, AP000503, AF064861, AL035420, AC000041, AC005781, AF051976, AC005342, AC005004, AC005901, AC006241, AP000302, AC002306, AC005779, AP000553, AC004148, AC002404, AL121825, AL008726, AC005157, AL031291, AC007308, AC000025, U63721, AL031681, AC004383, AC002369, AL008636, AC008018, AC003009, AC005029, AL034549, AC005225, AC005874, AL117337, AF134471, Z83826, AP000694, Z95116, AC005233, AC003043, AC006965, AF001549, AL031597, AC002504, AL137100, AP000050, AF196971, AC004966, AF030453, AC002550, AL031289, AL022721, AL050333, AL049830, Z97053, AL024509, AC006509, AC005209, AC005355, AC006057, AF126403, AC005261, AL035695, AL031846, AL031311, AC007773, AC005881, AL024507, AC006536, AF109907, AC006511, AC002544, AC004098, AC004799, AC002991, L78810, AL022165, AC002425, AC006251, AC004895, U62317, AC006449, AC004150, AC006262, AC002546, AF003529, AC005696, AC004526, AP000692, AC002551, AL133312, AL117352, AC007880, AC008115, AC016830, AL133353, AC005932, AL133382, AC002472, Z73420, AC003963, AC003007, Z97181, AF045555, AC005971, AL049780, AC005484, AC007226, AC006441, AC003010, AP000112,
--	--	--	--	---

				AC006014, AC007444, AL049759, AC007011, AP000313, AP000210, AP000132, AC007566, AC007676, AP000251, AC004885, AC007541, AC004408, AL109623, Z83844, AC007536, AL034548, AB020868, AC002301, AC002430, AC004938, AC000353, AC004477, AC006323, AC003962, AP000502, AP000248, AC005358, and AL117258.
15	HWBAO29	47	895563	AI906417, AW364583, AA211455, AA297168, AI907264, AA315241, AA298939, AA662043, AA642822, AI751043, T33915, AA297909, AI907412, AI860714, AA569247, AI907309, AA309515, AI907311, AL045688, AA350332, AW384282, AI907413, H30750, AW392621, AW392627, AW392625, AA297099, AW384151, AW392630, AW384273, AW392613, AI907308, AB002323, L08505, and D13896.
15	HWBAO29	48	897887	AI986267, AA775077, AA904275, AW407578, AI590906, AI281881, AW327868, AW192179, AL040374, AW304580, AI754170, AA533054, AW410354, AW069412, AI040051, AA713946, AA503298, AI149478, AI064864, AI745151, AI984168, H90844, T74524, AW073470, AI521525, AL048135, AI889794, AA491594, AI537020, AA084609, AW328202, AI926102, AA483606, AA570740, H53168, AC005207, AC005200, AP000036, AF165926, AL031432, AC005225, AC004031, AC005409, AC004659, AC006023, AL049712, AP000556, AP000510, AC006312, AP000263, AL034423, AC005972, AC005808, AC002480, AC002365, AC005901, AP000100, AP000193, AC007216, U63721, Z82195, AL049761, AL031255, AC000159, AC004757, AP000117, AC004686, AL031597, AL033524, AC005088, AC004967, Z85987, AC006536, AC002375, AC007993, AC005071, AC005962, AC005324, U95742, AC005527, AC005529, Z83847, AC006285, AC005632, AC005736, AL022336, AL022721, AC007011, AL022311, AC004000, AC002128, AC004253, AC006449, AC004466, AC007172, AP000046, AP000114, AC004106, AC004020, AC004150, AC005355, AC004878, AJ239322, AC005015, AL031602, AL049836, AC006252, AF134726, AC007731, AC005500, AC005486, AC008273, U95740, AC004834, AC005568, AC007664, AL008726, AC002550, AC000041, U91326, AP000350, AC002044, AC003101, AC002302, AF205588, AC006509, AL121825, AC019014, AC005971, AC005874, AF134471, AC007308, AC000025, AL024507, AC003009, AC006511, AC005245, AC006211, AP000503, AF064861, AP001053, AC003982, Z95116, AC005004, AC006241, AL109627, AC005726, AP000302, AC002306, AL031846, AC002119, AC005779, AC004033, AC002404, AL109623, Z99716,

				U62292, AC003043, AL031681, AC004383, AL022332, AL049839, AL049780, AJ011930, AC008018, AC005233, AC005029, AC002544, AL117337, Z83826, AC004966, AC002504, AF196969, AC006430, Z97053, AC006262, AL031291, AL024509, AC005209, AC006057, AC005261, AC002991, AL035695, AL035071, AL031311, AL034420, AF109907, AC002301, AP000050, AL121603, AP000141, AC005920, AC005332, L78810, AL049539, AC002425, AL049776, AC006251, AF196779, AC004895, AC006064, AL022165, AC006578, AC004755, AC002546, AP000466, AL031283, AC007151, AC004552, AC002551, AC004526, Z97181, AL049830, Z85986, AC010205, AC007880, L44140, AC005932, AL133382, AL133353, AC004143, AC002472, AP000133, AP000211, AF001549, AC003007, AC004024, AC002059, AP000356, AC005484, AC004752, AC006441, D87675, AC007263, AC007566, Z83844, AC005663, AC005288, AL033527, AP000251, AC009516, AF024533, AC002470, AL035410, AC007541, AC005291, AP000555, Z84467, AL034548, AB020868, AC003682, AC002430, AC004938, U91318, AL049760, AC000353, AC003962, AL050341, AC007055, AC006071, AL132777, AC005358, AC006323, AF118808, AL049829, AC009247, AP001068, AL121655, AP000694, AL034379, AC005907, AC007384, AC007437, and AL035587.
16	HTLJC07	26	1008753	AI200750, AW054886, AI358095, AI802410, AW182407, R48313, H28124, R48418, AI032851, AI986052, AA010034, AI719051, AW410484, AA478487, AA010033, AA551151, AI589428, AW080076, AI758270, AA975952, AI570966, AI800464, AW162194, F28295, AA806719, AI628325, AI445620, AW088899, AI432570, AW152369, AI537677, AW089006, AI874238, AI368579, AI689614, AI421662, AW022636, AI537643, AI698391, AI540458, AI870198, AA659314, AI141288, AA939199, AI656270, AI708043, AI889916, AI613201, AI225000, AI890507, AI799540, AI289791, AW020397, AI289310, AW103726, AI918408, AI687168, AI475270, AA983883, AA808175, AI470293, AW265004, AI933992, AI564259, AI621341, AI798456, AI802240, AI273034, AI865320, AI251221, AI538850, AI582932, F37471, AI923989, AI583578, AI538908, AI267185, AI680221, AI687568, AI434242, AI139802, AI859464, AI361701, AW025279, AW262565, AI963040, AI359787, AI340726, AI799234, AI571511, AI817373, AI269323, AI699823, AI684021, AW132107, AW168677, AL040333, AI929108, AA464646, AL037454, AW366372, AW079572, AW410842, AI553926, AI819202, AI963191,

				AL041150, AI925164, AW051088, AW021717, AW161202, AW028921, AI635958, AI469516, AI471429, AW161098, AW024564, AI433616, AI561356, AI702527, AI537187, AI282930, AI817103, AI446124, AI818562, AI687295, AI884459, AW020561, AI434731, AI524654, AW081383, AI699011, AI890448, AA911767, AI679550, AI961589, AW130430, AI819014, AW087199, AI499483, AI432507, AI658566, AI919600, AI633061, AI872722, AL036705, AL036652, AI866820, AI610667, AW118417, AI887389, AI539260, AI918554, AI474646, AI886055, AW023338, AW021373, AI812015, AI590043, AI586931, AL040011, AW168875, AW089844, AW079699, AW079432, AI365256, AI348777, AI250627, AI612130, AI539863, AI521594, AI677797, AA514684, AI345688, AW327527, AI638644, AI690813, AW194014, AI610714, AI335426, AL039390, AI499279, AI925404, AA830396, AW166681, R65859, AI582912, AI267379, AI927233, AW083750, AI866469, AI613038, AW050725, AI648699, AL042488, AI559599, AI623835, AI433611, AI290128, AI623941, AI564290, AW411043, AI679800, AI432532, AI814828, AW265409, AW191844, AI096481, AI765469, AI567582, AI249389, AW085786, AL036509, AI333104, N25033, AI679196, AI583567, AI491710, AI371984, AW028840, AW080326, AW150457, AI569294, AI678446, F34030, AI814594, AI240602, AA805566, AI921442, AW129616, AI860509, AI761468, AW020419, AI819663, AW163834, AI660432, AW084151, AI933926, AI684069, AI274495, AI282346, AI690389, AI697177, AI589004, AI690411, AW082532, AW025464, AI783792, AI858865, AW105087, I89947, I33392, A07588, X80340, AL080110, AF065135, AB025103, AL050116, AJ006417, AJ245569, AL080159, I48978, I32738, A12297, AL122098, I09499, AF182215, AL049430, AF031147, AF047716, U77594, E02349, AF113019, AF038847, AL133637, U73682, AF002672, AL050393, AR068466, A18777, AF111851, AL133014, A57389, AL137459, AL050138, AJ005690, U89295, X84990, AL080140, S68736, AL080126, AR034821, U35846, AL050277, AJ012755, AR020905, AL133104, AL137283, M85165, AL137660, AL049339, X66871, AF067728, AF115392, AB026128, A08910, AR038854, A08909, X79812, AF176651, AL117585, U90884, AB008792, AL137480, Z97214, AB008791, AF078844, A08907, AF119337, L10353, AL133558, A08908, AJ242859, A08913, AL117460, AL137711, AL110221, AF061795, AF151685, A08911, I00734, AF111112, AF119336, S82852,
--	--	--	--	---

				AL137574, AF090900, AF026008, A08912, E00617, E00717, E00778, AF106657, AF085809, X98834, AF051325, L13297, X06146, AL117416, S77771, U75370, A23630, X72889, U92992, AF100931, AF017437, AL133070, A76337, AL137271, AL133081, AL110296, AF017152, AL137656, AL133049, S76508, AL122111, AF067790, I89931, AF113677, AL117587, AL137258, U86379, AF036268, AF125949, S83440, AF044323, AL096728, AF081571, AL117435, X93495, AF102578, X99226, I49625, AF200464, I48979, AL122100, U57715, U57352, AL137292, A58524, A58523, AF106945, Y10080, U70981, AF114818, A03736, AL110280, U53505, I89934, A18788, AF113690, AR019470, AF087943, AF067420, AL137529, AJ003118, AF026816, S54890, X98066, AL137627, AF028823, L19437, A65340, A77033, A77035, AL049382, AF079763, AF094480, AF044221, AF106697, Z37987, AF000301, AL080127, AL117578, AL133062, A45787, X53587, AF012536, AL049996, AB016226, AL050172, AL110197, I17544, E01314, E06743, AJ010277, AF057300, A08916, AF057299, AF114170, U76419, X62580, AL133640, AF112208, AL050278, AF126488, AL049466, AF090886, M27260, AL137256, X99717, U80742, AL096751, AL133606, X75295, AL137526, AL109672, AF030165, E15582, AF125948, AL110225, AL133568, AL049426, AL137665, M92439, AC004987, E12747, AL110159, L04849, AL080086, Y10655, AL049324, L04852, AF145233, AL049300, AF090943, AL137478, AF150103, Z72491, Z13966, I26207, AF183393, AJ238278, A91160, E01963, Y14314, AL137712, AF017790, AF058921, AL133077, AL050108, U49434, AL133010, U36585, A91162, AL137550, AF008439, A93350, U75932, S61953, and AL122110.
16	HTLJC07	49	1001568	AI200750, AW054886, AI358095, AI802410, R48313, AW182407, H28124, AI032851, AI986052, AA010034, AI719051, AW410484, AA010033, R48418, AA478487, AW080076, AI589428, AI421662, AI474093, AI273034, AA975952, AW028921, AW152369, AI225000, AI628325, AI141288, AI874238, AI205869, AI537677, AI708043, AI381676, AI696583, AI570966, AI689614, AI632381, AI274452, AI870198, AI656270, AI287476, AI250646, AI139802, AI889916, AI613201, AA659314, AI696340, AW020397, AI419826, AI368579, AW103726, AI540458, AI824357, AW103523, AW265004, AW148303, AI553926, AI538850, AI862896, AI923989, AI798456, AI583578,

				AA806719, AI475270, AI224373, AW150750, AI687568, F37471, AI434242, AI220828, AI564259, AW025279, AI658566, AI884459, AI564290, AI680221, AI359787, AW262565, AI963040, AI799234, AI269323, AI684021, AW132107, AW168677, AL040333, AI571511, AW131228, AA853033, AI432570, AI879377, AW079699, AW410842, AW161202, AW088899, AI819202, AI963191, AI684300, AI961309, AI925164, AW161098, AI866691, AI433616, AW024564, AI446124, AI445620, AI537187, AI817103, AI818562, AI687295, AW079572, AW081383, AI262070, AI568852, AW089006, AI933992, AW020561, AW236186, AI499483, AI802240, AI473434, AW131994, AI633061, AL047611, AW130430, AI423585, AI918554, AI872722, AI886055, AW021373, AI799540, AW089844, AW190808, AW079432, AI365256, AL040319, AL048891, AW118417, AA911767, AI250627, AI677797, AA514684, AI919600, AI521594, AI582912, AL047039, AI612738, AI866419, AI569440, AW166681, AW168875, AA575874, AW081133, AI360195, AI812015, AI932739, AI699067, AI623835, AW411043, AI440509, AI886105, AW191844, AI539863, AI679800, AI814828, AI699011, AL042488, AW085786, AJ245569, AF044221, AR068466, I33392, AF065135, A07588, AB025103, M85165, AL050116, AJ006417, AI2297, AL122098, AJ005870, I09499, U73682, AF182215, L10353, AL080159, AR020905, AF098484, AF038847, AF026008, AL133637, AF148129, AF002672, AI8777, AL133014, X53777, A57389, AF031147, AL137459, AL096728, AL050138, U89295, AF192522, AF090432, X84990, AL080140, S68736, AF119336, AL050277, AL133057, AL049426, AJ012755, AL133104, AL133084, AL137283, AF067728, AL133070, AR038854, AL137562, AF176651, AL117585, AL137480, U57715, AF078844, AF119337, AJ242859, AL117460, AF126488, AL137711, AF061795, AF151685, AF047443, AF090900, S82852, AF085809, X98834, AF077051, AR012379, S77771, U75370, X06146, A23630, AF100931, AF017437, A76337, AL137271, AL133081, I22020, AF054831, X87224, AF167995, AF067790, U02475, AF036268, AF125949, AF081571, X93495, AF102578, AF016628, X99226, AF126372, AR066485, Y18680, AF200464, AL122100, A58524, A58523, AF106945, AL133629, AF114818, AL110280, AF113690, AF067420, U83980, A91160, AL137529, AJ003118, U58653, A91162, AL050208, AF026816, S54890, AL133559, A65340, AF118083, U90884, AL122111, AF106697,
--	--	--	--	---

				AL080127, AL117578, AJ006039, U83172, X93328, U83112, and AR030544.
16	HTLJC07	50	894761	AI719051, AW054886, AI200750, AW410484, AI358095, AI032851, AI802410, AW182407, R48313, AA010034, H28124, AI986052, AA010033, R48418, AA478487, D59502, D80164, C15076, D80195, AA305409, C14389, D81026, D59275, D59467, D80227, AA514188, D80269, D51799, D80022, D58283, D80166, D80193, D59859, D59619, D80210, D80391, D80240, D80045, C14331, D59787, D51423, D80253, D50979, D80043, D81030, AA305578, C14014, AA514186, D80038, D80212, D80196, D80219, D80366, D80188, D80248, D80522, D51060, D59927, D57483, D59610, D80378, D80133, D51022, D59889, D80024, D50995, D80302, AW360811, AW177440, D80268, D80251, D80241, C14429, AW178893, D80439, AW377671, AW375405, D80247, T03269, C75259, AW179328, AW178906, AW366296, D51103, AW360844, AW360817, AW375406, AW378534, AW179332, AW377672, AW179023, AW178905, D81111, C05695, AW378532, D59373, AW177501, AW177511, D59503, AW352171, AW377676, AW352170, AW177731, AW178907, AW178762, AW179019, AW179024, D80157, D80132, D51250, AW177505, D59695, AW360841, AW179020, D80134, AW178775, D51759, AW178909, AW177456, AW179329, D58253, AW178980, AW367967, AW177733, AW378528, AW178908, AW178754, AW179018, AW369651, AW352158, C06015, AW352117, AW176467, AW178983, D59627, AW179004, T48593, AW179012, AW178914, AW378525, AW352163, D52291, F13647, T11417, AW352174, AW178774, D80949, D59653, AW352120, C03092, AW179009, D80168, AI525923, AI910186, D80258, AW178911, AW177728, AW378543, AW177722, AW360834, C14227, D45260, D59317, AI905856, D58246, C14298, AW178781, AW378540, D80064, AW367950, C14407, AA809122, H67854, D58101, AI535850, H67866, C14077, T03116, D59551, AW177723, AW177508, AI535686, Z21582, AW178986, AI525925, AW177734, D51213, AW177497, D45273, AI525917, AI525227, D80014, D51221, C14973, C14344, AW378533, AI525920, D59474, D60010, AA514184, D60214, AA285331, D51097, AI557774, C14957, AI557751, C14046, T03048, AI525242, AI525235, AI525912, AW378542, AI525215, AW378539, C16955, C05763, Z33452, AI525928, T02974, AI525237, AI525222, AB028859, A84916, AJ132110, A62300, A62298, AR018138,

				AR008278, AF058696, A82595, AR060385, AB002449, X67155, Y17188, A94995, D26022, Y12724, A25909, A67220, D89785, A78862, D34614, AR008443, D88547, I50126, I50132, I50128, I50133, X82626, AR066488, AR016514, I82448, AR060138, AR016808, A45456, A26615, AR052274, Y09669, AR025207, A43192, A43190, AR038669, I14842, AR066487, A30438, AR066490, AR054175, I18367, D50010, Y17187, A63261, AR016691, AR016690, U46128, AR008277, AR008281, AR008408, AR062872, A70867, AB012117, I79511, D13509, A64136, A68321, AR060133, X68127, A85396, D88507, AR066482, A44171, A85477, I19525, A86792, X93549, U79457, AF123263, AR032065, AR060382, and AR008382.
18	HAVUR23	28	997371	Z20648, AL031781, and A75273.
18	HAVUR23	52	895017	AL031781.



Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

5

### Examples

#### Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector.

10 Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being

15 isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited</u>
	<u>Plasmid</u>	
	Lambda Zap	pBluescript (pBS)
20	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
25	pCMVSPORT 3.0	pCMVSPORT 3.0
	pCR <sup>®</sup> 2.1	pCR <sup>®</sup> 2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res.

30 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are

commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the fl origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the fl ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR<sup>®</sup>2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

- 5            Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with  $^{32}\text{P}$ - $\gamma$ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).)
- 10          The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate.
- 15          These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

- Alternatively, two primers of 17-20 nucleotides derived from both ends of the
- 20          SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25  $\mu\text{l}$  of reaction mixture with 0.5  $\mu\text{g}$  of the above cDNA template. A convenient reaction mixture is
- 25          1.5-5 mM  $\text{MgCl}_2$ , 0.01% (w/v) gelatin, 20  $\mu\text{M}$  each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and
- 30          the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

#### **Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide**

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

**Example 3: Tissue Distribution of Polypeptide**

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P<sup>32</sup> using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70 degree C overnight, and the films developed according to standard procedures.

**Example 4: Chromosomal Mapping of the Polynucleotides**

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C. This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

**Example 5: Bacterial Expression of a Polypeptide**

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp<sup>r</sup>), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan<sup>r</sup>). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.<sup>600</sup>) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with

high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then  
5 washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-  
10 NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50  
15 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC  
20 Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The  
25 promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR  
30 primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

**Example 6: Purification of a Polypeptide from an Inclusion Body**

5        The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10 degree C.

      Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10 degree C and the cells harvested by continuous  
10    centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

15        The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

20        The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree C overnight to allow further GuHCl extraction.

      Following high speed centrifugation (30,000 xg) to remove insoluble particles,  
25    the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C without mixing for 12 hours prior to further purification steps.

      To clarify the refolded polypeptide solution, a previously prepared tangential  
30    filtration unit equipped with 0.16 um membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive



Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

5 Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40  
10 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant  $A_{280}$  monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

15 The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 ug of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL  
20 assays.

#### **Example 7: Cloning and Expression of a Polypeptide in a Baculovirus**

##### **Expression System**

In this example, the plasmid shuttle vector pA2 is used to insert a  
25 polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the  
30 plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral

sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0 ug of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug  
5 of BaculoGold™ virus DNA and 5 ug of the plasmid are mixed in a sterile well of a microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded  
10 in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27 degrees C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed,  
15 as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page  
20 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are  
25 harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the  
30 medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 uCi of <sup>35</sup>S-methionine and 5 uCi <sup>35</sup>S-cysteine (available from Amersham) are added.

The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of  
5 purified protein may be used to determine the amino terminal sequence of the produced protein.

#### **Example 8: Expression of a Polypeptide in Mammalian Cells**

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which  
10 mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long  
15 terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV, HIV and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden),  
20 pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human HeLa, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

25 Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the  
30 encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of

interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279  
5 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

10 Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No.209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g.,  
15 with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate  
20 restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide.  
25 Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1%  
30 agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector

are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for  
5 transfection. Five  $\mu$ g of the expression plasmid pC6 a pC4 is cotransfected with 0.5  
ug of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-  
neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an  
enzyme that confers resistance to a group of antibiotics including G418. The cells are  
seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the  
10 cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in  
alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1  
mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in  
6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50  
nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest  
15 concentrations of methotrexate are then transferred to new 6-well plates containing  
even higher concentrations of methotrexate (1  $\mu$ M, 2  $\mu$ M, 5  $\mu$ M, 10 mM, 20 mM).  
The same procedure is repeated until clones are obtained which grow at a  
concentration of 100 - 200  $\mu$ M. Expression of the desired gene product is analyzed,  
for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

20

#### **Example 9: Protein Fusions**

The polypeptides of the present invention are preferably fused to other  
proteins. These fusion proteins can be used for a variety of applications. For  
example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG  
25 domains, and maltose binding protein facilitates purification. (See Example 5; see  
also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to  
IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization  
signals fused to the polypeptides of the present invention can target the protein to a  
specific subcellular localization, while covalent heterodimer or homodimers can  
30 increase or decrease the activity of a fusion protein. Fusion proteins can also create  
chimeric molecules having more than one function. Finally, fusion proteins can  
increase solubility and/or stability of the fused protein compared to the non-fused

protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

- 5 Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

- For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be  
10 destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

- 15 If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

- 20 Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAAACCTCACACATGCCACCGTGC  
CCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAAA  
CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGT  
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG  
25 ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA  
CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT  
GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA  
ACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC  
CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG  
30 GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT  
GGAGTGGGAGAGCAATGGGCAGCCGAGAACAACTACAAGACCACGCCT  
CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTG

GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA  
TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG  
GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

5 **Example 10: Production of an Antibody from a Polypeptide**

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred  
10 method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal  
15 antibodies can be prepared using hybridoma technology. (Köhler et al., Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more  
20 preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56 degrees C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

25 The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as  
30 described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.



Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')<sub>2</sub> and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

#### **Example 11: Production Of Secreted Protein For High-Throughput Screening**

##### **Assays**

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described herein.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at  $2 \times 10^5$  cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degrees C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl<sub>2</sub> (anhyd); 0.00130

mg/L  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ ; 0.050 mg/L of  $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$ ; 0.417 mg/L of  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ ;  
 311.80 mg/L of KCl; 28.64 mg/L of  $\text{MgCl}_2$ ; 48.84 mg/L of  $\text{MgSO}_4$ ; 6995.50 mg/L of  
 NaCl; 2400.0 mg/L of  $\text{NaHCO}_3$ ; 62.50 mg/L of  $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ ; 71.02 mg/L of  
 $\text{Na}_2\text{HPO}_4$ ; .4320 mg/L of  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ ; .002 mg/L of Arachidonic Acid ; 1.022 mg/L  
 5 of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic  
 Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of  
 Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of  
 Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-  
 Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml  
 10 of L-Asparagine- $\text{H}_2\text{O}$ ; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-  
 2HCL- $\text{H}_2\text{O}$ ; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0  
 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-  
 $\text{H}_2\text{O}$ ; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-  
 Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0  
 15 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22  
 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na- $2\text{H}_2\text{O}$ ; 99.65 mg/ml of L-  
 Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of  
 Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of  
 Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319  
 20 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and  
 0.680 mg/L of Vitamin B<sub>12</sub>; 25 mM of HEPES Buffer; 2.39 mg/L of Na  
 Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL;  
 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of  
 Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin  
 25 complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed  
 with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal)  
 with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L  
 DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for  
 endotoxin assay in 15ml polystyrene conical.

30 The transfection reaction is terminated, preferably by tag-teaming, at the end  
 of the incubation period. Person A aspirates off the transfection media, while person

B adds 1.5ml appropriate media to each well. Incubate at 37 degrees C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants  
5 from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the  
10 invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

#### **Example 12: Construction of GAS Reporter Construct**

One signal transduction pathway involved in the differentiation and  
15 proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors  
20 called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at  
25 higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2,  
30 Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

<u>Ligand</u>	<u>tyk2</u>	<u>JAKs</u>			<u>STATS</u>	<u>GAS(elements) or ISRE</u>
		<u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>		
<u>IFN family</u>						
IFN-a/B	+	+	-	-	1,2,3	ISRE
IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
Il-10	+	?	?	-	1,3	
<u>gp130 family</u>						
IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
Il-11(Pleiotrophic)	?	+	?	?	1,3	
OnM(Pleiotrophic)	?	+	+	?	1,3	
LIF(Pleiotrophic)	?	+	+	?	1,3	
CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
G-CSF(Pleiotrophic)	?	+	?	?	1,3	
IL-12(Pleiotrophic)	+	-	+	+	1,3	
<u>g-C family</u>						
IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
IL-7 (lymphocytes)	-	+	-	+	5	GAS
IL-9 (lymphocytes)	-	+	-	+	5	GAS
IL-13 (lymphocyte)	-	+	?	?	6	GAS
IL-15	?	+	?	+	5	GAS
<u>gp140 family</u>						
IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
IL-5 (myeloid)	-	-	+	-	5	GAS
GM-CSF (myeloid)	-	-	+	-	5	GAS
<u>Growth hormone family</u>						
GH	?	-	+	-	5	
PRL	?	+/-	+	-	1,3,5	
EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
<u>Receptor Tyrosine Kinases</u>						
EGF	?	+	+	-	1,3	GAS (IRF1)
PDGF	?	+	+	-	1,3	
CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

10 5':GCGCCTCGAGATTTCCTCGAAATCTAGATTTCCTCGAAATGATTTCCTCG  
GAAATGATTTCCTCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

15 PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

20 5':CTCGAGATTTCCTCGAAATCTAGATTTCCTCGAAATGATTTCCTCGAAA  
TGATTTCCTCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCTCG  
CCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCT  
CCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCC  
TCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCT  
25 AGGCTTTTTGCAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol  
30 acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not  
5 contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance  
10 gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS  
15 with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-  
20 2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

**Example 13: High-Throughput Screening Assay for T-cell Activity.**

25 The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway.  
30 The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.



Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 5 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells 10 containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

15 During the incubation period, count cell concentration, spin down the required number of cells ( $10^7$  per transfection), and resuspend in OPTI-MEM to a final concentration of  $10^7$  cells/ml. Then add 1ml of  $1 \times 10^7$  cells in OPTI-MEM to T25 flask and incubate at 37 degrees C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

20 The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing polypeptides of the invention and/or induced polypeptides of the invention as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and 25 resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells 30 into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the  
5 assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and  
10 stored at -20 degrees C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4 degrees C and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the  
15 positive control wells.

The above protocol may be used in the generation of both transient, as well as, stable transfected cells, which would be apparent to those of skill in the art.

#### **Example 14: High-Throughput Screening Assay Identifying Myeloid Activity**

20 The following protocol is used to assess myeloid activity by determining whether polypeptides of the invention proliferates and/or differentiates myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is  
25 U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest  $2 \times 10^7$  U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing  
30 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM Na<sub>2</sub>HPO<sub>4</sub>·7H<sub>2</sub>O, 1 mM MgCl<sub>2</sub>, and 675 uM CaCl<sub>2</sub>. Incubate at 37 degrees C for 45 min.

- 5 Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degrees C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

- 10 These cells are tested by harvesting  $1 \times 10^8$  cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of  $5 \times 10^5$  cells/ml. Plate 200 ul cells per well in the 96-well plate (or  $1 \times 10^5$  cells/well).

- Add 50 ul of the supernatant prepared by the protocol described in Example 15
11. Incubate at 37 degrees C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

20 **Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.**

- When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the
- 25 EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

- Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor).
- 30 The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

- 5            5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)  
             5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the  
10 EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and  
15 allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is  
20 done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine  
25 growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640  
30 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count

the cell number and add more low serum medium to reach final cell density as  $5 \times 10^5$  cells/ml.

Add 200  $\mu$ l of the cell suspension to each well of 96-well plate (equivalent to  $1 \times 10^5$  cells/well). Add 50  $\mu$ l supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ $\mu$ l of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

#### 10 **Example 16: High-Throughput Screening Assay for T-cell Activity**

NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF-KB would be useful in treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTCCCC) (SEQ ID NO:8), 18 bp of sequence

complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC  
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

- 5        The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

- PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is  
10 digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)  
      Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

- 5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC  
15 ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC  
ATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA  
CTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTA  
TTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAA  
GCTT:3' (SEQ ID NO:10)

20

      Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

- 25        In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

- 30        Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described

in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

**Example 17: Assay for SEAP Activity**

- 5 As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

- 10 Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

- 15 Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

- 20 Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

**Reaction Buffer Formulation:**

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5

25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

**Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability**

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO<sub>2</sub> incubator for



20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO<sub>2</sub> incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to  $2-5 \times 10^6$  cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to  $1 \times 10^6$  cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca<sup>++</sup> concentration.

#### **Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity**

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is

unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include  
5 receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

10 Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

15 Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or  
20 polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar  
25 Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of  
30 Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in

Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub> and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is  
5 shaken on a rotating shaker for 5 minutes at 4 degrees C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after  
10 detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degrees C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

15 Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for  
20 a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg<sub>2</sub><sup>+</sup> (5mM ATP/50mM MgCl<sub>2</sub>), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>,  
25 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30 degrees C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

30 Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degrees C for 20

min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degrees C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

#### **Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity**

As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degrees C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and

cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

- 5           After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard  
10       procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

15       **Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

- RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA  
20       is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95 degrees C for 30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

- PCR products are then sequenced using primers labeled at their 5' end with T4  
25       polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

- 30       PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United

States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

#### **Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in

Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

### **Example 23: Formulation**

The invention also provides methods of treatment and/or prevention diseases, disorders, and/or conditions (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about 1 ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Therapeutics can be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials



(for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., 5 Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., Id.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988).

Sustained-release Therapeutics also include liposomally entrapped  
10 Therapeutics of the invention (*see* generally, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang  
15 et al., Proc. Natl. Acad. Sci.(USA) 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the  
20 optimal Therapeutic.

In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see* Langer, *supra*; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)).

25 Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically  
30 acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.

For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both.

5 Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

10 The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten  
15 residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar  
20 alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or  
25 stabilizers will result in the formation of polypeptide salts.

Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a  
30 stopper pierceable by a hypodermic injection needle.

Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized

formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

5           The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use  
10 or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

          The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, alum, alum plus  
15 deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG, and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to,  
20 Monophosphoryl lipid immunomodulator, AduVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B,  
25 whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic  
30 mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate

administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not  
5 limited to, other members of the TNF family, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are  
10 administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

15 In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta),  
20 OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6 (International Publication No. WO 98/30694), OPG, and neutrokin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF),  
25 and soluble forms of Fas, CD30, CD27, CD40 and 4-IBB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International  
30 Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors. Nucleoside reverse transcriptase inhibitors that may be administered in combination  
5 with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but  
10 are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents,  
15 nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that  
20 may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™,  
25 FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™,  
30 DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In

another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment,

5 Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat

10 or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with

15 ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific embodiment,

20 Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered

25 with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin,

30 beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin,

erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamthoxazole, and vancomycin.

Conventional nonspecific immunosuppressive agents, that may be administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells.

In specific embodiments, Therapeutics of the invention are administered in combination with immunosuppressants. Immunosuppressants preparations that may be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONE™ (OKT3), SANDIMMUNE™/NEORAL™/SANGDYA™ (cyclosporin), PROGRAF™ (tacrolimus), CELLCEPT™ (mycophenolate), Azathioprine, glucocorticosteroids, and RAPAMUNE™ (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, and GAMIMUNE™. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

In an additional embodiment, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-

acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

5 In another embodiment, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-  
10 FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl  
15 estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephalen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and  
20 etoposide).

In a specific embodiment, Therapeutics of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another embodiment, Therapeutics of the invention are administered in combination with  
25 Rituximab. In a further embodiment, Therapeutics of the invention are administered with Rituxmab and CHOP, or Rituxmab and any combination of the components of CHOP.

In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered  
30 with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered



with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PlGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PlGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by reference herein.

In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, LEUKINE™ (SARGRAMOSTIM™) and NEUPOGEN™ (FILGRASTIM™).

In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but

are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example,  
5 radiation therapy.

**Example 24: Method of Treating Decreased Levels of the Polypeptide**

The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising  
10 administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the  
15 secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily  
20 dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

**Example 25: Method of Treating Increased Levels of the Polypeptide**

25 The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

30 In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of

decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer. For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

**Example 26: Method of Treatment Using Gene Therapy-Ex Vivo**

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is

maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

5           The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the  
10 packaging cells are now referred to as producer cells).

          Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is  
15 removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been  
20 efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

          The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

25   **Example 27: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention**

          Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent  
30 NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935

(1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of endogenous polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol precipitation.

In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the polynucleotide in the cell. Expression may be detected by immunological staining, or any other method known in the art.

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining  
5 cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na<sub>2</sub> HPO<sub>4</sub>, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains  
10 approximately  $3 \times 10^6$  cells/ml. Electroporation should be performed immediately following resuspension.

Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with  
15 HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3' end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3' end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5' end and a HindIII site at the 3' end. The CMV promoter and the  
20 fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap  
25 (Bio-Rad). The final DNA concentration is generally at least 120 µg/ml. 0.5 ml of the cell suspension (containing approximately  $1.5 \times 10^6$  cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960 µF and 250-300 V, respectively. As voltage increases, cell survival decreases, but  
30 the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following  
5 day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a  
10 patient as described above.

#### **Example 28: Method of Treatment Using Gene Therapy - In Vivo**

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the  
15 introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in  
20 the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata et al., Cardiovasc. Res. 35(3):470-479 (1997); Chao et al., Pharmacol. Res. 35(6):517-522 (1997); Wolff, Neuromuscul. Disord. 7(5):314-318 (1997); Schwartz et al., Gene Ther. 3(5):405-411 (1996); Tsurumi et al., Circulation 94(12):3281-3290 (1996) (incorporated herein by reference).

25 The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

30 The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or

precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg



body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence  
5 can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or  
10 mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard  
15 recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on  
20 the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

25 After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA  
30 in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper

dosages and other treatment parameters in humans and other animals using naked DNA.

**Example 29: Transgenic Animals.**

5       The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are  
10       used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (*i.e.*, polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear  
15       microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic  
20       stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, *e.g.*, Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-  
25       mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into  
30       enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding

strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of  
5 heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of  
10 interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in  
15 ameliorating such diseases, disorders, and/or conditions.

**Example 30: Knock-Out Animals.**

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*,  
20 see Smithies et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding  
25 regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination,  
30 results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas &

Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

5           In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not  
10   limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention,  
15   e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve  
20   expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

          Alternatively, the cells can be incorporated into a matrix and implanted in the  
25   body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

30           When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For

example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

### 10 **Example 31: Production of an Antibody**

#### a) Hybridoma Technology

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing polypeptide(s) of the invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide(s) of the invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

Monoclonal antibodies specific for polypeptide(s) of the invention are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with polypeptide(s) of the invention, or, more preferably, with a secreted polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line

(SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which  
5 secrete antibodies capable of binding the polypeptide(s) of the invention.

Alternatively, additional antibodies capable of binding polypeptide(s) of the invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In  
10 accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the polypeptide(s) of the invention protein-specific antibody can be blocked by polypeptide(s) of the invention.  
15 Such antibodies comprise anti-idiotypic antibodies to the polypeptide(s) of the invention protein-specific antibody and are used to immunize an animal to induce formation of further polypeptide(s) of the invention protein-specific antibodies.

For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells  
20 producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO  
25 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

#### b) Isolation Of Antibody Fragments Directed

polypeptide(s) of the invention From A Library Of scFvs

30 Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide(s) of the

invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library. A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 10<sup>9</sup> E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10<sup>8</sup> TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10<sup>13</sup> transducing units/ml (ampicillin-resistant clones).

Panning of the Library. Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10<sup>13</sup> TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to



stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders. Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

### **Example 32: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation**

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can,

in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Purified polypeptides of the invention, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the polypeptides of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added  $10^5$  B-cells suspended in culture medium (RPMI 1640 containing 10% FBS,  $5 \times 10^{-5}$ M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and  $10^{-5}$  dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse (1uCi/well) with  $^3$ H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of a polypeptide of the invention, or truncated forms thereof. Mice

receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with polypeptides of the invention identify the results of the activity of the polypeptides on spleen cells, such as the diffusion of peri-  
5 arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell  
10 representation within loosely defined B-cell zones that infiltrate established T-cell regions.

Flow cytometric analyses of the spleens from mice treated with polypeptide is used to indicate whether the polypeptide specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

15 Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and polypeptide-treated mice.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
20 test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

### **Example 33: T Cell Proliferation Assay**

#### **Proliferation assay for Resting PBLs.**

25 A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of <sup>3</sup>H-thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100 microliters per well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 °C (1 microgram/ml in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral  
30 blood and added to quadruplicate wells (5 x 10<sup>4</sup>/well) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of TNF Delta and/or TNF Epsilon protein (total volume 200 microliters). Relevant protein buffer and medium alone are controls.

After 48 hr. culture at 37 °C, plates are spun for 2 min. at 1000 rpm and 100 microliters of supernatant is removed and stored -20 °C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100 microliters of medium containing 0.5 microcuries of <sup>3</sup>H-thymidine and cultured at 37 °C for 18-24 hr. Wells are harvested and incorporation of <sup>3</sup>H-thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of TNF Delta and/or TNF Epsilon proteins.

Alternatively, a proliferation assay on resting PBL (peripheral blood lymphocytes) is measured by the up-take of <sup>3</sup>H-thymidine. The assay is performed as follows. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% (Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non-adherent cells are collected, washed and used in the proliferation assay. The assay is performed in a 96 well plate using 2 x 10<sup>4</sup> cells/well in a final volume of 200 microliters. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector (negative control), IL-2 (\*), IFN $\gamma$ , TNF $\alpha$ , IL-10 and TR2. In addition to the control supernatants, recombinant human IL-2 (R & D Systems, Minneapolis, MN) at a final concentration of 100ng/ml is also used. After 24 hours of culture, each well is pulsed with 1uCi of <sup>3</sup>H-thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of <sup>3</sup>H-thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

(\*) The amount of the control cytokines IL-2, IFN $\gamma$ , TNF $\alpha$  and IL-10 produced in each transfection varies between 300pg to 5ng/ml.

**Costimulation assay.**

A costimulation assay on resting PBL (peripheral blood lymphocytes) is performed in the presence of immobilized antibodies to CD3 and CD28. The use of antibodies specific for the invariant regions of CD3 mimic the induction of T cell activation that would occur through stimulation of the T cell receptor by an antigen. Cross-linking of the TCR (first signal) in the absence of a costimulatory signal (second signal) causes very low induction of proliferation and will eventually result in a state of "anergy", which is characterized by the absence of growth and inability to produce cytokines. The addition of a costimulatory signal such as an antibody to CD28, which mimics the action of the costimulatory molecule. B7-1 expressed on activated APCs, results in enhancement of T cell responses including cell survival and production of IL-2. Therefore this type of assay allows to detect both positive and negative effects caused by addition of supernatants expressing the proteins of interest on T cell proliferation.

The assay is performed as follows. Ninety-six well plates are coated with 100ng/ml anti-CD3 and 5ug/ml anti-CD28 (Pharmingen, San Diego, CA) in a final volume of 100ul and incubated overnight at 4C. Plates are washed twice with PBS before use. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% FCS(Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non adherent cells are collected, washed and used in the proliferation assay. The assay is performed in a 96 well plate using  $2 \times 10^4$  cells/well in a final volume of 200ul. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector only (negative control), IL-2, IFN $\gamma$ , TNF $\alpha$ , IL-10 and TR2. In addition to the control supernatants recombinant human IL-2 (R & D Systems, Minneapolis, MN) at a final concentration of 10ng/ml is also used. After 24 hours of culture, each well is

pulsed with 1uCi of  $^3\text{H}$ -thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of  $^3\text{H}$ -thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

**5 Costimulation assay: IFN  $\gamma$  and IL-2 ELISA**

The assay is performed as follows. Twenty-four well plates are coated with either 300ng/ml or 600ng/ml anti-CD3 and 5ug/ml anti-CD28 (Pharmingen, San Diego, CA) in a final volume of 500ul and incubated overnight at 4C. Plates are washed twice with PBS before use. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% FCS(Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non adherent cells are collected, washed and used in the costimulation assay. The assay is performed in the pre-coated twenty-four well plate using  $1 \times 10^5$  cells/well in a final volume of 900ul. The supernatants (293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 300ul are added to 600ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector only(negative control), IL-2, IFN $\gamma$ , IL-12 and IL-18. In addition to the control supernatants recombinant human IL-2 (all cytokines were purchased from R & D Systems, Minneapolis, MN) at a final concentration of 10ng/ml, IL-12 at a final concentration of 1ng/ml and IL-18 at a final concentration of 50ng/ml are also used. Controls and unknown samples are tested in duplicate. Supernatant samples (250ul) are collected 2 days and 5 days after the beginning of the assay. ELISAs to test for IFN $\gamma$  and IL-2 secretion are performed using kits purchased from R & D Systems, (Minneapolis, MN). Results are expressed as an average of duplicate samples plus or minus standard error.

30

**Proliferation assay for preactivated-resting T cells.**

A proliferation assay on preactivated-resting T cells is performed on cells that are previously activated with the lectin phytohemagglutinin (PHA). Lectins are polymeric plant proteins that can bind to residues on T cell surface glycoproteins including the TCR and act as polyclonal activators. PBLs treated with PHA and then  
5 cultured in the presence of low doses of IL-2 resemble effector T cells. These cells are generally more sensitive to further activation induced by growth factors such as IL-2. This is due to the expression of high affinity IL-2 receptors that allows this population to respond to amounts of IL-2 that are 100 fold lower than what would have an effect on a naïve T cell. Therefore the use of this type of cells might enable  
10 to detect the effect of very low doses of an unknown growth factor, that would not be sufficient to induce proliferation on resting (naïve ) T cells.

The assay is performed as follows. PBMC are isolated by F/H gradient centrifugation from human peripheral blood, and are cultured in 10% FCS (Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD) in the  
15 presence of 2 µg/ml PHA (Sigma, Saint Louis, MO) for three days. The cells are then washed in PBS and cultured in 10% FCS/RPMI in the presence of 5 ng/ml of human recombinant IL-2 (R & D Systems, Minneapolis, MN) for 3 days. The cells are washed and rested in starvation medium (1% FCS/RPMI) for 16 hours prior to the beginning of the proliferation assay. An aliquot of the cells is analyzed by FACS to  
20 determine the percentage of T cells (CD3 positive cells) present; this usually ranges between 93-97% depending on the donor. The assay is performed in a 96 well plate using  $2 \times 10^4$  cells/well in a final volume of 200 µl. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60 µl are added to 140 µl of 10% FCS/RPMI containing the cells. Control  
25 supernatants are used at the same final dilution and express the following proteins: vector (negative control), IL-2, IFN $\gamma$ , TNF $\alpha$ , IL-10 and TR2. In addition to the control supernatants recombinant human IL-2 at a final concentration of 10 ng/ml is also used. After 24 hours of culture, each well is pulsed with 1 µCi of  $^3\text{H}$ -thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing  
30 and incorporation of  $^3\text{H}$ -thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

The studies described in this example test activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

5

**Example 34: Effect of Polypeptides of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells**

10 Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- $\alpha$ , causes a rapid  
15 change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC $\gamma$ RII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3  
20 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

25

Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to  
30 measure the IL-12 release as follows. Dendritic cells ( $10^6$ /ml) are treated with increasing concentrations of polypeptides of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell



cultures are then collected and analyzed for IL-12 content using commercial ELISA kit (e.g., R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

5           Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the  
10   antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of polypeptides of the invention or  
15   LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

20           Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or activator of monocytes. Polypeptides, agonists, or antagonists of the invention can be  
25   screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

30

Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results

from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of  $2 \times 10^6$ /ml in PBS containing PI at a final concentration of 5 µg/ml, and then incubated at room temperature for 5 minutes before FACSscan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of  $5 \times 10^5$  cells/ml with increasing concentrations of the a polypeptide of the invention and under the same conditions, but in the absence of the polypeptide. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of a polypeptide of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g., R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

Oxidative burst. Purified monocytes are plated in 96-w plate at  $2 \times 10^5$  cell/well. Increasing concentrations of polypeptides of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20 µl 1N NaOH per well. The absorbance is read at 610

nm. To calculate the amount of H<sub>2</sub>O<sub>2</sub> produced by the macrophages, a standard curve of a H<sub>2</sub>O<sub>2</sub> solution of known molarity is performed for each experiment.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polypeptides, polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

### **Example 35: Biological Effects of Polypeptides of the Invention**

#### **Astrocyte and Neuronal Assays**

10 Recombinant polypeptides of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate a polypeptide of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA* 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of a polypeptide of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

30 **Fibroblast and endothelial cell assays**

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE<sub>2</sub> assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or polypeptides of the invention with or without IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for PGE<sub>2</sub> by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without polypeptides of the invention IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or polypeptides of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with polypeptides of the invention.

#### Parkinson Models.

The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP<sup>+</sup>) and released.

Subsequently, MPP<sup>+</sup> is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP<sup>+</sup> is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

Based on the data with FGF-2, polypeptides of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential effect of a polypeptide of the invention is first examined *in vitro* in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm<sup>2</sup> on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if a polypeptide of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the polypeptide may be involved in Parkinson's Disease.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

5

**Example 36: The Effect of Polypeptides of the Invention on the Growth of Vascular Endothelial Cells**

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at  $2.5 \times 10^4$  cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. A polypeptide having the amino acid sequence of SEQ ID NO:Y, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that the polypeptide of the invention may proliferate vascular endothelial cells.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 37: Stimulatory Effect of Polypeptides of the Invention on the Proliferation of Vascular Endothelial Cells**

For evaluation of mitogenic activity of growth factors, the colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) was performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000 cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight. After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF<sub>165</sub> or a

polypeptide of the invention in 0.5% FBS) with or without Heparin (8 U/ml) are added to wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is subtracted, and seven wells are performed in parallel for each condition. See, Leak *et al.* *In Vitro Cell. Dev. Biol.* 30A:512-518 (1994).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 38: Inhibition of PDGF-induced Vascular Smooth Muscle Cell Proliferation Stimulatory Effect**

HAoSMC proliferation can be measured, for example, by BrdUrd incorporation. Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with 10% calf serum and 6 mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4 degrees C for 2 h after being exposed to denaturing solution and then incubated with the streptavidin-peroxidase and diaminobenzidine. After counterstaining with hematoxylin, the cells are mounted for microscopic examination, and the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for individual cells by the concomitant use of bright field illumination and dark field-UV fluorescent illumination. See, Hayashida et al., *J. Biol. Chem.* 6:271(36):21985-21992 (1996).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 39: Stimulation of Endothelial Migration**

5 This example will be used to explore the possibility that a polypeptide of the invention may stimulate lymphatic endothelial cell migration.

Endothelial cell migration assays are performed using a 48 well microchemotaxis chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., et al., J. Immunological Methods 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8 um (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours  
10 at room temperature and dried under sterile air. Test substances are diluted to appropriate concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25 ul of the final dilution is placed in the lower chamber of the modified Boyden apparatus. Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter  
15 between lower and upper chamber,  $2.5 \times 10^5$  cells suspended in 50 ul M199 containing 1% FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at 37°C in a humidified chamber with 5% CO<sub>2</sub> to allow cell migration. After the incubation period, the filter is removed and the upper side of the filter with the non-migrated cells is scraped with a rubber policeman. The filters are fixed with methanol and stained with a  
20 Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by counting cells of three random high-power fields (40x) in each well, and all groups are performed in quadruplicate.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
25 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 40: Stimulation of Nitric Oxide Production by Endothelial Cells**


30 Nitric oxide released by the vascular endothelium is believed to be a mediator of vascular endothelium relaxation. Thus, activity of a polypeptide of the invention can be



assayed by determining nitric oxide production by endothelial cells in response to the polypeptide.

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various levels of a positive control (such as VEGF-1) and the polypeptide of the invention. Nitric oxide in the medium is determined by use of the Griess reagent to measure total nitrite after reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of the polypeptide of the invention on nitric oxide release is examined on HUVEC.

Briefly, NO release from cultured HUVEC monolayer is measured with a NO-specific polarographic electrode connected to a NO meter (Iso-NO, World Precision Instruments Inc.) (1049). Calibration of the NO elements is performed according to the following equation:



The standard calibration curve is obtained by adding graded concentrations of  $\text{KNO}_2$  (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing KI and  $\text{H}_2\text{SO}_4$ . The specificity of the Iso-NO electrode to NO is previously determined by measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then bathed in 5 ml of filtered Krebs-Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) To maintain the temperature at 37°C. The NO sensor probe is inserted vertically into the wells, keeping the tip of the electrode 2 mm under the surface of the solution, before addition of the different conditions. S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of released NO is expressed as picomoles per  $1 \times 10^6$  endothelial cells. All values reported are means of four to six measurements in each group (number of cell culture wells). See, Leak *et al. Biochem. and Biophys. Res. Comm.* 217:96-105 (1995).

The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 41: Effect of Polypeptides of the Invention on Cord Formation in Angiogenesis**

Another step in angiogenesis is cord formation, marked by differentiation of endothelial cells. This bioassay measures the ability of microvascular endothelial cells to form capillary-like structures (hollow structures) when cultured *in vitro*.

CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the *in vitro* angiogenesis assay, the wells of a 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium (200 µl/well) for 30 min. at 37°C. CADMEC are seeded onto the coated wells at 7,500 cells/well and cultured overnight in Growth Medium. The Growth Medium is then replaced with 300 µl Cell Applications' Chord Formation Medium containing control buffer or a polypeptide of the invention (0.1 to 100 ng/ml) and the cells are cultured for an additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the Boeckeler VIA-170 video image analyzer. All assays are done in triplicate.

Commercial (R&D) VEGF (50 ng/ml) is used as a positive control. b-esteradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also utilized as a control.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 42: Angiogenic Effect on Chick Chorioallantoic Membrane**

Chick chorioallantoic membrane (CAM) is a well-established system to examine angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The ability of polypeptides of the invention to stimulate angiogenesis in CAM can be examined.

Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese quail (*Coturnix coturnix*) are incubated at 37.8°C and 80% humidity. Differentiated CAM of 16-day-old chick and 13-day-old quail embryos is studied with the following methods.

On Day 4 of development, a window is made into the egg shell of chick eggs. The embryos are checked for normal development and the eggs sealed with cellotape. They are further incubated until Day 13. Thermanox coverslips (Nunc, Naperville, IL) are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in distilled water and about 3.3 mg/ 5 ml are pipetted on the disks. After air-drying, the inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope [Wild M8] and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 43: Angiogenesis Assay Using a Matrigel Implant in Mouse**

*In vivo* angiogenesis assay of a polypeptide of the invention measures the ability of an existing capillary network to form new vessels in an implanted capsule of murine extracellular matrix material (Matrigel). The protein is mixed with the liquid Matrigel at 4 degree C and the mixture is then injected subcutaneously in mice where it solidifies. After 7 days, the solid "plug" of Matrigel is removed and examined for the presence of new blood vessels. Matrigel is purchased from Becton Dickinson Labware/Collaborative Biomedical Products.

When thawed at 4 degree C the Matrigel material is a liquid. The Matrigel is mixed with a polypeptide of the invention at 150 ng/ml at 4 degrees C and drawn into cold 3 ml syringes. Female C57Bl/6 mice approximately 8 weeks old are injected with the mixture of Matrigel and experimental protein at 2 sites at the midventral aspect of the abdomen (0.5 ml/site). After 7 days, the mice are sacrificed by cervical dislocation, the

Matrigel plugs are removed and cleaned (i.e., all clinging membranes and fibrous tissue is removed). Replicate whole plugs are fixed in neutral buffered 10% formaldehyde, embedded in paraffin and used to produce sections for histological examination after staining with Masson's Trichrome. Cross sections from 3 different regions of each plug are processed. Selected sections are stained for the presence of vWF. The positive control for this assay is bovine basic FGF (150 ng/ml). Matrigel alone is used to determine basal levels of angiogenesis.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 44: Rescue of Ischemia in Rabbit Lower Limb Model**

To study the in vivo effects of polynucleotides and polypeptides of the invention on ischemia, a rabbit hindlimb ischemia model is created by surgical removal of one femoral arteries as described previously (Takeshita *et al.*, *Am J. Pathol* 147:1649-1660 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb is dependent upon collateral vessels originating from the internal iliac artery (Takeshita *et al.* *Am J. Pathol* 147:1649-1660 (1995)). An interval of 10 days is allowed for post-operative recovery of rabbits and development of endogenous collateral vessels. At 10 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked expression plasmid containing a polynucleotide of the invention by arterial gene transfer technology using a hydrogel-coated balloon catheter as described (Riessen *et al.* *Hum Gene Ther.* 4:749-758 (1993); Leclerc *et al.* *J. Clin. Invest.* 90: 936-944 (1992)). When a polypeptide of the invention is used in the treatment, a single bolus of 500 mg polypeptide of the invention or control is delivered into the internal iliac artery of the ischemic limb over a period of 1 min. through an infusion catheter. On day 30, various parameters are measured in these rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow

during undilated condition and Max FL: the blood flow during fully dilated condition (also an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh; (d) Capillary density - The number of collateral capillaries determined in light microscopic sections taken from hindlimbs.

The studies described in this example tested activity of polynucleotides and polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the agonists, and/or antagonists of the invention.

#### **Example 45: Effect of Polypeptides of the Invention on Vasodilation**

Since dilation of vascular endothelium is important in reducing blood pressure, the ability of polypeptides of the invention to affect the blood pressure in spontaneously hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900 mg/kg) of the polypeptides of the invention are administered to 13-14 week old spontaneously hypertensive rats (SHR). Data are expressed as the mean +/- SEM. Statistical analysis are performed with a paired t-test and statistical significance is defined as  $p < 0.05$  vs. the response to buffer alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 46: Rat Ischemic Skin Flap Model**

The evaluation parameters include skin blood flow, skin temperature, and factor VIII immunohistochemistry or endothelial alkaline phosphatase reaction. Expression of polypeptides of the invention, during the skin ischemia, is studied using in situ hybridization.

The study in this model is divided into three parts as follows:

- a) Ischemic skin
- b) Ischemic skin wounds
- c) Normal wounds

The experimental protocol includes:

- 5 a) Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).
- b) An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).
- c) Topical treatment with a polypeptide of the invention of the excisional wounds (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.
- 10 d) Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
15 invention.

#### **Example 47: Peripheral Arterial Disease Model**

Angiogenic therapy using a polypeptide of the invention is a novel therapeutic  
20 strategy to obtain restoration of blood flow around the ischemia in case of peripheral arterial diseases. The experimental protocol includes:

- a) One side of the femoral artery is ligated to create ischemic muscle of the hindlimb, the other side of hindlimb serves as a control.
- b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is  
25 delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3 weeks.
- c) The ischemic muscle tissue is collected after ligation of the femoral artery at 1, 2, and 3 weeks for the analysis of expression of a polypeptide of the invention and histology. Biopsy is also performed on the other side of normal muscle of the  
30 contralateral hindlimb.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to

test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 48: Ischemic Myocardial Disease Model**

5

A polypeptide of the invention is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after coronary artery occlusion. Alteration of expression of the polypeptide is investigated in situ. The experimental protocol includes:

- 10       a) The heart is exposed through a left-side thoracotomy in the rat. Immediately, the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.
- b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4 weeks.
- 15       c) Thirty days after the surgery, the heart is removed and cross-sectioned for morphometric and in situ analyzes.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

20

**Example 49: Rat Corneal Wound Healing Model**

This animal model shows the effect of a polypeptide of the invention on neovascularization. The experimental protocol includes:

25

- a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.
- b) Inserting a spatula below the lip of the incision facing the outer corner of the eye.
- 30       c) Making a pocket (its base is 1-1.5 mm from the edge of the eye).
- d) Positioning a pellet, containing 50ng- 5ug of a polypeptide of the invention, within the pocket.

e) Treatment with a polypeptide of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 50: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing**

##### **Models**

##### ***A. Diabetic db+/db+ Mouse Model.***

To demonstrate that a polypeptide of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)).

The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al.* *Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*, *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*, *Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These



homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of Pathol.* 136:1235-1246 (1990)).

Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

A polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

- 5 Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post  
10 treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

- 15 Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by  
20 treatment with a polypeptide of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

- 25 Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

- 30 Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer can serve as a positive tissue control and human brain tissue can be used as a negative tissue control. Each specimen includes a section with omission of the primary

antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is  
5 considered significant.

### ***B. Steroid Impaired Rat Model***

The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-  
10 Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahl *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert *et al.*, *Am. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*,  
15 *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth*  
20 *Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

To demonstrate that a polypeptide of the invention can accelerate the healing  
25 process, the effects of multiple topical applications of the polypeptide on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and  
30 are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad*

*libitum*. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

5           The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue  
10       punch. The wounds are left open for the duration of the experiment. Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

          Wounds are visually examined and photographed at a fixed distance at the day of  
15       wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

          The polypeptide of the invention is administered using at a range different doses,  
20       from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

          Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue  
25       cassettes between biopsy sponges for further processing.

          Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

          Wound closure is analyzed by measuring the area in the vertical and horizontal  
30       axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8).

The wound area on day 1 is  $64\text{mm}^2$ , the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

5

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with a polypeptide of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. A p value of  $< 0.05$  is considered significant.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### 20 **Example 51: Lymphadema Animal Model**

or The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of a polypeptide of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing.

Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's Blue. Circumference and volumetric measurements are then made following injection of  
5 dye into paws.

Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main  
10 lymphatic vessels in this area are then electrically coagulated suture ligated.

Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and ligated by suturing. The popliteal lymph node, and any accompanying adipose  
15 tissue, is then removed by cutting connective tissues.

Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying  
20 muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated  
25 places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb  
30 movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then  
5 dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and  $\text{Ca}^{2+}$  comparison.

10 Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quilltine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

Histological Preparations: The transverse muscle located behind the knee  
15 (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
20 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 52: Suppression of TNF alpha-induced adhesion molecule expression  
by a Polypeptide of the Invention**

25 The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and  
30 endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and

extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

5 Tumor necrosis factor alpha (TNF- $\alpha$ ), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

The potential of a polypeptide of the invention to mediate a suppression of TNF- $\alpha$  induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF- $\alpha$  treated ECs when co-stimulated with a member of the FGF family of proteins.

10 To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO<sub>2</sub>. HUVECs are seeded in 96-well plates at concentrations of  $1 \times 10^4$  cells/well in EGM medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

20 Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90  $\mu$ l of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10  $\mu$ l volumes). Plates are incubated at 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with Ca<sup>++</sup> and Mg<sup>++</sup>) is added to each well. Plates are held at 4°C for 30 min.

25 Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10  $\mu$ l of diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10  $\mu$ g/ml (1:10 dilution



of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

Then add 20 µl of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with

5 PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100 µl of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer:  $1:5,000$  ( $10^0$ )  $> 10^{-0.5}$   $> 10^{-1}$   $> 10^{-1.5}$ . 5 µl of each dilution is added to triplicate wells and the resulting AP content in each well is

10 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 µl of pNPP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50 µl of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [

15 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the

20 invention.

### **Example 53: Assay for the Stimulation of Bone Marrow CD34+ Cell**

#### **Proliferation**

This assay is based on the ability of human CD34+ to proliferate in the

25 presence of hematopoietic growth factors and evaluates the ability of isolated polypeptides expressed in mammalian cells to stimulate proliferation of CD34+ cells.

It has been previously shown that most mature precursors will respond to only a single signal. More immature precursors require at least two signals to respond. Therefore, to test the effect of polypeptides on hematopoietic activity of a wide range

30 of progenitor cells, the assay contains a given polypeptide in the presence or absence of other hematopoietic growth factors. Isolated cells are cultured for 5 days in the presence of Stem Cell Factor (SCF) in combination with tested sample. SCF alone

has a very limited effect on the proliferation of bone marrow (BM) cells, acting in such conditions only as a "survival" factor. However, combined with any factor exhibiting stimulatory effect on these cells (e.g., IL-3), SCF will cause a synergistic effect. Therefore, if the tested polypeptide has a stimulatory effect on a hematopoietic progenitors, such activity can be easily detected. Since normal BM cells have a low level of cycling cells, it is likely that any inhibitory effect of a given polypeptide, or agonists or antagonists thereof, might not be detected. Accordingly, assays for an inhibitory effect on progenitors is preferably tested in cells that are first subjected to *in vitro* stimulation with SCF+IL+3, and then contacted with the compound that is being evaluated for inhibition of such induced proliferation.

Briefly, CD34+ cells are isolated using methods known in the art. The cells are thawed and resuspended in medium (QBSF 60 serum-free medium with 1% L-glutamine (500ml) Quality Biological, Inc., Gaithersburg, MD Cat# 160-204-101). After several gentle centrifugation steps at 200 x g, cells are allowed to rest for one hour. The cell count is adjusted to  $2.5 \times 10^5$  cells/ml. During this time, 100  $\mu$ l of sterile water is added to the peripheral wells of a 96-well plate. The cytokines that can be tested with a given polypeptide in this assay is rhSCF (R&D Systems, Minneapolis, MN, Cat# 255-SC) at 50 ng/ml alone and in combination with rhSCF and rhIL-3 (R&D Systems, Minneapolis, MN, Cat# 203-ML) at 30 ng/ml. After one hour, 10  $\mu$ l of prepared cytokines, 50  $\mu$ l SID (supernatants at 1:2 dilution = 50  $\mu$ l) and 20  $\mu$ l of diluted cells are added to the media which is already present in the wells to allow for a final total volume of 100  $\mu$ l. The plates are then placed in a 37°C/5% CO<sub>2</sub> incubator for five days.

Eighteen hours before the assay is harvested, 0.5  $\mu$ Ci/well of [3H] Thymidine is added in a 10  $\mu$ l volume to each well to determine the proliferation rate. The experiment is terminated by harvesting the cells from each 96-well plate to a filtermat using the Tomtec Harvester 96. After harvesting, the filtermats are dried, trimmed and placed into OmniFilter assemblies consisting of one OmniFilter plate and one OmniFilter Tray. 60  $\mu$ l Microscint is added to each well and the plate sealed with TopSeal-A press-on sealing film. A bar code 15 sticker is affixed to the first plate for counting. The sealed plates is then loaded and the level of radioactivity determined

via the Packard Top Count and the printed data collected for analysis. The level of radioactivity reflects the amount of cell proliferation.

The studies described in this example test the activity of a given polypeptide to stimulate bone marrow CD34<sup>+</sup> cell proliferation. One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof. As a nonlimiting example, potential antagonists tested in this assay would be expected to inhibit cell proliferation in the presence of cytokines and/or to increase the inhibition of cell proliferation in the presence of cytokines and a given polypeptide. In contrast, potential agonists tested in this assay would be expected to enhance cell proliferation and/or to decrease the inhibition of cell proliferation in the presence of cytokines and a given polypeptide.

The ability of a gene to stimulate the proliferation of bone marrow CD34<sup>+</sup> cells indicates that polynucleotides and polypeptides corresponding to the gene are useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein.

**Example 54: Assay for Extracellular Matrix Enhanced Cell Response (EMECCR)**

The objective of the Extracellular Matrix Enhanced Cell Response (EMECCR) assay is to identify gene products (e.g., isolated polypeptides) that act on the hematopoietic stem cells in the context of the extracellular matrix (ECM) induced signal.

Cells respond to the regulatory factors in the context of signal(s) received from the surrounding microenvironment. For example, fibroblasts, and endothelial and epithelial stem cells fail to replicate in the absence of signals from the ECM. Hematopoietic stem cells can undergo self-renewal in the bone marrow, but not in *in vitro* suspension culture. The ability of stem cells to undergo self-renewal *in vitro* is dependent upon their interaction with the stromal cells and the ECM protein fibronectin (fn). Adhesion of cells to fn is mediated by the  $\alpha_5\beta_1$  and  $\alpha_4\beta_1$  integrin receptors, which are expressed by human and mouse hematopoietic stem cells. The factor(s) which integrate with the ECM environment and responsible for stimulating

stem cell self-renewal has not yet been identified. Discovery of such factors should be of great interest in gene therapy and bone marrow transplant applications

Briefly, polystyrene, non tissue culture treated, 96-well plates are coated with fn fragment at a coating concentration of  $0.2 \mu\text{g}/\text{cm}^2$ . Mouse bone marrow cells are  
5 plated (1,000 cells/well ) in 0.2 ml of serum-free medium. Cells cultured in the presence of IL-3 ( 5 ng/ml ) + SCF ( 50 ng/ml ) would serve as the positive control, conditions under which little self-renewal but pronounced differentiation of the stem cells is to be expected. Gene products are tested with appropriate negative controls in the presence and absence of SCF(5.0 ng/ml), where test factor supernates represent  
10 10% of the total assay volume. The plated cells are then allowed to grow by incubating in a low oxygen environment ( 5%  $\text{CO}_2$ , 7%  $\text{O}_2$ , and 88%  $\text{N}_2$  ) tissue culture incubator for 7 days. The number of proliferating cells within the wells is then quantitated by measuring thymidine incorporation into cellular DNA. Verification of the positive hits in the assay will require phenotypic characterization  
15 of the cells, which can be accomplished by scaling up of the culture system and using appropriate antibody reagents against cell surface antigens and FACScan.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

20 If a particular gene product is found to be a stimulator of hematopoietic progenitors, polynucleotides and polypeptides corresponding to the gene may be useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein. The gene product may  
25 also be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Additionally, the polynucleotides and/or polypeptides of the gene of interest and/or agonists and/or antagonists thereof, may also be employed to inhibit the proliferation and differentiation of hematopoietic cells and therefore may be  
30 employed to protect bone marrow stem cells from chemotherapeutic agents during chemotherapy. This antiproliferative effect may allow administration of higher doses

of chemotherapeutic agents and, therefore, more effective chemotherapeutic treatment.

Moreover, polynucleotides and polypeptides corresponding to the gene of interest may also be useful for the treatment and diagnosis of hematopoietic related disorders such as, for example, anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

#### **Example 55: Human Dermal Fibroblast and Aortic Smooth Muscle Cell Proliferation**

The polypeptide of interest is added to cultures of normal human dermal fibroblasts (NHDF) and human aortic smooth muscle cells (AoSMC) and two co-assays are performed with each sample. The first assay examines the effect of the polypeptide of interest on the proliferation of normal human dermal fibroblasts (NHDF) or aortic smooth muscle cells (AoSMC). Aberrant growth of fibroblasts or smooth muscle cells is a part of several pathological processes, including fibrosis, and restenosis. The second assay examines IL6 production by both NHDF and SMC. IL6 production is an indication of functional activation. Activated cells will have increased production of a number of cytokines and other factors, which can result in a proinflammatory or immunomodulatory outcome. Assays are run with and without co-TNF $\alpha$  stimulation, in order to check for costimulatory or inhibitory activity.

Briefly, on day 1, 96-well black plates are set up with 1000 cells/well (NHDF) or 2000 cells/well (AoSMC) in 100  $\mu$ l culture media. NHDF culture media contains: Clonetics FB basal media, 1mg/ml hFGF, 5mg/ml insulin, 50mg/ml gentamycin, 2%FBS, while AoSMC culture media contains Clonetics SM basal media, 0.5  $\mu$ g/ml hEGF, 5mg/ml insulin, 1 $\mu$ g/ml hFGF, 50mg/ml gentamycin, 50  $\mu$ g/ml Amphotericin B, 5%FBS. After incubation @ 37°C for at least 4-5 hours culture media is aspirated and replaced with growth arrest media. Growth arrest media for NHDF contains fibroblast basal media, 50mg/ml gentamycin, 2% FBS, while growth arrest media for

AoSMC contains SM basal media, 50mg/ml gentamycin, 50µg/ml Amphotericin B, 0.4% FBS. Incubate at 37C until day 2.

On day 2, serial dilutions and templates of the polypeptide of interest are designed which should always include media controls and known-protein controls.

- 5 For both stimulation and inhibition experiments, proteins are diluted in growth arrest media. For inhibition experiments, TNFa is added to a final concentration of 2ng/ml (NHDF) or 5ng/ml (AoSMC). Then add 1/3 vol media containing controls or supernatants and incubate at 37C/5% CO<sub>2</sub> until day 5.

- 10 Transfer 60µl from each well to another labeled 96-well plate, cover with a plate-sealer, and store at 4C until Day 6 (for IL6 ELISA). To the remaining 100 µl in the cell culture plate, aseptically add Alamar Blue in an amount equal to 10% of the culture volume (10µl). Return plates to incubator for 3 to 4 hours. Then measure fluorescence with excitation at 530nm and emission at 590nm using the CytoFluor. This yields the growth stimulation/inhibition data.

- 15 On day 5, the IL6 ELISA is performed by coating a 96 well plate with 50-100 ul/well of Anti-Human IL6 Monoclonal antibody diluted in PBS, pH 7.4, incubate ON at room temperature.

- On day 6, empty the plates into the sink and blot on paper towels. Prepare Assay Buffer containing PBS with 4% BSA. Block the plates with 200 µl/well of  
20 Pierce Super Block blocking buffer in PBS for 1-2 hr and then wash plates with wash buffer (PBS, 0.05% Tween-20). Blot plates on paper towels. Then add 50 µl/well of diluted Anti-Human IL-6 Monoclonal, Biotin-labeled antibody at 0.50 mg/ml. Make dilutions of IL-6 stock in media (30, 10, 3, 1, 0.3, 0 ng/ml). Add duplicate samples to top row of plate. Cover the plates and incubate for 2 hours at RT on shaker.

- 25 Wash plates with wash buffer and blot on paper towels. Dilute EU-labeled Streptavidin 1:1000 in Assay buffer, and add 100 µl/well. Cover the plate and incubate 1 h at RT. Wash plates with wash buffer. Blot on paper towels.

- Add 100 µl/well of Enhancement Solution. Shake for 5 minutes. Read the plate on the Wallac DELFIA Fluorometer. Readings from triplicate samples in each  
30 assay were tabulated and averaged.

A positive result in this assay suggests AoSMC cell proliferation and that the gene product of interest may be involved in dermal fibroblast proliferation and/or

smooth muscle cell proliferation. A positive result also suggests many potential uses of polypeptides, polynucleotides, agonists and/or antagonists of the gene/gene product of interest. For example, inflammation and immune responses, wound healing, and angiogenesis, as detailed throughout this specification. Particularly, polypeptides of the gene product and polynucleotides of the gene may be used in wound healing and dermal regeneration, as well as the promotion of vascularogenesis, both of the blood vessels and lymphatics. The growth of vessels can be used in the treatment of, for example, cardiovascular diseases. Additionally, antagonists of polypeptides of the gene product and polynucleotides of the gene may be useful in treating diseases, disorders, and/or conditions which involve angiogenesis by acting as an anti-vascular (e.g., anti-angiogenesis). These diseases, disorders, and/or conditions are known in the art and/or are described herein, such as, for example, malignancies, solid tumors, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis. Moreover, antagonists of polypeptides of the gene product and polynucleotides of the gene may be useful in treating anti-hyperproliferative diseases and/or anti-inflammatory known in the art and/or described herein.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

**Example 56: Cellular Adhesion Molecule (CAM) Expression on Endothelial****Cells**

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Briefly, endothelial cells (e.g., Human Umbilical Vein Endothelial cells (HUVECs)) are grown in a standard 96 well plate to confluence, growth medium is removed from the cells and replaced with 100  $\mu$ l of 199 Medium (10% fetal bovine serum (FBS)). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10  $\mu$ l volumes). Plates are then incubated at 37°C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with Ca<sup>++</sup> and Mg<sup>++</sup>) is added to each well. Plates are held at 4°C for 30 min. Fixative is removed from the wells and wells are washed 1X with PBS(+Ca,Mg) + 0.5% BSA and drained. 10  $\mu$ l of diluted primary antibody is added to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10  $\mu$ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed three times with PBS(+Ca,Mg) + 0.5% BSA. 20  $\mu$ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution, referred to herein as the working dilution) are added to each well and incubated at 37°C for 30 min. Wells are washed three times with PBS(+Ca,Mg)+0.5% BSA. Dissolve 1 tablet of p-Nitrophenol Phosphate pNPP per 5 ml of glycine buffer (pH 10.4). 100  $\mu$ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of



the ExtrAvidin-Alkaline Phosphatase in glycine buffer:  $1:5,000$  ( $10^0$ )  $> 10^{-0.5} > 10^{-1} > 10^{-1.5}$ . 5  $\mu$ l of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100  $\mu$ l of pNNP reagent is then added to each of the standard wells. The plate is incubated at 37°C for 4h. A volume of 50  $\mu$ l of 3M NaOH is added to all wells. The plate is read on a plate reader at 405 nm using the background subtraction option on blank wells filled with glycine buffer only. Additionally, the template is set up to indicate the concentration of AP-conjugate in each standard well [ 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

10

#### **Example 57: Alamar Blue Endothelial Cells Proliferation Assay**

This assay may be used to quantitatively determine protein mediated inhibition of bFGF-induced proliferation of Bovine Lymphatic Endothelial Cells (LECs), Bovine Aortic Endothelial Cells (BAECs) or Human Microvascular Uterine Myometrial Cells (UTMECs). This assay incorporates a fluorometric growth indicator based on detection of metabolic activity. A standard Alamar Blue Proliferation Assay is prepared in EGM-2MV with 10 ng /ml of bFGF added as a source of endothelial cell stimulation. This assay may be used with a variety of endothelial cells with slight changes in growth medium and cell concentration. Dilutions of the protein batches to be tested are diluted as appropriate. Serum-free medium (GIBCO SFM) without bFGF is used as a non-stimulated control and Angiostatin or TSP-1 are included as a known inhibitory controls.

Briefly, LEC, BAECs or UTMECs are seeded in growth media at a density of 5000 to 2000 cells/well in a 96 well plate and placed at 37-C overnight. After the overnight incubation of the cells, the growth media is removed and replaced with GIBCO EC-SFM. The cells are treated with the appropriate dilutions of the protein of interest or control protein sample(s) (prepared in SFM ) in triplicate wells with additional bFGF to a concentration of 10 ng/ ml. Once the cells have been treated with the samples, the plate(s) is/are placed back in the 37° C incubator for three days. After three days 10 ml of stock alamar blue (Biosource Cat# DAL1100) is added to each well and the plate(s) is/are placed back in the 37°C incubator for four hours. The

plate(s) are then read at 530nm excitation and 590nm emission using the CytoFluor fluorescence reader. Direct output is recorded in relative fluorescence units.

Alamar blue is an oxidation-reduction indicator that both fluoresces and changes color in response to chemical reduction of growth medium resulting from cell growth. As cells grow in culture, innate metabolic activity results in a chemical reduction of the immediate surrounding environment. Reduction related to growth causes the indicator to change from oxidized (non-fluorescent blue) form to reduced (fluorescent red) form. i.e. stimulated proliferation will produce a stronger signal and inhibited proliferation will produce a weaker signal and the total signal is proportional to the total number of cells as well as their metabolic activity. The background level of activity is observed with the starvation medium alone. This is compared to the output observed from the positive control samples (bFGF in growth medium) and protein dilutions.

**Example 58: Detection of Inhibition of a Mixed Lymphocyte Reaction**

This assay can be used to detect and evaluate inhibition of a Mixed Lymphocyte Reaction (MLR) by gene products (e.g., isolated polypeptides). Inhibition of a MLR may be due to a direct effect on cell proliferation and viability, modulation of costimulatory molecules on interacting cells, modulation of adhesiveness between lymphocytes and accessory cells, or modulation of cytokine production by accessory cells. Multiple cells may be targeted by these polypeptides since the peripheral blood mononuclear fraction used in this assay includes T, B and natural killer lymphocytes, as well as monocytes and dendritic cells.

Polypeptides of interest found to inhibit the MLR may find application in diseases associated with lymphocyte and monocyte activation or proliferation. These include, but are not limited to, diseases such as asthma, arthritis, diabetes, inflammatory skin conditions, psoriasis, eczema, systemic lupus erythematosus, multiple sclerosis, glomerulonephritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, arteriosclerosis, cirrhosis, graft vs. host disease, host vs. graft disease, hepatitis, leukemia and lymphoma.

Briefly, PBMCs from human donors are purified by density gradient centrifugation using Lymphocyte Separation Medium (LSM<sup>®</sup>, density 1.0770 g/ml,

Organon Teknika Corporation, West Chester, PA). PBMCs from two donors are adjusted to  $2 \times 10^6$  cells/ml in RPMI-1640 (Life Technologies, Grand Island, NY) supplemented with 10% FCS and 2 mM glutamine. PBMCs from a third donor is adjusted to  $2 \times 10^5$  cells/ml. Fifty microliters of PBMCs from each donor is added to wells of a 96-well round bottom microtiter plate. Dilutions of test materials (50  $\mu$ l) is added in triplicate to microtiter wells. Test samples (of the protein of interest) are added for final dilution of 1:4; rhuIL-2 (R&D Systems, Minneapolis, MN, catalog number 202-IL) is added to a final concentration of 1  $\mu$ g/ml; anti-CD4 mAb (R&D Systems, clone 34930.11, catalog number MAB379) is added to a final concentration of 10  $\mu$ g/ml. Cells are cultured for 7-8 days at 37°C in 5% CO<sub>2</sub>, and 1  $\mu$ C of [<sup>3</sup>H] thymidine is added to wells for the last 16 hrs of culture. Cells are harvested and thymidine incorporation determined using a Packard TopCount. Data is expressed as the mean and standard deviation of triplicate determinations.

Samples of the protein of interest are screened in separate experiments and compared to the negative control treatment, anti-CD4 mAb, which inhibits proliferation of lymphocytes and the positive control treatment, IL-2 (either as recombinant material or supernatant), which enhances proliferation of lymphocytes.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties. Additionally, the contents of U.S. Provisional Applications Serial Nos. 60/166,415 and 60/215,136 are all hereby incorporated by reference in their entirety.


391

Applicant's or agent's file reference number	PS717PCT	International application No.	UNASSIGNED
---	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13 bis)

<b>A.</b> The indications made below relate to the microorganism referred to in the description on page <u>57</u> , line <u>N/A</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 26 October 1999	Accession Number PTA-871
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC). Continued on the Attached Pages 2 & 3	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<b>For receiving Office use only</b> <input checked="" type="checkbox"/> This sheet was received with the international application  Authorized officer 	<b>For International Bureau use only</b> <input type="checkbox"/> This sheet was received by the International Bureau on:  Authorized officer
---	--

**ATCC Deposit No. PTA-871****Page No. 2****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**ATCC Deposit No.: PTA-871****Page No. 3****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

***What Is Claimed Is:***

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- 5 (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit
- 10 No:Z, which is hybridizable to SEQ ID NO:X;
- (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- 15 (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X,
- 20 having biological activity;
- (f) a polynucleotide which is a variant of SEQ ID NO:X;
- (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
- (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
- 25 (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

5 3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

10 4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

15 5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

20 6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

25

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. A recombinant host cell produced by the method of claim 8.

30

10. The recombinant host cell of claim 9 comprising vector sequences.



11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

5 (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

10 (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

15 (g) a variant of SEQ ID NO:Y;

(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

25 14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

30 (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount  
5 of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of  
10 claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to  
15 a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.  
20

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the  
25 polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. A method of identifying an activity in a biological assay, wherein the  
30 method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

<110> Human Genome Sciences, Inc.

<120> 18 Human Secreted Proteins

<130> PS717PCT

<140> Unassigned

<141> 2000-11-15

<150> 60/166,415

<151> 1999-11-19

<150> 60/215,136

<151> 2000-06-30

<160> 161

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga	gcccaaattct	tctgacaaaa	ctcacacatg	cccaccgtgc	ccagcacctg	60
aattcgaggg	tgaccggtca	gtcttcctct	tcccccaaa	acccaaggac	accctcatga	120
tctcccgga	tctgaggtc	acatgcgtgg	tggtggacgt	aagccacgaa	gaccctgagg	180
tcaagttcaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	aagccgcggg	240
aggagcagta	caacagcacg	taccgtgtgg	tcagcgtcct	caccgtcctg	caccaggact	300
ggctgaatgg	caaggagtac	aagtgaagg	tctccaacaa	agccctccca	accccatcg	360
agaaaacccat	ctccaaagcc	aaagggcagc	cccgagaacc	acaggtgtac	accctgcccc	420
catcccgga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctggtc	aaaggcttct	480
atccaagcga	catcgccgtg	gagtgggaga	gcaatgggca	gccggagAAC	aactacaaga	540
ccacgcctcc	cgtgctggac	tccgacggct	ccttcttcct	ctacagcaag	ctcaccgtgg	600
acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	gaggctctgc	660
acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaatagtg	cgacggccgc	720
gactctagag	gat					733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp Ser Xaa Trp Ser

1

5

<210> 3

<211> 86

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60  
cccgaatat ctgccatctc aattag 86

&lt;210&gt; 4

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

gcggcaagct ttttgcaaag cctagggc 27

&lt;210&gt; 5

&lt;211&gt; 271

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 5

ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60  
aaatatctgc catctcaatt agtcagcaac catagtcccc ccctaactc cgcccatccc 120  
gcccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat 180  
ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240  
ttttggaggc ctaggctttt gcaaaaagct t 271

&lt;210&gt; 6

&lt;211&gt; 32

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

gcgctcgagg gatgacagcg atagaacccc gg 32

&lt;210&gt; 7

&lt;211&gt; 31

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

gcgaagcttc gcgactcccc ggatccgcct c 31

&lt;210&gt; 8

&lt;211&gt; 12

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 8

ggggactttc cc 12

&lt;210&gt; 9

<211> 73  
 <212> DNA  
 <213> Homo sapiens

<400> 9  
 gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60  
 ccatctcaat tag 73

<210> 10  
 <211> 256  
 <212> DNA  
 <213> Homo sapiens

<400> 10  
 ctcgagggga ctttcccgga gactttccgg ggactttccg ggactttcca tctgccatct 60  
 caattagtca gcaaccatag tcccggccct aactccggcc atcccgcccc taactccgcc 120  
 cagttccgcc cattctccgc cccatggctg actaatTTTT tttatttatg cagaggccga 180  
 ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240  
 cttttgcaaa aagctt 256

<210> 11  
 <211> 1921  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (68)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1021)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1772)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1854)  
 <223> n equals a,t,g, or c

<400> 11  
 ccactatara aggyacgcct gcaggtaccg gtccggaatt cccgggtcga cccacgcgtc 60  
 cgctttgnta gtttacctgt tctgatgatg tgtgtggtcc tcaccacact gccctgcctc 120  
 accttttcca tagcagtgc tgaggttcaa aagagcatta atgggtccgc tgatgtctta 180  
 cctgatatgt tacctgacct gcccgtatct ctggttctgt tatccctgat catggttgat 240  
 attattgaaa aactcaggat atatcctctt agagggagtc aaaagagtag tgaaaatgga 300  
 cacatccatt caacctcttt gcaacacata aaaactgtga cggagcaagt gaggcaaagt 360  
 ccagaaaacg ctgcatctcc ccaggcaacc aacagcacc cagggtgcga gccatcagga 420  
 gccatgacac ggagccagga gtctgtgttc atgggacccc aggagccctc ctgtgactcc 480  
 ggaatcctga gaatgatgtc ccggcgagat gtccgggcag agttattctt atggagcttt 540  
 ctccctgtgt ctgacacgat agaaatggtg cgtgtggctg gtcaccccaa cgtgtacaag 600

tcaagctggc	tatacccagt	ctacatatcc	agttttatct	ctctccttcg	aattacattc	660
actcccaaaa	accctcttct	caattccctg	agcgtccctg	tgcaagattt	accattcggt	720
tttggttagac	ttggtttaat	cattgcccctg	gggactatca	cacccgtact	gggcctgtgt	780
aaaaatatcc	tcgtgactct	ctcttacatt	tacttcaatt	acctaaccag	aatcaggatt	840
ttttctgcct	ttgaaatgtc	tccattttta	aaaggaaatg	ggatctagta	aggcctcttt	900
gtgatacctg	tgtgcacatt	tgtaatccct	cttttttctt	tggggcgtag	gtgtttgcac	960
tataaaggaa	atgactagat	tgtagagaat	aagccatttt	tactaactct	agcatatcag	1020
nttttttttt	acatatataa	atggtgctaa	atttaagtaa	agtaatatcc	ttataagttg	1080
gctctcaggt	atttctagaa	aatgttagca	gctaatttta	gttagttatg	tatactgagg	1140
tccccaaccc	ctggaccatg	gtcccagtag	tgggtccgtg	tctgttagca	agcagaccgc	1200
acagcacgtg	gtgaacctca	aactgagcgt	tcccgcctgc	attccgcctc	ctgtcagatc	1260
agcagcagca	ttagatcctc	ataggagccc	aaaccctatt	gtgaactgcg	tatgcaaggg	1320
atctagcttt	cgctctttta	gaaaatctaa	tacctgatga	tctgaggtgg	gacagtttca	1380
tcccagaacc	caacccccacc	cccaaccctg	gctgtggaaa	aattgtcttc	cacaaaacta	1440
gtccctgggt	ccaaaaaggt	tggggaccac	tgtgtataac	cacgcttttt	ctaagaatac	1500
tcttcaacgg	agccctttta	aaaactaaga	accttttcca	tcaagttagc	ccaagaataa	1560
gattttttatc	ttttatatag	atagcattat	atgaattgat	tgattaaatt	tagttttaaa	1620
aaacacactt	gaaattattg	aataattttt	aggttatact	tttttttttt	ttttgagacg	1680
atgtctcgct	cttgtccctt	aggctggagt	gcgatggcgc	gktctcagct	cactgcagcc	1740
tggatctccc	aggaggattg	cttgagcccc	gnaggtcaag	gctacagtga	gctatgatca	1800
tggcactgca	ctycagactg	ggcaacagag	tgacacccat	ctaaaaaaa	taanagagaa	1860
ttgacgttgg	ggtawtctac	gttcaccaa	tacctctccc	ttggcaccc	gctycctttc	1920
c						1921

&lt;210&gt; 12

&lt;211&gt; 2577

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 12

cggcacgagg	gtctgagggg	gcgatggcgg	tacgcgcgtt	gaagctgctg	accacactgc	60
tggctgtcgt	ggccgctgcc	tcccaagccg	aggtcgagtc	cgaggcagga	tggggcatgg	120
tgacgcctga	tctgctcttc	gccgagggga	ccgcagccta	cgcgcgcggg	gactggcccc	180
gggtggctcc	gagcatggaa	cgggcgctgc	gtcccggggc	agccctccgc	gcccttcgcc	240
tgcgctgccg	cacccagtg	gccgcgcgact	tcccgtggga	gctggacccc	gactgggtccc	300
ccagcccgcc	ccaggcctcg	ggcgcccgcc	ccctgcgcga	cctgagcttc	ttcgggggcc	360
ttctgcgtcg	cgctgcctgc	ctgcgcgcgt	gcctcggggc	gccggccgcc	cactcgctca	420
gcgaagagat	ggagctggag	ttccgcgaag	ggagccccta	caactacctg	caggtcgcct	480
acttcaagat	caacaagttg	gagaaagctg	ttgctgcagc	acacaccttc	ttcgtgggca	540
atcctgagca	catggaaatg	cagcagaacc	tagactatta	ccaaaccatg	tctggagtga	600
aggaggccga	cttcaaggat	cttgagactc	aaccccatat	gcaagaattt	cgactgggag	660
tgcgactcta	ctcagaggaa	cagccacagg	aagctgtgcc	ccacctagag	gcggcgctgc	720
aagaataactt	tgtggcctat	gaggagtgcc	gtgccctctg	cgaaggggccc	tatgactacg	780
atggctacaa	ctaccttgag	tacaacgctg	acctcttcca	ggccatcaca	gatcattaca	840
tccaggtcct	caactgtaag	cagaactgtg	tcacggagct	tgcttcccac	ccaagtcgag	900
agaagccctt	tgaagacttc	ctcccatcgc	attataatta	tctgcagttt	gcctactata	960
acattgggaa	ttatacacag	gctgttgaat	gtgccaaagc	ctatcttctc	ttcttcccca	1020
atgacgaggt	gatgaaccaa	aatttggccc	tattatgcag	ctatgcttgg	agaagaacac	1080
accagatcca	tcggcccccg	tgagagtgcc	aaggatgacc	gacagcgaag	cctactggaa	1140
aaagaactgc	ttttcttcgc	ttatgatgtt	tttggaattc	cctttgtgga	tccggattca	1200
tggactccag	aagaagtgat	tcccaagaga	ttgcaagaag	aaacagaagt	cagaacggga	1260
aacagccgta	cgcactctcc	aggagattgg	gaaccttatg	aaggaaatcg	agacccttgt	1320
ggaagagaag	accaaggagt	cactggatgt	gagcagactg	acccgggaag	gtggccccct	1380
gctgtatgaa	ggcatcagtc	tcaccatgaa	ctccaaactc	ctgaatggtt	cccagcgggt	1440
ggtgatggac	ggcgtaatct	ctgaccacga	gtgtcaggag	ctgcagagac	tgaccaatgt	1500
ggcagcaacc	tcaggagatg	gctaccgggg	tcagacctcc	ccacatactc	ccaatgaaaa	1560
gttctatggt	gtcactgtct	tcaaagccct	caagctgggg	caagaaggca	aagttcctct	1620

gcagagtgcc	cacctgtact	acaacgtgac	ggagaagggtg	cggcgcacatca	tggagtccta	1680
cttcgcgctg	gatacgcccc	tctacttttc	ctactctcat	ctggtgtgcc	gcactgccat	1740
cgaagaggtc	caggcagaga	ggaaggatga	tagtcatcca	gtccacgtgg	acaactgcat	1800
cctgaatgcc	gagaccctcg	tgtgtgtcaa	agagccccc	gcctacacct	tccgcgacta	1860
cagcgccatc	ctttacctaa	atggggactt	cgatggcgga	aacttttatt	tcactgaact	1920
ggatgccaa	accgtgacgg	cagaggtgca	gcctcagtg	ggaagagccg	tgggattctc	1980
ttcaggcact	gaaaaccac	atggagtga	ggctgtcacc	agggggcagc	gctgtgccat	2040
cgccctgtgg	ttcaccttg	accctcgaca	cagcgagcgg	gacaggggtg	aggcagatga	2100
cctggtgaag	atgctcttca	gcccagaaga	gatggacctc	tcccaggagc	agcccctgga	2160
tgcccagcag	ggcccccccg	aacctgcaca	agagtctctc	tcaggcagtg	aatcgaagcc	2220
caaggatgag	ctatgacagc	gtccagggtc	gacggatggg	tgactagacc	catggagagg	2280
aactcttctg	cactctgagc	tggccagccc	ctcggggctg	cagagcagtg	agcctacatc	2340
tgccactcag	ccgaggggac	cctgtctaca	gccttctaca	tgggtgtact	gctcttgagg	2400
tgagactgac	cagacaccgc	accccctgga	tctggctgag	ggctcaggac	acaggcccag	2460
ccacccccag	gggcctccac	aggccgtgc	ataacagcga	tacagtactt	aagtgtctgt	2520
gtagacaacc	aaagaataaa	tgattcatgg	ttttttttaa	aaaaaaaaaa	aaaaaaa	2577

&lt;210&gt; 13

&lt;211&gt; 3665

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (4)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (16)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (29)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 13

ctcncacta	attggnacaa	aagccgganc	tccaccgcgg	tggcggccgc	tctagaacta	60
gtggatcccc	cgggtgcag	gaattcgga	cgagctcgtg	ccgctcgtgc	cgctcgtgcc	120
gcgcgcggcg	aggatggcgg	cgcggggccc	ggggctgctg	ctgctgacgc	tgtcggtgct	180
gttggcggcg	ggccctccg	ccgctgcggc	caagctcaac	atccccaaag	tgctgctgcc	240
cttcacgcgg	gccacgcgcg	ttaacttcac	gctggaggcc	tggagggtct	gctaccgctg	300
gttgtccacc	cggccggagg	tggccagcat	cgagccgctg	ggcctggacg	agcagcagtg	360
ctcccagaag	gcagtgggtg	aggcccgcct	gaccagcct	gcccgcctca	ccagcatcat	420
cttcgcagag	gacatcacca	caggccaggt	cctgcgctgt	gatgccattg	tggacctcat	480
ccatgacatc	cagatcgtct	ccaccacccg	cgagctctac	ctggaggact	ccccctgga	540
gctgaagatc	caggccctgg	actccgaagg	gaacaccttc	agcactctgg	ctggactggt	600
cttcgagtgg	acgattgtga	aggactccga	ggcgacagg	ttctcagact	cccacaatgc	660
gctgcgaatc	ctcactttct	tggagtctac	gtacatccct	ccttcttaca	tctcagagat	720
ggagaaggct	gccaagcaag	gggacacccat	cctggtgtct	gggatgaaga	ccgggagctc	780
caagctcaag	gctcgcaccc	aggaggctgt	ctacaagaat	gtacgccctg	cagaagtcag	840
gctgctgatt	ttggaaaaca	tccttctgaa	cccggcctat	gacgtctacc	tgatgggtgg	900
aacctccatt	cactacaagg	tgcagaagat	caggcaaggg	aaaattacag	aactctccat	960
gccttccgat	cagtacgagt	tgcagcttca	gaacagcatc	ccgggccccg	aaggagaccc	1020
aaccggcccg	gtggctgtct	tggcccagga	cacgtcgatg	gtcactgcac	tcagctggg	1080
acagagcagc	ctcgtccttg	gccacaggag	tattcgcgatg	caagggtgctt	ctaggttacc	1140



caacagcact	atctacgtgg	tcgaacctgg	atacctaggg	ttcactgttc	accctgggtga	1200
caggtgggtg	ctggagaccg	gccgcctgta	tgaaatcacc	atcgaagttt	ttgacaagtt	1260
cagcaacaag	gtctatgtat	ctgacaacat	ccgaattgaa	actgtgcttc	ctgctgagtt	1320
cttcgagggtg	ctctcgtcct	cccagaatgg	gtcataccat	cgcatcaggg	cactaaagag	1380
gggacagacg	gccattgacg	cggccctcac	ctctgtggtg	gaccaggatg	gaggggtcca	1440
catactacag	gtgcctgtgt	ggaaccagca	ggagggtgaa	attcacatcc	cgatcacccct	1500
gtatcccagc	atcttgacat	ttccgtggca	accaaagacg	ggcgccctatc	agtacacaat	1560
aagggcccac	ggtggcagtg	ggaacttcag	ctgggtcttcg	tcaagccacc	tggttgccac	1620
agttactgtc	aagggcgtga	tgaccacagg	cagtgcacatc	gggttcagtg	tgatccaggc	1680
acatgatgtg	cagaaccac	tccatttcgg	tgagatgaag	gtgtatgtga	tcgagcccca	1740
cagcatggag	tttgccccgt	gccagggtgga	ggcacgtgtg	ggccaggccc	tggagctgcc	1800
cctgaggatc	agtggcctca	tgccccggcg	ggccagtga	gtggtcacct	tgagcgactg	1860
ctcccacttt	gacttggtgt	tcgagggtgga	gaaccagggt	gtgttcacagc	cactcccagg	1920
gagggctcgc	ccaggctctg	agcactgcag	cggcgtccgg	gtaaaggccg	aggcccagg	1980
ctctaccacg	cttcttgtga	gctacagaca	cggccacgtc	cacctgagtg	ccaagatcac	2040
cattgctgcc	tacctgcccc	tcaaggctgt	ggatccctcc	tctgttgctt	tggtaacctt	2100
gggctcctca	aaggagatgc	tgtttgaagg	aggtcccaga	ccttggatcc	tcgagccgtc	2160
caaattcttc	cagaacgtca	ccgctgagga	actgcacagc	atcgccctgg	ctctctttgc	2220
ccccatttcc	tcccgggaatt	atcagcaaca	ctggatccct	gtgacctgtc	aggccttggg	2280
tgagcaggtc	atcgccctgt	cgggtgggaa	caagcccagg	ctcaccaacc	cctttcctgc	2340
ggtggagctc	ccggtgggtga	agttcgtctg	cgccccaccg	tccaggctca	ccctcgtgcc	2400
tgtctacacc	agccccacgc	tggacatgtc	ctgtccgctg	ctgcagcaga	acaagcagg	2460
ggtcccagtg	tccagccacc	gcaacccctt	gctggacctg	gctgcttacg	accaggagg	2520
ccgcccgttc	gacaacttca	gctctctgag	catccagtgg	gagtcacca	ggccagtgtt	2580
ggcagcatcg	agcctgagct	gccatgcagc	tggtgtccca	ggacgatgag	agtggccaaa	2640
agaagctgca	cggtttgtag	gccatttttg	tcacgaggca	tcaggaacca	cmgcatcact	2700
gccactgcca	ctggctacca	ggagtcccat	ctcagctctg	ycagaacaaa	gcagccgcat	2760
gacctctctg	tgccctctgtc	ggcctccata	gagctcatcc	tggtggagga	cgtgagggtg	2820
agcccagaag	agggtgacct	ctacaaccac	cctggcatcc	aggcagagct	ccgcatcagg	2880
gaaggctcag	gttactttctt	cctcaacacc	agcaccgcag	atgttgtcaa	ggtggcctac	2940
caggaggcca	ggggtgtcgc	catggtgcac	cctttgtctc	cgggctcatc	caccatcatg	3000
atccatgact	tgtgcctcgt	cttcccggcc	ccagccaagg	ctgtcgttta	cgtgtcggac	3060
attcaggagc	tgtacatccg	tgtggttgac	aagggtggaga	ttgggaagac	agtgaaggca	3120
tacgtccgcg	tgtctgacct	gcacaagaag	cccttccttg	ccaaataactt	ccccttcatg	3180
gacctgaagc	tccgagcagc	ctccccgata	attacattgg	tggcccttga	tgaagccctt	3240
gacaactaca	ccatcacatt	cctcatccgc	ggtgtggcca	tcggccagac	cagtctaact	3300
gcaagtgtga	ccaataaagc	tggacagaga	atcaactcag	ccccacaaca	gattgaagtc	3360
tttccccctg	tcaggctgat	gccagggaag	gtgacactgc	ttatcggggc	cacgatgcag	3420
gtcacctccg	agggcgggcc	ccagcctcag	tccaacatcc	ttttctccat	cagcaatgag	3480
agcgttgccg	tggtagcgcg	tgctgggctg	gtacagggcc	tcgccatcgg	gaacggcact	3540
gtgtctgggc	tcgtgcaggc	agtggatgca	gagaccggca	agggtggtcat	catctctcag	3600
gacctcgtgc	aggtggaagt	gctgctgcta	agggcctgtc	tcttatacac	atctcaacct	3660
gcagg						3665

&lt;210&gt; 14

&lt;211&gt; 4603

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

ccccgggct	gcaggaattc	ggcacgagg	gcgcggcggc	agtcggctct	atgttcgcgg	60
tcttaacctc	tcctctggcc	gagtccttgc	aagaagtga	ttacccgacc	ctgcaaaaca	120
cttactatct	tggagttaa	agtatgtcat	catggcaag	tttcggagaa	ggacttgcat	180
cattttggca	ctttttatct	tatttatctt	ctctctgatg	atgggtttta	aaatgctgag	240
accaaataca	gctacttttg	gagctccttt	tggacttgac	cttcttccag	aacttcatca	300
acgaactatt	catttgggga	aaaattttga	tttccaaaag	agtgacagaa	tcaacagtga	360
aacaaatacc	aagaatttaa	aaagtgttga	aatcactatg	aaacctcca	aagcctctga	420

acttaacttg	gatgaactac	cacctctgaa	caattatcta	catgtatfff	attacagttg	480
gtatggaaat	ccacaatttg	atgggtaaata	tatacattgg	aatcatccag	tgtagagca	540
ttgggacccc	tagaatagcc	aagaattatc	cacaaggagg	acacaaccct	ccagatgaca	600
ttggctccag	cttttatcct	gaattggcaa	gttacagttc	tcgggatcct	tctgtcatag	660
aaactcacat	gagacaaatg	cgctcagctt	caattggtgt	actagccctc	tcttggtacc	720
cacctgatgt	aaatgatgaa	aatggagaac	ctactgataa	cttggtaccc	actatfff	780
ataaagctca	taaatataac	ctaaaggtta	cttttcacat	agaaccatat	agcaatcgag	840
atgatcaaaa	catgtacaaa	aatgtcaagt	atattataga	caaatatgga	aatcatccgg	900
ccttttacag	gtacaagacg	aagactggca	atgctcttcc	tatgttttat	gtctatgatt	960
cctatattac	caagcctgaa	aaatgggcca	atctgttaac	cacctcaggg	tctcggagta	1020
ttcgcaattc	tccttatgat	ggactgttta	ttgcccttct	ggtagaagaa	aaacataagt	1080
atgatattct	tcaaagtggg	tttgatggaa	tttacacata	ttttgccaca	aatggcttta	1140
cttatggctc	atcacatcag	aattgggcta	gcctaaaatt	atftttgtgat	aaatacaact	1200
taatatfttat	cccaagtgtg	ggcccaggat	acatagatac	cagcatccgt	ccatggaaca	1260
cgcaaaacac	tcggaaccga	atcaatggga	agtattatga	aattggtctg	agtgccgcac	1320
ttcaagacac	gccccagct	taatttctat	cacctctftt	aatgagtggg	catgaaggaa	1380
ctcagattga	aaaagctggt	cccaaaagaa	ccagtaatac	agtgtacct	gattaccgtc	1440
ctcataaacc	aggtctttac	ctagaactga	ctcgcaagtg	gtctgaaaaa	tacagtaagg	1500
aaagagcaac	ttatgcatta	gatcgccagc	tgctgttttc	ttaatgcatt	gattaaagtt	1560
taatagtftat	caaaatcacc	taattfttta	aaatagcttt	cgfttttgagt	tctggaagaa	1620
aaactgtcaa	aatcagtata	tactattagt	tatattftaa	aatattfttt	taaattcttt	1680
acagataata	ttatacttgt	tacctttcac	aataccacat	gagaaaatat	ctgagacaaa	1740
atgtatacaa	atataftcct	tatggcataa	tttattgcat	ttctgactga	aatcaaaatt	1800
cttattftgat	ggcaattgaa	ttttcatftt	acaatagata	aatgctftgtg	ttacctaaag	1860
cacttagcac	acagttaaat	tatattftaca	tcctagacct	aaataaatag	gattgtgtgt	1920
atattftggga	tatctattga	agaaaaaaag	aaaaccctt	aaaaataatg	tacatgcttc	1980
atgtcatgtc	tttaaaataa	tttaatcaac	tttattgtct	tagtattftag	actctggata	2040
actctacaat	aatgaggaaa	ttcttaagaa	taacaaaatc	actgtacctt	cctctcaatt	2100
ttgctgtgaa	cctgaaatgg	ctttaaatta	atactcttat	ttttattfta	atttaattac	2160
ataaattftaa	ccttaccatg	accaaattgt	gttaggaagg	cctgctatct	acagcacagt	2220
gtgtcattftg	cagattftgtg	gttacctata	ccacgctagg	tgftttgaca	tgftttagtt	2280
ttctgctftta	cagtgtctgaa	ttccatattt	tagaagctat	gaaagtcctt	ttatgaaaaa	2340
gttactgatt	gcttctcagt	tattaggaaa	acagttgttt	cacaattatt	atgtagatat	2400
gatgcccaaa	tatcatfttt	agtatatctt	gtcgtatctt	aagttgttac	tattgtgtta	2460
ttcatgtctt	taaatcagat	accaaatatt	ttttaggaaa	gaaaaatggt	attactgtca	2520
ttaggttgtc	ttttaatact	ttaaagttatt	ttgacgaaaa	gtaatagaga	aaatttactt	2580
agcattfttag	attctagaga	catggaaatg	aaaattattt	tatgtctaga	gtaggtcctg	2640
aagttftggct	ttacattftaag	tttagcactg	tatcagaatg	aagaaactaa	tattfttcat	2700
aaaaactaat	actfttcaatt	ttttatatag	taatatcccc	atftttgtaa	tgfttagactt	2760
ttatcatacc	tgtaagttaa	aatactftgtt	atcaataact	tgtcatattg	tgacaaattg	2820
atcactftgtg	tacgaaaaat	aaatctcctt	aaaaactaaa	taaaaatgcac	tgtattctta	2880
cagttaatgt	ttataactat	agtaaaaaat	taatatatat	cctattacat	aaatgttatt	2940
tcttaggtgt	tccattftaaga	agagcaatag	aataatgcta	aaaaataatg	cctataaatc	3000
ttcagagtat	aaagacatcc	attcagaaac	aaaaatttagc	actaaattftt	ttataaaata	3060
gaccagatga	caaaattftat	tttattfttta	aacagtgggt	ttgacacaaa	ttatgttatt	3120
gaaaagcatt	attftaattg	aattftattta	aaattfttggg	atfttgccatt	tctcagacaa	3180
tgatcaggcc	ttaggaaatt	aatacagtag	tagtaatcat	tttctagggg	aaaataaaag	3240
aataaatcac	tatactgata	ttttgatata	agcaagcact	tacatggtaa	tcactatata	3300
gatccaaact	gtggattfttc	ttcttatgtc	cattftaacta	gaatatattta	ttttaggtat	3360
aattftacaaa	tgtcacacct	aataatcttt	tataatatac	catattftcat	taaagttftt	3420
ttagagaagt	atctaccaca	gaggagtftt	tgctattftg	tacgttftgt	atftgaaccc	3480
accatgacag	aaagtaaat	ttaggaaata	gttatgagat	taagggaata	tctataaaaa	3540
caaggtttagc	atattctcaa	cacagatacc	accactfttct	ttttcccat	atagacatgg	3600
tgaatccaca	cagcatactt	catctctgag	ctftgtftgtg	attcctcaac	acattaccct	3660
aaccagccag	cagtaacaga	tttcagagta	agataaagca	gattctgtct	tcattgcaaa	3720
aagttattct	caatgggaaga	atggcatctg	atctcataat	tactagttta	tattftaata	3780
gtftttftct	ccctftttta	taaaaataat	acagtcatcc	ctcagtgtct	gtgggggatt	3840
ggftccagtt	acccttatag	ataccaaaaat	ctgcagatgc	tcaagtcctt	gatataaact	3900

ggcatagtag	ttgcatataa	tctatgcaca	tcctcctgta	tacattaagt	catctctaga	3960
ttattttataa	cacttaatac	aatgtaaatg	ctatgtagtt	gttataccat	actggtagt	4020
gaataattac	atgaaaaaaa	agagtctgta	catcttcaga	gtttcagtcg	gcaatttctt	4080
ggccatggat	gtagaaccta	cagataaggt	gagccaactg	cattaggaaa	taactctaata	4140
aattctgtta	attcttagag	aggaaaactt	tcaaaatctt	cctcagggtat	ttattacaac	4200
tgcctttacc	atttttagttg	taacacagtt	taaattgtta	tgataacaag	taaataagag	4260
caaagaattt	atttcttaat	tcaaaactat	acgtttgaat	tcaatatggg	ataacttaaa	4320
gtggtataat	acatacaatg	catgaatcat	aatggattct	tttataagtt	attaattttt	4380
atggtttaat	cagtctaatt	gttttgactg	ttatagaaac	caaataattt	actgtttctt	4440
ttaaggacta	atattgtcaa	aaactgctgt	tattaaacttc	acttgagttg	tttaacttcc	4500
ttctgtttta	agattgtaat	taaaaattac	tattttgtta	tatggaatgg	ttaatTTTTA	4560
cctaataaaa	acatagggca	cgaggggggg	cccgtaccca	att		4603

&lt;210&gt; 15

&lt;211&gt; 1190

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

ggcacgagcc	ggctactcct	gctcagcatg	gctgctttag	tgactgttct	cttcacaggt	60
gtccggaggc	tgactgcag	cgcagccgct	tgggcggggc	gccagtggcg	actacagcag	120
ggactggctg	ccaacccctc	cggctacggg	ccccttaccg	agctcccaga	ctggtcatat	180
gcggatggcc	gcctgctcc	cccaatgaaa	ggccagcttc	gaagaaaagc	tgaaagggag	240
acgtttgcaa	gacgagttgt	actgctgtca	caggaaatgg	acgctggatt	acaagcatgg	300
cagctcaggc	agcagaagtt	gcaggaagaa	caaaggaagc	aggaaaatgc	tcttaaacc	360
aaaggggctt	caactgaagag	cccacttcca	agtcaataaa	aagcaactcc	tgccctccct	420
cctcaccctg	tctctggatt	tcttttctat	cacctagatg	cttcatccag	ccagaagata	480
gccttcacgt	tccccactctg	tcttcagagc	aaaagagctg	ggacaccaag	aacaagctgt	540
tagatcactg	cctgggaggc	ttggcttagt	actctcatct	ctggttccat	tccagttcag	600
ctaagtcttg	ctttaaaatt	ttacctcct	agctgggtgc	ggtggctcac	gcctgtaatc	660
ccagcacttt	gggaggctga	ggcgggcaga	tcacaagatc	aggagtccga	gaccagcctg	720
gccaacccag	cctggtcaac	atggtgaaac	cctgtcccta	ctaaagatac	aaacaattag	780
ccgggcgttg	tggggtgcgc	ttgtaatccc	agctactcag	gaggctgagg	caggagaatc	840
gcttaaacct	gggaggtaga	ggttgcagtg	agccaaagtc	acaccattgc	actccaacct	900
gggcgacagg	gcgagactct	gtctcaaaaa	aaaaaaaaaa	tttacctcct	ttgcaggcca	960
taggactagc	ccaactatga	gaaatagctg	ttctgtgaac	gtgaaaagg	gacagcagtt	1020
ttcccagttt	tggccaggca	gtcaagcctt	taacagctca	tgacagttt	aggccatgta	1080
cagctggcat	ctaataaatg	tttcatgaa	aaagaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1140
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa		1190

&lt;210&gt; 16

&lt;211&gt; 1699

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

tcgagttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	60
tttttttttt	tttttttttt	ttttkgccag	gcctccaggc	gtttattcag	ccccttccct	120
ctgccgccag	ctgcttgagt	gaagccccc	ctccatgagg	agccttgaga	cccctccagt	180
cctgtgctca	gaggctgagt	ctgggcccc	cacgcagagc	tggtgctgc	tcacgcctgg	240
ctgcctttac	ccactcgccg	atgatggtgg	cctccagctt	ccgcgcctca	accacggaag	300
caggatcttc	tgggtgggag	gctctgaggt	cgaggtggtg	cgctcccccc	tggtggtga	360
cggcgatgac	tgaggcactc	aggttcctcc	gaatcccgcc	ccctgccag	gggtccaggt	420
tcccgttgga	gaagatgatg	ttgctggcgg	ctctragatc	acccccccag	aagctggtea	480
gcagccagtc	gggcccgggc	cacacgcccc	agggtgccag	gcagtaccgc	tggcggagct	540
gctcagtgaa	gggcaggtcg	gggaacatat	cggtcacatt	ggtgctggcg	aaggtcaggt	600

tgatctcggg	gcaggcctgg	tagtcccagg	ccctggcgtc	ggggccgggtg	ccgcagccag	660
tggggtcagc	acagctgtgg	tagagccggg	agatgtcgta	gcagtgtctg	gagcccaggg	720
cgttgtagac	cagccctgcc	agtgtctgca	gccccgtgat	cctctggggc	tcactcagca	780
gccgatcaca	gcccaccttg	acgggggttg	cagggagggg	acccaggaag	tcagtggggg	840
aggggtagtc	catcatggcc	agcacgggtga	aggcattccg	ggcgaacatg	aagagctggg	900
tcaggctcct	ctcgtctgac	agcggctggc	agggtgccga	ctcccagcgg	accgtgtcgt	960
aggctccctg	taggaacaag	tccttgatct	gtcggaaacg	ttcccgcaca	ccctgggtgc	1020
atttgggact	ctggccctca	aagtccgccc	tgacgtcccc	gaagaactgg	ttggagtcgc	1080
cgaggcctgc	cacagctaga	acgggcgcgc	tggccgcagc	cgcccccgcc	accaggtggg	1140
gataacttcat	cctcaggtag	gcaactgagca	tccccccata	acttccaccg	aaggcgtatg	1200
cgggggcatc	ctggggcccc	aggctcgcgc	gtagcgcgcg	gagcagctct	gcgaagtcgg	1260
caggggcctg	ctccaccgtc	agcagctccg	tgtgcccgcg	ctgcgtggac	tgccgaccga	1320
acggcagcga	cttcccgtag	tagcgggtgt	ccgcgaagac	cagtagagcc	ccccgctcgg	1380
ccgccagctc	cgcgacgaag	scgcagttgt	tggcgaaggc	ccacacgtcg	ccctcgttcc	1440
cagtgtagaa	gaagatgggc	ccctcgcccc	ggacccagaa	cctgtccgac	accaggaagc	1500
gctgagggaa	ggtcttgttg	ccgaagcgct	cgaagttgaa	gtggtccaga	cgctgctgga	1560
agaagcgctc	ctggaagccg	gggtccgggg	ccctcggggc	ccccgcctgg	aggccgcgca	1620
gcccagagcg	cagcagcagg	accggggccc	agggagcgga	gcccattgtc	cssacgcgtg	1680
ggtcgaccgg	ggaattccg					1699

&lt;210&gt; 17

&lt;211&gt; 2437

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 17

aattcccggg	tcgacccacg	cgcccgcccc	cgcgtccgag	tgggctgctt	ggacacgcgt	60
gtgcatgtgc	acgcatgctg	gtgtgcatgc	tgggctgcct	ggcaaatctg	gtggtgggtg	120
gattcctcaa	ggagaaaaca	ttccctcttg	caatggcaag	aactaggggc	agttctctgt	180
ccctcctccc	aacccctcct	ttccctcgcc	cttgtcctga	tgcctcaagg	cttagagaga	240
aacattgtat	ccagaccgag	ggctctgctg	cttctttcca	gaaagtgatt	ggcaaggctt	300
tggagagaag	agcagttctg	cagctggcct	tgttccttca	tcattccctc	tccttgtgca	360
ttatgcactt	gctgtgcctt	cctgggctct	gatagaaggg	cagggtgtgt	gagcctggat	420
gggtggaggc	ttaggtagcc	ggacctgcct	gccacctcc	tctccactc	aggcacaatg	480
gtgcctaaag	tgtttccaat	ctctgggacc	tctgtaccca	aactgaaact	ctaaattggg	540
gccctaacta	attttccctt	tgaggttggt	ggcataagtg	ctgatctaga	atacagtctg	600
ggtcccacac	tgtgtctcag	tgagactggt	gatgccttga	gatgaccatt	tcagatctga	660
atcccatggg	tgtgagggtg	atgggtactc	caggactggc	ctatgctgtg	ttgtgggctt	720
tggttcggct	ttatcagggg	ccaggcatat	gggttctaga	gtacctacca	tgacctagaa	780
gcatttatga	tttatttgaa	gccacactgt	ttgcatgggt	gttacttgte	tgtacctcag	840
agtctgagga	tgttaacttt	ggaactcgca	gtcctctaga	acagcttcag	attatggctt	900
tttcttttga	ggaagaaatt	attcactcca	gatgcatgcc	ctgagccaga	cctcactgct	960
gcactttcca	agggtgtaag	attgctgctc	tccaatgcta	actttctgac	acagtgtctt	1020
agaacctgc	ctgtgggtcct	gagcactgat	cagcttagct	agaccatggt	tgactcttct	1080
tggagatttt	cacttggtcc	tagaatgtgg	caacgtagtt	gtgctcgcca	gaacgtggga	1140
ccaaattggc	ctcagggtgtt	gagtcagac	ttctgctttt	gagagagggc	tgcacttttt	1200
catggatttt	ctaggggagg	tggtaggctg	catgtgccac	ttggtcttgt	tgtgagtatg	1260
ctgacaccag	aaactcagag	ccagcttggt	gcaagcagtt	ggggtggggg	gtctctgact	1320
tgctcaggac	aaactaggcc	agtgttttcc	aaactgcttg	gcagagccct	gaagtttcct	1380
aggggttgcc	tcaggagtcc	ttggggagat	gaaggggggtg	gggagctgag	caggctgggc	1440
aatttgccct	caaacagaac	agctcccctt	gtagctgtct	tacatattgg	ggttcagggg	1500
aagattttat	ttgcattaa	gggtttgctg	ctgaaaaaaa	ggttgaaaac	cactgactag	1560
accatcggtc	ccaaattgga	gtctgtgctt	ccttccccag	gtatggagca	cactcttcac	1620
cctaccctct	accacaggac	acatatccct	gtagcattc	cccgggacct	ttagccaaga	1680
ggagctgcag	ggaccatggc	caggttacca	aaatgccttg	ctctgaagcc	ttgacacctg	1740
ggtggaaaaga	gaggctgttt	tctgaaaggg	taaagggtt	gggtctggatt	cccagaagca	1800
tagcttagat	gggaccacag	tgggcaattt	tgacctgtcc	tgccttctct	agcttgaagg	1860

. 10

gaaacccag	agactcttct	gtcagggaaa	actagggact	ctcttctaga	gcatatagtt	1920
tccttgggat	tagctcttgg	ccaagaaggc	tgagtatggt	tcccaatttt	taaatccatt	1980
tcatttttta	aaaaataagg	gaaataaatg	taattgccat	ttttcaaaga	ttaagtagga	2040
ggagaggggt	ttcttgctct	ccagagccca	aagggaacaa	tagggacttt	gtttaggcca	2100
aggaaggagc	ggaagtaggg	caactcgggc	ctgcgattat	taatccact	ccccacttat	2160
tctagggcac	acaaacacta	ttttactttt	ttaaaatcat	aaaacggcag	aacagatttg	2220
gttagtttag	aagaaaagaa	agctctataa	atataaatct	atattcctgt	atttttattt	2280
aataatttat	aaataccaag	ttcatttgac	ttttattttt	gtgtaatatg	taatgatcgt	2340
attaaaaaca	ataaataaag	cccagaagtt	taatgagaag	gaaaaaaaaa	aaaaaaaaaa	2400
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaa			2437

&lt;210&gt; 18

&lt;211&gt; 1762

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 18

ggcacgagcc	agaccaggag	tgtccagtc	ttgggccttg	gtcagcctgg	agcagttgct	60
cgccccctg	tggtgggggc	actatggagc	gacatcggac	ttgtgagggg	ggtcctgggg	120
tggcaccatg	ccaggcccg	gacacagagc	aacggcagga	gtgtaacctg	cagccctgcc	180
ctgagtgccc	ccctggccag	gtgcttagtg	cctgtgccac	ctcatgcccg	tgcctctgct	240
ggcatctgca	gcctgggtgcc	atctgtgtgc	aggagccctg	ccagcctggc	tgtggctgcc	300
ctggagggca	gctgctgcac	aatggcacgt	gtgtgcctcc	cactgcctgc	ccctgcaccc	360
agcattctct	gcctgggggc	ctcaccctga	ccctggaaga	gcaggcccag	gagctgcccc	420
cagggactgt	gtcaccctgg	aactgcaccc	gctgtgtctg	ccacggtgga	gccttcagct	480
gctccctcgt	tgactgtcag	gagtgcctcc	tggggaacg	tggcagcagg	tggccccggg	540
ggagctgggg	ctctgcgagc	agacgtgcct	ggagatgaac	gccacaaaga	cccagagtaa	600
ctgcagttca	gctcgagcct	cgggctgcgt	gtgccagccc	gggcacttcc	gcagccaggc	660
aggccctgc	gtccccgaag	accactgcga	gtgtgggcac	cttgggcgtc	cccacctgcc	720
tggatctgaa	tggcaggagg	cctgtgagag	ctgcctctgc	ctcagtggga	ggcctgtctg	780
caccacgac	tgctccccac	tcacctgtgc	tcagggcgag	gagatggtgc	tggagccagg	840
gagctgctgt	ccctcttgcc	gcagggaggc	tccggaggag	cagtcgccct	cctgccagct	900
cctcacggag	cttcgaaact	tcaccaaagg	gacctgttac	ctggaccagg	tagaagttag	960
ctactgcagt	gggtactgcc	catccagcac	ccatgtcatg	ccagaggagc	catacctgca	1020
gagccagtgt	gactgctgca	gctaccgtct	agaccggag	agccctgtgc	ggatcctgaa	1080
cctgcgctgt	ctgggtggcc	acacagagcc	cgtggtgctg	ccggtcatcc	acagctgcca	1140
gtgcagctcc	tgccaggggg	cggggtttcg	ccatgttgcc	caggctgttc	ttgaactcct	1200
gggctcgagt	gatccacctg	cctcagcctc	ccaatgcgct	ggggttacag	gcaggaaacca	1260
ctgcacccag	ccccctgacc	tcacttttta	agcaaggctg	acattgctat	gcaggcttgt	1320
tgggtggact	tggtgagggc	acgcgtgtga	agtggctggc	aggtgcctag	ttctgttaag	1380
cacctgccat	atgataacct	gaggtcccac	tgtgtggcag	atgaagggga	aacagaggtg	1440
gaaggcaccc	gtgccacctg	ggtggagcac	agtggaaagg	ctggtgttgg	ctctgggcgt	1500
cctcctggca	ccagcctgac	cactctgcct	ctcttactaa	cccatctctc	cctcacgtgt	1560
cccctgggag	gtgacttctc	aaagcgctaa	caggctccgc	tgggtgagtc	cacagctgtc	1620
cctctgtgta	tcatgggact	cagcagcact	gaccacgtcc	ttccacgtc	tctcacctgc	1680
cccactgg	gggcccata	cttggcatta	gcattgtcca	aataaagtga	tactggcaac	1740
aaaaaaaaaa	aaaaaaaaaa	aa				1762

&lt;210&gt; 19

&lt;211&gt; 1482

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 19

ggcacgagca	tggtctggaa	gaaactgggc	tcccgcact	tctccagctg	ccccagtggc	60
tccatccagt	ggatatggga	tgtgttgggt	gaatgtgccc	aggacggctg	ggacgaggcc	120

agcgtggggc	tgggcttgat	ctccattctc	tgttttgcgt	catctacctt	ccccagttc	180
atcaaagcct	acaagacggg	caacatggac	caggcgctgt	ccctgtgggt	cctcctgggc	240
tggattggcg	gagactcctg	caacctcctc	ggctccttcc	ttgttgacca	gctgcccctg	300
cagacctaca	cggctgtgta	ttatgtcttg	gcagacctgg	tgatgctgac	gctgtacttt	360
tactacaagt	tcaggacgcg	ccccctctctg	ttgtctgccc	ccatcaactc	cgtgctgttg	420
ttcctcatgg	ggatggcgtg	cgccacaccg	ctgctgagtg	ctgctggggc	cgtggctggc	480
cctagggaa	ccttccgggg	gcgggcgctc	ctgtccgtgg	agtcgggcag	caagcccttc	540
acccggcagg	aagtcattgg	cttcgtcctc	ggctccatct	ccagcgtgtt	gtacctgctt	600
tcccggctgc	ctcagatccg	caccaacttc	ctccgggaagt	ccaccagggg	gatctcctac	660
tctctgttgc	cgtctggtgat	gctggggaa	acgctgtatg	ggctgagcgt	gctgctcaaa	720
aaccccgagg	agggccagag	cgagggcagc	tacctgctgc	accacctgcc	ctggcttgtg	780
ggcagcctgg	gcgtgctgct	gctcgacacc	atcatctcca	tccagtctct	gggtgtacagg	840
cgcgaccag	cgcctcgga	gcttgagccc	ctcctcccca	gctgaccaga	accaggtgga	900
gcgcaggagg	acaggcacca	ccggatgcca	caccaggcag	gaggaggtgt	ggacagtgat	960
ggtagggcgg	ccctgcctca	gcctgcgggt	ggcctctgga	tcctccgtgg	accgaaccgt	1020
ccccccagga	acacaccttc	aggtagaccc	cgaagcctca	aggccggggc	tggagcggag	1080
accccgaggc	ctctcaggag	acagttaggc	tgccccctct	accacctacc	tcattctgcc	1140
tactcaggac	tgctctgtca	actccagaca	actgaataaa	caggccgggt	acagtggctc	1200
gcacctgtaa	ccctagcact	ttgggaggcc	gaagcgggtg	gaccacttga	cgtccgtagt	1260
tcgagaccag	cctggccaac	atggtgaaac	cccatctcta	ctaaaaatac	aaaaattagc	1320
caggtgtggt	ggcacacatc	tgtagtccca	gctacttggg	aggctgaggc	aggagaactg	1380
tttgaacctg	ggagacagag	gttgcggtga	accgagatcg	tgccactgta	ctccagcctg	1440
ggtgacagag	tgagactccg	tctcaaaaaa	aaaaaaaaaa	aa		1482

&lt;210&gt; 20

&lt;211&gt; 1481

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 20

ggcacgagcc	tggcagagag	actctgaaat	gagggattag	aggtgttcaa	ggagcaagag	60
cttcagcctg	aagacaaggg	agcagtccct	gaagacgctt	ctactgagag	gtctgccatg	120
gcctctcttg	gcctccaact	tgtgggtac	atcctaggcc	ttctggggct	tttgggcaca	180
ctgggttgcca	tgctgctccc	cagctggaaa	acaagtctct	atgtcgggtg	cagcattgtg	240
acagcagttg	gcttctccaa	gggcctctgg	atggaatgtg	ccacacacag	cacaggcatc	300
acccagtgtg	acatctatag	cacccttctg	ggcctgcccg	ctgacatcca	ggctgcccag	360
gccatgatgg	tgacatccag	tgcaatctcc	tccctggcct	gcattatctc	tgtgggtggc	420
atgagatgca	cagtcttctg	ccaggaatcc	cgagccaaag	acagagtggc	ggtagcaggt	480
ggagtctttt	tcctccttgg	aggcctcctg	ggattcatct	ctgttgccctg	gaatcttcat	540
gggactctac	gggacttcta	ctcaccactg	gtgcctgaca	gcattgaaat	tgagattgga	600
gaggtctctt	acttgggcat	tatttcttcc	ctgttctccc	tgatagctgg	aatcatcttc	660
tgcttttctt	gctcatccca	gagaaatcgc	tccaactact	acgatgccta	ccaagcccaa	720
cctcttgcca	caaggagctc	tccaaggcct	ggtcaacctc	ccaaagtcaa	gagtgagttc	780
aattcctaca	gcctgacagg	gtatgtgtga	agaaccaggg	gccagagctg	gggggtggct	840
gggtctgtga	aaaacagtgg	acagcaccct	gagggccaca	ggtgagggac	actaccactg	900
gatcgtgtca	gaaggtgctg	ctgaggatag	actgactttg	gccattggat	tgagcaaagg	960
cagaaatggg	ggctagtgtg	acagcatgca	ggttgaattg	ccaaggatgc	tcgccatgcc	1020
agcctttctg	ctttctctac	cttgcctgct	ccctgcctta	agtcctccaa	cctcaacttg	1080
aaacccattt	cccttaagcc	aggactcaga	ggatcccttt	gccctctggg	ttacctggga	1140
ctccatcccc	aaacccacta	atcacatccc	actgactgac	cctctgtgat	caaagaccct	1200
ctctctggct	gaggttggct	cttagctcat	tgtctgggat	gggaaggaga	agcagtggct	1260
tttctgggca	ttgctctaac	ctacttctca	agcttccctc	caaagaaact	gattggccct	1320
ggaacctcca	tccactctt	gttatgactc	cacagtgtcc	agactaattt	gtgcatgaac	1380
tgaataaaaa	ccatcctacg	gtatccaggg	aacagaaagc	aggatgcagg	atgggaggac	1440
aggaaggcag	cctgggacat	ttaaaaaaaa	aaaaaaaaaa	a		1481

<210> 21  
 <211> 1865  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1859)  
 <223> n equals a,t,g, or c

<400> 21  
 cgagcctctt tggtagcagg aggctggaag aaaggacaga agtagctctg gctgtgatgg 60  
 ggatcttact gggcctgcta ctcttggggc acctaacagt ggacacttat ggccgtccca 120  
 tcttggaagt gccagagagt gtaacaggac cttggaaagg ggatgtgaat cttccctgca 180  
 cctatgaccc cctgcaaggc tacacccaag tcttggtgaa gtggctggta caacgtggct 240  
 cagaccctgt caccatcttt ctacgtgact cttctggaga ccatatccag caggcaaagt 300  
 accagggccg cctgcatgtg agccacaagg ttccaggaga tgtatccctc caattgagca 360  
 ccctggagat ggtgaccgg agccactaca cgtgtgaagt cacctggcag actcctgatg 420  
 gcaaccaagt cgtgagagat aagattactg agtcctcgtt ccagaaactc tctgtctcca 480  
 agccccagt gacaactggc agcggttatg gcttcacggt gccccaggga atgaggatta 540  
 gccttcaatg ccaggctcgg ggttctcctc ccatcagtta tatttggtat aagcaacaga 600  
 ctaataacca ggaacccatc aaagtagcaa ccctaagtac cttactcttc aagcctgcgg 660  
 tgatagccga ctcaggctcc tatttctgca ctgccaaggg ccagggtggc tctgagcagc 720  
 acagcgacat tgtgaagttt gtggtcaaag actcctcaaa gctactcaag accaagactg 780  
 aggcacctac aaccatgaca tacccttga aagcaacatc tacagtgaag cagtcctggg 840  
 actggaccac tgacatggat ggctaccttg gagagaccag tgctgggcca ggaaagagcc 900  
 tgctgtctt tgccatcatc ctcatcatct ccttgtgctg tatggtggtt tttaccatgg 960  
 cctatatcat gctctgtcgg aagacatccc aacaagagca tgtctacgaa gcagccaggg 1020  
 cacatgccag agaggccaac gactctggag aaacatgag ggtggccatc ttcgcaagtg 1080  
 gctgctccag tgatgagcca acttcccaga atctgggcaa caactactct gatgagccct 1140  
 gcataggaca ggagtaccag atcatcgccc agatcaatgg caactacgcc cgcctgctgg 1200  
 acacagttcc tctggattat gagtttctgg ccactgaggg caaaagtgtc tgtaaaaaat 1260  
 gccccattag gccaggatct gctgacataa ttgcctagtc agtccttgcc ttctgcatgg 1320  
 ccttcttccc tgctacctct ctctctggat agcccaaagt gtccgcctac caaactgga 1380  
 gccgctggga gtcactggct ttgccctgga atttgccaga tgcattctaa gtaagccagc 1440  
 tgctggattt ggctctgggc ccttctagta tctctgccgg gggttcttgg tactctctc 1500  
 taaataccag agggaagatg cccatagcac taggacttgg tcatcatgcc tacagacact 1560  
 attcaacttt ggcattctgc caccagaaga cccgaggagg gctcagctct gccagctcag 1620  
 aggaccagct atattcagga tcatttctct ttcttcaggg ccagacagct ttaattgaa 1680  
 attgttattt cacaggccag ggttcagttc tgctcctcca ctataagtct aatgttctga 1740  
 ctctctcctg gtgctcaata aatatctaata cataacagca aaaaaaaaaa aaaaaaaaaa 1800  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1860  
 aaaaaa 1865

<210> 22  
 <211> 2331  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (3)  
 <223> n equals a,t,g, or c

<400> 22  
 ggnatgaaca aagggrwatg samakctcct ataggkaaag ctggtagccc tgcaggtagc 60  
 ggtccggaat tcccgggtcg acccacgcgt ccgcttggac cctccccctc gcttctcgtt 120

ctactgcccc	aggagccccg	cgggtccggg	actcccgtcc	gtgccgggtgc	gggcgcgggc	180
atgtggctgt	gggaggacca	gggcggcctc	ctggggccctt	tctccttcct	gctgctagt	240
ctgctgctgg	tgacgcggag	cccgggtcaat	gcctgcctcc	tcaccggcag	cctcttcggt	300
ctactgcgcg	tcttcagctt	tgagccgggtg	ccctcttgca	gggccctgca	ggtgctcaag	360
ccccgggacc	gcattttctgc	catcgccac	cgtggcggca	gccacgacgc	gcccgaagac	420
acgttgccgg	ccatttcgca	ggcagctaag	aatggagcaa	caggcggtga	gttggacatt	480
gagtttactt	ctgacgggat	tcctgtctta	atgcacgata	acacagtaga	taggacgact	540
gatgggactg	ggcgattgtg	tgatttgaca	tttgaacaaa	ttaggaagct	gaatcctgca	600
gcaaaccaca	gactcaggaa	tgatttccct	gatgaaaaga	tccctaccct	aagggaagct	660
gttgccagagt	gcctaaacca	taacctcaca	atcttctttg	atgtcaaagg	ccatgcacac	720
aaggctactg	aggctctaaa	gaaaatgtat	atggaatttc	ctcaactgta	taataatagt	780
gtggctctgt	ctttcttgcc	agaagtattc	tacaagatga	gacaaacaga	tcgggatgta	840
ataacagcat	taactcacag	accttgagc	ctaagccata	caggagatgg	gaaaccacgc	900
tatgatactt	tctggaaaca	ttttatattt	gttatgatgg	acattttgct	cgattggagc	960
atgcataata	tcttggtgta	cctgtgtgga	atttcagctt	tcctcatgca	aaaggatttt	1020
gtatccccgg	cctacttgaa	gaagtgggtca	gctaaaggaa	tccagggtgt	tggttggtgact	1080
gttaatacct	ttgatgaaaa	gagttactac	gaatcccatc	ttgggtccag	ctatatcact	1140
gacagcatgg	tagaagactg	cgaacctcac	ttctagactt	tcacgggtggg	acgaaacggg	1200
ttcagaaact	gccagggggc	tcatacaggg	atatcaaaat	accctttgtg	ctagcccagg	1260
ccctggggaa	tcaggtgact	cacacaaatg	caatagttgg	tcactgcatt	tttacctgaa	1320
ccaaagctaa	accgggtgtt	gccaccatgc	accatggcat	gccagagttc	aacactgttg	1380
ctcttgaaaa	tctgggtctg	aaaaaacgca	caagagcccc	tgccctgccc	tagctgaggc	1440
acacaggggag	accagtgag	gataagcaca	gattgaattg	tacaatttgc	agatgcagat	1500
gtaaatgcat	gggacatgca	tgataactca	gagttgacat	tttaaaactt	gccacactta	1560
tttcaaatat	ttgtactcag	ctatgttaac	atgtactgta	gacatcaaac	ttgtggccat	1620
actaataaaa	ttattaaaag	gagcactaaa	ggaaaactgt	gtgccaagca	tcataatccta	1680
aggcatacgg	aatttgggga	agccaccatg	caatccagtg	aggcttcagt	gtacagcaac	1740
caaaatggta	gggaggtctt	gaagccaatg	agggatttat	agcatcttga	atagagagct	1800
gcaaaccacc	agggggcaga	gttgcaacttt	tccaggcttt	ttaggaagct	ctgcaacaga	1860
tgtgatctga	tcataggcaa	ttagaactgg	aagaaacttc	caaaaatatc	taggtttgtc	1920
ctcattttac	aaatgaggaa	actaaactct	gtggaaggga	aggggttgcc	tcaaaagtca	1980
cagcttagct	gggcacagtg	gctcatgccg	ataatcccag	caatttcagaa	agctgaggca	2040
ggaggattac	ttgaggccag	actgggcaat	atagcaagac	cccattctcta	aaaaattagg	2100
catggtgggtg	catgcctgta	ttcccagcta	ctcaggaggt	tgaggtggga	ggatcacttg	2160
agcccagaag	ttcaaggctg	caatgagcca	tgattacacc	acggcactac	aaccttggtg	2220
gcacagtga	aacctgactc	ttaaaaaaa	aaaaaaaaa	aaaggcgccg	cgctctagag	2280
gatccaagct	tacgtacgcg	tgcatgcgac	gtcatagctc	ttctatagt	t	2331

&lt;210&gt; 23

&lt;211&gt; 2277

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 23

gaattcccgg	gtcgaccac	gcgtccggac	agcgtgagcc	cgcgccggct	gctgccatgg	60
tggctggcgg	ccgggttaagg	gtctgagtg	atctcctgcc	aggccagagc	gccttcgggg	120
gccgcggcgg	aaggccagga	gtttgcagcc	agggcgccgg	gtttgtggtc	tgcatgtctg	180
tgaggctgag	gtgcagcatg	tctagactgg	gagccctggg	tggtgcccg	gccgggctgg	240
gactgttgct	gggtaccgcc	gccggccttg	gattcctgtg	cctcctttac	agccagcgat	300
ggaaaccggac	ccagcgctcat	ggccgcagcc	agagcctgcc	caactccctg	gactatacgc	360
agacttcaga	tcccggacgc	cacgtgatgc	tcctgcgggc	tgtcccagg	ggggctggag	420
atgcctcagt	gctgcccagc	cttcacggg	aaggacagga	gaagggtctg	gaccgcctgg	480
actttgtgct	gaccagcctt	gtggcgctgc	ggcgggaggt	ggaggagctg	agaagcagcc	540
tgcgagggtc	tgcgggggag	attgttgggg	aggtccgatg	ccacatggaa	gagaaccaga	600
gagtggctcg	gcggcggaagg	tttccgtttg	tcggggagag	gagtgactcc	actggctcca	660
gctctgtcta	ttcacggcc	tcctcgggag	ccagcttcac	agatgctgag	agtgaagggg	720
gttacacaac	agccaatgcg	gagcttgaca	atgagcggga	ctctgacaaa	gaaagtggag	780



acggggaaga	tgaagtgagc	tgtgagactg	tgaagatggg	gagaaaggat	tctcttgact	840
tgagggaaga	ggcagcttca	ggtgcctcca	gtgccctgga	ggctggaggt	tcctcaggct	900
tgagggatgt	gctgccccctc	ctgcagcagg	ccgacgagct	gcacaggggt	gatgagcaag	960
gcaagcgggga	gggcttccag	ctgctgctca	acaacaagct	ggtgtatgga	agccggcagg	1020
actttctctg	gcgcctggcc	cgagcctaca	gtgacatgtg	tgagctcact	gaggagggtga	1080
gcgagaagaa	gtcatatgcc	ctagatggaa	aagaagaagc	agaggctgct	ctggagaagg	1140
gggatgagag	tgctgactgt	cacctgtggt	atgcggtgct	ttgtggtcag	ctggctgagc	1200
atgagagcat	cgagaggcgc	atccagagtg	gcttttagctt	caaggagcat	gtggacaaag	1260
ccattgctct	ccagccagaa	aaccccatgg	ctcactttct	tcttggcagg	tggtgctatc	1320
aggtctctca	cctgagctgg	ctagaaaaaa	aaactgctac	agccttgctt	gaaagccctc	1380
tcagtgccac	tgtggaagat	gccctccaga	gcttcctaaa	ggctgaagaa	ctacagccag	1440
gattttccaa	agcaggaagg	gtatatatgt	ccaagtgtca	cagagaacta	gggaaaaact	1500
ctgaagctag	atggtggatg	aagttggccc	tggagctgcc	agatgtcacg	aaggaggatt	1560
tggtatcca	gaaggacctg	gaagaactgg	aagtcatttt	acgagactaa	ccacgtttca	1620
ctggccttca	tgacttgatg	ccactattta	aggtgggggg	gcggggaggc	ttttttcctt	1680
agaccttgct	gagatcagga	aaccacacaa	atctgtctcc	tgggtctgac	tgctaccac	1740
taccactccc	cattagttaa	tttattctaa	cctctaacct	aatctagaat	tggggcagta	1800
ctcatggctt	ccgtttctgt	tgttctctcc	cttgagtaat	ctcttaaaaa	aatcaagatt	1860
cacacctgcc	ccaggattac	acatgggtag	agcctgcaag	acctgagacc	ttccaattgc	1920
tggtgagggtg	gatgaacttc	aaagctatag	gaacaaagca	cataacttgt	cactttaatc	1980
tttttctactg	actaatagga	ctcagtacat	atagtcttaa	gatcatacct	tacctaccaa	2040
ggtaaaaaga	gggctcagag	tggcccacag	acattgcttt	cttatcacct	atcatgtgaa	2100
ttctacctgt	attcctgggc	tggaccactt	gataacttcc	agtgtcctgg	cagcttttgg	2160
aatgacagca	gtggtatggg	gtttatgatg	ctataaaaca	atgtctgaaa	agttgcctag	2220
aatatatattt	gttacaaact	tgaataaaac	caaatttgat	gttaaaaaaa	aaaaaaa	2277

&lt;210&gt; 24

&lt;211&gt; 811

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 24

ccacgcgtcc	gccagcacct	tcctctccca	ggcaaaatga	aaatacttgt	ggcattttctg	60
gtggtgctga	ccatcttttg	gatacaatct	catggatacg	aggtttttaa	catcatcagc	120
ccaagcaaca	atggtggcaa	tggtcaggag	acagtgacaa	ttgataatga	aaaaaatacc	180
gccatcatta	acatccatgc	aggatcatgc	tcttctacca	caatttttga	ctataaacat	240
ggctacattg	catccagggt	gctctcccg	agagcctgct	ttatcctgaa	gatggaccat	300
cagaacatcc	ctcctctgaa	caatctccaa	tggtacatct	atgagaaaca	ggctctggac	360
aacatgttct	ccagcaaata	cacctgggtc	aagtacaacc	ctctggagtc	tctgatcaaa	420
gacgtggatt	ggttccctgt	tgggtcaccc	attgagaaac	tctgcaaaca	tatccctttg	480
tataaggggg	aagtgggtga	aaacacacat	aatgtcgggtg	ctggaggctg	tgcaaaggct	540
gggctcctgg	gcatcttggg	aatttcaatc	tgtgcagaca	ttcatgttta	ggatgattag	600
ccctcttgtt	ttatcttttc	aaagaaatac	atccttgggt	tacactcaaa	agtcaaatta	660
aattcttttc	caatgcccc	actaattttg	agattcagtc	agaaaatata	aatgctgtat	720
ttataaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	780
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	a			811

&lt;210&gt; 25

&lt;211&gt; 1495

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 25

cgaagtgctg	ttttctaattg	actctgtgct	tgggtcacttt	cctcaccagt	ctcccaacga	60
gcgtgcccgc	ttgtacttcc	tgctggcctg	gtttcatgcg	atcatccaag	aacgcttacg	120
atacgcacca	ctggggtggt	caaagaagta	tgaatttgga	gagtcctgacc	tgcggtcagc	180

ttgcgatacg	gtggacacgt	ggctggatga	cacggccaag	gcaagtgtgg	gccatgccag	240
gacagacagt	ggacgtgtat	ctgggaagga	tgctgcaggg	cgtggtgctg	agaggccaga	300
ctctgcgtgg	aagagcgagc	tgacccctcg	tgaccgcca	agcctagctg	gccatgggga	360
gtgaggagga	aagctgtgcc	cctcgaaagg	aagccccggg	cctgcccgcc	tctgaccaca	420
cacacgaacc	ctgcttttcc	tccccaggg	caggcagaac	atctcaccgg	ataagatccc	480
gtggtctgca	ctaaagacct	taatggccca	gtccatttat	ggcgggcgcg	tggacaacga	540
gtttgaccag	cggctgctca	acaccttcct	ggagcgccctg	ttcacaacca	ggagtttcga	600
cagtgaagttt	aagctggcat	gcaaggtcga	cggacataaa	gacattcaaa	tgccagatgg	660
catcaggtat	gctgctgcct	gctggaatgg	agacagttgt	gatgtcaggg	cgtctggtgt	720
cactcagagg	tgacccctga	catcatttcc	aaatgcactg	gttttctagg	cgagaggagt	780
ttgtgcagtg	ggtggagttg	ctccccgaca	cccagacgcc	ctcctggctg	ggcctgccc	840
acaacgccga	gagagtccct	cttaccacac	agggtaggca	acaaggatcc	tccccacacg	900
cagggtgggt	ggcgagggtc	ccctcacgcg	gggtgggtgg	cgagggtccc	cacacgcagg	960
gtgagtgtgc	actgctgtcc	caggcccttc	cctgggttatg	ctgggtgtgg	ctctgtcagc	1020
ctcgcccttc	ctgccagtct	ccagctgctc	ctagctccac	tccgagggga	ggcagaggaa	1080
agaactggct	cttctctgca	gcatcaactc	agtctagag	aaaaggcttg	atatttatgt	1140
aaatgagcct	agaaataaca	tttagatgtt	catctcatat	tgaaaagcag	ttactggctg	1200
ggcacactgg	ctcacaccta	taatcccagc	actttgggag	gccaaaggcg	gcagatcact	1260
cgagggttagg	atttccagac	cagcctggtc	aacatggcaa	aacctcgtct	ctactaaaaa	1320
tacaaaaatt	aggtgagcat	ggtggcaggg	acctgtaatc	ccagctactc	aggaggctga	1380
ggcaggagaa	ttatttgaac	ccgggagatg	gaggttgcat	tgagctgaga	tcacaccatt	1440
gcactccagc	ctgggtgaca	gaggagagact	ccgtttcaaa	aaaaaaaaaa	aaaaa	1495

&lt;210&gt; 26

&lt;211&gt; 1251

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1250)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 26

ggagcatctg	agtctggccc	agcagaggct	gcaactggac	cgcgcacgac	aggacctgcc	60
ctctagcctc	gtgggtctgt	tccccagggc	ccagggccct	gcagcctcca	gccagagtgc	120
cctcatgcct	cctgctccca	ccaccggttg	gtgcagccag	ccgccaactg	gcctggaccc	180
cagccccttg	cacctccatg	ccaggctggc	actgctgagg	cacatggcag	agcaggaccg	240
tgacttcttg	gagaatgaac	agttcttcc	ggagaccctg	aagaaagggt	cctacaattt	300
gacatctcat	tcagcctgag	tgggacccca	gccgattccc	caacagaggg	ttcggacccc	360
agaactgtcc	tgttcctccg	gctgcctcca	tggaggcagt	gcctggggag	gattctgaga	420
tgcttgaggc	ctgatgacag	ctcttccgtg	gacagggtgc	aagtgcattc	tttccaaatg	480
tgccagcccg	gggcagcccc	tgccctctggg	gctctgtggg	gtaggctatc	ttaccatggc	540
tttggtctgc	ctgccccaaa	gccattggct	tggatctgag	ggctctgagt	ggcagcaagg	600
acccccagct	ctcactgggc	tctgtgggct	ccccctgggc	tctgtgggct	ccccctgctc	660
cacaggtaga	ctgktgtggg	ctctttttgs	ctgggacctc	tctgaggcag	gagctttctt	720
gagggatgcc	acaaacagcc	ttccctactc	cctgccagag	cagttccctc	cctgatgagc	780
tggagaaggg	ccctctggcc	tcctgacagt	acagggaggg	caccagctag	atccctccct	840
gtggtgtgag	atgttctctg	aactcagcca	ggccctcctc	ctcctgggct	tgcccagagc	900
cccacccta	ttcccagcat	tgcgcgaagg	accaaccagt	ttgggtgaac	agtggcctcc	960
tcagcttctc	ccccatctgg	gtgccccacc	ggcggcggag	ggagctgtgg	cgatggtggg	1020
gtgtggggag	ggacgaggag	ggaagcctct	gtgctgctca	cctgccccaa	gcccagctca	1080
gcgggtacgc	agtggaggcg	acaaggaaac	aatcacaaact	acagagggtt	ctctgatcct	1140
cctccactcc	cgctgcttca	acttgactaa	gcttaaaaaa	actgcttttg	ccatgaaaaa	1200
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	t	1251

<210> 27  
 <211> 595  
 <212> DNA  
 <213> Homo sapiens

<400> 27  
 ccacgcgtcc ggaatgtgtg tgtgcggtgt tatgccggac aagagggagg cgaccgcggc 60  
 ggcggtggct ctgtttattg tccctctcgg tgtgtggatg cgaggaagtc gggggtatag 120  
 cgctgtcac gaaggcagcc tttgaggcag cggcccggcg ttagctgcga ctccggcaac 180  
 cccagcggcc ggccttcgcg gagtgtgagg aaggacaagg cgcctttgcg tccccgccac 240  
 gtctggacgc cccgagcttt ccggtgcgc tcgcccgcgc cacctccggg ccccgggccg 300  
 gcttgccgtg ccgcccggcg gcgggcgaga aggaagcacc gcgcctcacc gctgccggcc 360  
 tctgtctcc ttctccacct ctctctcagc gacgggccta ggcggggcg actcggccgc 420  
 cgcgcctcga gtttgagggc gccgagcggc gcggcctcct cggcgggctc ggccgtccgt 480  
 ccgtcccggg ttctcagcat ggggcgcggg gggcgacgcc gctaggagca cggcgagcgg 540  
 agcggtcggt gcggagcaga ggggcccggc ggccggcagg aaggcgggag cggcc 595

<210> 28  
 <211> 451  
 <212> DNA  
 <213> Homo sapiens

<400> 28  
 ggcttttcgag cggccgcccc ggccaggtaca tgacaathtt tactccatht cttgttctct 60  
 tactttctagt caattctccc agatttttcta caataactct tatgaggctt ggttttcaca 120  
 acccatcagt ctgcttatct ttactctaa aacctcaatg ctacctgtt ttgatgtatc 180  
 agaagaacag gagacaagat gggcctcaaaag tattttttaa aactgcaaga cttaaagttct 240  
 atctcaatat aacagcaaaag tgacagcaca ggcaaatatc atataaatac tatatgtata 300  
 aatatgttca gagctcaaaa ccactaacct tccatctttt aaggtagggg gcaataacaa 360  
 cagaggttcc atggaaatgg aaaatagctc tatttataca gcaaatcaaa atatagtagc 420  
 ttgctaacct cggccgcgac cacgctaagc c 451

<210> 29  
 <211> 344  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (6)  
 <223> n equals a,t,g, or c

<400> 29  
 tccggnatt cccgggctag gagacctgtt ctgatgatgt gtgtggctct caccacactg 60  
 ccctgcctca ccttttccat agcagtgact gagggtcaaa agagcattaa tgggtccgct 120  
 gatgtcttac ctgatatgtt acctgacctg cccgtatctc tggttctgtt atccctgatc 180  
 atggttgata ttattgaaaa actcaggata taccctctta gaggagtc aaagagtagt 240  
 gaaaatggac acatccattc aacctctttg caacacataa aaactgtgac ggarcaagtg 300  
 aggcaaaagtc cagaaaacgc tgcattctcc caggcaacca acag 344

<210> 30  
 <211> 2615  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (5)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (2605)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (2609)  
 <223> n equals a,t,g, or c

<400> 30  
 tttcnttttag gtctgagggga gcgatggcggt tacgcgcgtt gaagctgctg accacactgc 60  
 tggctgtcgt ggccgctgcc tcccaagccg aggtcagatc cgaggcagga tggggcatgg 120  
 tgacgcctga tctgtctctt gccgagggga ccgcagccta cgcgcgcggg gactggcccc 180  
 ggggtggtcct gagcatggaa cgggcgctgc gctcccgggc agccctccgc gcccttcgcc 240  
 tgcgtgctccg caccagtggt gccgcgact tcccggtggga gctggacccc gactggtccc 300  
 ccagcccgcc ccaggcctcg ggccgcgcgc ccctgcgcga cctgagcttc ttcggggggc 360  
 ttctgcgtcg cgctgcctgc ctgcgcgcgt gcctcggggc gccggccgcc actcgctcag 420  
 cgaagagatg gagctggagt tccgcaagcg gacccctaca actacctgca ggtcgcctac 480  
 ttcaagatca acaagttgga gaaagctgtt gctgcagcac acaccttctt cgtgggcaat 540  
 cctgagcaca tggaaatgca gcagaacctt gactattacc aaacctgtc tggagtgaag 600  
 gaggccgact tcaaggatct tgagactcaa ccccatatgc aagaatttcg actgggagtg 660  
 cgactctact cagaggaaca gccacaggaa gctgtgcccc acctagaggc ggcgctgcaa 720  
 gaatactttg tggcctatga ggagtgccgt gccctctgcg aagggcccta tgactacgat 780  
 ggctacaact accttgagta caacgctgac ctcttccagg ccacacaga tcattacatc 840  
 caggctctca actgtaagca gaactgtgtc acggagcttg cttcccaccc aagtcgagag 900  
 aagccctttg aagacttccct cccatcgcat tataattatc tgcagtttgc ctactataac 960  
 attgggaatt atacacaggc tgttccaatg gccaaagacct atcttctctt cttccccaat 1020  
 gacgaggtga tgaacaaaaa tttggcctat tatgcagcta tgcttgagaa agaacacacc 1080  
 agatccatcg gcccccgta gagtgccaag gactaccgac agcgaagcct actggaaaaa 1140  
 gaactgcttt tcttcgctta tgatgttttt ggaattccct ttgtggatcc ggattcatgg 1200  
 actccagaag aagtgattcc caagagattg caagagaaac agaagtcaga acgggaaaca 1260  
 gccgtacgca tctcccagga gattgggaac cttatgaagg aaatcgagac cttgtggaa 1320  
 gagaagacca aggagtcact ggatgtgagc agactgaccc gggaaggtgg cccctgctg 1380  
 tatgaaggca tcagtctcac catgaactcc aaactcctga atggttccca gcgggtggtg 1440  
 atggacggcg taatctctga ccacgagtggt caggagctgc agagactgac caatgtggca 1500  
 gcaacctcag gagatggcta ccggggtcag acctcccac atactcccaa tgaaaagttc 1560  
 tatggtgtca ctgtcttcaa agccctcaag ctggggcaag aaggcaaagt tcctctgcag 1620  
 agtggccacc tgtactacaa cgtgacggag aagggtgcggc gcatcatgga gtcctacttc 1680  
 cgcttgata cgccctcta cttttcctac tctcatctgg tgtgccgcac tgccatcgaa 1740  
 gaggtccagg cagagaggaa ggatgatagt catccagtc acgtggacaa ctgcatcctg 1800  
 aatgccgaga ccctcgtgtg tgtcaaagag cccccagcct acaccttccg cgactacagc 1860  
 gccatccttt acctaaatgg ggaactcgat ggccgaaact tttatttcac tgaactggat 1920  
 gccaagaccg tgacggcaga ggtgcagcct cagtgtggaa gagccgtggg attctcttca 1980  
 ggcactgaaa acccacatgg agtgaaggct gtcaccaggg ggcagcgtg tgccatcgcc 2040  
 ctgtggttca ccctggaccc tcgacacagc gagcgggaca ggggtcaggc agatgacctg 2100  
 gtgaagatgc tcttcagccc agaagagatg gacctctccc aggagcagcc cctggatgcc 2160  
 cagcagggcc cccccaagcc tgcacaagag tctctctcag gcagtgaatc gaagcccaag 2220  
 gatgagctat gacagcgtcc aggtcagacg gatgggtgac tagaccatg gagaggaaact 2280  
 cttctgcact ctgagctggc cagccctcg gggctgcaga gcagtggcc tacatctgcc 2340  
 actcagccga ggggacccctg ctcacagcct tctacatggg gctactgctc ttggagtggg 2400  
 catgaccaga caccgcaccc cctggatctg gctgagggct caggacacag gccagccac 2460  
 cccagggggc ctccacaggc cgctgcatra cagcgatata gtacttaagt gtctgtgtag 2520

acaacccaaag	aataaatgat	tcatggtttt	ttttaaaaaa	aaaaaaaaaa	aaactcgagg	2580
gggggcccgt	acccaattcg	ccaanctana	gcca			2615

&lt;210&gt; 31

&lt;211&gt; 3599

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2675)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 31

gggagggcaa	cgggcgggcg	cgggcgggcg	ggcgagggt	ckcgggargt	gacrcgggc	60
gaggatggcg	gcgcgggggc	gggggctgct	gctgctgacg	ctgtcggtgc	tggtggcggc	120
gggccccctcc	gccgctgcgg	ycaagctcaa	catcccaaaa	gtgctgctgc	ccttcacrcg	180
ggccacgcgc	gttaacttca	cgctggaggc	ctcgaggggc	tgctaccgct	ggttgtccac	240
ccggccggag	gtggccagca	tcgagccgct	gggcctggac	gagcagcagt	gctcccagaa	300
ggcagtgggtg	caggccccgc	tgaccagcc	tgcccgcctc	accagcatca	tcttcgcaga	360
ggacatcacc	acaggccagg	tcctgcgctg	tgatgccatt	gtggacctca	tccatgacat	420
ccagatcgtc	tccaccaccc	gcgagctcta	cctggaggac	tccccctgg	agctgaagat	480
ccaggccctg	gactccgaag	ggaacacctt	cagcactctg	gctggactgg	tcttcgagt	540
gacgattgtg	aaggactccg	aggcggacag	gttctcagac	tcccacaatg	cgctgcgaat	600
cctcactttc	ttggagtcta	cgtacatccc	tccttcttac	atctcagaga	tgagaaaggc	660
tgccaagcaa	ggggacacca	tcctggtgtc	tgggatgaag	accgggagct	ycaagctcaa	720
ggctgcgcat	caggaggctg	tctacaagaa	tgtagccctc	gcakaaagtc	ggctgctgat	780
tttgaaaac	atccttctga	accggcccta	tgactgtctac	ctgatggtgg	gaacctccat	840
tcactacaag	gtgcagaaga	tcaggcaagg	gaaaattaca	gaactctyca	tgcttccga	900
tcagtacgag	ttgcagcttc	agaacagcat	cccgggcccc	gaaggagacc	caaccggcc	960
ggtggctgtc	ttggcccagg	acacgtcgat	ggtcactgca	ctgcagctgg	gacagagcag	1020
cctcgctcct	ggccacagga	gtattcgcat	gcaagggtgct	tctaggttac	ccaacagcac	1080
tatctacgtg	gtcgaacctg	gatacctagg	gttactgtt	cacctggtg	acagggtgggt	1140
gctggagacc	ggcgcctgt	atgaaatcac	catcgaagt	tttgacaagt	tcagcaacaa	1200
ggctctatgt	tctgacaaca	tccgaattga	aactgtgctt	cctgctgagt	tcttcgaggt	1260
gctctcgctc	tcccagaatg	ggtcatacca	tcgcatcagg	gcactaaaga	ggggacagac	1320
ggccattgac	gcggccctca	cctctgtggt	ggaccaggat	ggaggggtcc	acatactaca	1380
ggtgcctgtg	tggaaccagc	aggagggtgga	aattcacatc	ccgatcccc	tgtatcccag	1440
catcttgaca	tttccgtggc	aaccaaagac	gggcgcctat	cagtacacaa	taaggggcca	1500
cgggtggcagt	gggaacttca	gctggtcttc	gtcaagccac	ctggttgcca	cagttactgt	1560
caagggcgtg	atgaccacag	gcagtgaat	cgggttcagt	gtgatccagg	cacatgatgt	1620
gcagaaccca	ctccatttcg	gtgagatgaa	ggtgtatgtg	atcgagcccc	acagcatgga	1680
gtttgccccg	tgccagggtg	aggcacgtgt	gggccaggcc	ctggagctgc	ccctgaggat	1740
cagtggcctc	atgcccggcg	gggccagtga	ggtggtcacc	ttgagcgact	gctcccactt	1800
tgacttggct	gtcgagggtg	agaaccaggg	tgtgttccag	ccactcccag	ggaggctgcc	1860
gccaggctct	gagcactgca	gcggcgctcg	ggtaaaaggcc	gaggcccagg	gctctaccac	1920
gcttcttgtg	agctacagac	acggccacgt	ccacctgagt	gccaagatca	ccattgctgc	1980
ctacctgccc	ctcaaggctg	tggtacctc	ctctgttgcc	ttggtaaccc	tggtgctcctc	2040
aaaggagatg	ctggttgaag	gaggtcccag	acctggatc	ctcagccgt	ccaaattctt	2100
ccagaacgtg	acactgagag	acactgacag	catcgccctg	gctctctttg	cccccatctc	2160
ctcccggaat	tatcagcaac	actggatcct	tgtgacctgt	caggccttgg	gtgagcaggt	2220
catcgccctg	tcggtgggga	acaagcccag	cctcaccaac	cccttctctg	cgggtggagcc	2280
tgccgtgggtg	aagttcgtct	gcgccccacc	gtccaggctc	accctcgtgc	ctgtctacac	2340
cagccccccag	ctggacatgt	cctgtccgct	gctgcagcag	aacaagcagg	tggtcccagt	2400
gtccagccac	cgcaaccccc	tgctggacct	ggctgcttac	gaccaggagg	gccgcccgtt	2460
cgacaacttc	agctctctga	gcatccagt	ggagtcacc	aggccagtgt	tgccagcat	2520
cgagcctgag	ctgcccctgc	agctggtgtc	ccaggacgat	gagagtggcc	aaaagaagct	2580

gcacggtttg	caggccattt	tggttcacga	ggcatcagga	accacagcat	caactgccact	2640
gccactggct	accaggagtc	ccacctcagc	tctgncagaa	caaagcagcc	gcatgaccct	2700
ctggtgcctc	tgteggcctc	catagagctc	atcctgggtg	aggacgtgag	ggtgagccca	2760
gaagagggtga	ccatctacaa	ccacctggc	atccaggcag	agctccgcat	cagggaaggc	2820
tcaggttact	tcttctcaa	caccagcacc	gcagatgttg	tcaagggtggc	ctaccaggag	2880
gccagggtg	tgcccatgg	gcacctttg	ctcccggtg	catccaccat	catgatccat	2940
gacttggtgc	tcgtcttccc	ggccccagcc	aaggctgtcg	tttacgtgtc	ggacattcag	3000
gagctgtaca	tccgtgtgg	tgacaagggtg	gagattggga	agacagtga	ggcatacgtc	3060
cgcgtgctgg	acttgacaaa	gaagcccttc	cttgccaaat	acttcccctt	catggacctg	3120
aagctccgag	cagcctcccc	gatcattaca	ttggtggccc	ttgatgaagc	ccttgacaac	3180
tacaccatca	cattcctcat	ccgcggtgtg	gccatcggcc	agaccagtct	aactgcaagt	3240
gtgaccaata	aagctggaca	gagaatcaac	tcacccccac	aacagattga	agtctttccc	3300
ccgttcaggc	tgatgcccag	gaagggtgaca	ctgcttatcg	gggccacgat	gcagggtcac	3360
tccgaggcgc	gccccagcc	tcagtccaac	atccttttct	ccatcagcaa	tgagagcggt	3420
gcgctggtga	gcgctgctgg	gctggtacag	ggcctcgcca	tcgggaacgg	caactgtgtct	3480
gggctcgtgc	aggcagtgga	tgacagagacc	ggcaagggtg	tcacatcttc	tcaggacctc	3540
gtgcagggtg	aagtgtgtgt	gctaaggggc	tgtctcttat	acacatctca	acctgcagg	3599

&lt;210&gt; 32

&lt;211&gt; 1187

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (8)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (13)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (33)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 32

ccttcccncc	tcnttaatgg	gaaacaacca	gcnggagctc	caccgcggtg	gcggccgctc	60
tagaactagt	ggatcccccg	ggctgcagga	attcggcacg	aggggcgcgg	cggcagtcrg	120
ctctatgttc	gcggtcttaa	cctctcctct	ggccgagtcy	ttgcaagaag	tgawttacc	180
gaccctgcaa	aacacttact	atcttkgagt	ttaaagtatg	tcacatggc	aaagtttcgg	240
agaaggactt	gcatcatttt	ggcacttttw	attctattwa	ttttctctct	gatgatgggt	300
ttaaaaatgc	tgagacaaaa	tacagctact	tttgagctc	cttttggaact	tgaccttctt	360
ccagaacttc	atcaacgaac	tattcatttg	gggaaaaatt	ttgatttcca	aaagagtgc	420
agaatcaaca	gtgaaacaaa	taccaagaat	ttaaaaagt	ttgaaatcac	tatgaaacct	480
tccaaagcct	ctgaacttaa	cttgatgaa	ctaccacctc	tgaacaatta	tctacatgta	540
ttttattaca	gttggtatgg	aaatccacaa	tttgatggta	aatatataca	ttggaatcat	600
ccagtgktag	agcattggga	ccctagaata	gccaaagaat	atccacaagg	gagacacaa	660
cctycagatg	acattggcty	cagcttttat	cctgaattgg	gaagttacag	ttctcgggat	720
ccttctgtca	tagaaactca	catgagacaa	atgcgctcag	cttcaattgg	taattattgt	780
atataatat	atagtgtgt	gtttgtgtct	gtatatatgc	atataaatga	ttttttgtgt	840
aactttaata	gttaattttc	tcattattat	taattatatt	gttaagctca	tacctccaaa	900
ttaaactgta	tgatgatct	taaacatcca	ggcaaccaca	ttttaacact	gcccttaagt	960
tattattgtt	aatttttaca	ttctggagca	ttctggata	tattgttgat	ttctaattta	1020
attccctttc	tcaattttat	taaattatga	tttacataaa	atacaatgaa	tttccccctt	1080

taagtttaca gctcattgat gttactcaaa agtatatacc tgtttgaata ccccccaat	1140
caaaaagctc aaatatttct atagcccaaa aaaaaaaaaa aaaaaaa	1187

<210> 33  
 <211> 1476  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1223)  
 <223> n equals a,t,g, or c

<400> 33	
atcgacggca cggagggagg cttttttttt ttttacawtg tatttcatct atgtttttat	60
taggtaaaaa ttaaccattc catataacaa aatagtaatt ttttaattaca atctttaaac	120
agaaggaagt taaacaactc aagtgaagtt aataacagca gtttttgaca atattagtcc	180
ttaaaagaaa cagtaaaata tttggtttct ataacagtca aaacaattag actgattaaa	240
ccataaaaaat taataactta taaaagaatc cattatgatt catgcattgt atgtattata	300
ccactttaag ttataccata ttgaattcaa acgtatagtt ttgaattaag aaataaattc	360
tttgctctta ttacttgtt atcataacaa tttaaactgt gttacaacta aaatggtaaa	420
ggcagttgta ataaatacct gaggaagatt ttgaaagttt tcctctctaa gaattaacag	480
aattattaga gttatttcct aatgcagttg gtcacctta tctgtagggt ctacatccat	540
ggccaagaaa ttgccgactg aaactctgaa gatgtacaga ctctttttt tcatgtaatt	600
attcactaac cagtatggta taacaactac atagcattta cattgtatta agtggtataa	660
ataacttaga gatgacttaa tgtatacagg aggatgtgca tagattatat gcaactacta	720
tgccagttta tatcagggac ttgagcatct gcagattttg gtatctatag gggtaactgg	780
aaaccaatccc ccacagacac tgagggatga ctgtaattat tttattaaaa agggagaaaa	840
aaactatatt aatataaact agtaattatg agatcagatg ccattcttcc attgagaata	900
acttttttgca atgaagacag aatctgcttt atcttactct gaaatctgtt actgctggct	960
ggttagggta atgtgttgag gaatcacaa aaagctcaga gatgaagtat gctgtgtgga	1020
ttcaccatgt ctataatggg aaaaagaaa tggtgggtatc tgtgttgaga atatgctaac	1080
cttggtttta tagattttcc cttaatctca taactatttc ctaaaattta ctttctgtca	1140
tggtgggttc aaatacacaa cgtacacaat gacaaaaact cctctgtggg agatacttct	1200
ctaacaaaac tttaatgaaa tanggtatat tataaaagat tattaggtgt gacatttgta	1260
aattatacct aaaataatat attctagtta aatggacata agaagaaaat ccacaggttg	1320
gatctatata gtgattacca tgtaagtgtc tgcttatatc aaaatatcag tatagtgtt	1380
tattctttta ttttcccta gaaaatgatt actactactg tattaatttc ctaaggcctg	1440
atcattgtct gagaaatggc aaattccaaa atttta	1476

<210> 34  
 <211> 674  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (578)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (625)  
 <223> n equals a,t,g, or c

<220>

<221> SITE  
 <222> (628)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (671)  
 <223> n equals a,t,g, or c

<400> 34  
 gccggctact cctgctcagc atggctgctt tagkgactgt tctcttcaca ggtgtccgga 60  
 ggctgcactg cagcgcagcc gcttgggcgg gcggccagtg gcgactacag cagggactgg 120  
 ctgccaaacc ctccggctac gggccctta ccgagctccc agactggtca tatgcggatg 180  
 gccgacctgc tccccaatg aaaggccagc ttcgaagaaa agctgaaagg gagacgtttg 240  
 caagacgagt tgtactgctg tcacaggaaa tggacgctgg attacaagca tggcagctca 300  
 ggcagcagaa gttgcaggaa gaacaaagga agcaggaaaa tgctcttaaa cccaaagggg 360  
 cttcactgaa gagccactt ccaagtcaat aaaaagcaac tcctgcctcc cttcctcacc 420  
 ctgtctctgg atttcttttc tatcacctag atgcttcac cagccagaag atagccttca 480  
 cggtcccatc ctgtcttcag agcaaaagag ctgggacacc aagaacaagc tgktagatca 540  
 ctgctgggga ggtttggctt artactctca tctctggntc cattccagtt carctaagtc 600  
 ttgctttaaa awttttacct cctanctngg tgcsgtgggt acgcctggat cccacacttt 660  
 ggaggctgag nggc 674

<210> 35  
 <211> 1680  
 <212> DNA  
 <213> Homo sapiens

<400> 35  
 aattcccggg tcgaccacag cgtccgcgac atgggctccg ctccctgggc cccggctctg 60  
 ctgctggcgc tcgggctgcg cggcctccag gcggggggcc gcagggcccc ggacccgggc 120  
 ttccaggagc gcttcttcca gcagcgtctg gaccacttca acttcgagcg cttcggcaac 180  
 aagaccttcc ctacgcgctt cctggtgtcg gacaggttct ggggtccgggg cgaggggccc 240  
 atcttcttct acactgggaa cgaggcgac gtgtgggctc tcgccaacaa ctcgcccttc 300  
 gtcgaggagc tggcggccga gcggggggct ctactggctc tcgaggagca ccgctactac 360  
 gggaagtgcg tgccgttcgg tgcgcagtc acgcagcgcg ggcacacgga gctgctgacg 420  
 gtggagcagg ccctggccga cttcgagag ctgctccgcg cgctacgacg cgacctcggg 480  
 gcccaggatg ccccgccat cgccttcggg ggaagttagt gggggatgct cagtgcctac 540  
 ctgaggatga agtatcccca cctggtggcg ggggcgctgg cggccagcgc gccggttcta 600  
 gctgtggcag gcctcggcga ctccaaccag ttcttcggg acgtcacggc ggactttgag 660  
 ggccagagtc ccaaatgcac ccagggtgtg cgggaagcgt tccgacagat caaggacttg 720  
 ttctacagag gagcctacga cacggtccgc tgggagttcg gcacctgcca gccgtgtca 780  
 gacgagaagg acctgaccca gctcttcag ttcccccga atgccttcac cgtgctggcc 840  
 atgatggact accctaccc cactgacttc ctgggtcccc tccctgcaa ccccgtaag 900  
 gtgggctgtg atcggctgct gagtgaggcc cagaggatca cggggctgcg agcactggca 960  
 gggctggtct acaacgcctc gggctccgag cactgctacg acatctaccg gctctaccac 1020  
 agctgtgctg accccactgg ctgcggcacc ggcccagcgc ccagggcctg ggactaccag 1080  
 gcttgacccg agatcaacct gaccttcgac agcaacaatg tgaccgatat gttcccggac 1140  
 ctgcccctca ctgacgagct ccgccagcgg tactgcctgg acacctgggg cgtgtggccc 1200  
 cggcccagct ggctgctgac cagcttctgg gggggtgatc tcagagccgc cagcaacatc 1260  
 atcttctcca acgggaacct ggaccctgg gcagggggcg ggattcggag gaacctgagt 1320  
 gcctcagtc tgcgcgtcac catccagggg ggagcgcacc acctcgacct cagagcctcc 1380  
 caccagaag atctgcttc cgtggttgag gcgcggaagc tggaggccac catcatcggc 1440  
 gagtgggtaa aggcagccag gcgtgagcag cagccagctc tgcgtggggg gccagactc 1500  
 agcctctgag cacaggactg gaggggtctc aaggctcctc atggagtggg ggcttctactc 1560  
 aagcagctgg cggcagaggg aaggggctga ataaacgcct ggaggcctgg caaaaaaaaa 1620  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1680



<210> 36  
 <211> 593  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (504)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (578)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (584)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (589)  
 <223> n equals a,t,g, or c

<400> 36	
ggcggacgcg gaaggcgaca tgggctccgc tccctggggc cgggtcctgc tgctggcgct	60
cgggctgcgc ggccctccagg cggggggccc caggggcccc gaccccggt tccaggagcg	120
cttcttccag cagcgtctgg accacttcaa ctccgagcgc ttcggcaaca agaccttccc	180
tcagcgcttc ctggtgtcgg acaggttctg ggtccggggc gaggggcccc tcttcttcta	240
cactgggaac gagggcgacg tgtgggcctt cgccaacaac tcggccttcg tcgaggagct	300
ggcggccgag cgggggggctc tactggtctt cgcggagcac cgctactacg ggaagtgcgt	360
gccgttcggt gcgcagtcga cgcagcgcg caccaggagc tgctgacggt ggagcargcc	420
ctggccgact tcgcagagct gctccgcgcg ctacgacgcg acctcggggc cargatgccc	480
ccgscatcrc ctccggtggg aagntatggg ggggaatgct taagtggcta accttgagga	540
atgaaagtaa ttcccaacct ggggtggggc gggggccnct tggncgggnc caa	593

<210> 37  
 <211> 2755  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (953)  
 <223> n equals a,t,g, or c

<400> 37	
agagaaatgc ccttgaaga agtggagttg gtggatgggt gggcatggaa caggatgggc	60
agagaaaggg tagtgtgtga gggagctgag taggccaggt aggcgattgg aagagtgagc	120
aggacacaga ggggagggga atgttttggc aagttaggg gcacaggaga tgtagtcgtt	180
ccagggtctg gggaggtggg agggatcacg cctatagggtg tgggcacatg aaacgacctg	240
gaacttgctt cacagccctg aggaaggtgg acttacataa gcagctgtat tccattagat	300
gagtgggatt tagggaacgc agaaggcaca tccctttgga atggaagctt aggggttctc	360
aggtgatagg gagaggtggc tgtaaacagt gggctgcttg gacacgcgtg tgcatgtgca	420

cgcattgctgg	tgtgcatgct	gggctgcctg	gcaaactctgg	tggtgggtggg	attcctcaag	480
gagaaaacat	tccctcttgc	aatggcaaga	actaggggca	gttctctgtc	cctcctccca	540
acccctcctt	tccctgccc	ttgtcctgat	gcctcaaggc	ttagagagaa	acattgtatc	600
cagaccgagg	gctctgctgc	ttctttccag	aaagtgattg	gcaaggcttt	ggagagaaga	660
gcagttctgc	agctggcctt	gttcttccat	catccccctt	ccttgtgcat	tatgcacttg	720
ctgctgcctc	ctgggctctg	atagaagggc	agggctgttg	agctggatgg	gtggaggctt	780
aggtagccgg	acctgcctgc	caccctcttc	tyccactcag	gcacaatggg	gctaaaagtg	840
tttccaatct	ctgggacctc	tgtacccaaa	ctgaaactct	aaattggggc	cctaactaat	900
tttctttttg	agggttgtgg	cataagtsct	gatctagaat	acagtctggg	tsncacactg	960
tgtctcagtg	agactggtga	tgccttgaga	tgaccatttc	agatctgaat	cccatgggtg	1020
tgagggtgat	gggtactcca	ggactggcct	atgctgtgtt	gtgggctttg	gttcggcttt	1080
atcaggggcc	aggcatatgg	gttctagagt	acctaccatg	acctagaagc	atztatgatt	1140
tatttgaagc	cacactgttt	gcatgggtgt	tacttgtctg	tacctcagag	tctgaggatg	1200
ttacttttgg	aactgcagtg	cctctagaac	agcttcagat	tatggctttt	tcttttgagg	1260
aagaaattat	tactccaga	tgcattgcct	gagccagacc	tactgctgc	actttccaag	1320
gtgctaagat	tgctgctctc	caatgctaac	ttcttgacac	agtgtcttag	aacctgcctt	1380
gtggtcctga	gcactgatca	gcttagctag	accatgggtg	actcttcttg	gagattttca	1440
cttggtccta	gaatgtggca	acgtagtgtt	gctcgccaga	acgtgggacc	aaattggcct	1500
caggtgttga	gtccagactt	ctgcttttga	gagagggctg	cactttttca	tggtatttct	1560
aggggaggtg	gtaggctgca	tgtgccactt	ggtcttgggt	tgagtatgct	gacaccagaa	1620
actcagagcc	agcttgtggc	aagcagttgg	gggtgggggt	ctctgacttg	ctcaggacaa	1680
actaggccag	tggttttcaa	actgcttggc	agagccctga	agtttcctag	gggttgcttc	1740
aggagtccct	ggggagatga	aggggggtgg	gagctgagca	ggctgggcaa	tttgctcaa	1800
acagaacagc	tcccttgtga	gctgtcttac	atattggggg	tcagggttaag	atztatttg	1860
cattaagggg	tttgctgctg	aaaaaaagtt	ggaaaaccac	tgactagacc	atcggtcca	1920
aattggagtc	tgtgcttctt	tccccaggta	tgagcacac	tcttcacctt	acctctacc	1980
acaggacaca	tatccctgtt	agcattcccc	gggaccttta	gccaagagga	gctgcaggga	2040
ccatggccag	gttaccaaaa	tgcctgtctc	tgaagccttg	acacctgggt	ggaaagagag	2100
gctgttttct	gaaagggtaa	agggttgggt	ctggattccc	agaagcatag	cttagatggg	2160
accacagtgg	gcaattttga	cctgtcctgc	ccttcttagc	ttgaaggga	accccagaga	2220
ctcttctgtc	agggaaaact	agggactctc	ttctagagcc	atatagttcc	ttgggattag	2280
ctcttgccca	agaaggctga	gtatggttcc	caatttttaa	atccatttca	ttttttaaaa	2340
aataaggga	ataaatgtaa	ttgccatttt	tcaaagatta	agtaggagga	gaggggtttc	2400
ttgtctccca	gagcccaaa	ggacaaatag	ggactttggt	taggccaagg	aaggagcgga	2460
agtagggcaa	ctcggctcctg	cgattattaa	tccactccc	cacttattct	agggcacaca	2520
aacactatct	tactttttta	aaatcataaa	acggcagaac	agatttggtt	agtttagaag	2580
aaaagaaagc	tctataaata	taaactctata	ttctgtatt	tttatttaat	aatttataaa	2640
taccaagttc	atttgacttt	tatttttgtg	taatatgtaa	tgatcgtatt	aaaaacaata	2700
aataaagccc	agaagtttaa	tgagaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaa	2755

&lt;210&gt; 38

&lt;211&gt; 501

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (375)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (483)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (490)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (492)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 38

gccagaccag	gagtgtccag	tccttgggcc	ttgggtcagcc	tgagcagtt	gctcggcccc	60
ctgtgggtggg	ggcactatgg	agcgacatcg	gacttgtgag	gggggtcctg	gggtggcacc	120
atgccaggcc	caggacacag	agcaacggca	ggagtgtaac	ctgcagccct	gccctgagtg	180
ccccctggc	caggtgctta	gtgcctgtgc	cacctcatgc	ccgtgcctct	gctggcatct	240
gcagcctggg	gccaatctgtg	tgcaggagcc	ctgccagcct	ggctgtggct	gcctggaggg	300
cagctgctgc	acaatggcac	gtgtgtgcct	yccactgcct	gcccctgcac	ccagcattct	360
ctgccctggg	gcctnaccct	gaccctggaa	garcaggccc	aggagctgsc	cccagggact	420
gtgctcacc	ggaactgcac	cccgtgtgt	ctgccactgt	ggagccttca	gctgctccct	480
cgntgactgn	angagtgccc	c				501

&lt;210&gt; 39

&lt;211&gt; 847

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (649)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (655)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (732)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (752)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (799)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (811)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (824)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (828)

<223> n equals a,t,g, or c

<400> 39

cgggcccccc	ctcgagtttt	tttttttttt	ttttttttgt	tgccagtatc	actttatttg	60
gaacatgcta	atgccaagtc	atgggcccc	agttgggggc	aggtgagaga	gcgtggaagg	120
acgtgggtcag	tgctgctgag	tcccatgac	acaagagggg	cagctgtgga	ctcaccacagc	180
ggagcctgtt	agcgctttga	gaagtcacct	cccagggggac	acgtgagggg	gagatgggtt	240
agtaagagag	gcagagtggg	caggctgggt	ccaggaggac	gcccagagcc	aacaccaggc	300
cttccactgt	gctccacca	ggtggcacgg	gtgccttcca	cctctgtttc	cccttcactc	360
gccacacagt	gggacctcag	gttatcatat	ggcaggtgct	taacagaact	aggcacctgc	420
cagccacttc	acacgcgtgc	cctcaccaag	tccaccaaac	aagcctgcat	agcaatgtca	480
gccttgctta	aaagatgagg	tcagggggct	gggtgcagt	gttcctgcct	gtaaccccag	540
cgcattggga	ggctgaggca	ggtggatcac	tcgagcccag	gagttcaaga	acagcctggg	600
caacatggcg	aaaccccgtc	ccctggcgag	agctgcactg	gcagctgtng	atgancggca	660
gcaccacggg	ctctgtgtgg	ccaccacagc	agcgcagggt	caggattccg	cacagggttc	720
tccgggttta	anacgggtaa	ctgcaagcag	tnaacacttg	ggttcttcaa	ggtattggct	780
ccctctttgg	gcaattaana	ttggggctct	ngaatttggg	caanttancc	caacttggaa	840
gttaagc						847

<210> 40

<211> 1550

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (909)

<223> n equals a,t,g, or c

<400> 40

gccggagctc	caccgcggtg	gcggccgctc	tagaactagt	ggatcccccg	ggctgcagga	60
attcggcacg	agcatgggtc	ggaagaaact	gggctcccg	aacttctcca	gctgccccag	120
tggctccatc	cagtggatat	gggatgtgtt	gggtgaatgt	gcccaggacg	gctgggacga	180
ggccagcgtg	ggcctgggct	tgatctccat	tctctgcttt	gctgcatcta	ccttccccca	240
gttcatcaaa	gcctacaaga	cgggcaacat	ggaccaggcg	ctgtccctgt	ggttcctcct	300
gggctggatt	ggcggagact	cctgcaacct	catcggtccc	ttccttgctg	accagctgcc	360
cctgcagacc	tacacggctg	tgtattatgt	cttggcagac	ctgggtgatg	tgacgctgta	420
cttttactac	aagttcagga	cgcgcccctc	tctgttgtct	gcccccatca	actccgtgct	480
gttgttcctc	atggggatgg	cgtgcgccac	accgctkctg	agtgtgtgct	ggcccgtggc	540
tgccccctag	gaagccttcc	gggggcgggc	gctcctgtcc	gtggagtcgg	gcagcaagcc	600
cttcaccggg	caggaagtca	ttggcttcgt	catcggctyc	atctccagcg	tgktgtacct	660
gctttcccg	ctgctcaga	tccgcaccaa	cttctccgg	aagtcacacc	aggggatctc	720
ctactctctg	ttcgcgctgg	tgatgctggg	gaacacgctg	tatgggctga	gcgtgctgct	780
caaaaacccc	gaggaggggc	agagcgaggg	cagctacctg	ctgcaccacc	tgccccggct	840
tgtgggcagc	ctgggcgtgc	tgtgtctcga	caccatcatc	tccatccagt	tcttggtgta	900
caggcgcana	ccgcgcctc	ggagcttgag	cccctcctyc	ccagctgacc	agaaccaggc	960
tgagcgcagg	aggacaggca	ccaccggatg	ccacaccagg	caggaggagg	tgtggacagt	1020
gatggtacgg	cggccctgca	tcagcctgcg	ggtggcctct	ggatcctccg	tggaaccgaac	1080
cgtcccccca	ggaacacacc	ttcaggtaga	ccccgaagcc	tcaaggccgg	ggctggagcg	1140
gagaccccag	ggcctctcag	gagacagtga	ggctgcccc	cctaccacct	acctcattct	1200
gcctactcag	gactgtcctg	tcaactccag	acaactgaat	aaacaggccg	ggtacagtgg	1260
ctcgcacctg	taatcctagc	actttgggag	gccgaagcgg	gtggaccact	tgacgtccgt	1320

agttcgagac	cagcctggcc	aacatgggtga	aaccccatct	ctactaaaaa	tacaaaaatt	1380
agccagggtgt	ggtggcacac	atctgtagtc	ccagctactt	gggaggctga	ggcaggagaa	1440
ctgtttgaac	ctgggagaca	gaggttgcg	tgaaccgaga	tcgtgccact	gtactccagc	1500
ctgggtgaca	gagtgagact	ccgtctcaaa	aaaaaaaaaa	aaaaactcga		1550

<210> 41  
 <211> 530  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (517)  
 <223> n equals a,t,g, or c

<400> 41						
gcctggcaga	gagactctga	aatgagggat	tagagggtgt	caaggagcaa	gagcttcagc	60
ctgaagacaa	gggagcagtc	cctgaagacg	cttctactga	gaggtctgcc	atggcctctc	120
ttggcctcca	acttggtggc	tacatcctag	gccttctggg	gcttttgggc	acactggttg	180
ccatgctgct	ccccagctgg	aaaacaagtt	cttatgtcgg	tgccagcatt	gtgacagcag	240
ttggcttctc	caagggcctc	tggatggaat	gtgccacaca	cagcacaggc	atcaccctag	300
gtgacatcta	tagcaccctt	ctgggcctgc	ccgtgacat	ccaggtgcc	caggccatga	360
tggtgacatc	cagtgcacat	tcctccctgg	cctgcattat	ctctgtggtg	ggcatgagat	420
gcacagtctt	ctgccaggaa	tcccagagcca	aagacagagt	ggcggtagca	ggtggagtct	480
ttttcatcct	tgggaagcctc	ctgggattca	ttcctgntgc	ctggaatctt		530

<210> 42  
 <211> 1046  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (587)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (606)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1014)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1033)  
 <223> n equals a,t,g, or c

<400> 42						
gtaccgggcc	ccccctcgag	tttttttttt	ttttttttta	aatgtcccag	gctgccttcc	60
tgtcctccca	tcctgcatcc	tgctttctgt	tccttgata	ccgtaggatg	gttttatctc	120
agttcatgca	caaattagtc	tggacactgt	ggagtcataa	caagagtggg	atggagggtc	180
cagggccaat	cagtttcttt	ggagggaagc	ttgagaagta	ggtagagca	atgcccacaa	240

aagccactgc	ttctccttcc	catccccagc	aatgagctaa	gagccaacct	cagccagaga	300
gagggctctt	gatcacagag	ggtcagtcag	tgggatgtga	ttagtgggtt	tggggatgga	360
gtcccaggta	aaccagaggg	caaagggatc	ctctgagtc	tggcttaagg	gaatgggggt	420
tcaagttgag	ggttggggac	ttagggcagg	ggascagcaa	ggtgaggaaa	acagaaaggc	480
tggcaatggc	agcatccttg	gcaattcaac	ctgcatgtcg	ttacactagc	ccccatttct	540
gcctttgctc	aatccaatgg	ccaaagtcag	tctatcctca	gcagcanctt	ctgacacgat	600
ccagtngtaa	tgtccctcac	ctgtggcctc	ggggtgctgt	ccactgtttt	tcacagaccc	660
agccamcccc	cagytctggc	ccctggttct	tcacacatac	cctgtcargc	tgtaggaatt	720
gaactcactc	ttgacttttg	gaggttgacc	aggccttgga	gagctccttg	tggcaagagg	780
ttgggcttgg	taggcacgt	agtagttgga	gcgatttctc	tggsatgagc	aggaaaagca	840
gaggatgatt	ccagmtatca	gggagaacag	ggaagaaata	atgcccaagt	aaagagcctc	900
tccaatctca	aatttcagtc	tgtcaggcac	cagtgggtgag	tagaagcgtc	ttcagggact	960
gtcccttgt	cttgcaggct	gaagctcttg	ctccttgaac	acctctaata	cctnatttca	1020
gagtctctct	gcnaggctga	cttctc				1046

&lt;210&gt; 43

&lt;211&gt; 1754

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 43

tttttttttt	tttgtttaaa	tgatacaact	taattttatt	aggacagacg	ctggcggcca	60
ccagaagttt	gagcctcttt	ggtagcagga	ggctggaaga	aaggacagaa	gtagctctgg	120
ctgtgatggg	gatcttactg	ggcctgctac	tcctgggggc	cctaacagtg	gacacttatg	180
gccgtcccat	cctggaagtg	ccagagagtg	taacaggacc	ttggaaaggg	gatgtgaatc	240
ttccctgcac	ctatgacccc	ctgcaaggct	acacccaagt	cttgggtgaag	tggctggtac	300
aacgtggctc	agaccctgtc	accatctttc	tacgtgactc	ttctggagac	catatccagc	360
aggcaaagta	ccagggccgc	ctgcatgtga	gccacaaggt	tccaggagat	gtatccctcc	420
aattgagcac	cctggagatg	gatgaccgga	gccactacac	gtgtgaagtc	acctggcaga	480
ctcctgatgg	caaccaagtc	gtgagagata	agattactga	gctccgtgtc	cagaaactct	540
ctgtctccaa	gcccacagtg	acaactggca	gcggttatgg	cttcacggtg	ccccagggaa	600
tgaggattag	ccttcaatgc	caggctcggg	gttctcctcc	catcagttat	atttgggtata	660
agcaacagag	taataccag	gaacccatca	aagtagcaac	cctaagtacc	ttactcttca	720
agcctgcggt	gatagccgac	tcaggctcct	atttctgcac	tgccaagggc	cagggttggt	780
ctgagcagca	cagcgacatt	gtgaagtttg	tgggtcaaaga	ctcctcaaag	ctactcaaga	840
ccaagactga	ggcacctaca	accatgacat	acccttgaa	agcaacatct	acagtgaagc	900
agtccctggg	ctggaccact	gacatggatg	gctaccttgg	agagaccagt	gctgggcccag	960
gaaagagcct	gcctgtcttt	gccatcatcc	tcacatctc	cttgtgctgt	atgggtggtt	1020
ttaccatggc	ctatatcatg	ctctgtcgga	agacatccca	acaagagcat	gtctacgaag	1080
cagccagggc	acatgccaga	gaggccaacg	actctggaga	aacctagagg	gtggccatct	1140
tcgcaagtgg	ctgctccagt	gatgagccaa	cttcccagaa	tctgggcaac	aactactctg	1200
atgagccctg	cataggacag	gagtaccaga	tcacgcacca	gatcaatggc	aactacgccc	1260
gcctgctgga	cacagttcct	ctggattatg	agtttctggc	cactgagggc	aaaagtgtct	1320
gttaaaaatg	ccccattagg	ccaggatctg	ctgacataat	tgcctagtca	gtccttgctt	1380
tctgcatggc	cttcttccct	gctacctctc	ttcctggata	gccc aaagtg	tccgcctacc	1440
aacactggag	ccgctgggag	tactggctt	tgcctggaa	tttgccagat	gcactctcaag	1500
taagccagct	gctggatttg	gctctgggct	ctctgctggg	ggcttctggg	ggcttctggg	1560
actcctctct	aaataccaga	gggaagatgc	ccatagcact	aggacttggg	catcatgcct	1620
acagacacta	ttcaactttg	gcatcttgcc	accagaagac	ccgagggagg	ctcagctctg	1680
ccagctcaga	ggaccagcta	tatccaggat	cattggaatt	cgatatcaag	cttatcgata	1740
ccgtcgacct	cgag					1754

&lt;210&gt; 44

&lt;211&gt; 263

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (14)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 44

gacggggggac	gggnaggaaa	aaggggaagct	cctatagggga	aagctgggtac	gcctgcaggt	60
accgggtccgg	aattcccggg	tcgacccacg	cgtccgatag	gggtacattt	acattctgta	120
agagattgag	cctgaactct	cttagtcata	aaaacatcaa	atggccacat	gtccactacc	180
aagcttcttc	tatgttaaaa	aaataataat	aaagcagttt	taacctgcaa	aaaaaaaaaa	240
aaaaaaaaaa	aaaaaaaaag	ggg				263

&lt;210&gt; 45

&lt;211&gt; 2135

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 45

ggcacgaggg	cggtgctgc	catggtggct	ggcgccggg	tgacgcatgt	ctagactggg	60
agccctgggt	ggtgcccgtg	ccgggctggg	actggtgctg	ggtaccgccg	ccggccttgg	120
attcctgtgc	ctcctttaca	gccagcgatg	gaaacggacc	cagcgtcatg	gccgcagcca	180
gagcctgccc	aactccctgg	actatacgca	gacttcagat	cccggacgcc	acgtgatgct	240
cctgcgggct	gtcccaggtg	gggctggaga	tgctcagtg	ctgcccagcc	ttccacggga	300
aggacaggag	aaggtgctgg	accgcctgga	ctttgtgctg	accagccttg	tggcgctgcg	360
gcgggaggtg	gaggagctga	gaagcagcct	gcgagggctt	gcgggggaga	ttgttgggga	420
ggtccgatgc	cacatggaag	agaaccagag	agtggctcgg	cggcgaaagg	ttccgtttgt	480
ccgggagagg	agtgactcca	ctggctccag	ctctgtctac	ttcacggcct	cctcgggagc	540
cacgttcaca	gatgctgaga	gtgaaggggg	ttacacaaca	gccaatgcgg	agtctgacaa	600
tgagcgggac	tctgacaaa	aaagtgagga	cggggaagat	gaagtgagct	gtgagactgt	660
gaagatgggg	agaaaggatt	ctcttgactt	ggaggaagag	gcagcttcag	gtgcctccag	720
tgccctggag	gctggagggt	cctcaggctt	ggaggatgtg	ctgcccctcc	tgacgagggc	780
cgacgagctg	cacaggggtg	atgagcaagg	caagcgggag	ggcttccagc	tgctgtctaa	840
caacaagctg	gtgtatggaa	gccggcagga	ctttctctgg	cgcctggccc	gagcctacag	900
tgacatgtgt	agggtcactg	aggaggtgag	cgagaagaag	tcatatgccc	tagatggaaa	960
agaagaagca	gaggctgctc	tggagaaggg	ggatgagagt	gctgactgtc	acctgtggta	1020
tgcggtgctt	tgtggtcagc	tggctgagca	tgagagcatc	cagaggcgca	tccagagtgg	1080
ctttagcttc	aaggagcatg	tggacaaagc	cattgtctct	cagccagaaa	accccatggc	1140
tactttcttc	cttggcagggt	ggtgctatca	ggtctctcac	ctgagctggc	tagaaaaaaa	1200
aactgctaca	gccttgcttg	aaagccctct	cagtggccact	gtggaagatg	ccctccagag	1260
cttcctaaag	gctgaagaac	tacagccagg	atthtccaaa	gcaggaaggg	tatatatttc	1320
caagtgtctac	agagaactag	ggaaaaactc	tgaagctaga	tgggtggatga	agttggccct	1380
ggagctgccca	gatgtcacga	aggaggattt	ggctatccag	aaggacctgg	agaactgga	1440
agtcatttta	cgagactaac	cacgtttcac	tggccttcat	gacttgatgc	cactatttaa	1500
ggtggggggg	cggggaggct	tttttcctta	gaccttgctg	agatcaggaa	accacacaaa	1560
tctgtctcct	gggtctgact	gctaccact	accactcccc	attagttaat	ttattctaac	1620
ctctaaccta	atctagaatt	ggggcagtac	tcattggcttc	cgtttctgtt	gttctctccc	1680
ttgagtaatc	tcttaaaaaa	atcaagattc	acacctgccc	caggattaca	catgggtaga	1740
gcctgcaaga	ctgagacct	tccaattgct	ggtgaggtgg	atgaacttca	aagcttagag	1800
aacaaagcac	ataacttgct	actttaactc	ttttcactga	ctaataggac	tcagtacata	1860
tagtcttaag	atcatacctt	acctaccaag	gtaaaaagag	ggatcagagt	ggcccacaga	1920
cattgctttc	ttatcaccta	tcattgtgaat	tctacctgta	ttcctgggct	ggaccacttg	1980
ataacttcca	gtgtcctggc	agcttttgga	atgacagcag	tggtatgggg	tttatgatgc	2040
tataaaacaa	tgtctgaaaa	gttgccctaga	atatattttg	ttacaaactt	gaaataaacc	2100
aaatttgatg	ttaaaaaaa	aaaaagggcg	gccgc			2135

<210> 46  
 <211> 755  
 <212> DNA  
 <213> Homo sapiens

<400> 46  
 cactcgcctcc ggatttcccg ggtcgaccca cgcgtccgcc agcaccttcc tctcccaggc 60  
 aaaatgaaaa tacttgtggc atttctggtg gtgctgacca tctttgggat acaatctcat 120  
 ggatacgagg tttttaacat catcagccca agcaacaatg gtggcaatgt tcaggagaca 180  
 gtgacaattg ataatgaaaa aaataccgcc atcattaaca tccatgcagg atcatgctct 240  
 tctaccacaa tttttgacta taaacatggc tacattgcat ccagggtgct ctcccgaaga 300  
 gcctgcttta tcctgaagat ggaccatcag aacatccctc ctctgaacaa tctccaatgg 360  
 tacatctatg agaaacaggc tctggacaac atgttctcca gcaaatacac ctgggtcaag 420  
 tacaaccctc tggagtctct gatcaaagac gtggattggt tcctgcttgg gtcacccatt 480  
 gagaaactct gcaaacatat ccctttgtat aagggggaag tggttgaaaa cacacataat 540  
 gtcggtgctg gaggtgtgac aaaggctggg ctctgaggca tcttgggaat ttcaatctgt 600  
 gcagacattc atgttttaga tgattagccc tcttgtttta tcttttcaa gaaatacatc 660  
 cttggtttac actcaaaagt caaattaaat tctttcccaa tgccccaact aattttgaga 720  
 ttcagtcaga aaatataaat gctgtattta taaaa 755

<210> 47  
 <211> 733  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (721)  
 <223> n equals a,t,g, or c

<400> 47  
 ccggaattcc cggtcgaccc acgcgtccgc gaagtgcgtg tttctaataga ctctgtgctt 60  
 ggtcactttc ctcaccagtc tcccaacgag cgtgcccgtc tgtacttctc gctggcctgg 120  
 tttcatgcga tcattcaaga acgcttacga tacgcaccac tggggtgggc aaagaagtat 180  
 gaatttggag agtctgacct gcggtcagct tgcgatacgg tggacacgtg gctggatgac 240  
 acggccaagg caagtgtggg ccatgccagg acagacagtg gacgtgtatc tgggaaggat 300  
 gctgcagggc gtggtgctga gaggccagac tctgcgtgga agagcgagst gacccctcgt 360  
 gaccgccaata gcctagctgg ccatggggag tgaggaggaa agctgtgccc ctcgaaaagga 420  
 agccccgggc ctgcccgcct ctgaccacac acacgaaccc tgcttttctc cccccagggc 480  
 aggcagaaca tctcaccgga taagatcccc tgggtctgcac taaagacctt aatggcccag 540  
 tccatttatg gcgggcgcgt ggacaacgag tttgaccagc gtctgctcaa caccttcctg 600  
 gagcgctgtg tcacaaccag gartttcgac agtgagttta agctggcatg caaggctgac 660  
 ggacataaag acattcaaata gccagatggc atcagggtatg ctgctgcctg ctggaatgga 720  
 nacaggttgt gat 733

<210> 48  
 <211> 495  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (485)  
 <223> n equals a,t,g, or c

<400> 48



gcggccgccc	tttttttttt	ttttttttga	aacggagtct	ccctctgtca	cccaggettg	60
agtgaatgg	tgtgatctca	gctcactgca	acctccatct	cccgggttca	aataattctc	120
ctgcctcagc	ctcctgagta	gctgggatta	cagggtgectg	ccaccatgct	cacctaattt	180
ttgtattttt	agtagagacg	aggttttgcc	atgttgacca	ggctggctctg	gaaatcctaa	240
cctcgagtga	tctgcccgcc	ttggcctccc	aaagtgtctg	gattataggt	gtgagccagt	300
gtgcccagcc	agtaactgct	tttcaatatg	agatgaacat	ctaaatgtta	tttctaggct	360
catttacata	aatatcaagc	cttttctcta	gaactgagtt	gatgctgcag	agaagagcca	420
gtttcttctc	ctgcctcccc	tcggagtggg	gctaggagca	gctggagact	ggcaggaagg	480
ccgangctga	cagag					495

&lt;210&gt; 49

&lt;211&gt; 559

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 49

ggcagagct	gggcctcttc	tgaggcagga	gctttcttga	gggatgccac	aaacagcctt	60
ccctactccc	tgccagagca	gttccctccc	tgatgagctg	gagaagggcc	ctctggcctc	120
ctgacagtac	agggagggca	ccagctagat	cctcccttgt	ggtgtgagat	gttcctggaa	180
ctcagccagg	ccctcctcct	cctgggcttg	cccagagccc	ccaccctatt	cccagcattg	240
cccgaaggac	caaccagttt	gggtgaacag	tgccctcctc	agcttctctc	ccatctgggt	300
gccccaccgg	cggcggaggg	agctgtggcg	atggtggggt	gtggggaggg	acgaggaggg	360
aagcctctgt	gctgctcacc	tgcccaaagc	ccagctcagc	gggtacgcag	tggaggcgac	420
aaggaaccaa	tcacaactac	agaggtttct	ctgatcctcc	tccactcccg	ctgcttcaac	480
ttgactaagc	ttaaaaaaaa	tgcttttgcc	atgaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	540
aaaaaaaaaa	aaaaaaaaaa					559

&lt;210&gt; 50

&lt;211&gt; 898

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 50

tcaaaagctg	gagctccacc	gcgggtggcg	ccgctctaga	actagtggat	ccccgggct	60
gcaggaattc	ggcagagct	gggcctcttc	tgaggcagga	gctttcttga	gggatgccac	120
aaacagcctt	ccctactccc	tgccagagca	gttccctccc	tgatgagctg	gagaagggcc	180
ctctggcctc	ctgacagtac	agggagggca	ccagctagat	cctcccttgt	ggtgtgagat	240
gttcctggaa	ctcagccagg	ccctcctcct	cctgggcttg	cccagagccc	ccaccctatt	300
cccagcattg	cccgaaggac	caaccagttt	gggtgaacag	tgccctcctc	agcttctctc	360
ccatctgggt	gccccaccgg	cggcggaggg	agctgtggcg	atggtggggt	gtggggaggg	420
acgaggaggg	aagcctctgt	gctgctcacc	tgcccaaagc	ccagctcagc	gggtacgcag	480
tggaggcgac	aaggaaccaa	tcacaactac	agaggtttct	ctgatcctcc	tccactcccg	540
ctgcttcaac	ttgactaagc	ttaaaaaaaa	tgcttttgcc	atggctcatc	ggagtttata	600
cttattttct	agaaaatgtt	tctgtttatt	tgctggacaa	gtcccaaaga	acaggcagat	660
gttcttatta	aaagatcagc	ctataagatt	ggtcaggacc	aggcgctct	ggccacgtgc	720
ctctcccctc	caggcctgcg	gtctgcggtg	gcacctggca	gctggaccac	agccaggaga	780
agggactat	tagccctgct	tcaaacatgc	agaaactgag	gcccggggag	attaaataac	840
ctgcctgaaa	tgacagttag	gtatgcgcct	ggatttgagt	tctgctctgg	ctcgtgcc	898

&lt;210&gt; 51

&lt;211&gt; 612

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

<221> SITE  
 <222> (514)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (525)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (563)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (603)  
 <223> n equals a,t,g, or c

<400> 51  
 tcgacccacg cgtccggaat gtgtgtgtgc ggtgttatgc cggacaagag ggaggcgacc 60  
 gcggcgccgg tggctctgtt tattgtccct ctccggtgtg ggatgcgagg aagtcggggg 120  
 tatagcgtg ctcacgaagg cagcctttga ggcagcggcc cggcgtttag tgcgactccg 180  
 gcaaccccag cggccggcct tcgcggagtg tgaggaagga caaggcgccct ttgcgtcccc 240  
 gccacgtctg gacgccccga gctttccggc tgcgctcgcc gcgcgcacct ccgggccccg 300  
 gcccggttg ccgtgccgcc ggcggggcgg cgagaaggaa gcaccgcgcc tcaccgctgc 360  
 cggcctcctg ctcccttctc caccctcttc tcagcgacgg gcctaggccc gggcgactcg 420  
 gccgcccgcg ctcgagtttg agggcgccga gcggcgccgg ctccctcgcg gctcgcccg 480  
 ccgtccgtcc cgggtctcag cgatggggcg cggngggcga cgccnctagg agcacggcga 540  
 gcggagcggc cggkgcggag canaggggcc ccggcggccg gcaggaaggc gggaacgcgg 600  
 ccnctctgct ca 612

<210> 52  
 <211> 272  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (272)  
 <223> n equals a,t,g, or c

<400> 52  
 aattcggtt tcgagcggcc gcccgggcag gtacatgaca atttttactc catttcttgt 60  
 tctcttactt ctagtcaatt ctcccagatt ttctacaata actcttatga ggtctggttt 120  
 tcacaacca tcagtctgct tatcttttac tctaaaacct caatgctacc ttgttttgat 180  
 gtatcagaag aacaggagac aagatgggtc aaaagtattt tttaaaactg caagactaaa 240  
 gttctatctc aatataacag caaagtgaca gn 272

<210> 53  
 <211> 261  
 <212> PRT  
 <213> Homo sapiens

<400> 53  
 Met Met Cys Val Val Leu Thr Thr Leu Pro Cys Leu Thr Phe Ser Ile

32

1	5	10	15
Ala Val Thr	Glu Val Gln Lys	Ser Ile Asn Gly Ser	Ala Asp Val Leu
	20	25	30
Pro Asp Met	Leu Pro Asp Leu	Pro Val Ser Leu Val	Leu Leu Ser Leu
	35	40	45
Ile Met Val	Asp Ile Ile Glu Lys	Leu Arg Ile Tyr Pro	Leu Arg Gly
	50	55	60
Ser Gln Lys	Ser Ser Glu Asn Gly	His Ile His Ser Thr	Ser Leu Gln
	65	70	75
His Ile Lys	Thr Val Thr Glu Gln	Val Arg Gln Ser Pro	Glu Asn Ala
	85	90	95
Ala Ser Pro	Gln Ala Thr Asn Ser	Thr Gln Val Ser Gln	Pro Ser Gly
	100	105	110
Ala Met Thr	Arg Ser Gln Glu Ser	Val Phe Met Gly Pro	Gln Glu Pro
	115	120	125
Ser Cys Asp	Ser Gly Ile Leu Arg	Met Met Ser Arg Arg	Asp Val Arg
	130	135	140
Ala Glu Leu	Phe Leu Trp Ser Phe	Leu Leu Trp Ser Asp	Thr Ile Glu
	145	150	155
Met Val Arg	Val Ala Gly His Pro	Asn Val Tyr Lys Ser	Ser Trp Leu
	165	170	175
Tyr Pro Val	Tyr Ile Phe Ser Phe	Ile Ser Leu Leu Arg	Ile Thr Phe
	180	185	190
Thr Pro Gln	Asn Pro Leu Leu Asn	Ser Leu Ser Val Leu	Leu Gln Asp
	195	200	205
Leu Pro Phe	Val Phe Val Arg Leu	Gly Leu Ile Ile Ala	Leu Gly Thr
	210	215	220
Ile Thr Pro	Val Leu Gly Leu Cys	Lys Asn Ile Leu Val	Thr Leu Ser
	225	230	235
Tyr Ile Tyr	Phe Asn Tyr Leu Thr	Arg Ile Arg Ile Phe	Ser Ala Phe
	245	250	255
Glu Met Ser	Pro Phe		
	260		

&lt;210&gt; 54

&lt;211&gt; 359

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 54

Met Ala Val Arg Ala Leu Lys Leu Leu Thr Thr Leu Leu Ala Val Val

33

1	5	10	15
Ala Ala Ala	Ser Gln Ala Glu Val	Glu Ser Glu Ala Gly	Trp Gly Met
	20	25	30
Val Thr Pro	Asp Leu Leu Phe Ala Glu Gly Thr Ala Ala Tyr Ala Arg		
	35	40	45
Gly Asp Trp	Pro Gly Val Val Leu Ser Met Glu Arg Ala Leu Arg Ser		
	50	55	60
Arg Ala Ala	Leu Arg Ala Leu Arg Leu Arg Cys Arg Thr Gln Cys Ala		
	65	70	75
Ala Asp Phe	Pro Trp Glu Leu Asp Pro Asp Trp Ser Pro Ser Pro Ala		
	85	90	95
Gln Ala Ser	Gly Ala Ala Ala Leu Arg Asp Leu Ser Phe Phe Gly Gly		
	100	105	110
Leu Leu Arg	Arg Ala Ala Cys Leu Arg Arg Cys Leu Gly Pro Pro Ala		
	115	120	125
Ala His Ser	Leu Ser Glu Glu Met Glu Leu Glu Phe Arg Lys Arg Ser		
	130	135	140
Pro Tyr Asn	Tyr Leu Gln Val Ala Tyr Phe Lys Ile Asn Lys Leu Glu		
	145	150	155
Lys Ala Val	Ala Ala Ala His Thr Phe Phe Val Gly Asn Pro Glu His		
	165	170	175
Met Glu Met	Gln Gln Asn Leu Asp Tyr Tyr Gln Thr Met Ser Gly Val		
	180	185	190
Lys Glu Ala	Asp Phe Lys Asp Leu Glu Thr Gln Pro His Met Gln Glu		
	195	200	205
Phe Arg Leu	Gly Val Arg Leu Tyr Ser Glu Glu Gln Pro Gln Glu Ala		
	210	215	220
Val Pro His	Leu Glu Ala Ala Leu Gln Glu Tyr Phe Val Ala Tyr Glu		
	225	230	235
Glu Cys Arg	Ala Leu Cys Glu Gly Pro Tyr Asp Tyr Asp Gly Tyr Asn		
	245	250	255
Tyr Leu Glu	Tyr Asn Ala Asp Leu Phe Gln Ala Ile Thr Asp His Tyr		
	260	265	270
Ile Gln Val	Leu Asn Cys Lys Gln Asn Cys Val Thr Glu Leu Ala Ser		
	275	280	285
His Pro Ser	Arg Glu Lys Pro Phe Glu Asp Phe Leu Pro Ser His Tyr		
	290	295	300
Asn Tyr Leu	Gln Phe Ala Tyr Tyr Asn Ile Gly Asn Tyr Thr Gln Ala		
	305	310	315
			320

<400> 55																
Met	Ala	Ala	Arg	Gly	Arg	Gly	Leu	Leu	Leu	Leu	Thr	Leu	Ser	Val	Leu	
1				5					10					15		
Leu	Ala	Ala	Gly	Pro	Ser	Ala	Ala	Ala	Ala	Lys	Leu	Asn	Ile	Pro	Lys	
			20					25					30			
Val	Leu	Leu	Pro	Phe	Thr	Arg	Ala	Thr	Arg	Val	Asn	Phe	Thr	Leu	Glu	
		35					40					45				
Ala	Ser	Glu	Gly	Cys	Tyr	Arg	Trp	Leu	Ser	Thr	Arg	Pro	Glu	Val	Ala	
	50					55					60					
Ser	Ile	Glu	Pro	Leu	Gly	Leu	Asp	Glu	Gln	Gln	Cys	Ser	Gln	Lys	Ala	
65					70					75					80	
Val	Val	Gln	Ala	Arg	Leu	Thr	Gln	Pro	Ala	Arg	Leu	Thr	Ser	Ile	Ile	
				85					90					95		
Phe	Ala	Glu	Asp	Ile	Thr	Thr	Gly	Gln	Val	Leu	Arg	Cys	Asp	Ala	Ile	
			100					105					110			
Val	Asp	Leu	Ile	His	Asp	Ile	Gln	Ile	Val	Ser	Thr	Thr	Arg	Glu	Leu	
		115					120					125				
Tyr	Leu	Glu	Asp	Ser	Pro	Leu	Glu	Leu	Lys	Ile	Gln	Ala	Leu	Asp	Ser	
	130					135					140					
Glu	Gly	Asn	Thr	Phe	Ser	Thr	Leu	Ala	Gly	Leu	Val	Phe	Glu	Trp	Thr	
145					150					155					160	
Ile	Val	Lys	Asp	Ser	Glu	Ala	Asp	Arg	Phe	Ser	Asp	Ser	His	Asn	Ala	
				165					170					175		
Leu	Arg	Ile	Leu	Thr	Phe	Leu	Glu	Ser	Thr	Tyr	Ile	Pro	Pro	Ser	Tyr	
			180					185					190			
Ile	Ser	Glu	Met	Glu	Lys	Ala	Ala	Lys	Gln	Gly	Asp	Thr	Ile	Leu	Val	
		195					200					205				
Ser	Gly	Met	Lys	Thr	Gly	Ser	Ser	Lys	Leu	Lys	Ala	Arg	Ile	Gln	Glu	
	210					215					220					

Ala Val Tyr Lys Asn Val Arg Pro Ala Glu Val Arg Leu Leu Ile Leu  
 225 230 235 240  
 Glu Asn Ile Leu Leu Asn Pro Ala Tyr Asp Val Tyr Leu Met Val Gly  
 245 250 255  
 Thr Ser Ile His Tyr Lys Val Gln Lys Ile Arg Gln Gly Lys Ile Thr  
 260 265 270  
 Glu Leu Ser Met Pro Ser Asp Gln Tyr Glu Leu Gln Leu Gln Asn Ser  
 275 280 285  
 Ile Pro Gly Pro Glu Gly Asp Pro Thr Arg Pro Val Ala Val Leu Ala  
 290 295 300  
 Gln Asp Thr Ser Met Val Thr Ala Leu Gln Leu Gly Gln Ser Ser Leu  
 305 310 315 320  
 Val Leu Gly His Arg Ser Ile Arg Met Gln Gly Ala Ser Arg Leu Pro  
 325 330 335  
 Asn Ser Thr Ile Tyr Val Val Glu Pro Gly Tyr Leu Gly Phe Thr Val  
 340 345 350  
 His Pro Gly Asp Arg Trp Val Leu Glu Thr Gly Arg Leu Tyr Glu Ile  
 355 360 365  
 Thr Ile Glu Val Phe Asp Lys Phe Ser Asn Lys Val Tyr Val Ser Asp  
 370 375 380  
 Asn Ile Arg Ile Glu Thr Val Leu Pro Ala Glu Phe Phe Glu Val Leu  
 385 390 395 400  
 Ser Ser Ser Gln Asn Gly Ser Tyr His Arg Ile Arg Ala Leu Lys Arg  
 405 410 415  
 Gly Gln Thr Ala Ile Asp Ala Ala Leu Thr Ser Val Val Asp Gln Asp  
 420 425 430  
 Gly Gly Val His Ile Leu Gln Val Pro Val Trp Asn Gln Gln Glu Val  
 435 440 445  
 Glu Ile His Ile Pro Ile Thr Leu Tyr Pro Ser Ile Leu Thr Phe Pro  
 450 455 460  
 Trp Gln Pro Lys Thr Gly Ala Tyr Gln Tyr Thr Ile Arg Ala His Gly  
 465 470 475 480  
 Gly Ser Gly Asn Phe Ser Trp Ser Ser Ser Ser His Leu Val Ala Thr  
 485 490 495  
 Val Thr Val Lys Gly Val Met Thr Thr Gly Ser Asp Ile Gly Phe Ser  
 500 505 510  
 Val Ile Gln Ala His Asp Val Gln Asn Pro Leu His Phe Gly Glu Met  
 515 520 525

Lys Val Tyr Val Ile Glu Pro His Ser Met Glu Phe Ala Pro Cys Gln  
 530 535 540  
 Val Glu Ala Arg Val Gly Gln Ala Leu Glu Leu Pro Leu Arg Ile Ser  
 545 550 555 560  
 Gly Leu Met Pro Gly Gly Ala Ser Glu Val Val Thr Leu Ser Asp Cys  
 565 570 575  
 Ser His Phe Asp Leu Ala Val Glu Val Glu Asn Gln Gly Val Phe Gln  
 580 585 590  
 Pro Leu Pro Gly Arg Leu Pro Pro Gly Ser Glu His Cys Ser Gly Val  
 595 600 605  
 Arg Val Lys Ala Glu Ala Gln Gly Ser Thr Thr Leu Leu Val Ser Tyr  
 610 615 620  
 Arg His Gly His Val His Leu Ser Ala Lys Ile Thr Ile Ala Ala Tyr  
 625 630 635 640  
 Leu Pro Leu Lys Ala Val Asp Pro Ser Ser Val Ala Leu Val Thr Leu  
 645 650 655  
 Gly Ser Ser Lys Glu Met Leu Phe Glu Gly Gly Pro Arg Pro Trp Ile  
 660 665 670  
 Leu Glu Pro Ser Lys Phe Phe Gln Asn Val Thr Ala Glu Asp Thr Asp  
 675 680 685  
 Ser Ile Gly Leu Ala Leu Phe Ala Pro His Ser Ser Arg Asn Tyr Gln  
 690 695 700  
 Gln His Trp Ile Leu Val Thr Cys Gln Ala Leu Gly Glu Gln Val Ile  
 705 710 715 720  
 Ala Leu Ser Val Gly Asn Lys Pro Ser Leu Thr Asn Pro Phe Pro Ala  
 725 730 735  
 Val Glu Pro Ala Val Val Lys Phe Val Cys Ala Pro Pro Ser Arg Leu  
 740 745 750  
 Thr Leu Val Pro Val Tyr Thr Ser Pro Gln Leu Asp Met Ser Cys Pro  
 755 760 765  
 Leu Leu Gln Gln Asn Lys Gln Val Val Pro Val Ser Ser His Arg Asn  
 770 775 780  
 Pro Leu Leu Asp Leu Ala Ala Tyr Asp Gln Glu Gly Arg Arg Phe Asp  
 785 790 795 800  
 Asn Phe Ser Ser Leu Ser Ile Gln Trp Glu Ser Thr Arg Pro Val Leu  
 805 810 815  
 Ala Ala Ser Ser Leu Ser Cys His Ala Ala Gly Val Pro Gly Arg  
 820 825 830

<210> 56  
 <211> 133  
 <212> PRT  
 <213> Homo sapiens

<400> 56  
 Met Ala Lys Phe Arg Arg Arg Thr Cys Ile Ile Leu Ala Leu Phe Ile  
 1 5 10 15  
 Leu Phe Ile Phe Ser Leu Met Met Gly Leu Lys Met Leu Arg Pro Asn  
 20 25 30  
 Thr Ala Thr Phe Gly Ala Pro Phe Gly Leu Asp Leu Leu Pro Glu Leu  
 35 40 45  
 His Gln Arg Thr Ile His Leu Gly Lys Asn Phe Asp Phe Gln Lys Ser  
 50 55 60  
 Asp Arg Ile Asn Ser Glu Thr Asn Thr Lys Asn Leu Lys Ser Val Glu  
 65 70 75 80  
 Ile Thr Met Lys Pro Ser Lys Ala Ser Glu Leu Asn Leu Asp Glu Leu  
 85 90 95  
 Pro Pro Leu Asn Asn Tyr Leu His Val Phe Tyr Tyr Ser Trp Tyr Gly  
 100 105 110  
 Asn Pro Gln Phe Asp Gly Lys Tyr Ile His Trp Asn His Pro Val Leu  
 115 120 125  
 Glu His Trp Asp Pro  
 130

<210> 57  
 <211> 123  
 <212> PRT  
 <213> Homo sapiens

<400> 57  
 Met Ala Ala Leu Val Thr Val Leu Phe Thr Gly Val Arg Arg Leu His  
 1 5 10 15  
 Cys Ser Ala Ala Ala Trp Ala Gly Gly Gln Trp Arg Leu Gln Gln Gly  
 20 25 30  
 Leu Ala Ala Asn Pro Ser Gly Tyr Gly Pro Leu Thr Glu Leu Pro Asp  
 35 40 45  
 Trp Ser Tyr Ala Asp Gly Arg Pro Ala Pro Pro Met Lys Gly Gln Leu  
 50 55 60  
 Arg Arg Lys Ala Glu Arg Glu Thr Phe Ala Arg Arg Val Val Leu Leu  
 65 70 75 80  
 Ser Gln Glu Met Asp Ala Gly Leu Gln Ala Trp Gln Leu Arg Gln Gln  
 85 90 95



38

Lys Leu Gln Glu Glu Gln Arg Lys Gln Glu Asn Ala Leu Lys Pro Lys  
 100 105 110

Gly Ala Ser Leu Lys Ser Pro Leu Pro Ser Gln  
 115 120

&lt;210&gt; 58

&lt;211&gt;

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 58

115

120

&lt;210&gt; 59

&lt;211&gt; 105

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 59

Met Leu Val Cys Met Leu Gly Cys Leu Ala Asn Leu Val Val Val Gly  
 1 5 10 15

Phe Leu Lys Glu Lys Thr Phe Pro Leu Ala Met Ala Arg Thr Arg Gly  
 20 25 30

Ser Ser Leu Ser Leu Leu Pro Thr Pro Pro Phe Pro Cys Pro Cys Pro  
 35 40 45

Asp Ala Ser Arg Leu Arg Glu Lys His Cys Ile Gln Thr Glu Gly Ser  
 50 55 60

Ala Ala Ser Phe Gln Lys Val Ile Gly Lys Ala Leu Glu Arg Arg Ala  
 65 70 75 80

Val Leu Gln Leu Ala Leu Phe Leu His His Pro Pro Ser Leu Cys Ile  
 85 90 95

Met His Leu Leu Leu Pro Pro Gly Leu  
 100 105

&lt;210&gt; 60

&lt;211&gt; 89

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 60

Met Pro Val Pro Leu Leu Ala Ser Ala Ala Trp Cys His Leu Cys Ala  
 1 5 10 15

Gly Ala Leu Pro Ala Trp Leu Trp Leu Pro Trp Arg Ala Ala Ala  
 20 25 30

Gln Trp His Val Cys Ala Ser His Cys Leu Pro Leu His Pro Ala Phe

39

35                      40                      45  
 Ser Ala Leu Gly Pro His Pro Asp Pro Gly Arg Ala Gly Pro Gly Ala  
     50                      55                      60  
 Ala Pro Arg Asp Cys Ala His Pro Glu Leu His Pro Leu Cys Leu Pro  
     65                      70                      75                      80  
 Arg Trp Ser Leu Gln Leu Leu Pro Arg  
                                  85

<210> 61  
 <211> 226  
 <212> PRT  
 <213> Homo sapiens

<400> 61  
 Met Asp Gln Ala Leu Ser Leu Trp Phe Leu Leu Gly Trp Ile Gly Gly  
     1                      5                      10                      15  
 Asp Ser Cys Asn Leu Ile Gly Ser Phe Leu Ala Asp Gln Leu Pro Leu  
                          20                      25                      30  
 Gln Thr Tyr Thr Ala Val Tyr Tyr Val Leu Ala Asp Leu Val Met Leu  
                  35                      40                      45  
 Thr Leu Tyr Phe Tyr Tyr Lys Phe Arg Thr Arg Pro Ser Leu Leu Ser  
     50                      55                      60  
 Ala Pro Ile Asn Ser Val Leu Leu Phe Leu Met Gly Met Ala Cys Ala  
     65                      70                      75                      80  
 Thr Pro Leu Leu Ser Ala Ala Gly Pro Val Ala Ala Pro Arg Glu Ala  
                          85                      90                      95  
 Phe Arg Gly Arg Ala Leu Leu Ser Val Glu Ser Gly Ser Lys Pro Phe  
                  100                      105                      110  
 Thr Arg Gln Glu Val Ile Gly Phe Val Ile Gly Ser Ile Ser Ser Val  
                  115                      120                      125  
 Leu Tyr Leu Leu Ser Arg Leu Pro Gln Ile Arg Thr Asn Phe Leu Arg  
     130                      135                      140  
 Lys Ser Thr Gln Gly Ile Ser Tyr Ser Leu Phe Ala Leu Val Met Leu  
     145                      150                      155                      160  
 Gly Asn Thr Leu Tyr Gly Leu Ser Val Leu Leu Lys Asn Pro Glu Glu  
                  165                      170                      175  
 Gly Gln Ser Glu Gly Ser Tyr Leu Leu His His Leu Pro Trp Leu Val  
                  180                      185                      190  
 Gly Ser Leu Gly Val Leu Leu Leu Asp Thr Ile Ile Ser Ile Gln Phe  
                  195                      200                      205  
 Leu Val Tyr Arg Arg Ser Thr Ala Ala Ser Glu Leu Glu Pro Leu Leu

40

210                                      215                                      220  
 Pro Ser  
 225  
  
 <210> 62  
 <211> 230  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 62  
 Met Ala Ser Leu Gly Leu Gln Leu Val Gly Tyr Ile Leu Gly Leu Leu  
   1                                  5                                  10                                  15  
 Gly Leu Leu Gly Thr Leu Val Ala Met Leu Leu Pro Ser Trp Lys Thr  
                                   20                                  25                                  30  
 Ser Ser Tyr Val Gly Ala Ser Ile Val Thr Ala Val Gly Phe Ser Lys  
                                   35                                  40                                  45  
 Gly Leu Trp Met Glu Cys Ala Thr His Ser Thr Gly Ile Thr Gln Cys  
   50                                  55                                  60  
 Asp Ile Tyr Ser Thr Leu Leu Gly Leu Pro Ala Asp Ile Gln Ala Ala  
   65                                  70                                  75                                  80  
 Gln Ala Met Met Val Thr Ser Ser Ala Ile Ser Ser Leu Ala Cys Ile  
                                   85                                  90                                  95  
 Ile Ser Val Val Gly Met Arg Cys Thr Val Phe Cys Gln Glu Ser Arg  
                                   100                                  105                                  110  
 Ala Lys Asp Arg Val Ala Val Ala Gly Gly Val Phe Phe Ile Leu Gly  
                                   115                                  120                                  125  
 Gly Leu Leu Gly Phe Ile Pro Val Ala Trp Asn Leu His Gly Ile Leu  
   130                                  135                                  140  
 Arg Asp Phe Tyr Ser Pro Leu Val Pro Asp Ser Met Lys Phe Glu Ile  
   145                                  150                                  155                                  160  
 Gly Glu Ala Leu Tyr Leu Gly Ile Ile Ser Ser Leu Phe Ser Leu Ile  
                                   165                                  170                                  175  
 Ala Gly Ile Ile Leu Cys Phe Ser Cys Ser Ser Gln Arg Asn Arg Ser  
                                   180                                  185                                  190  
 Asn Tyr Tyr Asp Ala Tyr Gln Ala Gln Pro Leu Ala Thr Arg Ser Ser  
   195                                  200                                  205  
 Pro Arg Pro Gly Gln Pro Pro Lys Val Lys Ser Glu Phe Asn Ser Tyr  
   210                                  215                                  220  
  
 Ser Leu Thr Gly Tyr Val  
 225                                  230

<210> 63  
 <211> 399  
 <212> PRT  
 <213> Homo sapiens

<400> 63

```

Met Gly Ile Leu Leu Gly Leu Leu Leu Leu Gly His Leu Thr Val Asp
 1           5           10           15

Thr Tyr Gly Arg Pro Ile Leu Glu Val Pro Glu Ser Val Thr Gly Pro
          20           25           30

Trp Lys Gly Asp Val Asn Leu Pro Cys Thr Tyr Asp Pro Leu Gln Gly
          35           40           45

Tyr Thr Gln Val Leu Val Lys Trp Leu Val Gln Arg Gly Ser Asp Pro
 50           55           60

Val Thr Ile Phe Leu Arg Asp Ser Ser Gly Asp His Ile Gln Gln Ala
 65           70           75           80

Lys Tyr Gln Gly Arg Leu His Val Ser His Lys Val Pro Gly Asp Val
          85           90           95

Ser Leu Gln Leu Ser Thr Leu Glu Met Asp Asp Arg Ser His Tyr Thr
          100          105          110

Cys Glu Val Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Val Arg Asp
          115          120          125

Lys Ile Thr Glu Leu Arg Val Gln Lys Leu Ser Val Ser Lys Pro Thr
          130          135          140

Val Thr Thr Gly Ser Gly Tyr Gly Phe Thr Val Pro Gln Gly Met Arg
          145          150          155          160

Ile Ser Leu Gln Cys Gln Ala Arg Gly Ser Pro Pro Ile Ser Tyr Ile
          165          170          175

Trp Tyr Lys Gln Gln Thr Asn Asn Gln Glu Pro Ile Lys Val Ala Thr
          180          185          190

Leu Ser Thr Leu Leu Phe Lys Pro Ala Val Ile Ala Asp Ser Gly Ser
          195          200          205

Tyr Phe Cys Thr Ala Lys Gly Gln Val Gly Ser Glu Gln His Ser Asp
          210          215          220

Ile Val Lys Phe Val Val Lys Asp Ser Ser Lys Leu Leu Lys Thr Lys
          225          230          235          240

Thr Glu Ala Pro Thr Thr Met Thr Tyr Pro Leu Lys Ala Thr Ser Thr
          245          250          255

Val Lys Gln Ser Trp Asp Trp Thr Thr Asp Met Asp Gly Tyr Leu Gly
          260          265          270

Glu Thr Ser Ala Gly Pro Gly Lys Ser Leu Pro Val Phe Ala Ile Ile

```

275                      280                      285  
 Leu Ile Ile Ser Leu Cys Cys Met Val Val Phe Thr Met Ala Tyr Ile  
     290                      295                      300  
 Met Leu Cys Arg Lys Thr Ser Gln Gln Glu His Val Tyr Glu Ala Ala  
     305                      310                      315                      320  
 Arg Ala His Ala Arg Glu Ala Asn Asp Ser Gly Glu Thr Met Arg Val  
                     325                      330                      335  
 Ala Ile Phe Ala Ser Gly Cys Ser Ser Asp Glu Pro Thr Ser Gln Asn  
                     340                      345                      350  
 Leu Gly Asn Asn Tyr Ser Asp Glu Pro Cys Ile Gly Gln Glu Tyr Gln  
                     355                      360                      365  
 Ile Ile Ala Gln Ile Asn Gly Asn Tyr Ala Arg Leu Leu Asp Thr Val  
                     370                      375                      380  
 Pro Leu Asp Tyr Glu Phe Leu Ala Thr Glu Gly Lys Ser Val Cys  
     385                      390                      395  
  
 <210> 64  
 <211> 331  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 64  
 Met Trp Leu Trp Glu Asp Gln Gly Gly Leu Leu Gly Pro Phe Ser Phe  
     1                      5                      10                      15  
 Leu Leu Leu Val Leu Leu Leu Val Thr Arg Ser Pro Val Asn Ala Cys  
                     20                      25                      30  
 Leu Leu Thr Gly Ser Leu Phe Val Leu Leu Arg Val Phe Ser Phe Glu  
                     35                      40                      45  
 Pro Val Pro Ser Cys Arg Ala Leu Gln Val Leu Lys Pro Arg Asp Arg  
                     50                      55                      60  
 Ile Ser Ala Ile Ala His Arg Gly Gly Ser His Asp Ala Pro Glu Asn  
     65                      70                      75                      80  
 Thr Leu Ala Ala Ile Arg Gln Ala Ala Lys Asn Gly Ala Thr Gly Val  
                     85                      90                      95  
 Glu Leu Asp Ile Glu Phe Thr Ser Asp Gly Ile Pro Val Leu Met His  
                     100                      105                      110  
 Asp Asn Thr Val Asp Arg Thr Thr Asp Gly Thr Gly Arg Leu Cys Asp  
                     115                      120                      125  
 Leu Thr Phe Glu Gln Ile Arg Lys Leu Asn Pro Ala Ala Asn His Arg  
                     130                      135                      140  
 Leu Arg Asn Asp Phe Pro Asp Glu Lys Ile Pro Thr Leu Arg Glu Ala

43

145                      150                      155                      160  
 Val Ala Glu Cys Leu Asn His Asn Leu Thr Ile Phe Phe Asp Val Lys  
                                  165                      170                      175  
 Gly His Ala His Lys Ala Thr Glu Ala Leu Lys Lys Met Tyr Met Glu  
                                  180                      185                      190  
 Phe Pro Gln Leu Tyr Asn Asn Ser Val Val Cys Ser Phe Leu Pro Glu  
                                  195                      200                      205  
 Val Ile Tyr Lys Met Arg Gln Thr Asp Arg Asp Val Ile Thr Ala Leu  
                                  210                      215                      220  
 Thr His Arg Pro Trp Ser Leu Ser His Thr Gly Asp Gly Lys Pro Arg  
 225                                   230                      235                      240  
 Tyr Asp Thr Phe Trp Lys His Phe Ile Phe Val Met Met Asp Ile Leu  
                                  245                      250                      255  
 Leu Asp Trp Ser Met His Asn Ile Leu Trp Tyr Leu Cys Gly Ile Ser  
                                  260                      265                      270  
 Ala Phe Leu Met Gln Lys Asp Phe Val Ser Pro Ala Tyr Leu Lys Lys  
                                  275                      280                      285  
 Trp Ser Ala Lys Gly Ile Gln Val Val Gly Trp Thr Val Asn Thr Phe  
                                  290                      295                      300  
 Asp Glu Lys Ser Tyr Tyr Glu Ser His Leu Gly Ser Ser Tyr Ile Thr  
 305                                   310                      315                      320  
 Asp Ser Met Val Glu Asp Cys Glu Pro His Phe  
                                  325                      330

&lt;210&gt; 65

&lt;211&gt; 470

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 65

Met Ser Arg Leu Gly Ala Leu Gly Gly Ala Arg Ala Gly Leu Gly Leu  
   1                      5                      10                      15  
 Leu Leu Gly Thr Ala Ala Gly Leu Gly Phe Leu Cys Leu Leu Tyr Ser  
                                  20                      25                      30  
 Gln Arg Trp Lys Arg Thr Gln Arg His Gly Arg Ser Gln Ser Leu Pro  
                                  35                      40                      45  
 Asn Ser Leu Asp Tyr Thr Gln Thr Ser Asp Pro Gly Arg His Val Met  
                                  50                      55                      60  
 Leu Leu Arg Ala Val Pro Gly Gly Ala Gly Asp Ala Ser Val Leu Pro  
   65                      70                      75                      80  
 Ser Leu Pro Arg Glu Gly Gln Glu Lys Val Leu Asp Arg Leu Asp Phe

95

Val	Leu	Thr	Ser	Leu	Val	Ala	Leu	Arg	Arg	Glu	Val	Glu	Leu	Arg
			100					105					110	
Ser	Ser	Leu	Arg	Gly	Leu	Ala	Gly	Glu	Ile	Val	Gly	Glu	Val	Arg
		115					120					125		Cys
His	Met	Glu	Glu	Asn	Gln	Arg	Val	Ala	Arg	Arg	Arg	Arg	Phe	Pro
	130					135					140		Phe	Phe
Val	Arg	Glu	Arg	Ser	Asp	Ser	Thr	Gly	Ser	Ser	Ser	Val	Tyr	Phe
145					150					155				160
Ala	Ser	Ser	Gly	Ala	Thr	Phe	Thr	Asp	Ala	Glu	Ser	Glu	Gly	Gly
				165					170					175
Thr	Thr	Ala	Asn	Ala	Glu	Ser	Asp	Asn	Glu	Arg	Asp	Ser	Asp	Lys
			180					185					190	Glu
Ser	Glu	Asp	Gly	Glu	Asp	Glu	Val	Ser	Cys	Glu	Thr	Val	Lys	Met
		195					200					205		Gly
Arg	Lys	Asp	Ser	Leu	Asp	Leu	Glu	Glu	Glu	Ala	Ala	Ser	Gly	Ala
	210					215					220			Ser
Ser	Ala	Leu	Glu	Ala	Gly	Gly	Ser	Ser	Gly	Leu	Glu	Asp	Val	Leu
225					230					235				240
Leu	Leu	Gln	Gln	Ala	Asp	Glu	Leu	His	Arg	Gly	Asp	Glu	Gln	Gly
				245					250					255
Arg	Glu	Gly	Phe	Gln	Leu	Leu	Leu	Asn	Asn	Lys	Leu	Val	Tyr	Gly
			260					265					270	Ser
Arg	Gln	Asp	Phe	Leu	Trp	Arg	Leu	Ala	Arg	Ala	Tyr	Ser	Asp	Met
		275					280					285		Cys
Glu	Leu	Thr	Glu	Glu	Val	Ser	Glu	Lys	Lys	Ser	Tyr	Ala	Leu	Asp
		290				295					300			Gly
Lys	Glu	Glu	Ala	Glu	Ala	Ala	Leu	Glu	Lys	Gly	Asp	Glu	Ser	Ala
305					310					315				320
Cys	His	Leu	Trp	Tyr	Ala	Val	Leu	Cys	Gly	Gln	Leu	Ala	Glu	His
				325					330					335
Ser	Ile	Gln	Arg	Arg	Ile	Gln	Ser	Gly	Phe	Ser	Phe	Lys	Glu	His
			340					345					350	Val
Asp	Lys	Ala	Ile	Ala	Leu	Gln	Pro	Glu	Asn	Pro	Met	Ala	His	Phe
		355					360					365		Leu
Leu	Gly	Arg	Trp	Cys	Tyr	Gln	Val	Ser	His	Leu	Ser	Trp	Leu	Glu
		370				375					380			Lys
Lys	Thr	Ala	Thr	Ala	Leu	Leu	Glu	Ser	Pro	Leu	Ser	Ala	Thr	Val
385					390					395				400

45

Asp Ala Leu Gln Ser Phe Leu Lys Ala Glu Glu Leu Gln Pro Gly Phe  
                             405                            410                            415  
 Ser Lys Ala Gly Arg Val Tyr Ile Ser Lys Cys Tyr Arg Glu Leu Gly  
                             420                            425                            430  
 Lys Asn Ser Glu Ala Arg Trp Trp Met Lys Leu Ala Leu Glu Leu Pro  
                             435                            440                            445  
 Asp Val Thr Lys Glu Asp Leu Ala Ile Gln Lys Asp Leu Glu Glu Leu  
                             450                            455                            460  
 Glu Val Ile Leu Arg Asp  
 465                            470

<210> 66  
 <211> 184  
 <212> PRT  
 <213> Homo sapiens

<400> 66  
 Met Lys Ile Leu Val Ala Phe Leu Val Val Leu Thr Ile Phe Gly Ile  
   1                            5                            10                            15  
 Gln Ser His Gly Tyr Glu Val Phe Asn Ile Ile Ser Pro Ser Asn Asn  
                             20                            25                            30  
 Gly Gly Asn Val Gln Glu Thr Val Thr Ile Asp Asn Glu Lys Asn Thr  
                             35                            40                            45  
 Ala Ile Ile Asn Ile His Ala Gly Ser Cys Ser Ser Thr Thr Ile Phe  
                             50                            55                            60  
 Asp Tyr Lys His Gly Tyr Ile Ala Ser Arg Val Leu Ser Arg Arg Ala  
   65                            70                            75                            80  
 Cys Phe Ile Leu Lys Met Asp His Gln Asn Ile Pro Pro Leu Asn Asn  
                             85                            90                            95  
 Leu Gln Trp Tyr Ile Tyr Glu Lys Gln Ala Leu Asp Asn Met Phe Ser  
                             100                            105                            110  
 Ser Lys Tyr Thr Trp Val Lys Tyr Asn Pro Leu Glu Ser Leu Ile Lys  
                             115                            120                            125  
 Asp Val Asp Trp Phe Leu Leu Gly Ser Pro Ile Glu Lys Leu Cys Lys  
                             130                            135                            140  
 His Ile Pro Leu Tyr Lys Gly Glu Val Val Glu Asn Thr His Asn Val  
   145                            150                            155                            160  
 Gly Ala Gly Gly Cys Ala Lys Ala Gly Leu Leu Gly Ile Leu Gly Ile  
                             165                            170                            175  
 Ser Ile Cys Ala Asp Ile His Val  
                             180



<210> 67  
 <211> 120  
 <212> PRT  
 <213> Homo sapiens

<400> 67  
 Glu Val Leu Phe Ser Asn Asp Ser Val Leu Gly His Phe Pro His Gln  
           1                          5                          10                          15  
 Ser Pro Asn Glu Arg Ala Arg Leu Tyr Phe Leu Leu Ala Trp Phe His  
                           20                          25                          30  
 Ala Ile Ile Gln Glu Arg Leu Arg Tyr Ala Pro Leu Gly Trp Ser Lys  
                           35                          40                          45  
 Lys Tyr Glu Phe Gly Glu Ser Asp Leu Arg Ser Ala Cys Asp Thr Val  
           50                          55                          60  
 Asp Thr Trp Leu Asp Asp Thr Ala Lys Ala Ser Val Gly His Ala Arg  
           65                          70                          75                          80  
 Thr Asp Ser Gly Arg Val Ser Gly Lys Asp Ala Ala Gly Arg Gly Ala  
                           85                          90                          95  
 Glu Arg Pro Asp Ser Ala Trp Lys Ser Glu Leu Thr Pro Arg Asp Arg  
                           100                          105                          110  
 Gln Ser Leu Ala Gly His Gly Glu  
           115                          120

<210> 68  
 <211> 133  
 <212> PRT  
 <213> Homo sapiens

<400> 68  
 Met Phe Leu Glu Leu Ser Gln Ala Leu Leu Leu Gly Leu Pro Arg  
           1                          5                          10                          15  
 Ala Pro Thr Leu Phe Pro Ala Leu Pro Glu Gly Pro Thr Ser Leu Gly  
                           20                          25                          30  
 Glu Gln Trp Pro Pro Gln Leu Pro Pro His Leu Gly Ala Pro Pro Ala  
           35                          40                          45  
 Ala Glu Gly Ala Val Ala Met Val Gly Cys Gly Glu Gly Arg Gly Gly  
           50                          55                          60  
 Lys Pro Leu Cys Cys Ser Pro Ala Gln Ser Pro Ala Gln Arg Val Arg  
           65                          70                          75                          80  
 Ser Gly Gly Asp Lys Glu Pro Ile Thr Thr Thr Glu Val Ser Leu Ile  
                           85                          90                          95  
 Leu Leu His Ser Arg Cys Phe Asn Leu Thr Lys Leu Lys Lys Thr Ala

47

100 105 110  
 Phe Ala Met Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
 115 120 125  
 Lys Lys Lys Lys Lys  
 130

<210> 69  
 <211> 37  
 <212> PRT  
 <213> Homo sapiens

<400> 69  
 Met Pro Asp Lys Arg Glu Ala Thr Ala Ala Ala Val Ala Leu Phe Ile  
 1 5 10 15  
 Val Pro Leu Gly Val Trp Met Arg Gly Ser Arg Gly Tyr Ser Ala Ala  
 20 25 30  
 His Glu Gly Ser Leu  
 35

<210> 70  
 <211> 77  
 <212> PRT  
 <213> Homo sapiens

<400> 70  
 Met Thr Ile Phe Thr Pro Phe Leu Val Leu Leu Leu Val Asn Ser  
 1 5 10 15  
 Pro Arg Phe Ser Thr Ile Thr Leu Met Arg Ser Gly Phe His Asn Pro  
 20 25 30  
 Ser Val Cys Leu Ser Phe Thr Leu Lys Pro Gln Cys Tyr Leu Val Leu  
 35 40 45  
 Met Tyr Gln Lys Asn Arg Arg Gln Asp Gly Ser Lys Val Phe Phe Lys  
 50 55 60  
 Thr Ala Arg Leu Lys Phe Tyr Leu Asn Ile Thr Ala Lys  
 65 70 75

<210> 71  
 <211> 103  
 <212> PRT  
 <213> Homo sapiens

<400> 71  
 Met Met Cys Val Val Leu Thr Thr Leu Pro Cys Leu Thr Phe Ser Ile  
 1 5 10 15  
 Ala Val Thr Glu Val Gln Lys Ser Ile Asn Gly Ser Ala Asp Val Leu  
 20 25 30

48

Pro Asp Met Leu Pro Asp Leu Pro Val Ser Leu Val Leu Leu Ser Leu  
           35                          40                          45

Ile Met Val Asp Ile Ile Glu Lys Leu Arg Ile Tyr Pro Leu Arg Gly  
           50                          55                          60

Ser Gln Lys Ser Ser Glu Asn Gly His Ile His Ser Thr Ser Leu Gln  
       65                          70                          75                          80

His Ile Lys Thr Val Thr Glu Gln Val Arg Gln Ser Pro Glu Asn Ala  
                           85                          90                          95

Ala Ser Pro Gln Ala Thr Asn  
                           100

&lt;210&gt; 72

&lt;211&gt; 173

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 72

Met Ala Val Arg Ala Leu Lys Leu Leu Thr Thr Leu Leu Ala Val Val  
   1                          5                          10                          15

Ala Ala Ala Ser Gln Ala Glu Val Glu Ser Glu Ala Gly Trp Gly Met  
           20                          25                          30

Val Thr Pro Asp Leu Leu Phe Ala Glu Gly Thr Ala Ala Tyr Ala Arg  
           35                          40                          45

Gly Asp Trp Pro Gly Val Val Leu Ser Met Glu Arg Ala Leu Arg Ser  
       50                          55                          60

Arg Ala Ala Leu Arg Ala Leu Arg Leu Arg Cys Arg Thr Gln Cys Ala  
       65                          70                          75                          80

Ala Asp Phe Pro Trp Glu Leu Asp Pro Asp Trp Ser Pro Ser Pro Ala  
           85                          90                          95

Gln Ala Ser Gly Ala Ala Ala Leu Arg Asp Leu Ser Phe Phe Gly Gly  
           100                          105                          110

Leu Leu Arg Arg Ala Ala Cys Leu Arg Arg Cys Leu Gly Pro Pro Ala  
       115                          120                          125

Ala Thr Arg Ser Ala Lys Arg Trp Ser Trp Ser Ser Ala Ser Gly Pro  
       130                          135                          140

Leu Gln Leu Pro Ala Gly Arg Leu Leu Gln Asp Gln Gln Val Gly Glu  
       145                          150                          155                          160

Ser Cys Cys Cys Ser Thr His Leu Leu Arg Gly Gln Ser  
           165                          170

&lt;210&gt; 73

<211> 886  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (26)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (216)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (234)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (275)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (871)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 73  
 Met Ala Ala Arg Gly Arg Gly Leu Leu Leu Leu Thr Leu Ser Val Leu  
     1                    5                    10                    15  
 Leu Ala Ala Gly Pro Ser Ala Ala Ala Xaa Lys Leu Asn Ile Pro Lys  
                     20                    25                    30  
 Val Leu Leu Pro Phe Thr Arg Ala Thr Arg Val Asn Phe Thr Leu Glu  
                     35                    40                    45  
 Ala Ser Glu Gly Cys Tyr Arg Trp Leu Ser Thr Arg Pro Glu Val Ala  
                     50                    55                    60  
 Ser Ile Glu Pro Leu Gly Leu Asp Glu Gln Gln Cys Ser Gln Lys Ala  
                     65                    70                    75                    80  
 Val Val Gln Ala Arg Leu Thr Gln Pro Ala Arg Leu Thr Ser Ile Ile  
                     85                    90                    95  
 Phe Ala Glu Asp Ile Thr Thr Gly Gln Val Leu Arg Cys Asp Ala Ile  
                     100                    105                    110  
 Val Asp Leu Ile His Asp Ile Gln Ile Val Ser Thr Thr Arg Glu Leu  
                     115                    120                    125  
 Tyr Leu Glu Asp Ser Pro Leu Glu Leu Lys Ile Gln Ala Leu Asp Ser  
                     130                    135                    140  
 Glu Gly Asn Thr Phe Ser Thr Leu Ala Gly Leu Val Phe Glu Trp Thr

50

145		150		155		160
Ile Val Lys Asp Ser Glu Ala Asp Arg Phe Ser Asp Ser His Asn Ala						
	165			170		175
Leu Arg Ile Leu Thr Phe Leu Glu Ser Thr Tyr Ile Pro Pro Ser Tyr						
	180		185			190
Ile Ser Glu Met Glu Lys Ala Ala Lys Gln Gly Asp Thr Ile Leu Val						
	195		200			205
Ser Gly Met Lys Thr Gly Ser Xaa Lys Leu Lys Ala Arg Ile Gln Glu						
	210		215			220
Ala Val Tyr Lys Asn Val Arg Pro Ala Xaa Val Arg Leu Leu Ile Leu						
	225		230			235
Glu Asn Ile Leu Leu Asn Pro Ala Tyr Asp Val Tyr Leu Met Val Gly						
		245		250		255
Thr Ser Ile His Tyr Lys Val Gln Lys Ile Arg Gln Gly Lys Ile Thr						
	260		265			270
Glu Leu Xaa Met Pro Ser Asp Gln Tyr Glu Leu Gln Leu Gln Asn Ser						
	275		280			285
Ile Pro Gly Pro Glu Gly Asp Pro Thr Arg Pro Val Ala Val Leu Ala						
	290		295			300
Gln Asp Thr Ser Met Val Thr Ala Leu Gln Leu Gly Gln Ser Ser Leu						
	305		310			315
Val Leu Gly His Arg Ser Ile Arg Met Gln Gly Ala Ser Arg Leu Pro						
		325		330		335
Asn Ser Thr Ile Tyr Val Val Glu Pro Gly Tyr Leu Gly Phe Thr Val						
	340		345			350
His Pro Gly Asp Arg Trp Val Leu Glu Thr Gly Arg Leu Tyr Glu Ile						
	355		360			365
Thr Ile Glu Val Phe Asp Lys Phe Ser Asn Lys Val Tyr Val Ser Asp						
	370		375			380
Asn Ile Arg Ile Glu Thr Val Leu Pro Ala Glu Phe Phe Glu Val Leu						
	385		390			395
Ser Ser Ser Gln Asn Gly Ser Tyr His Arg Ile Arg Ala Leu Lys Arg						
		405		410		415
Gly Gln Thr Ala Ile Asp Ala Ala Leu Thr Ser Val Val Asp Gln Asp						
	420		425			430
Gly Gly Val His Ile Leu Gln Val Pro Val Trp Asn Gln Gln Glu Val						
	435		440			445
Glu Ile His Ile Pro Ile Thr Leu Tyr Pro Ser Ile Leu Thr Phe Pro						
	450		455			460

Trp Gln Pro Lys Thr Gly Ala Tyr Gln Tyr Thr Ile Arg Ala His Gly  
 465 470 475 480  
 Gly Ser Gly Asn Phe Ser Trp Ser Ser Ser Ser His Leu Val Ala Thr  
 485 490 495  
 Val Thr Val Lys Gly Val Met Thr Thr Gly Ser Asp Ile Gly Phe Ser  
 500 505 510  
 Val Ile Gln Ala His Asp Val Gln Asn Pro Leu His Phe Gly Glu Met  
 515 520 525  
 Lys Val Tyr Val Ile Glu Pro His Ser Met Glu Phe Ala Pro Cys Gln  
 530 535 540  
 Val Glu Ala Arg Val Gly Gln Ala Leu Glu Leu Pro Leu Arg Ile Ser  
 545 550 555 560  
 Gly Leu Met Pro Gly Gly Ala Ser Glu Val Val Thr Leu Ser Asp Cys  
 565 570 575  
 Ser His Phe Asp Leu Ala Val Glu Val Glu Asn Gln Gly Val Phe Gln  
 580 585 590  
 Pro Leu Pro Gly Arg Leu Pro Pro Gly Ser Glu His Cys Ser Gly Val  
 595 600 605  
 Arg Val Lys Ala Glu Ala Gln Gly Ser Thr Thr Leu Leu Val Ser Tyr  
 610 615 620  
 Arg His Gly His Val His Leu Ser Ala Lys Ile Thr Ile Ala Ala Tyr  
 625 630 635 640  
 Leu Pro Leu Lys Ala Val Asp Pro Ser Ser Val Ala Leu Val Thr Leu  
 645 650 655  
 Gly Ser Ser Lys Glu Met Leu Phe Glu Gly Gly Pro Arg Pro Trp Ile  
 660 665 670  
 Leu Glu Pro Ser Lys Phe Phe Gln Asn Val Thr Ala Glu Asp Thr Asp  
 675 680 685  
 Ser Ile Gly Leu Ala Leu Phe Ala Pro His Ser Ser Arg Asn Tyr Gln  
 690 695 700  
 Gln His Trp Ile Leu Val Thr Cys Gln Ala Leu Gly Glu Gln Val Ile  
 705 710 715 720  
 Ala Leu Ser Val Gly Asn Lys Pro Ser Leu Thr Asn Pro Phe Pro Ala  
 725 730 735  
 Val Glu Pro Ala Val Val Lys Phe Val Cys Ala Pro Pro Ser Arg Leu  
 740 745 750  
 Thr Leu Val Pro Val Tyr Thr Ser Pro Gln Leu Asp Met Ser Cys Pro  
 755 760 765

52

Leu Leu Gln Gln Asn Lys Gln Val Val Pro Val Ser Ser His Arg Asn  
 770 775 780  
 Pro Leu Leu Asp Leu Ala Ala Tyr Asp Gln Glu Gly Arg Arg Phe Asp  
 785 790 795 800  
 Asn Phe Ser Ser Leu Ser Ile Gln Trp Glu Ser Thr Arg Pro Val Leu  
 805 810 815  
 Ala Ser Ile Glu Pro Glu Leu Pro Met Gln Leu Val Ser Gln Asp Asp  
 820 825 830  
 Glu Ser Gly Gln Lys Lys Leu His Gly Leu Gln Ala Ile Leu Val His  
 835 840 845  
 Glu Ala Ser Gly Thr Thr Ala Ser Leu Pro Leu Pro Leu Ala Thr Arg  
 850 855 860  
 Ser Pro Thr Ser Ala Leu Xaa Glu Gln Ser Ser Arg Met Thr Leu Trp  
 865 870 875 880  
 Cys Leu Cys Arg Pro Pro  
 885

&lt;210&gt; 74

&lt;211&gt; 209

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (15)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (18)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (128)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (147)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (152)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 74

Met Ala Lys Phe Arg Arg Arg Thr Cys Ile Ile Leu Ala Leu Xaa Ile  
 1 5 10 15

Leu Xaa Ile Phe Ser Leu Met Met Gly Leu Lys Met Leu Arg Pro Asn  
                   20                                  25                                  30  
 Thr Ala Thr Phe Gly Ala Pro Phe Gly Leu Asp Leu Leu Pro Glu Leu  
                   35                                  40                                  45  
 His Gln Arg Thr Ile His Leu Gly Lys Asn Phe Asp Phe Gln Lys Ser  
                   50                                  55                                  60  
 Asp Arg Ile Asn Ser Glu Thr Asn Thr Lys Asn Leu Lys Ser Val Glu  
                   65                                  70                                  75                                  80  
 Ile Thr Met Lys Pro Ser Lys Ala Ser Glu Leu Asn Leu Asp Glu Leu  
                                   85                                  90                                  95  
 Pro Pro Leu Asn Asn Tyr Leu His Val Phe Tyr Tyr Ser Trp Tyr Gly  
                                   100                                  105                                  110  
 Asn Pro Gln Phe Asp Gly Lys Tyr Ile His Trp Asn His Pro Val Xaa  
                   115                                  120                                  125  
 Glu His Trp Asp Pro Arg Ile Ala Lys Asn Tyr Pro Gln Gly Arg His  
                   130                                  135                                  140  
 Asn Pro Xaa Asp Asp Ile Gly Xaa Ser Phe Tyr Pro Glu Leu Gly Ser  
                   145                                  150                                  155                                  160  
 Tyr Ser Ser Arg Asp Pro Ser Val Ile Glu Thr His Met Arg Gln Met  
                                   165                                  170                                  175  
 Arg Ser Ala Ser Ile Gly Asn Tyr Cys Ile Tyr Ile Tyr Met Cys Val  
                                   180                                  185                                  190  
 Phe Val Ser Val Tyr Met His Ile Asn Asp Phe Leu Cys Asn Phe Asn  
                   195                                  200                                  205  
 Ser

&lt;210&gt; 75

&lt;211&gt; 81

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 75

Tyr Phe Asp Ile Ser Lys His Leu His Gly Asn His Tyr Ile Asp Pro  
                   1                                  5                                  10                                  15  
 Thr Cys Gly Phe Ser Ser Tyr Val His Leu Thr Arg Ile Tyr Tyr Phe  
                                   20                                  25                                  30  
 Arg Tyr Asn Leu Gln Met Ser His Leu Ile Ile Phe Tyr Asn Ile Pro  
                   35                                  40                                  45  
 Tyr Phe Ile Lys Val Leu Leu Glu Lys Tyr Leu Pro Gln Arg Ser Phe  
                   50                                  55                                  60



Cys His Cys Val Arg Cys Val Phe Glu Pro Thr Met Thr Glu Ser Lys  
 65 70 75 80

Phe

<210> 76

<211> 123

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (5)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 76

Met Ala Ala Leu Xaa Thr Val Leu Phe Thr Gly Val Arg Arg Leu His  
 1 5 10 15

Cys Ser Ala Ala Ala Trp Ala Gly Gly Gln Trp Arg Leu Gln Gln Gly  
 20 25 30

Leu Ala Ala Asn Pro Ser Gly Tyr Gly Pro Leu Thr Glu Leu Pro Asp  
 35 40 45

Trp Ser Tyr Ala Asp Gly Arg Pro Ala Pro Pro Met Lys Gly Gln Leu  
 50 55 60

Arg Arg Lys Ala Glu Arg Glu Thr Phe Ala Arg Arg Val Val Leu Leu  
 65 70 75 80

Ser Gln Glu Met Asp Ala Gly Leu Gln Ala Trp Gln Leu Arg Gln Gln  
 85 90 95

Lys Leu Gln Glu Glu Gln Arg Lys Gln Glu Asn Ala Leu Lys Pro Lys  
 100 105 110

Gly Ala Ser Leu Lys Ser Pro Leu Pro Ser Gln  
 115 120

<210> 77

<211> 492

<212> PRT

<213> Homo sapiens

<400> 77

Met Gly Ser Ala Pro Trp Ala Pro Val Leu Leu Leu Ala Leu Gly Leu  
 1 5 10 15

Arg Gly Leu Gln Ala Gly Ala Arg Arg Ala Pro Asp Pro Gly Phe Gln  
 20 25 30

Glu Arg Phe Phe Gln Gln Arg Leu Asp His Phe Asn Phe Glu Arg Phe  
 35 40 45

Gly Asn Lys Thr Phe Pro Gln Arg Phe Leu Val Ser Asp Arg Phe Trp  
 50 55 60  
 Val Arg Gly Glu Gly Pro Ile Phe Phe Tyr Thr Gly Asn Glu Gly Asp  
 65 70 75 80  
 Val Trp Ala Phe Ala Asn Asn Ser Ala Phe Val Ala Glu Leu Ala Ala  
 85 90 95  
 Glu Arg Gly Ala Leu Leu Val Phe Ala Glu His Arg Tyr Tyr Gly Lys  
 100 105 110  
 Ser Leu Pro Phe Gly Ala Gln Ser Thr Gln Arg Gly His Thr Glu Leu  
 115 120 125  
 Leu Thr Val Glu Gln Ala Leu Ala Asp Phe Ala Glu Leu Leu Arg Ala  
 130 135 140  
 Leu Arg Arg Asp Leu Gly Ala Gln Asp Ala Pro Ala Ile Ala Phe Gly  
 145 150 155 160  
 Gly Ser Tyr Gly Gly Met Leu Ser Ala Tyr Leu Arg Met Lys Tyr Pro  
 165 170 175  
 His Leu Val Ala Gly Ala Leu Ala Ala Ser Ala Pro Val Leu Ala Val  
 180 185 190  
 Ala Gly Leu Gly Asp Ser Asn Gln Phe Phe Arg Asp Val Thr Ala Asp  
 195 200 205  
 Phe Glu Gly Gln Ser Pro Lys Cys Thr Gln Gly Val Arg Glu Ala Phe  
 210 215 220  
 Arg Gln Ile Lys Asp Leu Phe Leu Gln Gly Ala Tyr Asp Thr Val Arg  
 225 230 235 240  
 Trp Glu Phe Gly Thr Cys Gln Pro Leu Ser Asp Glu Lys Asp Leu Thr  
 245 250 255  
 Gln Leu Phe Met Phe Ala Arg Asn Ala Phe Thr Val Leu Ala Met Met  
 260 265 270  
 Asp Tyr Pro Tyr Pro Thr Asp Phe Leu Gly Pro Leu Pro Ala Asn Pro  
 275 280 285  
 Val Lys Val Gly Cys Asp Arg Leu Leu Ser Glu Ala Gln Arg Ile Thr  
 290 295 300  
 Gly Leu Arg Ala Leu Ala Gly Leu Val Tyr Asn Ala Ser Gly Ser Glu  
 305 310 315 320  
 His Cys Tyr Asp Ile Tyr Arg Leu Tyr His Ser Cys Ala Asp Pro Thr  
 325 330 335  
 Gly Cys Gly Thr Gly Pro Asp Ala Arg Ala Trp Asp Tyr Gln Ala Cys  
 340 345 350

56

Thr Glu Ile Asn Leu Thr Phe Ala Ser Asn Asn Val Thr Asp Met Phe  
 355 360 365  
 Pro Asp Leu Pro Phe Thr Asp Glu Leu Arg Gln Arg Tyr Cys Leu Asp  
 370 375 380  
 Thr Trp Gly Val Trp Pro Arg Pro Asp Trp Leu Leu Thr Ser Phe Trp  
 385 390 395 400  
 Gly Gly Asp Leu Arg Ala Ala Ser Asn Ile Ile Phe Ser Asn Gly Asn  
 405 410 415  
 Leu Asp Pro Trp Ala Gly Gly Gly Ile Arg Arg Asn Leu Ser Ala Ser  
 420 425 430  
 Val Ile Ala Val Thr Ile Gln Gly Gly Ala His His Leu Asp Leu Arg  
 435 440 445  
 Ala Ser His Pro Glu Asp Pro Ala Ser Val Val Glu Ala Arg Lys Leu  
 450 455 460  
 Glu Ala Thr Ile Ile Gly Glu Trp Val Lys Ala Ala Arg Arg Glu Gln  
 465 470 475 480  
 Gln Pro Ala Leu Arg Gly Gly Pro Arg Leu Ser Leu  
 485 490

&lt;210&gt; 78

&lt;211&gt; 128

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 78

Met Gly Ser Ala Pro Trp Ala Pro Val Leu Leu Leu Ala Leu Gly Leu  
 1 5 10 15  
 Arg Gly Leu Gln Ala Gly Ala Arg Arg Ala Pro Asp Pro Gly Phe Gln  
 20 25 30  
 Glu Arg Phe Phe Gln Gln Arg Leu Asp His Phe Asn Phe Glu Arg Phe  
 35 40 45  
 Gly Asn Lys Thr Phe Pro Gln Arg Phe Leu Val Ser Asp Arg Phe Trp  
 50 55 60  
 Val Arg Gly Glu Gly Pro Ile Phe Phe Tyr Thr Gly Asn Glu Gly Asp  
 65 70 75 80  
 Val Trp Ala Phe Ala Asn Asn Ser Ala Phe Val Ala Glu Leu Ala Ala  
 85 90 95  
 Glu Arg Gly Ala Leu Leu Val Phe Ala Glu His Arg Tyr Tyr Gly Lys  
 100 105 110  
 Ser Leu Pro Phe Gly Ala Gln Ser Thr Gln Arg Gly Thr Arg Ser Cys  
 115 120 125

<210> 79  
 <211> 105  
 <212> PRT  
 <213> Homo sapiens

<400> 79  
 Met Leu Val Cys Met Leu Gly Cys Leu Ala Asn Leu Val Val Val Gly  
   1                  5                  10                  15  
 Phe Leu Lys Glu Lys Thr Phe Pro Leu Ala Met Ala Arg Thr Arg Gly  
                   20                  25                  30  
 Ser Ser Leu Ser Leu Leu Pro Thr Pro Pro Phe Pro Cys Pro Cys Pro  
           35                  40                  45  
 Asp Ala Ser Arg Leu Arg Glu Lys His Cys Ile Gln Thr Glu Gly Ser  
   50                  55                  60  
 Ala Ala Ser Phe Gln Lys Val Ile Gly Lys Ala Leu Glu Arg Arg Ala  
   65                  70                  75                  80  
 Val Leu Gln Leu Ala Leu Phe Leu His His Pro Pro Ser Leu Cys Ile  
                   85                  90                  95  
 Met His Leu Leu Leu Pro Pro Gly Leu  
           100                  105

<210> 80  
 <211> 89  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (39)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (65)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 80  
 Met Pro Val Pro Leu Leu Ala Ser Ala Ala Trp Cys His Leu Cys Ala  
   1                  5                  10                  15  
 Gly Ala Leu Pro Ala Trp Leu Trp Leu Pro Gly Gly Gln Leu Leu His  
           20                  25                  30  
 Asn Gly Thr Cys Val Pro Xaa Thr Ala Cys Pro Cys Thr Gln His Ser  
           35                  40                  45  
 Leu Pro Trp Gly Leu Thr Leu Thr Leu Glu Glu Gln Ala Gln Glu Leu

58

50                      55                      60  
Xaa Pro Gly Thr Val Leu Thr Arg Asn Cys Thr Pro Leu Cys Leu Pro  
65                      70                      75                      80  
Leu Trp Ser Leu Gln Leu Leu Pro Arg  
85

<210> 81  
<211> 79  
<212> PRT  
<213> Homo sapiens

<400> 81  
Ser Gly Trp Gln Val Pro Ser Ser Val Lys His Leu Pro Tyr Asp Asn  
1                      5                      10                      15  
Leu Arg Ser His Cys Val Ala Asp Glu Gly Glu Thr Glu Val Glu Gly  
20                      25                      30  
Thr Arg Ala Thr Trp Val Glu His Ser Gly Arg Pro Gly Val Gly Ser  
35                      40                      45  
Gly Arg Pro Pro Gly Thr Ser Leu Thr Thr Leu Pro Leu Leu Leu Thr  
50                      55                      60  
His Leu Ser Leu Thr Cys Pro Leu Gly Gly Asp Phe Ser Lys Arg  
65                      70                      75

<210> 82  
<211> 334  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (124)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (129)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (214)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (224)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 82  
Met Asp Gln Ala Leu Ser Leu Trp Phe Leu Leu Gly Trp Ile Gly Gly

59

1	5	10	15
Asp Ser Cys Asn Leu Ile Gly Ser Phe Leu Ala Asp Gln Leu Pro Leu	20	25	30
Gln Thr Tyr Thr Ala Val Tyr Tyr Val Leu Ala Asp Leu Val Met Leu	35	40	45
Thr Leu Tyr Phe Tyr Tyr Lys Phe Arg Thr Arg Pro Ser Leu Leu Ser	50	55	60
Ala Pro Ile Asn Ser Val Leu Leu Phe Leu Met Gly Met Ala Cys Ala	65	70	75
Thr Pro Leu Leu Ser Ala Ala Gly Pro Val Ala Ala Pro Arg Glu Ala	85	90	95
Phe Arg Gly Arg Ala Leu Leu Ser Val Glu Ser Gly Ser Lys Pro Phe	100	105	110
Thr Arg Gln Glu Val Ile Gly Phe Val Ile Gly Xaa Ile Ser Ser Val	115	120	125
Xaa Tyr Leu Leu Ser Arg Leu Pro Gln Ile Arg Thr Asn Phe Leu Arg	130	135	140
Lys Ser Thr Gln Gly Ile Ser Tyr Ser Leu Phe Ala Leu Val Met Leu	145	150	155
Gly Asn Thr Leu Tyr Gly Leu Ser Val Leu Leu Lys Asn Pro Glu Glu	165	170	175
Gly Gln Ser Glu Gly Ser Tyr Leu Leu His His Leu Pro Trp Leu Val	180	185	190
Gly Ser Leu Gly Val Leu Leu Leu Asp Thr Ile Ile Ser Ile Gln Phe	195	200	205
Leu Val Tyr Arg Arg Xaa Pro Pro Pro Arg Ser Leu Ser Pro Ser Xaa	210	215	220
Pro Ala Asp Gln Asn Gln Ala Glu Arg Arg Arg Thr Gly Thr Thr Gly	225	230	235
Cys His Thr Arg Gln Glu Glu Val Trp Thr Val Met Val Arg Arg Pro	245	250	255
Cys Ile Ser Leu Arg Val Ala Ser Gly Ser Ser Val Asp Arg Thr Val	260	265	270
Pro Pro Gly Thr His Leu Gln Val Asp Pro Glu Ala Ser Arg Pro Gly	275	280	285
Leu Glu Arg Arg Pro Gln Gly Leu Ser Gly Asp Ser Glu Ala Ala Pro	290	295	300
Pro Thr Thr Tyr Leu Ile Leu Pro Thr Gln Asp Cys Pro Val Asn Ser	305	310	315
			320

60

Arg Gln Leu Asn Lys Gln Ala Gly Tyr Ser Gly Ser His Leu  
                   325                  330

&lt;210&gt; 83

&lt;211&gt; 140

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (136)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 83

Met Ala Ser Leu Gly Leu Gln Leu Val Gly Tyr Ile Leu Gly Leu Leu  
   1                  5                  10                  15

Gly Leu Leu Gly Thr Leu Val Ala Met Leu Leu Pro Ser Trp Lys Thr  
                   20                  25                  30

Ser Ser Tyr Val Gly Ala Ser Ile Val Thr Ala Val Gly Phe Ser Lys  
                   35                  40                  45

Gly Leu Trp Met Glu Cys Ala Thr His Ser Thr Gly Ile Thr Gln Cys  
                   50                  55                  60

Asp Ile Tyr Ser Thr Leu Leu Gly Leu Pro Ala Asp Ile Gln Ala Ala  
   65                  70                  75                  80

Gln Ala Met Met Val Thr Ser Ser Ala Ile Ser Ser Leu Ala Cys Ile  
                   85                  90                  95

Ile Ser Val Val Gly Met Arg Cys Thr Val Phe Cys Gln Glu Ser Arg  
                   100                  105                  110

Ala Lys Asp Arg Val Ala Val Ala Gly Gly Val Phe Phe Ile Leu Gly  
                   115                  120                  125

Ser Leu Leu Gly Phe Ile Pro Xaa Ala Trp Asn Leu  
   130                  135                  140

&lt;210&gt; 84

&lt;211&gt; 86

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (33)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (43)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 84

```

Arg Arg Phe Tyr Ser Pro Leu Val Pro Asp Ser Met Lys Phe Glu Ile
 1           5           10           15
Gly Glu Ala Leu Tyr Leu Gly Ile Ile Ser Ser Leu Phe Ser Leu Ile
          20           25           30
Xaa Gly Ile Ile Leu Cys Phe Ser Cys Ser Xaa Gln Arg Asn Arg Ser
          35           40           45
Asn Tyr Tyr Asp Ala Tyr Gln Ala Gln Pro Leu Ala Thr Arg Ser Ser
          50           55           60
Pro Arg Pro Gly Gln Pro Pro Lys Val Lys Ser Glu Phe Asn Ser Tyr
          65           70           75           80
Ser Leu Thr Gly Tyr Val
          85

```

&lt;210&gt; 85

&lt;211&gt; 399

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 85

```

Met Gly Ile Leu Leu Gly Leu Leu Leu Leu Gly His Leu Thr Val Asp
 1           5           10           15
Thr Tyr Gly Arg Pro Ile Leu Glu Val Pro Glu Ser Val Thr Gly Pro
          20           25           30
Trp Lys Gly Asp Val Asn Leu Pro Cys Thr Tyr Asp Pro Leu Gln Gly
          35           40           45
Tyr Thr Gln Val Leu Val Lys Trp Leu Val Gln Arg Gly Ser Asp Pro
          50           55           60
Val Thr Ile Phe Leu Arg Asp Ser Ser Gly Asp His Ile Gln Gln Ala
          65           70           75           80
Lys Tyr Gln Gly Arg Leu His Val Ser His Lys Val Pro Gly Asp Val
          85           90           95
Ser Leu Gln Leu Ser Thr Leu Glu Met Asp Asp Arg Ser His Tyr Thr
          100          105          110
Cys Glu Val Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Val Arg Asp
          115          120          125
Lys Ile Thr Glu Leu Arg Val Gln Lys Leu Ser Val Ser Lys Pro Thr
          130          135          140
Val Thr Thr Gly Ser Gly Tyr Gly Phe Thr Val Pro Gln Gly Met Arg
          145          150          155          160
Ile Ser Leu Gln Cys Gln Ala Arg Gly Ser Pro Pro Ile Ser Tyr Ile

```



62

	165		170		175
Trp Tyr Lys Gln Gln Thr Asn Asn Gln Glu Pro Ile Lys Val Ala Thr	180		185		190
Leu Ser Thr Leu Leu Phe Lys Pro Ala Val Ile Ala Asp Ser Gly Ser	195		200		205
Tyr Phe Cys Thr Ala Lys Gly Gln Val Gly Ser Glu Gln His Ser Asp	210		215		220
Ile Val Lys Phe Val Val Lys Asp Ser Ser Lys Leu Leu Lys Thr Lys	225		230		235
Thr Glu Ala Pro Thr Thr Met Thr Tyr Pro Leu Lys Ala Thr Ser Thr	245		250		255
Val Lys Gln Ser Trp Asp Trp Thr Thr Asp Met Asp Gly Tyr Leu Gly	260		265		270
Glu Thr Ser Ala Gly Pro Gly Lys Ser Leu Pro Val Phe Ala Ile Ile	275		280		285
Leu Ile Ile Ser Leu Cys Cys Met Val Val Phe Thr Met Ala Tyr Ile	290		295		300
Met Leu Cys Arg Lys Thr Ser Gln Gln Glu His Val Tyr Glu Ala Ala	305		310		315
Arg Ala His Ala Arg Glu Ala Asn Asp Ser Gly Glu Thr Met Arg Val	325		330		335
Ala Ile Phe Ala Ser Gly Cys Ser Ser Asp Glu Pro Thr Ser Gln Asn	340		345		350
Leu Gly Asn Asn Tyr Ser Asp Glu Pro Cys Ile Gly Gln Glu Tyr Gln	355		360		365
Ile Ile Ala Gln Ile Asn Gly Asn Tyr Ala Arg Leu Leu Asp Thr Val	370		375		380
Pro Leu Asp Tyr Glu Phe Leu Ala Thr Glu Gly Lys Ser Val Cys	385		390		395

&lt;210&gt; 86

&lt;211&gt; 27

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 86

Gly Thr Pro Ala Gly Thr Gly Pro Glu Phe Pro Gly Arg Pro Thr Arg	1	5	10	15
---	---	---	----	----

Pro Ile Gly Val His Leu His Ser Val Arg Asp	20	25
---	----	----

63

&lt;210&gt; 87

&lt;211&gt; 485

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 87

```

Ala Arg Gly Arg Leu Leu Pro Trp Trp Leu Ala Ala Gly Cys Ser Met
 1             5             10             15

Ser Arg Leu Gly Ala Leu Gly Gly Ala Arg Ala Gly Leu Gly Leu Leu
          20             25             30

Leu Gly Thr Ala Ala Gly Leu Gly Phe Leu Cys Leu Leu Tyr Ser Gln
          35             40             45

Arg Trp Lys Arg Thr Gln Arg His Gly Arg Ser Gln Ser Leu Pro Asn
          50             55             60

Ser Leu Asp Tyr Thr Gln Thr Ser Asp Pro Gly Arg His Val Met Leu
          65             70             75             80

Leu Arg Ala Val Pro Gly Gly Ala Gly Asp Ala Ser Val Leu Pro Ser
          85             90             95

Leu Pro Arg Glu Gly Gln Glu Lys Val Leu Asp Arg Leu Asp Phe Val
          100            105            110

Leu Thr Ser Leu Val Ala Leu Arg Arg Glu Val Glu Glu Leu Arg Ser
          115            120            125

Ser Leu Arg Gly Leu Ala Gly Glu Ile Val Gly Glu Val Arg Cys His
          130            135            140

Met Glu Glu Asn Gln Arg Val Ala Arg Arg Arg Arg Phe Pro Phe Val
          145            150            155            160

Arg Glu Arg Ser Asp Ser Thr Gly Ser Ser Ser Val Tyr Phe Thr Ala
          165            170            175

Ser Ser Gly Ala Thr Phe Thr Asp Ala Glu Ser Glu Gly Gly Tyr Thr
          180            185            190

Thr Ala Asn Ala Glu Ser Asp Asn Glu Arg Asp Ser Asp Lys Glu Ser
          195            200            205

Glu Asp Gly Glu Asp Glu Val Ser Cys Glu Thr Val Lys Met Gly Arg
          210            215            220

Lys Asp Ser Leu Asp Leu Glu Glu Glu Ala Ala Ser Gly Ala Ser Ser
          225            230            235            240

Ala Leu Glu Ala Gly Gly Ser Ser Gly Leu Glu Asp Val Leu Pro Leu
          245            250            255

Leu Gln Gln Ala Asp Glu Leu His Arg Gly Asp Glu Gln Gly Lys Arg
          260            265            270

Glu Gly Phe Gln Leu Leu Leu Asn Asn Lys Leu Val Tyr Gly Ser Arg

```

64

275                      280                      285  
 Gln Asp Phe Leu Trp Arg Leu Ala Arg Ala Tyr Ser Asp Met Cys Glu  
     290                      295                      300  
 Leu Thr Glu Glu Val Ser Glu Lys Lys Ser Tyr Ala Leu Asp Gly Lys  
     305                      310                      315                      320  
 Glu Glu Ala Glu Ala Ala Leu Glu Lys Gly Asp Glu Ser Ala Asp Cys  
                     325                      330                      335  
 His Leu Trp Tyr Ala Val Leu Cys Gly Gln Leu Ala Glu His Glu Ser  
                     340                      345                      350  
 Ile Gln Arg Arg Ile Gln Ser Gly Phe Ser Phe Lys Glu His Val Asp  
                     355                      360                      365  
 Lys Ala Ile Ala Leu Gln Pro Glu Asn Pro Met Ala His Phe Leu Leu  
                     370                      375                      380  
 Gly Arg Trp Cys Tyr Gln Val Ser His Leu Ser Trp Leu Glu Lys Lys  
     385                      390                      395                      400  
 Thr Ala Thr Ala Leu Leu Glu Ser Pro Leu Ser Ala Thr Val Glu Asp  
                     405                      410                      415  
 Ala Leu Gln Ser Phe Leu Lys Ala Glu Glu Leu Gln Pro Gly Phe Ser  
                     420                      425                      430  
 Lys Ala Gly Arg Val Tyr Ile Ser Lys Cys Tyr Arg Glu Leu Gly Lys  
                     435                      440                      445  
 Asn Ser Glu Ala Arg Trp Trp Met Lys Leu Ala Leu Glu Leu Pro Asp  
                     450                      455                      460  
 Val Thr Lys Glu Asp Leu Ala Ile Gln Lys Asp Leu Glu Glu Leu Glu  
     465                      470                      475                      480  
 Val Ile Leu Arg Asp  
                     485

&lt;210&gt; 88

&lt;211&gt; 184

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 88

Met Lys Ile Leu Val Ala Phe Leu Val Val Leu Thr Ile Phe Gly Ile  
     1                      5                      10                      15

Gln Ser His Gly Tyr Glu Val Phe Asn Ile Ile Ser Pro Ser Asn Asn  
                     20                      25                      30

Gly Gly Asn Val Gln Glu Thr Val Thr Ile Asp Asn Glu Lys Asn Thr  
                     35                      40                      45

Ala Ile Ile Asn Ile His Ala Gly Ser Cys Ser Ser Thr Thr Ile Phe

65

50                      55                      60  
 Asp Tyr Lys His Gly Tyr Ile Ala Ser Arg Val Leu Ser Arg Arg Ala  
 65                      70                      75                      80  
 Cys Phe Ile Leu Lys Met Asp His Gln Asn Ile Pro Pro Leu Asn Asn  
                     85                      90                      95  
 Leu Gln Trp Tyr Ile Tyr Glu Lys Gln Ala Leu Asp Asn Met Phe Ser  
                     100                      105                      110  
 Ser Lys Tyr Thr Trp Val Lys Tyr Asn Pro Leu Glu Ser Leu Ile Lys  
                     115                      120                      125  
 Asp Val Asp Trp Phe Leu Leu Gly Ser Pro Ile Glu Lys Leu Cys Lys  
                     130                      135                      140  
 His Ile Pro Leu Tyr Lys Gly Glu Val Val Glu Asn Thr His Asn Val  
 145                      150                      155                      160  
 Gly Ala Gly Gly Cys Ala Lys Ala Gly Leu Leu Gly Ile Leu Gly Ile  
                     165                      170                      175  
 Ser Ile Cys Ala Asp Ile His Val  
                     180

&lt;210&gt; 89

&lt;211&gt; 101

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (101)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 89

Met Thr Leu Cys Leu Val Thr Phe Leu Thr Ser Leu Pro Thr Ser Val  
 1                      5                      10                      15  
 Pro Ala Cys Thr Ser Cys Trp Pro Gly Phe Met Arg Ser Ser Lys Asn  
                     20                      25                      30  
 Ala Tyr Asp Thr His His Trp Gly Gly Gln Arg Ser Met Asn Leu Glu  
                     35                      40                      45  
 Ser Leu Thr Cys Gly Gln Leu Ala Ile Arg Trp Thr Arg Gly Trp Met  
                     50                      55                      60  
 Thr Arg Pro Arg Gln Val Trp Ala Met Pro Gly Gln Thr Val Asp Val  
 65                      70                      75                      80  
 Tyr Leu Gly Arg Met Leu Gln Gly Val Val Leu Arg Gly Gln Thr Leu  
                     85                      90                      95  
 Arg Gly Arg Ala Xaa  
                     100

<210> 90  
 <211> 50  
 <212> PRT  
 <213> Homo sapiens

<400> 90  
 Lys Ala Val Thr Gly Trp Ala His Trp Leu Thr Pro Ile Ile Pro Ala  
 1 5 10 15  
 Leu Trp Glu Ala Lys Ala Gly Arg Ser Leu Glu Val Arg Ile Ser Arg  
 20 25 30  
 Pro Ala Trp Ser Thr Trp Gln Asn Leu Val Ser Thr Lys Asn Thr Lys  
 35 40 45  
 Ile Arg  
 50

<210> 91  
 <211> 130  
 <212> PRT  
 <213> Homo sapiens

<400> 91  
 Met Phe Leu Glu Leu Ser Gln Ala Leu Leu Leu Leu Gly Leu Pro Arg  
 1 5 10 15  
 Ala Pro Thr Leu Phe Pro Ala Leu Pro Glu Gly Pro Thr Ser Leu Gly  
 20 25 30  
 Glu Gln Trp Pro Pro Gln Leu Pro Pro His Leu Gly Ala Pro Pro Ala  
 35 40 45  
 Ala Glu Gly Ala Val Ala Met Val Gly Cys Gly Glu Gly Arg Gly Gly  
 50 55 60  
 Lys Pro Leu Cys Cys Ser Pro Ala Gln Ser Pro Ala Gln Arg Val Arg  
 65 70 75 80  
 Ser Gly Gly Asp Lys Glu Pro Ile Thr Thr Thr Glu Val Ser Leu Ile  
 85 90 95  
 Leu Leu His Ser Arg Cys Phe Asn Leu Thr Lys Leu Lys Lys Thr Ala  
 100 105 110  
 Phe Ala Met Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
 115 120 125  
 Lys Lys  
 130

<210> 92  
 <211> 184  
 <212> PRT

67

&lt;213&gt; Homo sapiens

&lt;400&gt; 92

```

Met Phe Leu Glu Leu Ser Gln Ala Leu Leu Leu Gly Leu Pro Arg
 1             5             10             15

Ala Pro Thr Leu Phe Pro Ala Leu Pro Glu Gly Pro Thr Ser Leu Gly
          20             25             30

Glu Gln Trp Pro Pro Gln Leu Pro Pro His Leu Gly Ala Pro Pro Ala
          35             40             45

Ala Glu Gly Ala Val Ala Met Val Gly Cys Gly Glu Gly Arg Gly Gly
          50             55             60

Lys Pro Leu Cys Cys Ser Pro Ala Gln Ser Pro Ala Gln Arg Val Arg
          65             70             75             80

Ser Gly Gly Asp Lys Glu Pro Ile Thr Thr Thr Glu Val Ser Leu Ile
          85             90             95

Leu Leu His Ser Arg Cys Phe Asn Leu Thr Lys Leu Lys Lys Thr Ala
          100            105            110

Phe Ala Met Ala His Arg Ser Leu Tyr Leu Phe Leu Arg Lys Cys Phe
          115            120            125

Leu Leu Phe Ala Gly Gln Val Pro Lys Asn Arg Gln Met Phe Leu Leu
          130            135            140

Lys Asp Gln Pro Ile Arg Leu Val Arg Thr Arg Arg Leu Trp Pro Arg
          145            150            155            160

Ala Ser Pro Leu Gln Ala Cys Gly Leu Arg Trp His Leu Ala Ala Gly
          165            170            175

Pro Gln Pro Gly Glu Gly Tyr Tyr
          180

```

&lt;210&gt; 93

&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 93

```

Met Pro Asp Lys Arg Glu Ala Thr Ala Ala Val Ala Leu Phe Ile
 1             5             10             15

Val Pro Leu Gly Val Trp Met Arg Gly Ser Arg Gly Tyr Ser Ala Ala
          20             25             30

His Glu Gly Ser Leu
          35

```

&lt;210&gt; 94

&lt;211&gt; 77

68

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 94

Met Thr Ile Phe Thr Pro Phe Leu Val Leu Leu Leu Val Asn Ser  
 1 5 10 15

Pro Arg Phe Ser Thr Ile Thr Leu Met Arg Ser Gly Phe His Asn Pro  
 20 25 30

Ser Val Cys Leu Ser Phe Thr Leu Lys Pro Gln Cys Tyr Leu Val Leu  
 35 40 45

Met Tyr Gln Lys Asn Arg Arg Gln Asp Gly Ser Lys Val Phe Phe Lys  
 50 55 60

Thr Ala Arg Leu Lys Phe Tyr Leu Asn Ile Thr Ala Lys  
 65 70 75

&lt;210&gt; 95

&lt;211&gt; 30

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 95

Arg Pro Val Met Met Met Cys Val Val Leu Thr Thr Leu Pro Ser Phe  
 1 5 10 15

Ile Phe Ser Ile Ala Val Thr Glu Val Gln Lys Thr Ile Asn  
 20 25 30

&lt;210&gt; 96

&lt;211&gt; 30

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 96

Arg Pro Val Leu Met Met Cys Val Val Leu Thr Thr Leu Pro Cys Leu  
 1 5 10 15

Thr Phe Ser Ile Ala Val Thr Glu Val Gln Lys Ser Ile Asn  
 20 25 30

&lt;210&gt; 97

&lt;211&gt; 28

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 97

Ile Ile Glu Asn Ser Gly Phe Ile Leu Leu Glu Gly Ile Lys Arg Val  
 1 5 10 15

Thr Lys Ile Asn Thr Ser Thr Arg Pro Leu Cys Asn  
 20 25

<210> 98  
 <211> 28  
 <212> PRT  
 <213> Homo sapiens

<400> 98  
 Leu Leu Lys Asn Ser Gly Tyr Ile Leu Leu Glu Gly Val Lys Arg Val  
     1                    5                    10                    15  
 Val Lys Met Asp Thr Ser Ile Gln Pro Leu Cys Asn  
           20                    25

<210> 99  
 <211> 592  
 <212> PRT  
 <213> Homo sapiens

<400> 99  
 Pro Tyr Asn Tyr Leu Gln Val Ala Tyr Phe Lys Ile Asn Lys Leu Glu  
     1                    5                    10                    15  
 Lys Ala Val Ala Ala Ala His Thr Phe Phe Val Gly Asn Pro Glu His  
           20                    25                    30  
 Met Glu Met Arg Gln Asn Leu Asp Tyr Tyr Gln Thr Met Ser Gly Val  
           35                    40                    45  
 Lys Glu Glu Asp Phe Lys Asp Leu Glu Ala Lys Pro His Met His Glu  
           50                    55                    60  
 Phe Arg Leu Gly Val Arg Leu Tyr Ser Glu Glu Lys Pro Leu Glu Ala  
     65                    70                    75                    80  
 Val Pro His Leu Glu Ala Ala Leu Gln Glu Tyr Phe Val Ala Asp Glu  
           85                    90                    95  
 Glu Cys Arg Ala Leu Cys Glu Gly Pro Tyr Asp Tyr Asp Gly Tyr Asn  
           100                    105                    110  
 Tyr Leu Asp Tyr Ser Ala Asp Leu Phe Gln Ala Ile Thr Asp His Tyr  
           115                    120                    125  
 Val Gln Val Leu Ser Cys Lys Gln Asn Cys Val Thr Glu Leu Ala Ser  
           130                    135                    140  
 His Pro Ser Arg Glu Lys Pro Phe Glu Asp Phe Leu Pro Ser His Tyr  
     145                    150                    155                    160  
 Asn Tyr Leu Gln Phe Ala Tyr Tyr Asn Ile Gly Asn Tyr Thr Gln Ala  
           165                    170                    175  
 Ile Glu Cys Ala Lys Thr Tyr Leu Leu Phe Phe Pro Asn Asp Glu Val  
           180                    185                    190  
 Met Ser Gln Asn Leu Ala Tyr Tyr Thr Ala Val Leu Gly Glu Glu Glu  
           195                    200                    205



Ala Ser Ser Ile Ser Pro Arg Glu Asn Ala Gln Glu Tyr Arg His Arg  
 210 215 220  
 Ser Leu Leu Glu Lys Glu Leu Leu Phe Phe Ala Tyr Asp Ile Phe Gly  
 225 230 235 240  
 Ile Pro Phe Val Asp Pro Asp Ser Trp Thr Pro Glu Glu Val Ile Pro  
 245 250 255  
 Lys Arg Leu Gln Glu Lys Gln Lys Ser Glu Arg Glu Thr Ala Val Arg  
 260 265 270  
 Ile Ser Gln Glu Ile Gly Asn Leu Met Lys Glu Ile Glu Thr Leu Val  
 275 280 285  
 Glu Glu Lys Thr Lys Glu Ser Leu Asp Val Ser Arg Leu Thr Arg Glu  
 290 295 300  
 Gly Gly Pro Leu Leu Tyr Glu Gly Ile Asn Leu Thr Met Asn Ser Lys  
 305 310 315 320  
 Val Leu Asn Gly Ser Gln Arg Val Val Met Asp Gly Val Ile Ser Asp  
 325 330 335  
 Asp Glu Cys Gln Glu Leu Gln Arg Leu Thr Asn Ala Ala Ala Thr Ser  
 340 345 350  
 Gly Asp Gly Tyr Arg Gly Gln Thr Ser Pro His Thr Pro Asn Glu Lys  
 355 360 365  
 Phe Tyr Gly Val Thr Val Leu Lys Ala Leu Lys Leu Gly Gln Glu Gly  
 370 375 380  
 Lys Val Pro Leu Gln Ser Ala His Met Tyr Tyr Asn Val Thr Glu Lys  
 385 390 395 400  
 Val Arg Arg Val Met Glu Ser Tyr Phe Arg Leu Asp Thr Pro Leu Tyr  
 405 410 415  
 Phe Ser Tyr Ser His Leu Val Cys Arg Thr Ala Ile Glu Glu Ser Gln  
 420 425 430  
 Ala Glu Arg Lys Asp Ser Ser His Pro Val His Val Asp Asn Cys Ile  
 435 440 445  
 Leu Asn Ala Glu Ser Leu Val Cys Ile Lys Glu Pro Pro Ala Tyr Thr  
 450 455 460  
 Phe Arg Asp Tyr Ser Ala Ile Leu Tyr Leu Asn Gly Asp Phe Asp Gly  
 465 470 475 480  
 Gly Asn Phe Tyr Phe Thr Glu Leu Asp Ala Lys Thr Val Thr Ala Glu  
 485 490 495  
 Val Gln Pro Gln Cys Gly Arg Ala Val Gly Phe Ser Ser Gly Thr Glu  
 500 505 510

```

<400> 100
Pro Tyr Asn Tyr Leu Gln Val Ala Tyr Phe Lys Ile Asn Lys Leu Glu
  1              5              10              15

Lys Ala Val Ala Ala Ala His Thr Phe Phe Val Gly Asn Pro Glu His
      20              25              30

Met Glu Met Gln Gln Asn Leu Asp Tyr Tyr Gln Thr Met Ser Gly Val
      35              40              45

Lys Glu Ala Asp Phe Lys Asp Leu Glu Thr Gln Pro His Met Gln Glu
  50              55              60

Phe Arg Leu Gly Val Arg Leu Tyr Ser Glu Glu Gln Pro Gln Glu Ala
  65              70              75              80

Val Pro His Leu Glu Ala Ala Leu Gln Glu Tyr Phe Val Ala Tyr Glu
      85              90              95

Glu Cys Arg Ala Leu Cys Glu Gly Pro Tyr Asp Tyr Asp Gly Tyr Asn
      100              105              110

Tyr Leu Glu Tyr Asn Ala Asp Leu Phe Gln Ala Ile Thr Asp His Tyr
      115              120              125

Ile Gln Val Leu Asn Cys Lys Gln Asn Cys Val Thr Glu Leu Ala Ser
      130              135              140

His Pro Ser Arg Glu Lys Pro Phe Glu Asp Phe Leu Pro Ser His Tyr
      145              150              155              160

Asn Tyr Leu Gln Phe Ala Tyr Tyr Asn Ile Gly Asn Tyr Thr Gln Ala
      165              170              175

```

Val Glu Cys Ala Lys Thr Tyr Leu Leu Phe Phe Pro Asn Asp Glu Val  
 180 185 190  
 Met Asn Gln Asn Leu Ala Tyr Tyr Ala Ala Met Leu Gly Glu Glu His  
 195 200 205  
 Thr Arg Ser Ile Gly Pro Arg Glu Ser Ala Lys Glu Tyr Arg Gln Arg  
 210 215 220  
 Ser Leu Leu Glu Lys Glu Leu Leu Phe Phe Ala Tyr Asp Val Phe Gly  
 225 230 235 240  
 Ile Pro Phe Val Asp Pro Asp Ser Trp Thr Pro Glu Glu Val Ile Pro  
 245 250 255  
 Lys Arg Leu Gln Glu Lys Gln Lys Ser Glu Arg Glu Thr Ala Val Arg  
 260 265 270  
 Ile Ser Gln Glu Ile Gly Asn Leu Met Lys Glu Ile Glu Thr Leu Val  
 275 280 285  
 Glu Glu Lys Thr Lys Glu Ser Leu Asp Val Ser Arg Leu Thr Arg Glu  
 290 295 300  
 Gly Gly Pro Leu Leu Tyr Glu Gly Ile Ser Leu Thr Met Asn Ser Lys  
 305 310 315 320  
 Leu Leu Asn Gly Ser Gln Arg Val Val Met Asp Gly Val Ile Ser Asp  
 325 330 335  
 His Glu Cys Gln Glu Leu Gln Arg Leu Thr Asn Val Ala Ala Thr Ser  
 340 345 350  
 Gly Asp Gly Tyr Arg Gly Gln Thr Ser Pro His Thr Pro Asn Glu Lys  
 355 360 365  
 Phe Tyr Gly Val Thr Val Phe Lys Ala Leu Lys Leu Gly Gln Glu Gly  
 370 375 380  
 Lys Val Pro Leu Gln Ser Ala His Leu Tyr Tyr Asn Val Thr Glu Lys  
 385 390 395 400  
 Val Arg Arg Ile Met Glu Ser Tyr Phe Arg Leu Asp Thr Pro Leu Tyr  
 405 410 415  
 Phe Ser Tyr Ser His Leu Val Cys Arg Thr Ala Ile Glu Glu Val Gln  
 420 425 430  
 Ala Glu Arg Lys Asp Asp Ser His Pro Val His Val Asp Asn Cys Ile  
 435 440 445  
 Leu Asn Ala Glu Thr Leu Val Cys Val Lys Glu Pro Pro Ala Tyr Thr  
 450 455 460  
 Phe Arg Asp Tyr Ser Ala Ile Leu Tyr Leu Asn Gly Asp Phe Asp Gly  
 465 470 475 480  
 Gly Asn Phe Tyr Phe Thr Glu Leu Asp Ala Lys Thr Val Thr Ala Glu

73

	485		490		495
Val Gln Pro Gln Cys Gly Arg Ala Val Gly Phe Ser Ser Gly Thr Glu					
	500		505		510
Asn Pro His Gly Val Lys Ala Val Thr Arg Gly Gln Arg Cys Ala Ile					
	515		520		525
Ala Leu Trp Phe Thr Leu Asp Pro Arg His Ser Glu Arg Asp Arg Val					
	530		535		540
Gln Ala Asp Asp Leu Val Lys Met Leu Phe Ser Pro Glu Glu Met Asp					
	545		550		555
Leu Ser Gln Glu Gln Pro Leu Asp Ala Gln Gln Gly Pro Pro Glu Pro					
		565		570	575
Ala Gln Glu Ser Leu Ser Gly Ser Glu Ser Lys Pro Lys Asp Glu Leu					
	580		585		590

<210> 101  
 <211> 83  
 <212> PRT  
 <213> Homo sapiens

<400> 101  
 Trp Asn Val Ala Ala Pro Asp Leu Leu Tyr Ala Glu Gly Thr Ala Ala  
 1 5 10 15  
 Tyr Ala Arg Gly Asp Trp Pro Gly Val Val Leu Asn Met Glu Arg Ala  
 20 25 30  
 Leu Arg Ser Arg Ala Ala Leu Arg Ala Leu Arg Leu Arg Cys Arg Thr  
 35 40 45  
 Arg Cys Ala Thr Glu Leu Pro Trp Ala Pro Asp Leu Asp Leu Gly Pro  
 50 55 60  
 Ala Ser Ser Leu Asn His Asp Pro Gly Ala Ala Ala Leu His Asp Leu  
 65 70 75 80  
 Arg Phe Phe

<210> 102  
 <211> 81  
 <212> PRT  
 <213> Homo sapiens

<400> 102  
 Trp Gly Met Val Thr Pro Asp Leu Leu Phe Ala Glu Gly Thr Ala Ala  
 1 5 10 15

74

Tyr Ala Arg Gly Asp Trp Pro Gly Val Val Leu Ser Met Glu Arg Ala  
                   20                                  25                                  30  
 Leu Arg Ser Arg Ala Ala Leu Arg Ala Leu Arg Leu Arg Cys Arg Thr  
                   35                                  40                                  45  
 Gln Cys Ala Ala Asp Phe Pro Trp Glu Leu Asp Pro Asp Trp Ser Pro  
                   50                                  55                                  60  
 Ser Pro Ala Gln Ala Ser Gly Ala Ala Ala Leu Arg Asp Leu Ser Phe  
                   65                                  70                                  75                                  80  
 Phe

<210> 103  
 <211> 337  
 <212> PRT  
 <213> Homo sapiens

<400> 103  
 Pro Arg Asp Cys Lys Lys Lys Gln Lys Ser Glu Arg Glu Thr Ala Val  
   1                                  5                                  10                                  15  
 Arg Ile Ser Gln Glu Ile Gly Asn Leu Met Lys Glu Ile Glu Thr Leu  
                   20                                  25                                  30  
 Val Glu Glu Lys Thr Lys Glu Ser Leu Asp Val Ser Arg Leu Thr Arg  
                   35                                  40                                  45  
 Glu Gly Gly Pro Leu Leu Tyr Glu Gly Ile Ser Leu Thr Met Asn Ser  
                   50                                  55                                  60  
 Lys Leu Leu Asn Gly Ser Gln Arg Val Val Met Asp Gly Val Ile Ser  
                   65                                  70                                  75                                  80  
 Asp His Glu Cys Gln Glu Leu Gln Arg Leu Thr Asn Val Ala Ala Thr  
                                   85                                  90                                  95  
 Ser Gly Asp Gly Tyr Arg Gly Gln Thr Ser Pro His Thr Pro Asn Glu  
                   100                                  105                                  110  
 Lys Phe Tyr Gly Val Thr Val Phe Lys Ala Leu Lys Leu Gly Gln Glu  
                   115                                  120                                  125  
 Gly Lys Val Pro Leu Gln Ser Ala His Leu Tyr Tyr Asn Val Thr Glu  
                   130                                  135                                  140  
 Lys Val Arg Arg Ile Met Glu Ser Tyr Phe Arg Leu Asp Thr Pro Leu  
                   145                                  150                                  155                                  160  
 Tyr Phe Ser Tyr Ser His Leu Val Cys Arg Thr Ala Ile Glu Glu Val  
                                   165                                  170                                  175  
 Gln Ala Glu Arg Lys Asp Asp Ser His Pro Val His Val Asp Asn Cys  
                   180                                  185                                  190

75

Ile Leu Asn Ala Glu Thr Leu Val Cys Val Lys Glu Pro Pro Ala Tyr  
 195 200 205  
 Thr Phe Arg Asp Tyr Ser Ala Ile Leu Tyr Leu Asn Gly Asp Phe Asp  
 210 215 220  
 Gly Gly Asn Phe Tyr Phe Thr Glu Leu Asp Ala Lys Thr Val Thr Ala  
 225 230 235 240  
 Glu Val Gln Pro Gln Cys Gly Arg Ala Val Gly Phe Ser Ser Gly Thr  
 245 250 255  
 Glu Asn Pro His Gly Val Lys Ala Val Thr Arg Gly Gln Arg Cys Ala  
 260 265 270  
 Ile Ala Leu Trp Phe Thr Leu Asp Pro Arg His Ser Glu Arg Asp Arg  
 275 280 285  
 Val Gln Ala Asp Asp Leu Val Lys Met Leu Phe Ser Pro Glu Glu Met  
 290 295 300  
 Asp Leu Ser Gln Glu Gln Pro Leu Asp Ala Gln Gln Gly Pro Pro Glu  
 305 310 315 320  
 Pro Ala Gln Glu Ser Leu Ser Gly Ser Glu Ser Lys Pro Lys Asp Glu  
 325 330 335

Leu

<210> 104  
 <211> 60  
 <212> PRT  
 <213> Homo sapiens

<400> 104  
 Tyr Tyr Ala Ala Met Leu Gly Glu Glu His Thr Arg Ser Ile Gly Pro  
 1 5 10 15  
 Arg Glu Ser Ala Lys Glu Tyr Arg Gln Arg Ser Leu Leu Glu Lys Glu  
 20 25 30  
 Leu Leu Phe Phe Ala Tyr Asp Val Phe Gly Ile Pro Phe Val Asp Pro  
 35 40 45  
 Asp Ser Trp Thr Pro Glu Glu Val Ile Pro Lys Arg  
 50 55 60

<210> 105  
 <211> 833  
 <212> PRT  
 <213> Homo sapiens

<400> 105  
 Ala Val Ala Ala Lys Leu Asn Ile Pro Lys Val Leu Leu Pro Phe Thr  
 1 5 10 15

Arg Ala Thr Arg Val Asn Phe Thr Leu Glu Ala Ser Glu Gly Cys Tyr  
                   20                  25                  30  
 Arg Trp Ser Ser Thr Arg Pro Glu Val Ala Ser Ile Glu Pro Leu Gly  
                   35                  40                  45  
 Ser Ser Glu Gln Gln Cys Ser Gln Lys Ala Val Val Gln Ala Arg Leu  
                   50                  55                  60  
 Thr Gln Pro Ala Arg Leu Thr Ser Ile Ile Phe Ala Glu Asp Ile Thr  
                   65                  70                  75                  80  
 Thr Gly Gln Val Leu Arg Cys Asp Ala Ile Val Asp Leu Ile His Gly  
                   85                  90                  95  
 Ile Gln Ile Val Ser Thr Thr Arg Glu Leu Tyr Leu Glu Asp Ser Pro  
                   100                  105                  110  
 Leu Glu Leu Lys Ile Gln Ala Leu Asp Ser Glu Gly Asn Thr Phe Ser  
                   115                  120                  125  
 Thr Leu Ala Gly Leu Val Phe Asp Trp Thr Ile Val Lys Asp Thr Glu  
                   130                  135                  140  
 Ala Asn Gly Phe Ser Asp Ser His Asn Ala Leu Arg Ile Leu Thr Phe  
                   145                  150                  155                  160  
 Leu Glu Ser Thr Tyr Ile Pro Pro Ser Tyr Ile Ser Glu Met Glu Lys  
                   165                  170                  175  
 Ala Ala Lys Gln Gly Asp Thr Ile Leu Val Ser Gly Met Lys Thr Gly  
                   180                  185                  190  
 Ser Ser Lys Leu Lys Ala Arg Ile Gln Glu Ala Val Tyr Lys Asn Val  
                   195                  200                  205  
 Arg Pro Ala Glu Val Arg Leu Leu Ile Leu Glu Asn Ile Leu Leu Asn  
                   210                  215                  220  
 Pro Ala Tyr Asp Val Tyr Leu Leu Val Gly Thr Ser Ile His Tyr Lys  
                   225                  230                  235                  240  
 Val Gln Lys Ile Arg Gln Gly Lys Ile Thr Glu Leu Ser Met Pro Ser  
                   245                  250                  255  
 Asp Gln Tyr Glu Leu Gln Leu Gln Asn Ser Ile Pro Asp Pro Gln Gly  
                   260                  265                  270  
 Asp Pro Ala Arg Pro Val Ala Val Leu Thr Gln Asp Thr Ser Arg Val  
                   275                  280                  285  
 Thr Ala Met Gln Met Gly Gln Ser Asn Leu Val Leu Gly His Arg Ser  
                   290                  295                  300  
 Ile Arg Met Gln Gly Ala Ser Arg Leu Pro Asn Ser Thr Ile Tyr Val  
                   305                  310                  315                  320

Val Glu Ala Gly Tyr Leu Gly Phe Thr Val His Pro Gly Asp Arg Trp  
 325 330 335  
 Val Leu Glu Thr Gly His Leu Tyr Ala Val Thr Ile Glu Val Phe Asp  
 340 345 350  
 Arg Ser Ser Asn Lys Val Tyr Pro Ser Asp Asn Ile Arg Ile Glu Ala  
 355 360 365  
 Val Phe Pro Ala Glu Phe Phe Glu Val Leu Ser Ser Ser Gln Asn Gly  
 370 375 380  
 Ser Tyr His His Val Arg Ala Ile Gln Ser Gly Gln Thr Thr Ile Ser  
 385 390 395 400  
 Ala Ser Leu Thr Ser Val Val Asp Gln Asp Gly Gly Val His Val Leu  
 405 410 415  
 Gln Val Pro Val Trp Asn Gln Gln Glu Val Asp Ile His Ile Pro Ile  
 420 425 430  
 Thr Leu Tyr Pro Ser Ile Leu Thr Phe Pro Trp Gln Pro Lys Thr Gly  
 435 440 445  
 Ala Tyr Gln Tyr Thr Ile Lys Ala His Gly Gly Ser Gly Asn Phe Thr  
 450 455 460  
 Trp Ser Ser Ser Ser Tyr Met Val Ala Thr Val Thr Val Lys Gly Val  
 465 470 475 480  
 Met Thr Thr Gly Gly Asp Thr Gly Leu Ser Val Ile Arg Ala His Asp  
 485 490 495  
 Val Gln Asn Pro Leu His Phe Gly Glu Met Lys Val Tyr Val Ile Glu  
 500 505 510  
 Pro Ser Ser Met Glu Phe Ala Pro Cys Gln Val Glu Ala Arg Val Gly  
 515 520 525  
 His Thr Leu Glu Leu Pro Leu Thr Ile Ser Gly Leu Met Pro Gly Gly  
 530 535 540  
 Ser Ser Glu Val Val Thr Leu Ser Asp Cys Ser His Phe Asp Leu Val  
 545 550 555 560  
 Val Glu Val Glu Asn Gln Gly Val Phe Gln Pro Leu Pro Gly Arg Leu  
 565 570 575  
 Pro Pro Gly Pro Glu His Cys Ser Gly Val Lys Val Arg Ala Asp Ala  
 580 585 590  
 Gln Gly Ser Thr Thr Leu Leu Val Ser Tyr Thr His Gly His Val His  
 595 600 605  
 Leu Gly Ala Lys Ile Thr Leu Ala Ala Tyr Leu Pro Leu Lys Ala Val  
 610 615 620  
 Asp Pro Ser Ser Val Ala Val Val Thr Leu Gly Ser Ser Lys Glu Met



78

625		630		635		640
Leu Phe Glu Gly Gly Pro Arg Pro Trp Val Leu Glu Pro Ser Lys Phe						
		645		650		655
Phe Arg Asn Val Thr Ser Glu Asp Thr Gly Ser Ile Ser Leu Ser Leu						
		660		665		670
Leu Gly Pro Pro Ala Ser Arg Asn Tyr Gln Gln His Arg Val Leu Val						
		675		680		685
Thr Cys Gln Ala Leu Gly Glu Gln Val Ile Ala Leu Ser Val Gly Asn						
		690		695		700
Arg Pro Ser Leu Ser Asn Pro Phe Pro Ala Val Glu Pro Thr Val Val						
705		710		715		720
Lys Ser Val Cys Ala Pro Pro Ser Arg Leu Thr Leu Met Pro Val Tyr						
		725		730		735
Ala Leu Pro Gln Leu Asp Leu Ser Cys Pro Leu Leu Gln Gln Asn Lys						
		740		745		750
Gln Val Val Pro Val Ser Ser His Arg Asn Pro Leu Leu Asp Leu Gly						
		755		760		765
Ala Tyr Asp Gln Gln Gly Arg Arg Phe Asp Asn Phe Ser Ser Leu Ser						
		770		775		780
Ile Gln Trp Glu Ser Phe Arg Pro Leu Leu Ala Ser Ile Glu Val Asp						
785		790		795		800
Gln Pro Met Gln Leu Val Ser Gln Asp Asp Gly Asn Gly Gln Lys Lys						
		805		810		815
Leu His Gly Leu Gln Thr Val Ser Val His Glu Ala Ser Gly Thr Thr						
		820		825		830
Ala						

&lt;210&gt; 106

&lt;211&gt; 833

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (4)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (194)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (212)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (253)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 106

Ala Ala Ala Xaa Lys Leu Asn Ile Pro Lys Val Leu Leu Pro Phe Thr  
 1 5 10 15

Arg Ala Thr Arg Val Asn Phe Thr Leu Glu Ala Ser Glu Gly Cys Tyr  
 20 25 30

Arg Trp Leu Ser Thr Arg Pro Glu Val Ala Ser Ile Glu Pro Leu Gly  
 35 40 45

Leu Asp Glu Gln Gln Cys Ser Gln Lys Ala Val Val Gln Ala Arg Leu  
 50 55 60

Thr Gln Pro Ala Arg Leu Thr Ser Ile Ile Phe Ala Glu Asp Ile Thr  
 65 70 75 80

Thr Gly Gln Val Leu Arg Cys Asp Ala Ile Val Asp Leu Ile His Asp  
 85 90 95

Ile Gln Ile Val Ser Thr Thr Arg Glu Leu Tyr Leu Glu Asp Ser Pro  
 100 105 110

Leu Glu Leu Lys Ile Gln Ala Leu Asp Ser Glu Gly Asn Thr Phe Ser  
 115 120 125

Thr Leu Ala Gly Leu Val Phe Glu Trp Thr Ile Val Lys Asp Ser Glu  
 130 135 140

Ala Asp Arg Phe Ser Asp Ser His Asn Ala Leu Arg Ile Leu Thr Phe  
 145 150 155 160

Leu Glu Ser Thr Tyr Ile Pro Pro Ser Tyr Ile Ser Glu Met Glu Lys  
 165 170 175

Ala Ala Lys Gln Gly Asp Thr Ile Leu Val Ser Gly Met Lys Thr Gly  
 180 185 190

Ser Xaa Lys Leu Lys Ala Arg Ile Gln Glu Ala Val Tyr Lys Asn Val  
 195 200 205

Arg Pro Ala Xaa Val Arg Leu Leu Ile Leu Glu Asn Ile Leu Leu Asn  
 210 215 220

Pro Ala Tyr Asp Val Tyr Leu Met Val Gly Thr Ser Ile His Tyr Lys  
 225 230 235 240

Val Gln Lys Ile Arg Gln Gly Lys Ile Thr Glu Leu Xaa Met Pro Ser  
 245 250 255

Asp Gln Tyr Glu Leu Gln Leu Gln Asn Ser Ile Pro Gly Pro Glu Gly  
 260 265 270  
 Asp Pro Thr Arg Pro Val Ala Val Leu Ala Gln Asp Thr Ser Met Val  
 275 280 285  
 Thr Ala Leu Gln Leu Gly Gln Ser Ser Leu Val Leu Gly His Arg Ser  
 290 295 300  
 Ile Arg Met Gln Gly Ala Ser Arg Leu Pro Asn Ser Thr Ile Tyr Val  
 305 310 315 320  
 Val Glu Pro Gly Tyr Leu Gly Phe Thr Val His Pro Gly Asp Arg Trp  
 325 330 335  
 Val Leu Glu Thr Gly Arg Leu Tyr Glu Ile Thr Ile Glu Val Phe Asp  
 340 345 350  
 Lys Phe Ser Asn Lys Val Tyr Val Ser Asp Asn Ile Arg Ile Glu Thr  
 355 360 365  
 Val Leu Pro Ala Glu Phe Phe Glu Val Leu Ser Ser Ser Gln Asn Gly  
 370 375 380  
 Ser Tyr His Arg Ile Arg Ala Leu Lys Arg Gly Gln Thr Ala Ile Asp  
 385 390 395 400  
 Ala Ala Leu Thr Ser Val Val Asp Gln Asp Gly Gly Val His Ile Leu  
 405 410 415  
 Gln Val Pro Val Trp Asn Gln Gln Glu Val Glu Ile His Ile Pro Ile  
 420 425 430  
 Thr Leu Tyr Pro Ser Ile Leu Thr Phe Pro Trp Gln Pro Lys Thr Gly  
 435 440 445  
 Ala Tyr Gln Tyr Thr Ile Arg Ala His Gly Gly Ser Gly Asn Phe Ser  
 450 455 460  
 Trp Ser Ser Ser Ser His Leu Val Ala Thr Val Thr Val Lys Gly Val  
 465 470 475 480  
 Met Thr Thr Gly Ser Asp Ile Gly Phe Ser Val Ile Gln Ala His Asp  
 485 490 495  
 Val Gln Asn Pro Leu His Phe Gly Glu Met Lys Val Tyr Val Ile Glu  
 500 505 510  
 Pro His Ser Met Glu Phe Ala Pro Cys Gln Val Glu Ala Arg Val Gly  
 515 520 525  
 Gln Ala Leu Glu Leu Pro Leu Arg Ile Ser Gly Leu Met Pro Gly Gly  
 530 535 540  
 Ala Ser Glu Val Val Thr Leu Ser Asp Cys Ser His Phe Asp Leu Ala  
 545 550 555 560  
 Val Glu Val Glu Asn Gln Gly Val Phe Gln Pro Leu Pro Gly Arg Leu

81

565 570 575  
 Pro Pro Gly Ser Glu His Cys Ser Gly Val Arg Val Lys Ala Glu Ala  
 580 585 590  
 Gln Gly Ser Thr Thr Leu Leu Val Ser Tyr Arg His Gly His Val His  
 595 600 605  
 Leu Ser Ala Lys Ile Thr Ile Ala Ala Tyr Leu Pro Leu Lys Ala Val  
 610 615 620  
 Asp Pro Ser Ser Val Ala Leu Val Thr Leu Gly Ser Ser Lys Glu Met  
 625 630 635 640  
 Leu Phe Glu Gly Gly Pro Arg Pro Trp Ile Leu Glu Pro Ser Lys Phe  
 645 650 655  
 Phe Gln Asn Val Thr Ala Glu Asp Thr Asp Ser Ile Gly Leu Ala Leu  
 660 665 670  
 Phe Ala Pro His Ser Ser Arg Asn Tyr Gln Gln His Trp Ile Leu Val  
 675 680 685  
 Thr Cys Gln Ala Leu Gly Glu Gln Val Ile Ala Leu Ser Val Gly Asn  
 690 695 700  
 Lys Pro Ser Leu Thr Asn Pro Phe Pro Ala Val Glu Pro Ala Val Val  
 705 710 715 720  
 Lys Phe Val Cys Ala Pro Pro Ser Arg Leu Thr Leu Val Pro Val Tyr  
 725 730 735  
 Thr Ser Pro Gln Leu Asp Met Ser Cys Pro Leu Leu Gln Gln Asn Lys  
 740 745 750  
 Gln Val Val Pro Val Ser Ser His Arg Asn Pro Leu Leu Asp Leu Ala  
 755 760 765  
 Ala Tyr Asp Gln Glu Gly Arg Arg Phe Asp Asn Phe Ser Ser Leu Ser  
 770 775 780  
 Ile Gln Trp Glu Ser Thr Arg Pro Val Leu Ala Ser Ile Glu Pro Glu  
 785 790 795 800  
 Leu Pro Met Gln Leu Val Ser Gln Asp Asp Glu Ser Gly Gln Lys Lys  
 805 810 815  
 Leu His Gly Leu Gln Ala Ile Leu Val His Glu Ala Ser Gly Thr Thr  
 820 825 830

Ala

&lt;210&gt; 107

&lt;211&gt; 315

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 107

Ala Ile Ser Ala Thr Ala Thr Gly Tyr Gln Gln Ser His Leu Ser Ala  
 1 5 10 15  
 Ala Gly Val Lys Gln Leu Arg Asp Pro Leu Val Pro Val Ser Ala Ser  
 20 25 30  
 Ile Glu Leu Ile Leu Val Glu Asp Val Arg Val Ser Pro Glu Glu Val  
 35 40 45  
 Thr Ile Tyr Asn His Pro Gly Val Gln Val Glu Leu His Ile Thr Glu  
 50 55 60  
 Gly Ser Gly Tyr Phe Phe Leu Asn Thr Ser Thr Gln Asp Ile Ile Asn  
 65 70 75 80  
 Val Ala Tyr Gln Asp Thr Arg Gly Val Ala Met Val His Pro Leu Phe  
 85 90 95  
 Pro Gly Ser Ser Thr Val Met Val His Asp Leu Cys Leu Thr Phe Pro  
 100 105 110  
 Ala Pro Ala Lys Ala Thr Ile His Val Ser Asp Ile Gln Glu Leu Tyr  
 115 120 125  
 Val Arg Val Val Asp Lys Val Glu Ile Gly Lys Ala Val Lys Ala Tyr  
 130 135 140  
 Val Arg Val Leu Asp Phe Tyr Lys Lys Pro Phe Leu Ala Lys Tyr Phe  
 145 150 155 160  
 Thr Phe Met Asp Leu Lys Leu Arg Ala Ala Ser Gln Ile Ile Thr Leu  
 165 170 175  
 Val Thr Leu Asp Glu Ala Leu Asp Asn Tyr Thr Ala Thr Phe Leu Val  
 180 185 190  
 His Gly Val Ala Ile Gly Gln Thr Ser Leu Ser Ala Ser Val Thr Asp  
 195 200 205  
 Lys Ser Gly Gln Arg Val Ser Ser Thr Ala Gln Gln Ile Glu Val Phe  
 210 215 220  
 Pro Pro Phe Arg Leu Ile Pro Arg Lys Val Thr Leu Ile Ile Gly Ala  
 225 230 235 240  
 Met Ile Gln Ile Thr Ser Glu Gly Gly Pro Gln Pro Gln Ser Asn Ile  
 245 250 255  
 Leu Phe Ser Ile Asn Asn Glu Ser Val Ala Ala Val Ser Ser Ala Gly  
 260 265 270  
 Leu Val Arg Gly Leu Met Val Gly Asn Gly Ser Val Leu Gly Val Val  
 275 280 285  
 Gln Ala Val Asp Ala Glu Thr Gly Lys Val Ile Ile Val Ser Gln Asp  
 290 295 300

His Val Glu Val Glu Val Leu Gln Leu Gln Ala  
 305 310 315

<210> 108

<211> 315

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (17)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (217)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 108

Ser Ile Thr Ala Thr Ala Thr Gly Tyr Gln Glu Ser His Leu Ser Ser  
 1 5 10 15

Xaa Arg Thr Lys Gln Pro His Asp Pro Leu Val Pro Leu Ser Ala Ser  
 20 25 30

Ile Glu Leu Ile Leu Val Glu Asp Val Arg Val Ser Pro Glu Glu Val  
 35 40 45

Thr Ile Tyr Asn His Pro Gly Ile Gln Ala Glu Leu Arg Ile Arg Glu  
 50 55 60

Gly Ser Gly Tyr Phe Phe Leu Asn Thr Ser Thr Ala Asp Val Val Lys  
 65 70 75 80

Val Ala Tyr Gln Glu Ala Arg Gly Val Ala Met Val His Pro Leu Leu  
 85 90 95

Pro Gly Ser Ser Thr Ile Met Ile His Asp Leu Cys Leu Val Phe Pro  
 100 105 110

Ala Pro Ala Lys Ala Val Val Tyr Val Ser Asp Ile Gln Glu Leu Tyr  
 115 120 125

Ile Arg Val Val Asp Lys Val Glu Ile Gly Lys Thr Val Lys Ala Tyr  
 130 135 140

Val Arg Val Leu Asp Leu His Lys Lys Pro Phe Leu Ala Lys Tyr Phe  
 145 150 155 160

Pro Phe Met Asp Leu Lys Leu Arg Ala Ala Ser Pro Ile Ile Thr Leu  
 165 170 175

Val Ala Leu Asp Glu Ala Leu Asp Asn Tyr Thr Ile Thr Phe Leu Ile  
 180 185 190

Arg Gly Val Ala Ile Gly Gln Thr Ser Leu Thr Ala Ser Val Thr Asn

195	200	205
Lys Ala Gly Gln Arg Ile	Asn Ser Xaa Pro Gln Gln Ile Glu Val Phe	
210	215	220
Pro Pro Phe Arg Leu Met	Pro Arg Lys Val Thr Leu Leu Ile Gly Ala	
225	230	235 240
Thr Met Gln Val Thr Ser Glu Gly Gly	Pro Gln Pro Gln Ser Asn Ile	
	245 250	255
Leu Phe Ser Ile Ser Asn Glu Ser Val Ala Leu Val Ser Ala Ala Gly		
	260 265	270
Leu Val Gln Gly Leu Ala Ile Gly Asn Gly Thr Val Ser Gly Leu Val		
	275 280	285
Gln Ala Val Asp Ala Glu Thr Gly Lys Val Val Ile Ile Ser Gln Asp		
	290 295	300
Leu Val Gln Val Glu Val Leu Leu Leu Arg Ala		
305	310	315

<210> 109  
 <211> 47  
 <212> PRT  
 <213> Homo sapiens

<400> 109  
 Pro Leu Ala Leu Thr Pro His Ala Ser Pro Gln His Ser Pro His Tyr  
 1 5 10 15  
 Leu Ala Ser Ser Pro Thr Ala Phe Asn Thr Leu Pro Ser Asp Arg Lys  
 20 25 30  
 Ala Ser Pro Pro Ser Gly Leu Trp Ser Pro Ala Tyr Ala Ser His  
 35 40 45

<210> 110  
 <211> 46  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (27)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (34)  
 <223> Xaa equals stop translation

<400> 110  
 Pro Phe Trp Phe Thr Arg His Gln Glu Pro Gln His His Cys His Cys  
 1 5 10 15

85

His Trp Leu Pro Gly Val Pro Pro Gln Leu Xaa Gln Asn Lys Ala Ala  
                   20                  25                  30

Ala Xaa Pro Ser Gly Ala Ser Val Gly Leu His Arg Ala His  
           35                  40                  45

<210> 111  
 <211> 123  
 <212> PRT  
 <213> Homo sapiens

<400> 111  
 Asp Phe Gln Arg Ser Asp Arg Ile Asp Met Glu Thr Asn Thr Lys Asp  
   1                  5                  10                  15

Leu Lys Gly Ala Gly Val Thr Val His Pro Pro Arg Ala Ser Glu Val  
                   20                  25                  30

Asn Leu Glu Glu Leu Pro Pro Leu Asn Tyr Phe Val His Ala Phe Tyr  
           35                  40                  45

Tyr Ser Trp Tyr Gly Asn Pro Gln Phe Asp Gly Lys Tyr Val His Trp  
   50                  55                  60

Asn His Pro Val Leu Glu His Trp Asp Pro Arg Ile Ala Lys Asn Tyr  
   65                  70                  75                  80

Pro Gln Gly Arg His Ser Pro Pro Asp Asp Ile Gly Ser Ser Phe Tyr  
                   85                  90                  95

Pro Glu Leu Gly Ser Tyr Ser Ser Arg Asp Pro Ser Val Ile Glu Thr  
           100                  105                  110

His Met Lys Gln Met Arg Ser Ala Ser Ile Gly  
           115                  120

<210> 112  
 <211> 123  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (69)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (88)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (93)  
 <223> Xaa equals any of the naturally occurring L-amino acids



86

&lt;400&gt; 112

Asp Phe Gln Lys Ser Asp Arg Ile Asn Ser Glu Thr Asn Thr Lys Asn  
 1 5 10 15

Leu Lys Ser Val Glu Ile Thr Met Lys Pro Ser Lys Ala Ser Glu Leu  
 20 25 30

Asn Leu Asp Glu Leu Pro Pro Leu Asn Asn Tyr Leu His Val Phe Tyr  
 35 40 45

Tyr Ser Trp Tyr Gly Asn Pro Gln Phe Asp Gly Lys Tyr Ile His Trp  
 50 55 60

Asn His Pro Val Xaa Glu His Trp Asp Pro Arg Ile Ala Lys Asn Tyr  
 65 70 75 80

Pro Gln Gly Arg His Asn Pro Xaa Asp Asp Ile Gly Xaa Ser Phe Tyr  
 85 90 95

Pro Glu Leu Gly Ser Tyr Ser Ser Arg Asp Pro Ser Val Ile Glu Thr  
 100 105 110

His Met Arg Gln Met Arg Ser Ala Ser Ile Gly  
 115 120

&lt;210&gt; 113

&lt;211&gt; 44

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 113

Ser Ile Gly Thr Pro Arg Ile Ala Lys Asn Tyr Pro Gln Gly Arg His  
 1 5 10 15

Asn Pro Pro Asp Asp Ile Gly Ser Ser Phe Tyr Pro Glu Leu Ala Ser  
 20 25 30

Tyr Ser Ser Arg Asp Pro Ser Val Ile Glu Thr His  
 35 40

&lt;210&gt; 114

&lt;211&gt; 224

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 114

Met Arg Gln Met Arg Ser Ala Ser Ile Gly Val Leu Ala Leu Ser Trp  
 1 5 10 15

Tyr Pro Pro Asp Val Asn Asp Glu Asn Gly Glu Pro Thr Asp Asn Leu  
 20 25 30

Val Pro Thr Ile Leu Asp Lys Ala His Lys Tyr Asn Leu Lys Val Thr  
 35 40 45

Phe	His	Ile	Glu	Pro	Tyr	Ser	Asn	Arg	Asp	Asp	Gln	Asn	Met	Tyr	Lys
50						55					60				
Asn	Val	Lys	Tyr	Ile	Ile	Asp	Lys	Tyr	Gly	Asn	His	Pro	Ala	Phe	Tyr
65					70					75					80
Arg	Tyr	Lys	Thr	Lys	Thr	Gly	Asn	Ala	Leu	Pro	Met	Phe	Tyr	Val	Tyr
				85					90					95	
Asp	Ser	Tyr	Ile	Thr	Lys	Pro	Glu	Lys	Trp	Ala	Asn	Leu	Leu	Thr	Thr
			100					105					110		
Ser	Gly	Ser	Arg	Ser	Ile	Arg	Asn	Ser	Pro	Tyr	Asp	Gly	Leu	Phe	Ile
		115					120					125			
Ala	Leu	Leu	Val	Glu	Glu	Lys	His	Lys	Tyr	Asp	Ile	Leu	Gln	Ser	Gly
	130					135					140				
Phe	Asp	Gly	Ile	Tyr	Thr	Tyr	Phe	Ala	Thr	Asn	Gly	Phe	Thr	Tyr	Gly
145					150					155					160
Ser	Ser	His	Gln	Asn	Trp	Ala	Ser	Leu	Lys	Leu	Phe	Cys	Asp	Lys	Tyr
				165					170					175	
Asn	Leu	Ile	Phe	Ile	Pro	Ser	Val	Gly	Pro	Gly	Tyr	Ile	Asp	Thr	Ser
			180					185					190		
Ile	Arg	Pro	Trp	Asn	Thr	Gln	Asn	Thr	Arg	Asn	Arg	Ile	Asn	Gly	Lys
		195					200					205			
Tyr	Tyr	Glu	Ile	Gly	Leu	Ser	Ala	Ala	Leu	Gln	Asp	Thr	Pro	Pro	Ala
	210					215					220				

```
<210> 115
<211> 268
<212> PRT
<213> Homo sapiens
```

```

<400> 115
Ser Ile Gly Thr Pro Arg Ile Ala Lys Asn Tyr Pro Gln Gly Arg His
 1                    5                10                15

Asn Pro Pro Asp Asp Ile Gly Ser Ser Phe Tyr Pro Glu Leu Ala Ser
      20                25                30

Tyr Ser Ser Arg Asp Pro Ser Val Ile Glu Thr His Met Arg Gln Met
      35                40                45

Arg Ser Ala Ser Ile Gly Val Leu Ala Leu Ser Trp Tyr Pro Pro Asp
      50                55                60

Val Asn Asp Glu Asn Gly Glu Pro Thr Asp Asn Leu Val Pro Thr Ile
      65                70                75                80

```

88

Leu Asp Lys Ala His Lys Tyr Asn Leu Lys Val Thr Phe His Ile Glu  
                                     85                                    90                                    95  
 Pro Tyr Ser Asn Arg Asp Asp Gln Asn Met Tyr Lys Asn Val Lys Tyr  
                                     100                                    105                                    110  
 Ile Ile Asp Lys Tyr Gly Asn His Pro Ala Phe Tyr Arg Tyr Lys Thr  
                                     115                                    120                                    125  
 Lys Thr Gly Asn Ala Leu Pro Met Phe Tyr Val Tyr Asp Ser Tyr Ile  
                                     130                                    135                                    140  
 Thr Lys Pro Glu Lys Trp Ala Asn Leu Leu Thr Thr Ser Gly Ser Arg  
                                     145                                    150                                    155                                    160  
 Ser Ile Arg Asn Ser Pro Tyr Asp Gly Leu Phe Ile Ala Leu Leu Val  
                                     165                                    170                                    175  
 Glu Glu Lys His Lys Tyr Asp Ile Leu Gln Ser Gly Phe Asp Gly Ile  
                                     180                                    185                                    190  
 Tyr Thr Tyr Phe Ala Thr Asn Gly Phe Thr Tyr Gly Ser Ser His Gln  
                                     195                                    200                                    205  
 Asn Trp Ala Ser Leu Lys Leu Phe Cys Asp Lys Tyr Asn Leu Ile Phe  
                                     210                                    215                                    220  
 Ile Pro Ser Val Gly Pro Gly Tyr Ile Asp Thr Ser Ile Arg Pro Trp  
                                     225                                    230                                    235                                    240  
 Asn Thr Gln Asn Thr Arg Asn Arg Ile Asn Gly Lys Tyr Tyr Glu Ile  
                                     245                                    250                                    255  
 Gly Leu Ser Ala Ala Leu Gln Asp Thr Pro Pro Ala  
                                     260                                    265

&lt;210&gt; 116

&lt;211&gt; 264

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 116

Pro Arg Ile Ala Lys Asn Tyr Pro Gln Gly Arg His Asn Pro Pro Asp  
   1                                    5                                    10                                    15  
 Asp Ile Gly Ser Ser Phe Tyr Pro Glu Leu Ala Ser Tyr Ser Ser Arg  
                                     20                                    25                                    30  
 Asp Pro Ser Val Ile Glu Thr His Met Arg Gln Met Arg Ser Ala Ser  
                                     35                                    40                                    45  
 Ile Gly Val Leu Ala Leu Ser Trp Tyr Pro Pro Asp Val Asn Asp Glu  
                                     50                                    55                                    60  
 Asn Gly Glu Pro Thr Asp Asn Leu Val Pro Thr Ile Leu Asp Lys Ala  
                                     65                                    70                                    75                                    80

89

His Lys Tyr Asn Leu Lys Val Thr Phe His Ile Glu Pro Tyr Ser Asn  
                                     85                                    90                                    95  
 Arg Asp Asp Gln Asn Met Tyr Lys Asn Val Lys Tyr Ile Ile Asp Lys  
                                     100                                    105                                    110  
 Tyr Gly Asn His Pro Ala Phe Tyr Arg Tyr Lys Thr Lys Thr Gly Asn  
                                     115                                    120                                    125  
 Ala Leu Pro Met Phe Tyr Val Tyr Asp Ser Tyr Ile Thr Lys Pro Glu  
                                     130                                    135                                    140  
 Lys Trp Ala Asn Leu Leu Thr Thr Ser Gly Ser Arg Ser Ile Arg Asn  
                                     145                                    150                                    155                                    160  
 Ser Pro Tyr Asp Gly Leu Phe Ile Ala Leu Leu Val Glu Glu Lys His  
                                     165                                    170                                    175  
 Lys Tyr Asp Ile Leu Gln Ser Gly Phe Asp Gly Ile Tyr Thr Tyr Phe  
                                     180                                    185                                    190  
 Ala Thr Asn Gly Phe Thr Tyr Gly Ser Ser His Gln Asn Trp Ala Ser  
                                     195                                    200                                    205  
 Leu Lys Leu Phe Cys Asp Lys Tyr Asn Leu Ile Phe Ile Pro Ser Val  
                                     210                                    215                                    220  
 Gly Pro Gly Tyr Ile Asp Thr Ser Ile Arg Pro Trp Asn Thr Gln Asn  
                                     225                                    230                                    235                                    240  
 Thr Arg Asn Arg Ile Asn Gly Lys Tyr Tyr Glu Ile Gly Leu Ser Ala  
                                     245                                    250                                    255  
 Ala Leu Gln Asp Thr Pro Pro Ala  
                                     260

<210> 117  
 <211> 56  
 <212> PRT  
 <213> Homo sapiens

<400> 117  
 Glu Gly Thr Gln Ile Glu Lys Ala Val Pro Lys Arg Thr Ser Asn Thr  
     1                                    5                                    10                                    15  
 Val Tyr Leu Asp Tyr Arg Pro His Lys Pro Gly Leu Tyr Leu Glu Leu  
                                     20                                    25                                    30  
 Thr Arg Lys Trp Ser Glu Lys Tyr Ser Lys Glu Arg Ala Thr Tyr Ala  
                                     35                                    40                                    45  
 Leu Asp Arg Gln Leu Pro Val Ser  
                                     50                                    55

<210> 118  
 <211> 74

90

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 118

Asp Phe Gln Lys Ser Asp Arg Ile Asn Ser Glu Thr Asn Thr Lys Asn  
 1 5 10 15

Leu Lys Ser Val Glu Ile Thr Met Lys Pro Ser Lys Ala Ser Glu Leu  
 20 25 30

Asn Leu Asp Glu Leu Pro Pro Leu Asn Asn Tyr Leu His Val Phe Tyr  
 35 40 45

Tyr Ser Trp Tyr Gly Asn Pro Gln Phe Asp Gly Lys Tyr Ile His Trp  
 50 55 60

Asn His Pro Val Leu Glu His Trp Asp Pro  
 65 70

&lt;210&gt; 119

&lt;211&gt; 84

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 119

Tyr Phe Gln Gln Lys Val Asp His Phe Gly Phe Asn Thr Val Lys Thr  
 1 5 10 15

Phe Asn Gln Arg Tyr Leu Val Ala Asp Lys Tyr Trp Lys Lys Asn Gly  
 20 25 30

Gly Ser Ile Leu Phe Tyr Thr Gly Asn Glu Gly Asp Ile Ile Trp Phe  
 35 40 45

Cys Asn Asn Thr Gly Phe Met Trp Asp Val Ala Glu Glu Leu Lys Ala  
 50 55 60

Met Leu Val Phe Ala Glu His Arg Tyr Tyr Gly Glu Ser Leu Pro Phe  
 65 70 75 80

Gly Asp Asn Ser

&lt;210&gt; 120

&lt;211&gt; 86

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 120

Phe Phe Gln Gln Arg Leu Asp His Phe Asn Phe Glu Arg Phe Gly Asn  
 1 5 10 15

Lys Thr Phe Pro Gln Arg Phe Leu Val Ser Asp Arg Phe Trp Val Arg  
 20 25 30

Gly Glu Gly Pro Ile Phe Phe Tyr Thr Gly Asn Glu Gly Asp Val Trp

91

35                      40                      45  
 Ala Phe Ala Asn Asn Ser Ala Phe Val Ala Glu Leu Ala Ala Glu Arg  
     50                      55                      60  
 Gly Ala Leu Leu Val Phe Ala Glu His Arg Tyr Tyr Gly Lys Ser Leu  
     65                      70                      75                      80  
 Pro Phe Gly Ala Gln Ser  
                             85

<210> 121  
 <211> 134  
 <212> PRT  
 <213> Homo sapiens

<400> 121  
 Ala Asp Ala Glu Gly Asp Met Gly Ser Ala Pro Trp Ala Pro Val Leu  
     1                      5                      10                      15  
 Leu Leu Ala Leu Gly Leu Arg Gly Leu Gln Ala Gly Ala Arg Arg Ala  
                     20                      25                      30  
 Pro Asp Pro Gly Phe Gln Glu Arg Phe Phe Gln Gln Arg Leu Asp His  
     35                      40                      45  
 Phe Asn Phe Glu Arg Phe Gly Asn Lys Thr Phe Pro Gln Arg Phe Leu  
     50                      55                      60  
 Val Ser Asp Arg Phe Trp Val Arg Gly Glu Gly Pro Ile Phe Phe Tyr  
     65                      70                      75                      80  
 Thr Gly Asn Glu Gly Asp Val Trp Ala Phe Ala Asn Asn Ser Ala Phe  
                     85                      90                      95  
 Val Ala Glu Leu Ala Ala Glu Arg Gly Ala Leu Leu Val Phe Ala Glu  
                     100                      105                      110  
 His Arg Tyr Tyr Gly Lys Ser Leu Pro Phe Gly Ala Gln Ser Thr Gln  
     115                      120                      125  
 Arg Gly Thr Arg Ser Cys  
     130

<210> 122  
 <211> 492  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (89)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 122  
 Met Gly Ser Ala Pro Trp Ala Pro Val Leu Leu Leu Ala Leu Gly Leu

92

1	5	10	15
Arg Gly Leu Gln Ala Gly Ala Arg Arg Ala Pro Asp Pro Gly Phe Gln	20	25	30
Glu Arg Phe Phe Gln Gln Arg Leu Asp His Phe Asn Phe Glu Arg Phe	35	40	45
Gly Asn Lys Thr Phe Pro Gln Arg Phe Leu Val Ser Asp Arg Phe Trp	50	55	60
Val Arg Gly Glu Gly Pro Ile Phe Phe Tyr Thr Gly Asn Glu Gly Asp	65	70	75
Val Trp Ala Phe Ala Asn Asn Ser Xaa Phe Val Ala Glu Leu Ala Ala	85	90	95
Glu Arg Gly Ala Leu Leu Val Phe Ala Glu His Arg Tyr Tyr Gly Lys	100	105	110
Ser Leu Pro Phe Gly Ala Gln Ser Thr Gln Arg Gly His Thr Glu Leu	115	120	125
Leu Thr Val Glu Gln Ala Leu Ala Asp Phe Ala Glu Leu Leu Arg Ala	130	135	140
Leu Arg Arg Asp Leu Gly Ala Gln Asp Ala Pro Ala Ile Ala Phe Gly	145	150	155
Gly Ser Tyr Gly Gly Met Leu Ser Ala Tyr Leu Arg Met Lys Tyr Pro	165	170	175
His Leu Val Ala Gly Ala Leu Ala Ala Ser Ala Pro Val Leu Ala Val	180	185	190
Ala Gly Leu Gly Asp Ser Asn Gln Phe Phe Arg Asp Val Thr Ala Asp	195	200	205
Phe Glu Gly Gln Ser Pro Lys Cys Thr Gln Gly Val Arg Glu Ala Phe	210	215	220
Arg Gln Ile Lys Asp Leu Phe Leu Gln Gly Ala Tyr Asp Thr Val Arg	225	230	235
Trp Glu Phe Gly Thr Cys Gln Pro Leu Ser Asp Glu Lys Asp Leu Thr	245	250	255
Gln Leu Phe Met Phe Ala Arg Asn Ala Phe Thr Val Leu Ala Met Met	260	265	270
Asp Tyr Pro Tyr Pro Thr Asp Phe Leu Gly Pro Leu Pro Ala Asn Pro	275	280	285
Val Lys Val Gly Cys Asp Arg Leu Leu Ser Glu Ala Gln Arg Ile Thr	290	295	300
Gly Leu Arg Ala Leu Ala Gly Leu Val Tyr Asn Ala Ser Gly Ser Glu	305	310	315
			320

His Cys Tyr Asp Ile Tyr Arg Leu Tyr His Ser Cys Ala Asp Pro Thr  
 325 330 335  
 Gly Cys Gly Thr Gly Pro Asp Ala Arg Ala Trp Asp Tyr Gln Ala Cys  
 340 345 350  
 Thr Glu Ile Asn Leu Thr Phe Ala Ser Asn Asn Val Thr Asp Met Phe  
 355 360 365  
 Pro Asp Leu Pro Phe Thr Asp Glu Leu Arg Gln Arg Tyr Cys Leu Asp  
 370 375 380  
 Thr Trp Gly Val Trp Pro Arg Pro Asp Trp Leu Leu Thr Ser Phe Trp  
 385 390 395 400  
 Gly Gly Asp Leu Arg Ala Ala Ser Asn Ile Ile Phe Ser Asn Gly Asn  
 405 410 415  
 Leu Asp Pro Trp Ala Gly Gly Gly Ile Arg Arg Asn Leu Ser Ala Ser  
 420 425 430  
 Val Ile Ala Val Thr Ile Gln Gly Gly Ala His His Leu Asp Leu Arg  
 435 440 445  
 Ala Ser His Pro Glu Asp Pro Ala Ser Val Val Glu Ala Arg Lys Leu  
 450 455 460  
 Glu Ala Thr Ile Ile Gly Glu Trp Val Lys Ala Ala Arg Arg Glu Gln  
 465 470 475 480  
 Gln Pro Ala Leu Arg Gly Gly Pro Arg Leu Ser Leu  
 485 490

&lt;210&gt; 123

&lt;211&gt; 100

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 123

Pro His Gln Glu Cys Pro Val Leu Gly Pro Trp Ser Ala Trp Ser Ser  
 1 5 10 15  
 Cys Ser Ala Pro Cys Gly Gly Gly Thr Met Glu Arg His Arg Thr Cys  
 20 25 30  
 Glu Gly Gly Pro Gly Val Ala Pro Cys Gln Ala Gln Asp Thr Glu Gln  
 35 40 45  
 Arg Gln Glu Cys Asn Leu Gln Pro Cys Pro Glu Cys Pro Pro Gly Gln  
 50 55 60  
 Val Leu Ser Ala Cys Ala Thr Ser Cys Pro Cys Leu Cys Trp His Leu  
 65 70 75 80  
 Gln Pro Gly Ala Ile Cys Val Gln Glu Pro Cys Gln Pro Gly Cys Gly  
 85 90 95



Cys Pro Gly Gly  
100

<210> 124  
<211> 100  
<212> PRT  
<213> Homo sapiens

<400> 124  
Pro Asp Gln Glu Cys Pro Val Leu Gly Pro Trp Ser Ala Trp Ser Ser  
1 5 10 15  
Cys Ser Ala Pro Cys Gly Gly Gly Thr Met Glu Arg His Arg Thr Cys  
20 25 30  
Glu Gly Gly Pro Gly Val Ala Pro Cys Gln Ala Gln Asp Thr Glu Gln  
35 40 45  
Arg Gln Glu Cys Asn Leu Gln Pro Cys Pro Glu Cys Pro Pro Gly Gln  
50 55 60  
Val Leu Ser Ala Cys Ala Thr Ser Cys Pro Cys Leu Cys Trp His Leu  
65 70 75 80  
Gln Pro Gly Ala Ile Cys Val Gln Glu Pro Cys Gln Pro Gly Cys Gly  
85 90 95  
Cys Leu Glu Gly  
100

<210> 125  
<211> 143  
<212> PRT  
<213> Homo sapiens

<400> 125  
Trp Ala Pro Trp Glu Pro Cys Ser Arg Ser Cys Gly Val Gly Gln Gln  
1 5 10 15  
Arg Arg Leu Arg Ala Tyr Arg Pro Pro Gly Pro Gly Gly His Trp Cys  
20 25 30  
Pro Asn Ile Leu Thr Ala Tyr Gln Glu Arg Arg Phe Cys Asn Leu Arg  
35 40 45  
Ala Cys Pro Glu Ala Gly Cys Pro Ala Gly Met Glu Val Val Thr Cys  
50 55 60  
Ala Asn Arg Cys Pro Arg Arg Cys Ser Asp Leu Gln Glu Gly Ile Val  
65 70 75 80  
Cys Gln Asp Asp Gln Val Cys Gln Lys Gly Cys Arg Cys Pro Lys Gly  
85 90 95  
Ser Leu Glu Gln Asp Gly Gly Cys Val Pro Ile Gly His Cys Asp Cys

Gly Ala Xaa Pro Xaa Pro Trp Lys Xaa Arg Pro Arg Ser Xaa Pro Gln  
115 120 125

Gly Leu Cys Ser Pro Gly Thr Ala Pro Arg Cys Val Cys His Cys Gly  
 130 135 140

Ala Phe Ser Cys Ser  
 145

<210> 127  
 <211> 27  
 <212> PRT  
 <213> Homo sapiens

<400> 127  
 His Glu Pro Asp Gln Glu Cys Pro Val Leu Gly Pro Trp Ser Ala Trp  
 1 5 10 15

Ser Ser Cys Ser Ala Pro Cys Gly Gly Gly Thr  
 20 25

<210> 128  
 <211> 164  
 <212> PRT  
 <213> Homo sapiens

<400> 128  
 Met Glu Arg His Arg Thr Cys Glu Gly Gly Pro Gly Val Ala Pro Cys  
 1 5 10 15

Gln Ala Gln Asp Thr Glu Gln Arg Gln Glu Cys Asn Leu Gln Pro Cys  
 20 25 30

Pro Glu Cys Pro Pro Gly Gln Val Leu Ser Ala Cys Ala Thr Ser Cys  
 35 40 45

Pro Cys Leu Cys Trp His Leu Gln Pro Gly Ala Ile Cys Val Gln Glu  
 50 55 60

Pro Cys Gln Pro Gly Cys Gly Cys Pro Gly Gly Gln Leu Leu His Asn  
 65 70 75 80

Gly Thr Cys Val Pro Pro Thr Ala Cys Pro Cys Thr Gln His Ser Leu  
 85 90 95

Pro Trp Gly Leu Thr Leu Thr Leu Glu Glu Gln Ala Gln Glu Leu Pro  
 100 105 110

Pro Gly Thr Val Leu Thr Arg Asn Cys Thr Arg Cys Val Cys His Gly  
 115 120 125

Gly Ala Phe Ser Cys Ser Leu Val Asp Cys Gln Glu Cys Pro Leu Gly  
 130 135 140

Lys Arg Gly Ser Arg Trp Pro Arg Gly Ser Trp Gly Ser Ala Ser Arg  
 145 150 155 160

Arg Ala Trp Arg

```
<210> 129
<211> 191
<212> PRT
<213> Homo sapiens
```

<400> 129																			
His	Glu	Pro	Asp	Gln	Glu	Cys	Pro	Val	Leu	Gly	Pro	Trp	Ser	Ala	Trp				
1				5					10					15					
Ser	Ser	Cys	Ser	Ala	Pro	Cys	Gly	Gly	Gly	Thr	Met	Glu	Arg	His	Arg				
			20					25					30						
Thr	Cys	Glu	Gly	Gly	Pro	Gly	Val	Ala	Pro	Cys	Gln	Ala	Gln	Asp	Thr				
		35					40					45							
Glu	Gln	Arg	Gln	Glu	Cys	Asn	Leu	Gln	Pro	Cys	Pro	Glu	Cys	Pro	Pro				
	50					55					60								
Gly	Gln	Val	Leu	Ser	Ala	Cys	Ala	Thr	Ser	Cys	Pro	Cys	Leu	Cys	Trp				
65					70					75					80				
His	Leu	Gln	Pro	Gly	Ala	Ile	Cys	Val	Gln	Glu	Pro	Cys	Gln	Pro	Gly				
				85					90					95					
Cys	Gly	Cys	Pro	Gly	Gly	Gln	Leu	Leu	His	Asn	Gly	Thr	Cys	Val	Pro				
			100					105					110						
Pro	Thr	Ala	Cys	Pro	Cys	Thr	Gln	His	Ser	Leu	Pro	Trp	Gly	Leu	Thr				
		115					120					125							
Leu	Thr	Leu	Glu	Glu	Gln	Ala	Gln	Glu	Leu	Pro	Pro	Gly	Thr	Val	Leu				
	130					135					140								
Thr	Arg	Asn	Cys	Thr	Arg	Cys	Val	Cys	His	Gly	Gly	Ala	Phe	Ser	Cys				
145					150					155					160				
Ser	Leu	Val	Asp	Cys	Gln	Glu	Cys	Pro	Leu	Gly	Lys	Arg	Gly	Ser	Arg				
				165					170					175					
Trp	Pro	Arg	Gly	Ser	Trp	Gly	Ser	Ala	Ser	Arg	Arg	Ala	Trp	Arg					
			180					185					190						

```
<210> 130
<211> 262
<212> PRT
<213> Homo sapiens
```

```
<400> 130  
Val Pro Pro Gly Glu Thr Trp Gln Gln Val Ala Pro Gly Glu Leu Gly  
   1                               10                          15  
  
Leu Cys Glu Gln Thr Cys Leu Glu Met Asn Ala Thr Lys Thr Gln Ser  
      20                25                  30
```

```
<210> 131
<211> 189
<212> PRT
<213> Homo sapiens
```

<400> 131  
Pro Asp Gln Glu Cys Pro Val Leu Gly Pro Trp Ser Ala Trp Ser Ser  
1 5 10 15  
Cys Ser Ala Pro Cys Gly Gly Gly Thr Met Glu Arg His Arg Thr Cys  
20 25 30

99

Glu Gly Gly Pro Gly Val Ala Pro Cys Gln Ala Gln Asp Thr Glu Gln  
           35                          40                          45  
 Arg Gln Glu Cys Asn Leu Gln Pro Cys Pro Glu Cys Pro Pro Gly Gln  
           50                          55                          60  
 Val Leu Ser Ala Cys Ala Thr Ser Cys Pro Cys Leu Cys Trp His Leu  
           65                          70                          75                          80  
 Gln Pro Gly Ala Ile Cys Val Gln Glu Pro Cys Gln Pro Gly Cys Gly  
                           85                          90                          95  
 Cys Pro Gly Gly Gln Leu Leu His Asn Gly Thr Cys Val Pro Pro Thr  
                           100                          105                          110  
 Ala Cys Pro Cys Thr Gln His Ser Leu Pro Trp Gly Leu Thr Leu Thr  
           115                          120                          125  
 Leu Glu Glu Gln Ala Gln Glu Leu Pro Pro Gly Thr Val Leu Thr Arg  
           130                          135                          140  
 Asn Cys Thr Arg Cys Val Cys His Gly Gly Ala Phe Ser Cys Ser Leu  
           145                          150                          155                          160  
 Val Asp Cys Gln Glu Cys Pro Leu Gly Lys Arg Gly Ser Arg Trp Pro  
                           165                          170                          175  
 Arg Gly Ser Trp Gly Ser Ala Ser Arg Arg Ala Trp Arg  
           180                          185

<210> 132  
 <211> 73  
 <212> PRT  
 <213> Homo sapiens

<400> 132  
 Glu Thr Glu Ser His Ser Val Thr Gln Ala Gly Val Gln Trp His Asp  
   1                          5                          10                          15  
 Leu Gly Ser Pro Gln Pro Leu Ser Pro Arg Phe Lys Gln Phe Ser Cys  
           20                          25                          30  
 Leu Ser Leu Pro Ser Ser Trp Asp Tyr Arg Cys Val Pro Pro His Leu  
           35                          40                          45  
 Ala Asn Phe Cys Ile Phe Ser Arg Asp Gly Val Ser Pro Cys Trp Pro  
           50                          55                          60  
 Gly Trp Ser Arg Thr Thr Asp Val Lys  
   65                          70

<210> 133  
 <211> 80  
 <212> PRT  
 <213> Homo sapiens

100

&lt;400&gt; 133

Glu Tyr Ser Gly Thr Ile Ser Val His Arg Asn Leu Cys Leu Pro Gly  
 1 5 10 15

Ser Asn Ser Ser Pro Ala Ser Ala Ser Gln Val Ala Gly Thr Thr Asp  
 20 25 30

Val Cys His His Thr Trp Leu Ile Phe Val Phe Leu Val Glu Met Gly  
 35 40 45

Phe His His Val Gly Gln Ala Gly Leu Glu Leu Arg Thr Ser Ser Gly  
 50 55 60

Pro Pro Ala Ser Ala Ser Gln Ser Ala Arg Ile Thr Gly Ala Ser His  
 65 70 75 80

&lt;210&gt; 134

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 134

Thr Ala Val Tyr Tyr Val Leu Ala Asp Leu Val Met Leu Thr Leu Tyr  
 1 5 10 15

Phe

&lt;210&gt; 135

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 135

Val Leu Leu Phe Leu Met Gly Met Ala Cys Ala Thr Pro Leu Leu Ser  
 1 5 10 15

Ala

&lt;210&gt; 136

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 136

Val Ile Gly Phe Val Ile Gly Ser Ile Ser Ser Val Leu Tyr Leu Leu  
 1 5 10 15

Ser

101

<210> 137  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 137  
Leu Phe Ala Leu Val Met Leu Gly Asn Thr Leu Tyr Gly Leu Ser Val  
1 5 10 15

Leu

<210> 138  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 138  
Ser Leu Gly Val Leu Leu Leu Asp Thr Ile Ile Ser Ile Gln Phe Leu  
1 5 10 15

Val

<210> 139  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 139  
Leu Ile Gly Ser Phe Leu Ala Asp Gln Leu Pro Leu  
1 5 10

<210> 140  
<211> 61  
<212> PRT  
<213> Homo sapiens

<400> 140  
Tyr Lys Phe Arg Thr Arg Pro Ser Leu Leu Ser Ala Pro Ile Asn Ser  
1 5 10 15

Val Leu Leu Phe Leu Met Gly Met Ala Cys Ala Thr Pro Leu Leu Ser  
20 25 30

Ala Ala Gly Pro Val Ala Ala Pro Arg Glu Ala Phe Arg Gly Arg Ala  
35 40 45

Leu Leu Ser Val Glu Ser Gly Ser Lys Pro Phe Thr Arg  
50 55 60

<210> 141  
<211> 18



102

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 141

Leu Pro Gln Ile Arg Thr Asn Phe Leu Arg Lys Ser Thr Gln Gly Ile  
 1 5 10 15

Ser Tyr

&lt;210&gt; 142

&lt;211&gt; 21

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 142

Lys Asn Pro Glu Glu Gly Gln Ser Glu Gly Ser Tyr Leu Leu His His  
 1 5 10 15

Leu Pro Trp Leu Val  
 20

&lt;210&gt; 143

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 143

Arg Arg Ser Thr Ala Ala Ser Glu Leu Glu Pro Leu Leu Pro Ser  
 1 5 10 15

&lt;210&gt; 144

&lt;211&gt; 113

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 144

Pro Asn Trp Arg Thr Ser Ser Tyr Val Gly Ala Ser Ile Val Thr Ala  
 1 5 10 15

Val Gly Phe Ser Lys Gly Leu Trp Met Glu Cys Ala Thr His Ser Thr  
 20 25 30

Gly Ile Thr Gln Cys Asp Ile Tyr Ser Thr Leu Leu Gly Leu Pro Ala  
 35 40 45

Asp Ile Gln Ala Ala Gln Ala Met Met Val Thr Ser Ser Ala Met Ser  
 50 55 60

Ser Leu Ala Cys Ile Ile Ser Val Val Gly Met Arg Cys Thr Val Phe  
 65 70 75 80

Cys Gln Asp Ser Arg Ala Lys Asp Arg Val Ala Val Val Gly Gly Val  
 85 90 95

103

Phe Phe Ile Leu Gly Gly Ile Leu Gly Phe Ile Pro Val Ala Trp Asn  
                   100                                  105                                  110

Leu

&lt;210&gt; 145

&lt;211&gt; 113

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (109)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 145

Pro Ser Trp Lys Thr Ser Ser Tyr Val Gly Ala Ser Ile Val Thr Ala  
   1                                  5                                  10                                  15

Val Gly Phe Ser Lys Gly Leu Trp Met Glu Cys Ala Thr His Ser Thr  
                   20                                  25                                  30

Gly Ile Thr Gln Cys Asp Ile Tyr Ser Thr Leu Leu Gly Leu Pro Ala  
                   35                                  40                                  45

Asp Ile Gln Ala Ala Gln Ala Met Met Val Thr Ser Ser Ala Ile Ser  
   50                                  55                                  60

Ser Leu Ala Cys Ile Ile Ser Val Val Gly Met Arg Cys Thr Val Phe  
   65                                  70                                  75                                  80

Cys Gln Glu Ser Arg Ala Lys Asp Arg Val Ala Val Ala Gly Gly Val  
                   85                                  90                                  95

Phe Phe Ile Leu Gly Ser Leu Leu Gly Phe Ile Pro Xaa Ala Trp Asn  
                   100                                  105                                  110

Leu

&lt;210&gt; 146

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 146

Met Val Thr Ser Ser Ala Ile Ser Ser Leu Ala Cys Ile Ile Ser Val  
   1                                  5                                  10                                  15

Val

&lt;210&gt; 147

&lt;211&gt; 17

104

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 147

Ala Val Ala Gly Gly Val Phe Phe Ile Leu Gly Gly Leu Leu Gly Phe  
1 5 10 15

Ile

&lt;210&gt; 148

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 148

Leu Gly Ile Ile Ser Ser Leu Phe Ser Leu Ile Ala Gly Ile Ile Leu  
1 5 10 15

Cys

&lt;210&gt; 149

&lt;211&gt; 24

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 149

Met Ala Ser Leu Gly Leu Gln Leu Val Gly Tyr Ile Leu Gly Leu Leu  
1 5 10 15

Gly Leu Leu Gly Thr Leu Val Ala  
20

&lt;210&gt; 150

&lt;211&gt; 56

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 150

Met Leu Leu Pro Ser Trp Lys Thr Ser Ser Tyr Val Gly Ala Ser Ile  
1 5 10 15

Val Thr Ala Val Gly Phe Ser Lys Gly Leu Trp Met Glu Cys Ala Thr  
20 25 30

His Ser Thr Gly Ile Thr Gln Cys Asp Ile Tyr Ser Thr Leu Leu Gly  
35 40 45

Leu Pro Ala Asp Ile Gln Ala Ala  
50 55

&lt;210&gt; 151

&lt;211&gt; 12

105

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 151

Arg Cys Thr Val Phe Cys Gln Glu Ser Arg Ala Lys  
 1 5 10

&lt;210&gt; 152

&lt;211&gt; 19

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 152

His Gly Ile Leu Arg Asp Phe Tyr Ser Pro Leu Val Pro Asp Ser Met  
 1 5 10 15

Lys Phe Glu

&lt;210&gt; 153

&lt;211&gt; 42

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 153

Arg Asn Arg Ser Asn Tyr Tyr Asp Ala Tyr Gln Ala Gln Pro Leu Ala  
 1 5 10 15

Thr Arg Ser Ser Pro Arg Pro Gly Gln Pro Pro Lys Val Lys Ser Glu  
 20 25 30

Phe Asn Ser Tyr Ser Leu Thr Gly Tyr Val  
 35 40

&lt;210&gt; 154

&lt;211&gt; 386

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 154

Thr Val Asp Thr Tyr Gly Arg Pro Ile Leu Glu Val Pro Glu Ser Val  
 1 5 10 15

Thr Gly Pro Trp Lys Gly Asp Val Asn Leu Pro Cys Thr Tyr Asp Pro  
 20 25 30

Leu Gln Gly Tyr Thr Gln Val Leu Val Lys Trp Leu Val Gln Arg Gly  
 35 40 45

Ser Asp Pro Val Thr Ile Phe Leu Arg Asp Ser Ser Gly Asp His Ile  
 50 55 60

Gln Gln Ala Lys Tyr Gln Gly Arg Leu His Val Ser His Lys Val Pro  
 65 70 75 80

106

Gly Asp Val Ser Leu Gln Leu Ser Thr Leu Glu Met Asp Asp Arg Ser  
                             85                            90                            95  
 His Tyr Thr Cys Glu Val Thr Trp Gln Thr Pro Asp Gly Asn Gln Val  
                             100                            105                            110  
 Val Arg Asp Lys Ile Thr Glu Leu Arg Val Gln Lys Leu Ser Val Ser  
                             115                            120                            125  
 Lys Pro Thr Val Thr Thr Gly Ser Gly Tyr Gly Phe Thr Val Pro Gln  
                             130                            135                            140  
 Gly Met Arg Ile Ser Leu Gln Cys Gln Ala Arg Gly Ser Pro Pro Ile  
                             145                            150                            155                            160  
 Ser Tyr Ile Trp Tyr Lys Gln Gln Thr Asn Asn Gln Glu Pro Ile Lys  
                             165                            170                            175  
 Val Ala Thr Leu Ser Thr Leu Leu Phe Lys Pro Ala Val Ile Ala Asp  
                             180                            185                            190  
 Ser Gly Ser Tyr Phe Cys Thr Ala Lys Gly Gln Val Gly Ser Glu Gln  
                             195                            200                            205  
 His Ser Asp Ile Val Lys Phe Val Val Lys Asp Ser Ser Lys Leu Leu  
                             210                            215                            220  
 Lys Thr Lys Thr Glu Ala Pro Thr Thr Met Thr Tyr Pro Leu Lys Ala  
                             225                            230                            235                            240  
 Thr Ser Thr Val Lys Gln Ser Trp Asp Trp Thr Thr Asp Met Asp Gly  
                             245                            250                            255  
 Tyr Leu Gly Glu Thr Ser Ala Gly Pro Gly Lys Ser Leu Pro Val Phe  
                             260                            265                            270  
 Ala Ile Ile Leu Ile Ile Ser Leu Cys Cys Met Val Val Phe Thr Met  
                             275                            280                            285  
 Ala Tyr Ile Met Leu Cys Arg Lys Thr Ser Gln Gln Glu His Val Tyr  
                             290                            295                            300  
 Glu Ala Ala Arg Ala His Ala Arg Glu Ala Asn Asp Ser Gly Glu Thr  
                             305                            310                            315                            320  
 Met Arg Val Ala Ile Phe Ala Ser Gly Cys Ser Ser Asp Glu Pro Thr  
                             325                            330                            335  
 Ser Gln Asn Leu Gly Asn Asn Tyr Ser Asp Glu Pro Cys Ile Gly Gln  
                             340                            345                            350  
 Glu Tyr Gln Ile Ile Ala Gln Ile Asn Gly Asn Tyr Ala Arg Leu Leu  
                             355                            360                            365  
 Asp Thr Val Pro Leu Asp Tyr Glu Phe Leu Ala Thr Glu Gly Lys Ser  
                             370                            375                            380  
 Val Cys

385

&lt;210&gt; 155

&lt;211&gt; 248

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 155

Ala Ile Arg Gln Ala Ala Lys Asn Gly Ala Thr Gly Val Glu Leu Asp  
 1 5 10 15  
 Ile Glu Phe Thr Ser Asp Gly Ile Pro Val Leu Met His Asp Asn Thr  
 20 25 30  
 Val Asp Arg Thr Thr Asp Gly Thr Gly Arg Leu Cys Asp Leu Thr Phe  
 35 40 45  
 Glu Gln Ile Arg Lys Leu Asn Pro Ala Ala Asn His Arg Leu Arg Asn  
 50 55 60  
 Asp Phe Pro Asp Glu Lys Ile Pro Thr Leu Arg Glu Ala Val Ala Glu  
 65 70 75 80  
 Cys Leu Asn His Asn Leu Thr Ile Phe Phe Asp Val Lys Gly His Ala  
 85 90 95  
 His Lys Ala Thr Glu Ala Leu Lys Lys Met Tyr Met Glu Phe Pro Gln  
 100 105 110  
 Leu Tyr Asn Asn Ser Val Val Cys Ser Phe Leu Pro Glu Val Ile Tyr  
 115 120 125  
 Lys Met Arg Gln Thr Asp Arg Asp Val Ile Thr Ala Leu Thr His Arg  
 130 135 140  
 Pro Trp Ser Leu Ser His Thr Gly Asp Gly Lys Pro Arg Tyr Asp Thr  
 145 150 155 160  
 Phe Trp Lys His Phe Ile Phe Val Met Met Asp Ile Leu Leu Asp Trp  
 165 170 175  
 Ser Met His Asn Ile Leu Trp Tyr Leu Cys Gly Ile Ser Ala Phe Leu  
 180 185 190  
 Met Gln Lys Asp Phe Val Ser Pro Ala Tyr Leu Lys Lys Trp Ser Ala  
 195 200 205  
 Lys Gly Ile Gln Val Val Gly Trp Thr Val Asn Thr Phe Asp Glu Lys  
 210 215 220  
 Ser Tyr Tyr Glu Ser His Leu Gly Ser Ser Tyr Ile Thr Asp Ser Met  
 225 230 235 240  
 Val Glu Asp Cys Glu Pro His Phe  
 245

108

<210> 156  
 <211> 89  
 <212> PRT  
 <213> Homo sapiens

<400> 156  
 Met Trp Leu Trp Glu Asp Gln Gly Gly Leu Leu Gly Pro Phe Ser Phe  
     1                    5                    10                    15  
 Leu Leu Leu Val Leu Leu Leu Val Thr Arg Ser Pro Val Asn Ala Cys  
             20                    25                    30  
 Leu Leu Thr Gly Ser Leu Phe Val Leu Leu Arg Val Phe Ser Phe Glu  
             35                    40                    45  
 Pro Val Pro Ser Cys Arg Ala Leu Gln Val Leu Lys Pro Arg Asp Arg  
             50                    55                    60  
 Ile Ser Ala Ile Ala His Arg Gly Gly Ser His Asp Ala Pro Glu Asn  
     65                    70                    75                    80  
 Thr Leu Ala Ala Ile Arg Gln Ala Ala  
                     85

<210> 157  
 <211> 20  
 <212> PRT  
 <213> Homo sapiens

<400> 157  
 Met Lys Ile Leu Val Ala Phe Leu Val Val Leu Thr Ile Phe Gly Ile  
     1                    5                    10                    15  
 Gln Ser His Gly  
             20

<210> 158  
 <211> 147  
 <212> PRT  
 <213> Homo sapiens

<400> 158  
 Tyr Glu Val Phe Asn Ile Ile Ser Pro Ser Asn Asn Gly Gly Asn Val  
     1                    5                    10                    15  
 Gln Glu Thr Val Thr Ile Asp Asn Glu Lys Asn Thr Ala Ile Ile Asn  
             20                    25                    30  
 Ile His Ala Gly Ser Cys Ser Ser Thr Thr Ile Phe Asp Tyr Lys His  
             35                    40                    45  
 Gly Tyr Ile Ala Ser Arg Val Leu Ser Arg Arg Ala Cys Phe Ile Leu  
             50                    55                    60  
 Lys Met Asp His Gln Asn Ile Pro Pro Leu Asn Asn Leu Gln Trp Tyr  
     65                    70                    75                    80

109

Ile Tyr Glu Lys Gln Ala Leu Asp Asn Met Phe Ser Ser Lys Tyr Thr  
                     85                    90                    95

Trp Val Lys Tyr Asn Pro Leu Glu Ser Leu Ile Lys Asp Val Asp Trp  
                     100                    105                    110

Phe Leu Leu Gly Ser Pro Ile Glu Lys Leu Cys Lys His Ile Pro Leu  
                     115                    120                    125

Tyr Lys Gly Glu Val Val Glu Asn Thr His Asn Val Gly Ala Gly Gly  
                     130                    135                    140

Cys Ala Lys  
 145

<210> 159  
 <211> 17  
 <212> PRT  
 <213> Homo sapiens

<400> 159  
 Ala Gly Leu Leu Gly Ile Leu Gly Ile Ser Ile Cys Ala Asp Ile His  
     1                    5                    10                    15

Val

<210> 160  
 <211> 74  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (50)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 160  
 Gln Gly Arg Gln Asn Ile Ser Pro Asp Lys Ile Pro Trp Ser Ala Leu  
     1                    5                    10                    15

Lys Thr Leu Met Ala Gln Ser Ile Tyr Gly Gly Arg Val Asp Asn Glu  
                     20                    25                    30

Phe Asp Gln Arg Leu Leu Asn Thr Phe Leu Glu Arg Leu Phe Thr Thr  
                     35                    40                    45

Arg Xaa Phe Asp Ser Glu Phe Lys Leu Ala Cys Lys Val Asp Gly His  
                     50                    55                    60

Lys Asp Ile Gln Met Pro Asp Gly Ile Arg  
     65                    70

<210> 161



110

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 161

Gln Ser Pro Asn Glu Arg Ala Arg Leu Tyr Phe Leu Leu Ala Trp Phe  
1 5 10 15

His Ala Ile Ile Gln Glu Arg Leu Arg Tyr Ala Pro Leu Gly Trp Ser  
20 25 30

Lys Lys Tyr Glu Phe Gly Glu Ser Asp Leu Arg Ser Ala Cys Asp Thr  
35 40 45

Val Asp Thr Trp Leu Asp Asp Thr Ala Lys  
50 55

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number  
**WO 01/36432 A3**

- (51) International Patent Classification<sup>7</sup>: C12N 15/11, C12Q 1/68, C12N 15/00
- (74) Agents: HOOVER, Kenley, K. et al.; c/o Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).
- (21) International Application Number: PCT/US00/31162
- (22) International Filing Date:  
15 November 2000 (15.11.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/166,415 19 November 1999 (19.11.1999) US  
60/215,136 30 June 2000 (30.06.2000) US
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).
- Published:  
— with international search report
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). KOMATSOULIS, George, A. [US/US]; 9518 Garwood Steet, Silver Spring, MD 20901 (US). BAKER, Kevin, P. [US/US]; 14006 Indian Run Drive, Darnestown, MD 20878 (US). YOUNG, Paul, E. [US/US]; 122 Beckwith Street, Gaithersburg, MD 20878 (US).
- (88) Date of publication of the international search report:  
10 May 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 01/36432 A3

(54) Title: 18 HUMAN SECRETED PROTEINS

(57) Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/31162

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(7) : C12N 15/11; C12Q 1/68; C12N 15/00 US CL : 536/23.1; 435/6, 435/69.1 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 536/23.1; 435/6, 435/69.1 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched EST; SPTREMBL_15; SWISSPROT_39; PIR_66 Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN; WEST		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99/57261 A2 (HOECHST MARION ROUSSEL LTD.) 11 NOVEMBER 1999 (11/11/99). See entire document.	1-10, 14, 15, 21
Y	WO 99/01550 A1 (DANA-FARBER CANCER INSTITUTE) 14 JANUARY 1999 (14/01/99). See entire document.	1-10, 14, 15, 21
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* *A* *B* *L* *O* *P*	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance earlier document published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	*T* *X* *Y* *G* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
Date of the actual completion of the international search 10 APRIL 2001		Date of mailing of the international search report 06 JUN 2001
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer HOPE ROBINSON Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/31162

## I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

is international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-10,14,15 AND 21

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/31162

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Groups 1-41, claim(s) 1-10, 14, 15 and 21, all in part, drawn to an isolated nucleic acid of SEQ ID NO X or a peptide of SEQ ID NO Y, wherein X and Y are values that correlate to those listed in Table 1, and correspond to one of the cDNA Clone IDs, respectively. For example,

If group 1 is elected, this correlates to Gene No 1, cDNA clone ID HDPTM61 of Table 1, wherein X is 11 and Y is 53.

If group 2 is elected, this correlates to Gene No 1, cDNA clone ID HDPTM61, wherein X is 29 and Y is 71.

Groups 42-82, claim(s) 11, 12, 16 and 23, all in part, each group directed to a peptide of SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 42 is elected, this correlates to Gene No 1, cDNA clone ID HDPTM61 of Table 1, wherein Y is 53.

If group 43 is elected, this correlates to Gene No 1, cDNA clone ID HDPTM61, wherein Y is 71.

Groups 83-123, claim 13, in part, drawn to an isolated antibody which binds to a protein with SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 123 is elected, this correlates to Gene No 1, cDNA clone ID HDPTM61 of Table 1, wherein Y is 53.

If group 124 is elected, this correlates to Gene No 1, cDNA clone ID HDPTM61, wherein Y is 71.

Groups 124-164, claim 17, in part, drawn to a method for preventing, treating or ameliorating an undefined medical condition by administering a polypeptide of SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 124 is elected, this correlates to Gene No 1, cDNA clone ID HDPTM61 of Table 1, wherein Y is 53.

If group 125 is elected, this correlates to Gene No 1, cDNA clone ID HDPTM61, wherein Y is 71.

Groups 165-205, claims 18 and 19, in part, drawn to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO X, wherein X correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 165 is elected, this correlates to Gene No 1, cDNA clone ID HDPTM61 of Table 1, wherein X is 11.

If group 166 is elected, this correlates to Gene No 1, cDNA clone ID HDPTM61, wherein X is 29.

Groups 206-246, claim 20, in part, drawn to a method of identifying a binding partner to a polypeptide defined by SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 206 is elected, this correlates to Gene No 1, cDNA clone ID HDPTM61 of Table 1, wherein Y is 53.

If group 207 is elected, this correlates to Gene No 1, cDNA clone ID HDPTM61, wherein Y is 71.

Group: 247-287, claim 22, in part, drawn to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polypeptide encoded by SEQ ID NO X, wherein X correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 247 is elected, this correlates to Gene No 1, cDNA clone ID HDPTM61 of Table 1, wherein X is 11.

If group 248 is elected, this correlates to Gene No 1, cDNA clone ID HDPTM61, wherein X is 29.

The inventions listed as Groups 1-287 do not relate to a single inventive concept under PCT Rule 13.1 because, under